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Preface 
A colleague once told me, “do you know what “Ph.D.” actually stands for? Personal holistic 
development”. I realized that this process did not just start when I received funding but has been 
developing for most of my life. While health and science research is praised for its objectivity – the 
reality is that both our personal and professional lives affect our purpose in and interpretation of 
research activities. 
Family members on both sides live with Type 2 Diabetes and have struggled with making decisions 
and managing symptoms in addition to their everyday lives and responsibilities. Where they live – in 
the US – healthcare is not a given. It is expensive, time-consuming, and challenging to get answers to 
the questions that you need to take care of yourself successfully.  
For nearly six years, I have been a researcher in the field of mobile health (mHealth). I have been part 
of the development and testing of an in-house developed diabetes self-management app. The focus of 
our team’s efforts has been on patient empowerment, patient-provider collaboration, and technology 
development that addresses end-users’ needs. Our publications – our voice in, and messages to, the 
academic community – have called for healthcare authorities and medical professionals to 
acknowledge and embrace mHealth as a means to engage patients in their chronic condition 
management. We have advocated for the potential of Do-It-Yourself, for peer support through social 
media, for treating individuals as partners in care, not objects of it, and we have called for the 
healthcare system to “keep up.” I have not only read about individuals’ accounts of diabetes self-
management online but also heard first-hand how excited and optimistic individuals are to have a 
sense of control over their own health and well-being. From personal experience, this feels like power, 
like we are more than symptoms and that we can affect our health just like we learn any new skill. 
Having the power to track and change one’s health makes the chaos manageable, whether that be 
through learned skill, social support, or technology or all of the above. When that switch clicks and 
health information starts making sense, as it applies to ourselves, it can be a relief. It can lead us to 
feel hopeful and overwhelmed at the same time.  
Given my personal and professional background, one would assume that I am pro-mHealth – all the 
way. I am not.  
As a researcher, I am cautiously optimistic about technology in our lives. While technology has made 
several aspects of our lives easier – from the ability to heat leftovers for dinner to the machines that 
keep us breathing after a traumatic car crash - it has also made us vulnerable in different ways. The 
dangers of privacy violations, being hacked by those who would take advantage of my personal 
information, the potential to misuse or misunderstand how to use technology, and the spread of 
misinformation are a daily concern. Our level of risk only decreases with education, awareness, and 
scepticism for these dangers.  
I believe in and have benefited from the compassion and training of care providers. I have been 
fortunate enough to work with care providers in several different fields who were willing to ask 
questions and listen to what I was experiencing to not only treat the symptoms but also understand the 
root problem and work through it with me. Since moving to Norway, I have experienced the benefits 
of being seen as not just a patient but a partner in my care – for anything from a cold to injuries. The 
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more I speak with healthcare professionals, through my work and personal life, the more I understand 
that these individuals want to help. They do not merely want to prescribe medication and schedule as 
many appointments in a day as possible – they want to provide their patients with guidance, support, 
and answers to the best of their ability. However, they also experience limitations and hurdles, just as 
all of us do when we aim to achieve something. Changes and limitations in funding, time, and specific 
fields of education, workforce, and other resources may hinder healthcare providers from helping an 
individual or a group.  
No system is perfect, including the medical and health research systems. We are all doing the best that 
we can and, when we are presented with new tools, ideas, questions, or challenges, we have the 
opportunity to explore how these might benefit our efforts. The intention of my Ph.D. is to incorporate 






While the PhD process is certainly an individual endeavour, no PhD candidate is an island. Without 
the support of my family in the US, friends and adoptive family here in Norway, and my cat Mulder I 
could not have achieved any of this – and certainly not with my sanity intact! 
I never expected to leave the US. I had moved here in the Autumn of 2014, only expecting to stay for 
a 10 month Fulbright research grant. Very soon after I arrived and settled in, Tromsø felt like home. I 
was determined to stay so that I could continue to work with the creative, supportive and enthusiastic 
researchers at NSE (formerly NST). I often joke that applying for the PhD was my way of staying here 
with the reindeers, Northern Lights, snow and fresh air. Yet the idea of getting to work in such an 
engaging research environment – with a focus on collaboration instead of competition and mind-set of 
“well-being over blind productivity” - was a major draw for doing a PhD. To be fair, it was probably a 
60/40 split.  
So, for making me feel at home and a valued member of the diabetes/mHealth research team and NSE 
as a whole, I have to give the warmest of thanks and appreciation to Astrid Grøttland, Line Helen 
Linstad, Siri Bjørvig, Gunn-Hilde Rotvold, and Per Hasvold. I am grateful that you all had enough 
faith in me to let me try, to stumble and learn from so many different opportunities. Thank you also to 
Elia, Dillys and Pietro who have been wonderful co-workers and friends. Of course, the one, the only, 
Eirik Årsand deserves a special thanks as my main supervisor – for motivating discussions, for 
listening, for putting up with me, and of course for helping me grow as a researcher and person – 
despite some instances of stubbornness. To my other supervisors – all five of them – Monika 
Johansen, Ragnar Joakimsen, Paolo Zanaboni, Louise Pape-Haugaard and Anne Helen Hansen, I 
would like to thank you for your guidance, your constructive criticism and your patience during this 
process. You made the challenges of this process worth every step and I will be a better researcher for 
it. To Kari and Maryam for your much needed guidance and wisdom at a particularly difficult time at 
the end of the PhD process. To the partners and collaborators in the FullFlow Project, thank you for 
your contribution to these works. Also, to fellow researchers abroad, thank you for sharing your 
expertise and giving me the opportunities to learn, especially in fields outside of my own.  
The past five years in Tromsø served as the setting of not only my professional development but 
personal as well. Toward the beginning, I received news that forced me to reassess much in my life. 
Over the following years, which coinciding with my PhD, I had to ask for help and receive support 
that I never expected I would need. While I struggled, my work gave me purpose and my friends and 
family gave me support and love. To Marit, Eirik, Siv and Gry - you were there to keep me going 
when I couldn’t be with my own family. To my mom and dad – thank you for the funny and creative 
distractions, and cheering you-go-girl! when I needed encouragement to take a day off. To my close 
friends – Lauren, Anna, Jan, Denise, Milan, Kari, Hattie, Julia, Christiane, Gabrielle and Isabel - for 
knowing when I needed to be alone and when I shouldn’t be alone. Whether here in Tromsø or abroad 
– cliché as it may be to say - you were truly always there when I needed to talk or receive a hug or 
funny picture. You set the bar for friendship and support.  
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If I did not mention you by name, please know that it is not because I do not appreciate your support, 
insights and friendship! If you are reading this, then you are someone who helped me – even if it was 
just to smile and say hello. The smallest forms of kindness have a greater impact than we realize.  
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Abstract 
BACKGROUND: Traditionally, health intervention evaluations provide long-term evidence of 
efficacy and safety via validated protocols, following a positivist paradigm, or approach, to research. 
However, modern mobile health (mHealth) technologies develop too quickly and outside of medical 
regulation, making it challenging for health research to keep pace.  
OBJECTIVE: This thesis explored and tested how research can incorporate mHealth approaches and 
resources to evaluate mHealth interventions comprehensively, which follows the pragmatism 
paradigm. The works described herein were part of a larger project that designed, developed, and 
tested a data-sharing system between patients and their healthcare providers (HCPs) during diabetes 
consultations. 
METHODS: The pragmatism paradigm underpins the mixed-methods, multi-phase design approach to 
exploring this overall objective. The following methods were performed using a sequential exploratory 
strategy. First, co-design workshops invited individuals with diabetes and HCPs to design an mHealth 
data-sharing system. Next, a scoping literature review identified research practices for evaluating 
mHealth interventions to-date. Then, app usage-logs, collected from a previous longitudinal study, 
were analyzed to explore how much additional information they could provide about patients’ self-
management. Finally, a mixed-method study was designed to test the feasibility of combining both 
traditional and mHealth approaches and resources to evaluate an intervention.   
RESULTS: Using the pragmatist paradigm as a scaffolding, these works provide evidence of how 
research can provide more comprehensive knowledge about mHealth interventions for diabetes care 
and self-management. Nine individuals with diabetes and six HCPs participated in the co-design 
workshops. Feedback included how a data-sharing system should work between patients and 
providers. The literature review identified how both traditional and mHealth-based approaches (n=15 
methods, n=21 measures) were used together to evaluate mHealth interventions. Usage-log analysis 
revealed that changes in Glycosylated haemoglobin (HbA1c) differed between groups organized by 
usage patterns and duration of use of mHealth. The mixed-method study demonstrated how to collect 
comprehensive and complementary information when combining traditional and mHealth-centered 
approaches and resources.  
CONCLUSION: Traditional positivist approaches and resources are not adequate, on their own, to 
comprehensively understand the impact of mHealth interventions. The presented studies demonstrate 
that it is both feasible and prudent to combine traditional research with mHealth approaches, such as 
analyzing usage-logs, arranging co-design workshops, and other patient-centered methods in a 
pragmatist approach to produce comprehensive evidence of mHealth’s impacts on both patients and 
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The entrance of modern mobile health (mHealth) technologies in the commercial market, 
approximately 2008, affected all medical and health stakeholders – from patients and providers to 
researchers and health authorities [1]. Historically, for chronic illness care, e.g. diabetes, there was a 
stable flow of information and influence between patients, providers, health authorities/policymakers, 
and researchers (Figure 1). Healthcare authorities and providers relied on objective, quantitatively 
measured, reliable and generalizable evidence from research that suggested best-practice protocols for 
achieving the most benefit for the most people. In other words, numbers ruled. The introduction of 
mHealth technologies to aid in effective behaviour change in one’s chronic illness self-management 
led to changes in the dynamics roles and needs of these stakeholders, especially the two end-user 
groups – patients and providers. Behaviour called to be understood, not measured.  
 
Figure 1 Traditional role of research in the production of information that is used by other stakeholders. 
The orange arrows illustrate the traditional flow of information that each stakeholder produces and provides for 
the subsequent stakeholder; research presents evidence of safety and efficacy of a tested intervention for health 
authorities. Then, health authorities determine how to implement relevant evidence into guidelines for clinical 
practice protocols and standards for care providers to follow. Finally, care providers make treatment decisions 
and self-management recommendations for patients that follow these protocols and standards. The blue arrows 
illustrate feedback loops in which the traditional flow of influence is directed, i.e., stakeholders who receive 
information inform and influence the activities of stakeholders before them in the process.   
The network in which diabetes care and self-management exist is complex. Main stakeholders to a 
patient’s care include the patient and healthcare provider primarily, yet tangential and outside forces 
affect the independent choices of and interaction between these two actors. Figure 2 below exemplifies 




* Please note that this is a simplistic illustration, is not meant to be exhaustive and the organization of the factors are open for interpretation 
and discussion. 
 
Figure 2 Illustration of some of the factors, actors and influences that contribute to the complexity of the diabetes 
care and self-management environment 
As will be described in the background section of this thesis, all of these actors and factors have their 
own capacities, limitations and opportunities that affect their priorities, decisions and actions. Such a 
network is considered a “complex adaptive system”, which is described by Plsek and Greenhalgh as “a 
collection of individual agents with freedom to act in ways that are not always totally predictable, and 
whose actions are interconnected such that one agent’s actions change the context for other agents” 
[2]. For research, this means knowing how, or at least being aware that, these factors are constantly 
shifting and affect what questions are relevant to ask and how, as well as who determines what is 
relevant, in order to produce necessary information and knowledge. Therefore, any intervention that 
affects the organization or delivery of healthcare services for diabetes care should seek to incorporate 
such complexity into research practices. Research of such complex systems is consistent with the 
Pragmatist Paradigm, which is an evolution that takes the best from both the traditional Positivist and 
Constructivist paradigms.  
In the early years of modern mHealth development, many articles and reports, both scientific [3] and 
public [4, 5], propagated the belief that mHealth would reduce cost and lower demand on the 
healthcare system and individuals. The reality, however, was not as quickly achieved as many would 
have hoped. As of early 2020, the confusion, uncertainty, hope, and frustration with the impacts of 
mHealth on the healthcare sector remain. Stakeholders from within the medical field are affected – 
searching for the appropriate and safe uses of the technologies, questioning how to adapt healthcare 
practices and services to mHealth. Given the possibilities of mHealth technologies to allow individuals 
to much more easily track the effect of their self-management activities, to allow researchers the 
opportunity to collect more continuous data on such activities, and to affect the relationships and 
connections within the diabetes care network, the process of scientific inquiry requires us to take a 




We as researchers are called to address and reflect changes in the real world in order to provide 
practical knowledge for healthcare. To understand how the new realm of mHealth interventions for 
diabetes self-management calls for changes in how scientific inquiry is approached and how research 
performed, I will provide the background of this complex adaptive system’s network of stakeholders, 
influencing societal trends and technological developments that characterizes mHealth and that need 
to be considered when performing mHealth intervention research. In the Methods and Results 
sections, I will describe how we, as a research team, endeavoured to iteratively explore concepts of 
this complex network via related studies and gain knowledge and understanding about the potential 
impacts of mHealth intervention research. In doing so, I aimed to address the research questions of 
this thesis, which explore approaches in which mHealth research can be performed through the lens of 
the pragmatist paradigm. Finally, I will discuss the impacts and limitations of i) the outcomes of the 
studies themselves as well as ii) the research practices that were performed through the lens of the 
pragmatist paradigm. 
2 Background 
I will provide the background information for the thesis beginning with describing and understanding 
the needs and challenges of chronic illness care, as a whole, followed by a focus on diabetes as the 
chronic illness use-case. A particular challenge to be aware of is that, for complex adaptive systems, 
individual players are partly interdependent and independent of one another making it difficult to 
predict the activities within the network [6]. Therefore, understanding as many points as is reasonably 
possible will aid in the design, administration and interpretation of research inquiries. I will then 
introduce mHealth as a more novel trend in the field of health care and self-management and the 
specific sub-set of mHealth technologies that I will focus on for this thesis. Finally, I will describe 
how mHealth is changing the way we as researchers and health professionals need to address diabetes 
care, individual’s self-management and intervention research through the foundational shift in 
research approaches, or paradigms. 
2.1 Supply and demand for chronic illness care 
In this section, I provide an overview of the growing imbalance between the supply of and demand for 
healthcare services and resources. The focus will be on the complex network of stakeholders related to 
chronic illness care. By understanding the relationship between these players (Figure 1), we can better 
understand how the introduction of mHealth technologies has affected these dynamics, and, in turn, 
the need for research evidence.   
Today, type of demand is largely influenced by patients with chronic illnesses who have specific 
questions about their self-management habits, experienced symptoms or health status. Demand can 
include unpredictable and preventable uses of healthcare services and resources depending on the 
treatment and support requests of its beneficiaries, i.e. patients. The supply of these resources and 
answers, on the other hand, changes less quickly and can include hospital beds, on-hand medications, 
and available technologies within a care facility [7]. This type of care is influenced by some of the 
same factors that mHealth aims to address, e.g., patients seeking specific answers and continuous 
support for chronic illnesses, etc. For example, technologies can influence when patients ask questions 
about their health, which answers they seek and, alternatively, when patients need treatment for 
experienced symptoms as the result of poor decisions or understanding of their chronic condition. This 
is detailed further in the sections below. 
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2.1.1 An overview of supply and demand 
The demand on health care and responsibilities assigned to providers has been on the rise for decades. 
A growing elderly population with complex medical needs, chronic illnesses, obesity, and other 
lifestyle conditions that require health intervention, in addition to the everyday scrapes, breaks, and 
colds – these are what awaits healthcare professionals when they enter clinical practice. The 
prevalence of those with chronic non-communicable diseases (NCDs) such as diabetes, chronic 
obstructive pulmonary disease (COPD), cancer, or cardiovascular diseases is growing. A 2016 report 
found that 14 million people in the United Kingdom (UK) lived with two or more chronic conditions 
[8]. In 2013, the World Health Organization (WHO) reported that the shortage of  HCPs was 1.6 
million, which was expected to rise to 4.1 million by 2030, with the largest shortage being that of 2.3 
million nurses [9]. A Statista report comparing the demand for doctors in the European Union (EU) 
between 2012 and 2017, noticed an increase in the number of consultations sought per person in these 
years [10]. Unfortunately, the supply of those who can provide medical care has plateaued in 
comparison to these demands, with some fields decreasing overall [11].  
It is hard to believe that in 2000, the US, for example, were considered to have more supply of, 
especially, primary healthcare providers than demand [12]. This trend has shifted drastically since 
then. A report published by the U.S. Department of Health and Human Services projected that by 
2013, the demand for primary care providers would be far greater than the supply. By 2032, it is 
expected that demand for general practitioners (GPs) will exceed their supply by between 21 and 
55,000 GPs [13]. Waitlists and rising costs in Europe follow this same trend, further constricting the 
ability of providers to deliver adequate information and necessary services [14].  
Professions are designed to evolve over time.  Many societies have undergone some form of 
healthcare reform in recent decades – whether it be initiated by healthcare findings and evidence of 
new treatment models or the reorganization of resources to promote more streamlined and cost-
effective medical systems or more effective care coordination [15]. Throughout the European area, 
programs, initiatives, reports, and plans have been rolled out in overwhelming numbers [16]. This can 
mean reallocation or reduction of budgets resulting in more responsibilities for different provider 
specialties, fewer available hours and staff to see those in need of medical care in certain fields, focus 
on training for certain specialties and skills, such as newly available technology, and not others [11, 
16, 17]. When these changes are initiated, providers must quickly learn and implement the new 
expectations of their practices. However, the resources in the medical system scheme needed to 
practically realize these expected benefits [18, 19], i.e., resources, specific practice guidelines from 
healthcare authorities, and funding lag behind, resulting in an extensive adjustment period and 
frustration for the healthcare community. For example, in Norway, the 2001 Regular GP Scheme was 
introduced to shift more responsibilities toward primary care [20]. It has been 18 years of adjustment, 
and while both patient and GP feedback has demonstrated high satisfaction, the added workload has 
some GPs concerned that at some point, they will soon have trouble providing the same frequency or 
continuity of care as before [21]. 
2.1.2 Self-management vs. treatment in chronic illness care 
Individuals with chronic illnesses are especially susceptible to the ill effects of this limited supply of 
care services and resources. Chronic illness self-management is a time- and resource-consuming 
process that requires a patient’s patience, willingness and understanding, and a healthcare provider’s 
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knowledge. Such treatment calls for providers to guide their patients and often coordinate care 
amongst several other providers and practices.    
Self-management is the responsibility of the patient. While there may be several different definitions 
for chronic illness self-management, the core principle is the same: patients have a responsibility to 
seek and apply an understanding of how their actions affect their health factors to improve or maintain 
their health [22]. Despite a certain level of dependence on care providers for formal guidance, clinical 
consultations for those with T1D typically only occur once or twice a year. And while those with T2D 
often seek more frequent contact and answers from their GPs, it is not always possible to gain all those 
answers in a brief consultation. Consequently, those with chronic health conditions spend more time 
on their own, reacting to changes in their environment or physical health by adjusting their habits or 
actions. Once diagnosed with diabetes, the roles and priorities of the individual should be to 
understand, track, and respond to changes in their lifestyle choices or the environment in order to self-
manage their chronic conditions. Outside of the clinic, options such as formal educational courses, 
pamphlets, and general information are available for those who have recently been diagnosed within 
the medical network. As the condition continues, individuals need formal guidance and resources to 
help them decide how best to improve their own health and lifestyle situation.  
GPs are also known as primary care providers. In many countries, you must first see a GP to assess 
your health concerns in order to be referred to a specialist, including those who care for diabetes, 
COPD, cancer, etc., when appropriate. However, those with T2D go primary to their GPs for treatment 
of their diabetes, as do the majority of the population. A survey of GPs in Norway in 2017 revealed an 
average workweek amounting to 55 hours - well over the typical Norwegian workweek of 37.5 hours - 
with a median patient list-length of 900-1200 and much variation between large and small 
municipalities [23]. As the gate-keepers to other medical services, it is important to acknowledge their 
capacity for care practice, i.e., their ability to identify patients’ risk for disease and correctly direct 
them to the appropriate secondary care. However, in the same 2017 GP survey, it was noted that those 
with chronic illnesses account for nearly 15% of working hours devoted to those with complex care 
needs [23]. This is one of the main reasons that GPs are the most used and needed care resource [24].  
Specialists, specifically internists, treat chronic illnesses related to organ structures. These providers 
are educated and trained to follow health policies and best-practice guidelines based on evidence 
produced by generations of medical testing and exploration. Specialists have historically acted as key 
resources of knowledge, guidance, and answers for specific chronic care needs. Individual patients can 
seek information about disease mechanisms, preventative measures, clinically approved treatment 
models, and general self-management recommendations. These general recommendations have been 
shown to work for the majority of the population. However, there needs to be an adequate supply of 
providers who can test, confirm, and recommend lifestyle changes to those diagnosed with a chronic 
condition.  
Treatment has traditionally been the responsibility of healthcare providers. Upon diagnosis, providers 
establish a treatment plan for that patient. These plans are general approaches to medication, service, 
and self-care options to reduce the symptoms and progression and prevent the onset of complications. 
Especially for the care of chronic conditions, a provider’s role is to continuously adapt their treatment 
plans and offer personalized recommendations based on the ever-changing needs of the patient and 
their health progress. When a patient schedules a consultation to seek answers about how to react to 
symptoms of, for example, frequent fatigue and lack of sleep, the provider looks at the evidence and 
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determines the best course of action for that patient. By reviewing lab results of blood chemistries 
combined with the patient’s description of their symptoms, a provider can effectively come to the 
conclusion that the dosage of a new medication is too high for that individual, and it should be 
lowered.  
For example, the diagnoses of diabetes or heart disease require individuals to change their lifestyles - 
whether that be diet, exercise, medication, or all of the above. As each individual is unique in their 
biological, psychological and socio-economic needs, patients and HCPs, together, must go through a 
series of trial and error to determine which medication, diet-exercise regimen or support services that 
individual may need to ensure that they are able to gain sustainable and effective self-management 
skills. This represents months or years of demand for healthcare services.  
However, as providers struggle to help as many patients as possible in a day, there is less time to meet 
each patient. In the UK, those who have been diagnosed with a chronic condition, such as cancer, 
often must wait for more than two months to see a specialist upon referral [25]. Statista reported that 
throughout Europe, those seeking first medical examinations and treatment are not able to access a 
provider due to factors such as expense and wait times [26]. When patients are able to access 
providers, however, issues still arise. Health consultations today are generally limited to 20-minutes 
[27], during which only few questions can be answered, let alone discussed and explained at length. 
For those with chronic NCDs, 15-minutes once or twice per year, is hardly enough time to gain 
effective support in time [28].  
2.1.3 Consequences of the supply-demand gap 
Unfortunately, the numbers do not lie. One of the gaps that result from the supply-demand imbalance 
is unmet health expectations for those with chronic conditions. Not all who have been diagnosed with 
complex chronic illnesses have achieved evidence-based clinical targets, i.e., indications of their 
disease health. Several studies during the last decade have found that less than half of their participants 
with diabetes achieved recommended levels of blood glucose (BG), a key factor in diabetes health. 
Even less (approximately 10%) achieved all of the clinical goals related to adequate diabetes health 
[29, 30], e.g., lipid levels, blood pressure (BP), cholesterol, etc. Receiving the type and level of care 
and support that patients demand from providers is essential to achieving these goals.  On top of the 
externally suggested health goals, patients themselves believe that more personalized 
recommendations from their providers about specific solutions, resources, or support would help them 
achieve better health [31].  
Another gap is based on a mismatch between patient and providers’ agendas and communication– a 
more self-management vs. treatment focus. Individuals need answers. A summary of a 2018 study 
reported that the common needs amongst 500,000 individuals with chronic conditions weighed more 
toward emotional support and specific answers about impacts of their illnesses on their daily lives, and 
less so on hard clinical outcomes [32]. Patients also have reported more and more desire to be part of 
the care process and contribute information upon which to base treatment and self-management 
decisions. A 2019 report by the Samueli Foundation found that while individuals with chronic 
conditions (72%) very much wished to discuss self-care strategies with their providers, approximately 
half of the providers who responded did not believe their patients would be interested in or able to 
hold such conversations  [33]. The limited amount of time and tradition to rely upon consulting and 
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providing concrete, validated, and quantitative information about a patient’s progress during 
consultations were also precipitating factors.  
These gaps – in expectations, in agendas, in the understanding of one another, in approaches to care – 
leads to adverse consequences, both for patients and providers. Even when providers and patients may 
agree, for example, about the importance of educating patients and access to adequate health services, 
the financial, informational, and systemic limitations of medical systems pose a significant barrier 
[34]. 
When individuals do not receive the care they need and demand, mentally, there can be a disconnect 
and distrust of the medical system in its ability to help them [35], as well as confusion, frustration and 
lack of confidence in their ability to self-manage their own health.  
Ideally, a more knowledgeable and capable patient would be able to answer and correct for health 
challenges that arise. As such, they would not require as much follow-up from their provider, would 
suffer fewer complications, and require fewer hospital admissions. However, if the services and 
resources are not available to a patient in order to gain sufficient self-efficacy in their chronic illness 
self-management, costly and resource-demanding consequences arise for both patients, providers, and 
the overall healthcare system.  
The consequence of poor chronic illness self-management and treatment are health complications and 
their costs, decreased motivation and engagement in one’s self-management, and lower levels of 
function in one’s daily life or disability. Given the willingness and engagement of the patient, often, 
these consequences could have been avoided with more personalized attention and instruction for 
improved self-management. 
2.2 Exploring the specific contexts of Type 1 and Type 2 
Diabetes Mellitus 
In this section, I describe diabetes as a use-case for this thesis. Diabetes requires a person to change 
their lifestyle, track their biological and habitual changes, participate in continuous coordination with 
HCPs, and cope mentally with the added pressure of learning and adjusting to their diagnosis. 
Research on mHealth interventions for diabetes self-management reflects the modern environment to 
which researchers, patients, and HCPs must adapt to produce effective knowledge and care for chronic 
illnesses in general. 
2.2.1 Types and prevalence 
There are three main types of diabetes mellitus: Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), and 
gestational diabetes. The activities of this thesis focus on the two types of chronic diabetes, T1, and 
T2D. T1D is known as juvenile or insulin-dependent diabetes, as it is most commonly diagnosed in 
children, but can also be diagnosed in young adults, with cases rising >3% annually in Europe [36]. 
T2D generally develops over time and is, therefore, also called adult-onset diabetes. As the most 
common type of diabetes, T2D accounts for 90% of the population of those with diabetes (9.3% of the 
global adult population) [37]. However, in recent years, due to more sedentary lifestyles of children, 
youth (0-19 years old) are also at risk for and shown to be developing T2D (1.3% of those with 
diabetes in Europe) [37, 38].  
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In 2011, it was estimated that approximately 50% of those with diabetes globally remain undiagnosed 
[39], which rose to nearly 67% in 2019 [37]. Some of the significant contributions to being 
undiagnosed or unaware of one’s diabetes are socioeconomic inequalities such as lack of access to 
health services and resources, lower education and health-literacy, lower-income, etc. [40].  
2.2.2 Underlying causes 
These diagnoses are based on imbalances in insulin and BG due to the ineffective functioning of the 
pancreas or the body’s cells. In healthy individuals, when BG rises, for example, as the result of eating 
a cookie, insulin is released from the pancreas, which signals glucose to be taken from the blood and 
stored into our cells. If our BG is too low, we get hungry and eat, thereby raising the BG to healthy 
levels, making the glucose available as fuel for our daily activities.      
Those with T2D have developed insulin resistance, largely due to sedentary habits, poor diets, and 
genetic susceptibility. The body is unable to effectively store glucose in the cells, leaving them to float 
around in the blood. While insulin is not typically needed for T2D, there are some cases, e.g., 
dangerously high prevailing BG levels, for which a HCP may prescribe a combination of insulin and 
oral medications. Those with T1D lack the ability to produce insulin and, therefore, must introduce 
insulin to maintain healthy levels of BG.  
2.2.3 Self-management and support 
Those with diabetes are often provided with general resources when they are diagnosed or have been 
found to have a specific issue with their self-management, e.g., carb-counting through Diabetes 
courses and diabetes self-management education (DSME) [41]. There are also official e-learning and 
online resources for information and guidance on how to perform effective self-management [42]. 
However, these do not cover many of the intricacies and situational changes that happen for 
individuals on a daily basis.  
Health professions agree that there are four main determinants of diabetes health: diet, exercise, 
medication, and BG [43]. Upon diagnosis, individuals are instructed to track their self-management of 
blood glucose (SMBG), diet, and medication delivery, traditionally using a paper diary. While these 
individuals are given general recommendations, you have to figure out what works for you each day. 
Additional factors to these four cornerstones include, e.g., BP, sleep, depression, and social support, 
which significantly affect an individual’s willingness and ability to maintain their health. In order to 
react appropriately with an effective self-management decision, you have to adjust the general 
recommendations to your lifestyle, changes in your body’s needs as you grow older, or changes in 
your resources based on socioeconomic status [44]. Even your surroundings play a role. For example, 
taking a vacation in a hotter climate can affect the absorption and chemical stability of your insulin 
[45].   
Those with T1D use different types of insulin, i.e., variations of short-acting and long-acting insulin, 
which have to be coordinated and administered throughout the day [46]. There are two medically 
available devices that aid a person in managing their insulin - insulin pumps and insulin pens [47]. 
Equipment used by the insulin pumps generally need to be changed, at the longest, every three days. 
Associated BG levels can be monitored by devices including CGMs, which track one’s BG every 5-
minutes, and flash glucose sensors, which require the users to hold a device up to the sensor in order to 
read the glucose level at that moment. These can be linked via Bluetooth and analyzed via algorithms 
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to coordinate the self-management of these two diabetes factors [48]. Except for the insulin pen, these 
devices are all connected to the body via a subcutaneous cannula or subcutaneous sensor. The use of 
the aforementioned medical devices for T2D is highly debated and is, therefore, not typically an 
option for these patients [49].  
Glycosylated hemoglobin (HbA1c) is a cumulative measure of BG representing an average of the 
previous 3-4 months of BG levels [50]. HCPs use this measure as the gold standard to diagnose, as 
well as track an individual’s overall diabetes health and risk of developing complications. HbA1c is 
typically taken together with other lab tests, e.g., lipid levels, at the clinic once or twice per year. 
Typically, the target HbA1c is <6.5-7% (53mmol/mol) [51]. While HbA1c is considered the gold 
standard for HCPs, it does not hold as much instructive or explanatory value for individuals living 
with diabetes. Luckily, advances in BG measurement technologies have allowed us to see more 
detailed accounts of individuals’ BG levels for any given period of time, i.e., amount of time in and 
out of the goal range of BG levels.  
Time-in-Range (TIR) and Time-Out-of-Range (TOOR or simply OOR) are measures of the 
percentage of time BG levels are in- or outside the target of 3.9-10 mmol/L (TIR). TIR and OOR more 
accurately demonstrate the variability of BG levels compared to HbA1c [52]. Whereas finger-prick 
tests, taken irregularly, give momentary measures of one’s BG, CGMs provide the type of detailed 
information that allows for improved calculation of TIR and OOR [53]. Graphs displaying this 
information can tell individuals, for example, times of the day when their OOR levels typically occur, 
or, compared to diet and physical activity levels, can help that person determine why those OOR 
levels may be happening. These OOR measures are especially important for those with T1D or for 
insulin-treated T2D, whose BG levels the most throughout the day.  
2.2.4 Consequences of poor diabetes self-management  
The consequences of consistently addressing and acting upon the needs of diabetes, or any chronic 
illness, not only affect individuals and their relatives but also demands on the healthcare system. For 
both types of diabetes, damage to entire organ systems may occur. In order to avoid complications, 
those with diabetes are instructed to maintain a BG level between 70-180 mg/dL, or 3.9-10 mmol/L 
[54].  
Short-term or rapid onset, consequences of poor diabetes self-management are usually seen in those 
with T1D. For this type of diabetes, BG changes can happen quickly due to nutritional intake, physical 
activity, and insulin – or lack thereof. Hypers, or hyperglycaemia, means that there is too much 
glucose in the blood, causing dehydration, severe fatigue, or blurry vision, to name a few [55]. A 
prolonged state of hyperglycaemia generally occurs in those with T2D, while those with T1D may 
experience several “hypers” and “hypos” throughout the day. Hypos, or hypoglycaemia, refer to lower 
BG levels, for example, due to excessive use of insulin or physical activity, or too little fuel (food). 
The symptoms of hypos include weakness and sweating or shaking, and, if left untreated, can lead to 
coma and death [55].  
Long-term, or cumulative, complications of prolonged, poor diabetes self-management can include 
problems with circulation to kidneys and eyes as well as nerve damage, or neuropathy [56]. 
Amputation of, for example, feet or legs, may also be necessary as well as prolonged healing times for 
wounds [57]. Those with diabetes can often suffer from depression, anxiety, and stress as the result of 
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having to live with diabetes, leading to frustration, poor outlook on one’s health and quality of life 
[58].  
These consequences can then negatively impact how one functions socially, e.g., experienced stigma, 
and vocationally, not to mention financial stability due to the high cost of treatment and/or risk of job 
loss due to disability. Cognitive dysfunction, e.g., deficits in learning, concentration memory, has been 
recently acknowledged as a potential consequence of persistently high BG levels for both types of 
diabetes [59]. 
2.3 mHealth technologies and trends 
In this section, I describe the origin and evolution of mHealth technologies for diabetes self-
management, and what contributed to their growth in popularity and accessibility amongst individuals 
with diabetes, including societal, regulatory, and technological changes.  
2.3.1 The evolving connotation of mHealth  
Mobile and remote health technologies are not a new concept, evolving from electronic health 
(eHealth) and telemedicine to the modern-day mobile health (mHealth) devices. From desktop to 
hand-held systems, mobile technologies for both patients [60] and HCPs have been meant to ease the 
ever-evolving challenges of an overwhelmed medical system [61]. 
Various terms - eHealth, telehealth, and telemedicine – cropped up to describe mobile health 
technologies. While there are no explicit differences between these terms, a 2005 systematic review of 
publications describing eHealth innovations “suggests that eHealth may refer more to services and 
systems rather than to the health of people” [62], due to their focus on access and connectivity to 
formal care services and systems rather than the improvement of individuals’ health measures or 
quality of life.  
Remote health support also expanded its inclusion of decision-making power in 2012 with the WHO’s 
statement that telemedicine and telehealth involved using information and communications 
technologies to enable greater access to healthcare services [63, 64]. Of note is the shift in language 
from the 2010 top-down description of “health information is provided to the right person” related to 
“diagnosis and clinical management” [65], to the 2012 version of “greater access to healthcare 
services.” The 2012 version demonstrates a more bottom-up approach as patients were empowered to 
seek care instead of being instructed to. With a variety of intended uses, such devices allow for an 
individual to collect health-related measurements outside of the clinic as well as track and share this 
data with whomever they choose.  
A major reason that contributed to the hierarchy, i.e., the disproportionate power in healthcare 
decision making, was access to information. HCPs were traditionally seen as the sources of 
information, health decision-making, and authority for chronic condition care. All information flowed 
toward and was filtered through them - from recent findings in research and condition-specific health 
goals developed by authorities, to patients (Figure 1). Technology was no different. The traditional 
role of health technologies was to supplement or extend healthcare services, enabling HCPs to track 
their patients’ health progress and recommendation adherence between consultations. Their 
development also followed a traditional path. Before the interventions, end-users - typically patients 
and HCPs – were invited to participate, the technologies were iteratively developed, vetted, and made 
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available through a top-down approach [66]. Health authorities provided the direction via population-
level or global health directives, e.g., Norway would provide goals for diabetes care for the country 
[67], and researchers would provide evidence for ways in which these goals could be achieved. It 
typically would take years to generate enough consistent evidence to ensure that the tested 
intervention was safe and effective enough to provide to the public. These new treatments or self-
management care options would be made available to HCPs, e.g. as standards for healthcare practice, 
and the HCPs would then offer options to their patients based on what they believed would be for that 
patient. 
Between approximately 2008 and today (2020), the power and authority to make healthcare decisions 
expanded to include not only HCPs and health authorities but also patients. mHealth supported this 
trend by empowering patients to use their own-gathered data to inform their self-management 
decisions outside of the clinic. mHealth has not only to acknowledge patients as the daily decision-
makers and largest determinant of their health status but more or less authorized them to make health 
decisions without the involvement of formal medical services. With the option to track, educate one’s 
self and respond to health needs as they arise through a device that is always available, in the palm of 
your hand, mHealth has contributed to the shift the power dynamic.  
Today, patients are able to access not only general information about their chronic condition via the 
internet or their HCPs; they are able to generate their own information - their own power in decision 
making. By this, I mean that patients are able to take the general principals of their self-management 
and build upon that understanding by recording, tracking, and reviewing the outcomes of their own 
health actions. By using mHealth applications (apps), wearables, and medical sensors, individuals are 
able to build a library of evidence of which lifestyle choices, actions, and situations lead to positive or 
negative changes in their health. In other words, mHealth could potentially facilitate more informed 
and sustainable behavior change decisions. As a result, those with diabetes experience a greater sense 
of ownership, responsibility, and confidence in their ability to self-manage [68].  
However, this freedom from clinical support presents risks – especially in the early years of modern 
mHealth. There are reasons why HCPs rely upon blood tests and standardized health measurements to 
support their clinical decision-making; a person’s health, wellbeing, and ultimately their life, are in the 
HCPs’ hands. To be so excited to try a new technology that promises ease-or-use, support, and 
answers that one trusts it without question is dangerous. HCPs’ most prevalent concerns began with 
the potential for individuals to erroneously enter the wrong data and security and privacy of data 
stored in the app. While these are smartphone apps, they did and still do not have the ability to 
determine if you have entered the wrong measurements. Any suggestions about health, medication, or 
lifestyle changes that an app provides can be dangerous if those suggestions are based on faulty data. 
Also, when an individual pushed the “agree to terms” button, upon downloading the app, they often 
overlook or simply are unconcerned with the fact that these technologies are provided by commercial 
companies or individuals. A major difference between mHealth technologies and those developed as 
part of clinical intervention trials was that mHealth development did not follow the strict protocols and 
quality medical standards. These entities have the ability to develop mHealth apps and devices without 
a clinical background and with intentions of profit, not altruism. Following regulations, safety, and 
effectiveness standards are often secondary goals.  
HCPs have been cautiously optimistic about the potential of these technologies to support patient self-
management from the beginning. However, for these reasons, they are hesitant when reviewing 
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patient-gathered app data and urge individuals to take app-recommendations with a grain of salt. More 
recently, individuals have been encouraged to ask their HCPs about which app to choose, i.e., to take 
the act of choosing an app just as seriously as a change in medication by consulting a professional 
[69]. However, this presents yet another challenge and demand on HCPs that must be addressed. This 
trend brings another concern to the HCPs’ table, i.e., not being able to relate to the patient-gathered 
data due to lack of clinical guidelines and protocols. Factors that have contributed to this network of 
concerns and possibilities are described below.   
2.3.2 Factors affecting mHealth use 
Several societal, economic, and technological changes contributed to the rapid growth of modern 
mHealth technologies. Figure 3 provides examples, between 2007 and 2019, of some of the major 
changes that occurred in parallel that contributed to the entrance and fast-paced growth and adoption 
of modern mHealth technologies. I focus on four major categories to illustrate the rapid development 
and capabilities of technology that coincided with an emphasis on patient empowerment - both of 




Figure 3 Timeline illustrating societal, regulatory and technological changes that occurred in parallel that allowed 
for mHealth spread [70-92] 
The availability of smartphones, wearables and apps was made possible with the release of the modern 
smartphone – the iPhone – in 2007 and the boom of the App Store in 2008 [1, 93]. The use of 
smartphones began to outpace the use of regular cellular phone use in 2012, as consumers wished for 
more advanced functionalities as apps [94]. What made a smartphone smart, was its ability to access 
the internet.  
Many of us can remember the sluggishness of a dial-up internet connection. The usability, popularity, 
and feasibility of smart technologies simply would not be possible without the “Internet-of-Things” 
(IoT), i.e., the ease of internet access [95]. With the ability to access the internet easily from the palm 
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of your hand, individuals could find health content via scientific literature or websites such as those 
hosted by fellow patients. Smartphones, wearables, and sensors grew ever more capable of collecting 
and storing detailed data sets thanks to their ability to connect to one another and access the internet 
via Bluetooth and WiFi.  
Available platforms grew to include other smart-devices as smartwatches and other wearables [96]. 
These devices take advantage of the IoT to collect and store data from smartwatches, sensors, bio-
patches, plug-in smartphone sensors, or even pair via Bluetooth with medical devices [97]. A key 
feature of these technologies was their ability to automatically capture data regarding an individual’s 
physical activity, e.g., heart rate coupled with the selected type of exercise, sleep patterns, ambient 
temperature, or sun exposure, to name a few [98].  
Apps spread like wildfire thanks to the speed of regulatory change and emphasis on the individual. As 
the gap between healthcare supply and patient demand grew [10], HCPs and authorities pushed for 
patient-empowerment. In theory, the more resources and information that individuals could access on 
their own, the less time they would take from formal healthcare services.  
The number of available apps reported by different companies and surveys varied widely over the 
years. As of July 2008, over 15,000 apps were available on the Apple App store, rising to 586,000 by 
2012 [99]. However, the increase in popularity of certain categories of apps, ever-specialized 
functionalities, and rates of growth illustrate consistent characteristics of the app market, e.g., rapid 
development, personalization, and accessibility. By 2014, not only were there over 100,000 health 
apps available, most of these targeted those with chronic conditions [96]. A report by the same 
company, Research2Guidance, just three years later, confirmed the sustainability of this trend with 
more than 325,000 health apps published and a third of the market focusing on providing 
functionalities related to self-management and patient-provider connection [1]. For individuals aiming 
to self-manage their health using apps, the near-constant development of these personal and 
commercially available technologies, to collect and collate more and more data, became a necessity. 
By 2016, it was estimated that Android app downloads outnumbered iOS (Apple) app downloads 3-to-
1 [100]. While overviews of the mHealth app market often note market growth in terms of revenue, 
many health apps could and can still be downloaded for free, with some offering in-app purchases 
depending on which level and functionalities the user chooses to use.  
However, not everything progressed at such a rapid pace. Considering the methodical, systematic and 
cautious nature of the medical system, it is understandable that regulatory and legislative changes in 
the healthcare system were – and are- implemented more slowly than the face-paced world of the 
commercial market. The delays in these regulations, including how to test and validate these 
technologies, allowed for nearly a rule-free environment in which technology developers could 
produce health apps. App developers acknowledged a need for accessible and easy-to-use health aids 
for individuals and found that these solutions were relatively easy and quick to make. A quote from 
the movie Pirates of the Caribbean comes to mind when considering the beginning of health app 
development; “the code is more what you'd call "guidelines" than actual rules” – Captain Barbossa 
[101]. Even some years into the mHealth boom, apps were being produced in public and commercial 
markets without strict requirements, standards, or limitations for health app developments [102].  
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2.3.3 Modern mHealth: a buffet of app options and information for 
individuals 
As a mainly commercial product, these technologies were constantly being covered in the news. many 
articles and reports, both scientific [3] and public [4, 5], propagated the belief that mHealth would 
reduce cost and lower demand on the healthcare system and individuals. The reality, however, was not 
as quickly achieved as many would have hoped. As of early 2020, the confusion, uncertainty, hope, 
and frustration with the impacts of mHealth on the healthcare sector remain. Stakeholders from within 
the medical field are affected – searching for the appropriate and safe uses of the technologies, 
questioning how to adapt healthcare practices and services. As someone researching and observing 
these changes as they happened, it was difficult to keep track of what was available and what was 
obsolete or no longer available [103]. The consequence of this was an overwhelming number of 
choices of health apps and information for everything from general health and wellness information to 
diagnosed chronic conditions.  
When any new item hits the market, one of the first things we do, if we are interested in purchasing it, 
is to look at the reviews. We try to sort through the useful information vs. the noise to find what is 
relevant to our unique needs. While the Android and Apple App stores provided information for each 
app, several organizations provided “app directories,” which included reviews and insights about 
specific apps by consumers and peers [104]. In doing so, they aimed to ease the daunting and 
overwhelming decision-making process for potential users, i.e., providing the individually relevant 
information that the healthcare system was not.  
The organization PatientView was the first to produce a completed “European Directory of Health 
Apps” in 2013 [104], updated in 2016 [105]. These reports categorized apps based on specialization, 
e.g., cancer, children’s health, or rare diseases, with information about app names, available platforms,
languages, and countries, as well as descriptions, reviews from other patients, cost, and full
descriptions of the developers. All of this was provided on one page per app. This meant an easy,
searchable, comprehensive, and transparent overview of the intention of health apps with information
that matters to end-users. The report published in 2016 included updated and relevant information for
the time, including “Approved by,” e.g., Conformitè Europëenne (CE) mark or the US Food and Drug
Administration (FDA).
The UK’s National Health Service (NHS) took a more formal approach in 2015 with the “Health Apps 
Library.” These reviews were based on input from HCPs, which attempted to add a level of clinical 
relevance and approval. However, this process of vetting the apps was unfeasible, with questions of 
quality of the reviews and reliability of the apps’ security [106], and the library was closed down for a 
time and relaunched more recently as the “NHS Apps Library” [107]. In this version, app developers 
review apps by including information provided by developers and input from HCPs. They were 
transparent in their app review process, describing that the developers were the ones who had to meet 
and submit reports of their compliance with standards of security, clinical relevance, etc. [108]. This 
“self-assessment” was positive in that it no longer required health professionals to take time from their 
schedules to evaluate apps, but also a challenge because it relied on developers to perform the work, 
i.e., the reviews and approval, which were not necessary for them to promote their apps.
These popular and public reviews demonstrate the difficulty of bridging the gap between the consumer 
and healthcare domains, specifically with providing quick, quality, secure, and relevant information to 
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end-users. Health researchers also attempted to provide medically and user-relevant reviews of both 
commercial and developing apps. However, their intention was more related to identifying clinical 
evidence, than information to individual users [109-111].  
2.3.4 Thesis focus: patient-operated mHealth for self-management of 
diabetes 
In this section, I will begin by explaining the appeal of mHealth technologies and the specific sub-
group of these upon which I will focus the remainder of this thesis. I will highlight the aspects of the 
modern mHealth environment that are specifically relevant for patient self-management of chronic 
conditions, with a focus on diabetes. I will also explain how the lack of specific regulatory guidelines 
for research evaluation and clinical practice presents an opportunity for researchers to explore 
alternative approaches and resources needed to appropriately adapt research to mHealth interventions 
for diabetes. 
Traditional medical device manufacturers target HCPs and healthcare organizations [112] to distribute 
their proprietary devices to the patients who demonstrated a need and ability to use them 
appropriately, as well as the ability to pay for them [113]. Although these devices were meant to aid in 
patient self-management, the collected and structured data were [114] and still are [115] meant to be 
analysed by the HCP, who would then explain to the patient which health habits should be changed. 
As such, most medical device companies did not provide all the support that patients needed outside of 
the clinic. 
These prescribed technologies, such as continuous glucose monitors (CGMs), insulin pumps, and 
insulin pens are expensive. In terms of time, energy, and out-of-pocket financial burden of self-
monitoring using such medical devices, the price for individuals is high [113, 116]. Imagine having to 
analyse each action you make or change in the environment to determine its effect on your health. It is 
a mentally exhausting endeavour. Technology took some of that burden away by acting almost as a 
personal self-managed secretary. However, not all individuals met the requirements that qualify to 
receive equipment to ease the everyday self-management burdens. For these individuals, few options 
existed to understand and aid patients in their attempts to follow self-management recommendations 
from their HCPs.  
The availability and accessibility of these technologies presented a three-fold benefit. The first benefit 
is time; the ability of many mHealth technologies to collect and collate the data in an understandable 
way freed individuals to spend less time processing each self-management decision they made. The 
second benefit was the always-present nature of smartphones and wearables. Patients need to self-
manage every day, not just during the consultations. They need specific answers when questions, 
symptoms, or other challenges to self-management arise. The third benefit coincides with control. 
Individual users are a primary target audience, initiators, and decision-makers. While HCPs can be 
secondary users of the data, i.e., taking on more of a supportive role rather than authoritative, the 
patient is in charge of their health, priorities, and decisions. 
2.3.5 mHealth: empowering patients with choices 
In this section, I highlight two key concepts that will be presented throughout this thesis – choice, and 
empowerment. Whereas health and research have historically focused on top-down suggestions, 
instructions, and recommendations from authorities and HCPs, mHealth has given patients options to 
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seek out on their own. These choices are important – the type of platform, functionalities, and data 
collected reflect how individuals use the technology to best suit them, not how HCPs and researchers 
assume the technology should be used. 
“Others may think that an individual with a particular disease, say diabetes, needs 
treatment, but it is the individual that determines their own demand and whether they 
seek treatment.” – SH Zuvekas [117] 
With knowledge comes power. By power, I refer to the core of “empowerment” or “the process of 
gaining freedom and power to do what you want or to control what happens to you” [118]. As 
individuals with chronic illnesses choose what is important to them, they invest themselves in self-
education about their health. This leads to the power of one to take control and make health decisions, 
for themselves, in the moment. They have a greater ability to take information, including HCPs’ 
recommendations, and turn them into actions. The beauty that mHealth apps promise is the ability to 
combine data from different sources patients themselves have control of in order to get a 
comprehensive understanding of how their lifestyle choices and environment affect the status of their 
chronic condition. 
In 2010 Apple Inc. coined the phrase “There’s an app for that” [119]. Not only did this make them an 
even stronger household name, but it also illustrated the seemingly endless number of options for app 
development as well as the functionalities that already exist. For some of those with chronic 
conditions, this may have sounded like a dream come true. Those with chronic conditions have to keep 
track of a myriad of factors, from the amount of medication to sleep to BG values or other biological 
measures.  
Individuals have begun to gather an enormous amount of health data via always-available smartphones 
from not just one but possibly several devices and apps that track sleep, diet, exercise, BP, weight, 
BG, and even body temperature. Connectivity is a key functionality that has allowed for this mass-data 
collection, as well as the growing potential to extract information by linking data via Bluetooth, to 
multiple devices, and sharing data with peers, HCPs and informal carers [120]. 
Big data, algorithms, etc. are buzz words associated with one thing that all stakeholders need – 
information. Information about patterns of self-management, indications of harmful health choices, 
and opportunities for improvement lie in health measures that individuals deem relevant enough to be 
recorded.  
However, at a certain point, individuals can only squeeze so much information and knowledge out of 
app-collected data on their own and are driven to seek outside help. The first and logical options are 
HCPs. While potentially informative, without clinical knowledge and medical training, an individual 
with newly diagnosed Type 1 Diabetes (T1D) may not be able to notice that their dangerously low BG 
levels at night are due to too much insulin or too few carbohydrates before bed. HCPs are trained to 
connect the dots and have the possibility to educate individuals beyond what they can learn on their 
own via the internet or their health apps. However, some problems cannot wait to see an HCP; those 
with chronic illnesses often need answers when symptoms arise, not at the next consultation.  
With any new technology, there are both expectations of its potential as well as challenges to achieve 
these promises. Figure 4 below summarizes this double-edged sword of modern mHealth 
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technologies, for both main end-users, i.e., patients and HCPs; individuals with diabetes and HCPs 
expect a great deal from mHealth (up arrows) which are met with potential benefits and challenges 
(down arrows). 
 
Figure 4 Summary of the potential benefits, challenges, and expectations of patients and HCPs related to 
mHealth technologies. 
The modern mHealth technologies encourage and facilitate the patients’ choice in self-management, 
with or without associated clinical support. This was the foundation for the expected benefits of 
mHealth amongst patients, HCPs, and healthcare authorities alike. The main benefits were 
interconnected and included i) reduction in cost and healthcare service demand, ii) increased patient-
engagement in their health and improved self-efficacy as well as physical and mental health, and iii) 
personalized and detailed feedback from HCPs to patients based on their collected app data for 
individuals paying for medical care [60, 120].  
HCPs had hoped that these tools could be educational and provide the immediate and daily answers 
that patients demanded. They also expected that, when they would meet patients, the collected data 
would help focus the consultation discussion so that they could give more tailored advice and 
guidance to their patients. By enabling self-education and facilitating motivation, patients could more 
efficiently use existing care services and participate in more collaborative care with their HCPs [121]. 
mHealth has the ability to strengthen the relationship between patients and their HCP in a way that 
will produce better clinical outcomes.  Outside of the clinic, mHealth could theoretically enable them 
to be more adept at taking information and acting appropriately to avoid health complications, and 
subsequently, the need for more financially and resource-expensive healthcare services. In doing so, 
mHealth would give individuals the confidence and sense of control of their health that would 
ultimately ease their anxiety and improve their overall perception of their health [122]. However, the 
reality more closely resembles driving a highway of potholes to be aware of and avoid. 
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2.4 Caveats of mHealth: concerns that we must address 
In this section, I discuss that, while mHealth offers many options and benefits, there are certain 
realities – both as a part of and surrounding the technology – that should be acknowledged before 
continuing the discussion of the impacts of mHealth on patients, HCPs, researchers and health 
authorities. I introduce the main concerns, limitations, and barriers of mHealth apps for patients with 
chronic conditions, with a focus on diabetes. I also post arguments against some of the assumptions of 
mHealth’s ability to aid health stakeholders. These will be important to keep in mind when I present 
the impacts of mHealth on those with diabetes and HCPs and the role of research in the coming 
sections. 
Apps can be used to facilitate patient empowerment in the patient-provider relationship and to aid 
HCPs’ understanding of patient behavior and decision making. mHealth has affected the demand for 
the type, frequency, and accessibility of healthcare services and resources. Apps on their own cannot 
solve the problems of high demand for healthcare support; supportive services, information, 
familiarity, and training are needed. Technology requires a different type of support than health self-
management. It is understandable that HCPs are challenged by the recent expectation to provide both 
forms of support, i.e., clinical and technical [123, 124]. Some patients may need more consultations 
with, e.g., nurses about the technology, i.e., health support with a different focus. 
2.4.1 Are apps for everyone? 
Largely due to the hype of “There’s an app for that” and rapid development of technology in the last 
decade, it seems as though anything is possible - any request for functionality can quickly and easily 
become available. But technology has limitations too. 
Just as there are certain recommendations or requirements that HCPs address when they decide which 
medical device to suggest for a patient, the same can be said about apps. While these technologies 
pride themselves on being easy-to-use, not all  are as intuitive and often require a certain level of 
health- and technology literacy [125, 126]. The effectiveness of an app largely has to do with the 
capabilities of the wearable or measurement device, as well as the user’s ability to accurately take the 
measurement. The concept of “the digital divide” is an important concept when considering who the 
intended end-users are. Motivation and willingness are also essential. Some individuals who are in 
poor health, disengaged with their self-management, and/or suffer many expensive health 
complications may not willing to use this information or technology. So, while the resources may be 
available, an mHealth app is essentially useless to this group unless they receive a different, more 
tailored form of support  [127, 128].   
For HCPs, the familiarity with apps, online platforms, and other publicly available is also limited. This 
might, in some cases, be due to a lack of interest or possibly a lack of time [129]. The breadth and 
depth of HCPs’ formal health education and guidelines for how to approach mHealth and patient-
gathered data in clinical practice have not caught up with the mHealth literacy of patients and informal 
carers.  
Imagine depending on an app to warn you when your BG is too low or when to take the necessary 
medications. Then imagine that the app fails to perform as expected, leaving you, the user, to deal with 
the consequences [130]. Similarly, if a patient presents an incomplete or inaccurate data set to their 
HCP during a consultation, there is only so much interpretation and guidance that can be given 
 
20 
without all of the necessary, reliable information. This remains one of the major concerns of HCPs 
today. 
2.4.2 Quantity or quality of use: apps don’t need to be used forever to be 
beneficial 
While there has been no conclusion as to how long you have to use an mHealth technology to reap the 
promised health benefits, how and why one uses an app determines its impact. It is reported that a 
significant portion of those who download mHealth apps do not use them often or for a long period of 
time [131]. While this is often due to frustration or dissatisfaction with the app itself, people do not 
necessarily need to use an app for the remainder of their lives in order to experience benefits. Health 
intervention studies, in which the effect of using new technology is measured, may only last a few 
weeks or months and still result in mental or physical health benefits [131]. Due to the diversity of 
available apps and wearables, one could simply use an app as an informational resource or trial self-
management aid for a short period of time in order to gain the benefit of improved knowledge and 
perceived self-efficacy. One study found that participant knowledge of their health condition improved 
after only one week of using an educational app [132]. Similarly, an individual with COPD or diabetes 
could learn what factors affect them and go through trial-and-error using the app to track their 
progress for a short period of time and then implement that experience over the long-term. One study 
found sustained health benefits several weeks [133] and, for some participants, nearly a year after an 
intervention had concluded [134].  
Despite some benefits seen from guided and controlled use of mHealth in studies, the mHealth 
environment is also an area in which much false information, misinformation, and misunderstanding 
are disseminated to, and amongst, individual users. In some cases, platforms such as YouTube and 
Facebook have been used by non-health professionals to propagate anecdotal and misleading 
information regarding the efficacy of some apps [135]. Apps themselves also do not necessarily follow 
the standards or guidelines about transparency or data use, set by health authorities [136]. Reliable 
groups, such as patient organizations, urge those who seek information about apps online to be 
cautious and judicious about which sources they choose to trust with their protected or personal health 
information (PHI) [137]. This is especially true when reviewing data protection and security content, 
as it was found that many developers and their apps do not follow standards to protect users’ privacy, 
and can even share their personal data with third parties [138, 139]. Data security is one of the main 
concerns, if not arguably the biggest concern, with mHealth today due to the amount of identifiable 
and personal information stored via health apps.  
2.4.3 Big data or data overload: human computational capacity and 
interoperability limitations 
The type and density of data that you can store in a health app determines the level and quality of 
impact you can receive from that app. Theoretically, “Big Data” can provide the previously 
inaccessible answers to questions about individuals’ health, challenges, and motivations. However, 
limitations exist when interpreting data [140]. For patients, even if an app summarizes and presents 
their meta-data, determining its meaning and deciding how to respond are dependent on their 
relationship with their HCPs and their guidance, the user’s health-literacy, self-efficacy and capacity 
to sift through these different types of information. For HCPs, these limitations are mainly due to a 
lack of interoperability between information systems. For example, whether printed-out from the app 
or electronically transferred, if a patient brings sleep data and BG data that is not in the format that is 
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used by the medical electronic health record (EHR) system or familiar to the HCP, then the HCP 
cannot easily work with, let alone integrate, that data into their practice [141]. 
2.4.4 Reliability or liability: life-threatening technical errors and dangers 
of misuse 
The limitations and effectiveness of apps and self-collected data do not stop at syntax and information 
overload. The impact of mHealth is also dependent upon the reliability and accuracy of the data that is 
entered into the app [142]. Several apps offer recommendations or advice to the users about how to 
respond to their, e.g., physical activity levels, weight, or BP. As with informed decision making in any 
context, information accuracy dictates how effective health-related decisions will be, whether they are 
made by an individual, their HCP, or based upon suggestions from their apps. Connectivity also 
presents several front-end challenges for the users, such as their own technology literacy, technical 
errors when transferring data, or app updates that happen at different times, causing interoperability 
issues [143].  
Reliability and liability are also significant concerns for HCPs when it comes to app-gathered data. As 
more patients bring their apps and own-gathered data to the consultations, HCPs have to keep in mind 
that they are not only ethically responsible but also legally liable for any recommendations they give 
to their patients [144]. 
2.5 Regulatory oversight of mHealth 
In this section, I describe the regulatory landscape that we, as mHealth researchers, must take into 
consideration when designing intervention studies. Between 2008 and 2020, there have been both 
legislative and commercial efforts to respond to the questions and expectations related to patient-
operated mHealth for chronic illness self-management. Compliance with these standards and 
guidelines is one of the pillars that research stands on, to which we must adhere in order to render our 
outcomes useful and usable in real-world situations. 
2.5.1 Main authoritative bodies 
From the evaluation and regulation of single devices to scaling up, formal regulations seemed to 
change with each season, yet still not as quickly as mHealth development. The FDA approval [145], 
CE-mark [146], and other country-specific certification processed selected apps to review or called for 
app developers to submit their apps for approval. A product is granted a CE-mark and approved to be 
sold in the European Union (EU) after the owners or developers have submitted evidence of its safety 
and efficacy and have been found to meet “all relevant EU-side requirements.” These requirements 
include such standards as the “General Product Safety Directive,” ensuring that all available products 
are transparent with consumers about product risks and safety [147], and more specifically, the EU 
Medical Device Regulation (MDR) for CE-marked Digital Health Apps, defining apps based on their 
level of risk to the user [146]. The FDA has taken a similar approach by classifying apps based on 
their level of risk to the user, with apps that, e.g., provide static health information, being classified as 
low risk vs. those that offer medical advice based on patient-registered data as being high risk.  
As illustrated in Figure 2 above, the lack of targeted regulatory oversight of mobile and digital health 
between 2008 and approximately 2016 allowed for the unrestricted development of personal health 
aids. Discussions erupted over concerns for patient and data safety. Iterative attempts have been made 
by healthcare authorities worldwide to determine what research needs to test, how they should test it, 
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and what evidence is necessary to ensure the safety and efficacy of the different types of mHealth 
technologies.  
Three main issues persist. First, these activities occurred in silos, further delaying consensus, and 
realization of evaluation activities. Several organizations tried to adapt historical health device 
regulations to both the needs of mHealth and their specific agendas, e.g., region or country. For 
example, Catalonia’s Agency for Health care Quality and Assessment of Catalonia (AQuAS) 
developed evaluation suggestions based on a hierarchy or taxonomy of health apps based on a 
combination of “person-specific risk” and “intervention-specific risk” [148]. Similarly, the 
Organization for the Review of Care and Health Applications (ORCHA) both provides an own review 
process based on selected standards and published results of health and care apps [149]. The UK also 
attempted a general recommendation directed at their developers, with identified requirements that 
applied to those in the UK [150].  
To address the issue of ineffective silos, the EU and the US sought to find common ground between 
their respective regulatory policies for mHealth based on mutual challenges and goals. Both based 
their mHealth evaluations on a risk-based metric, with different levels of classification representing 
their risk to patients. While both relied upon developers to seek classification, the FDA focused on a 
sub-set of devices, and the EU’s CE-mark cast a wider net on all mHealth to receive the correct risk 
classification [151]. Established in 2010, the Memorandum of Understanding for transatlantic 
Cooperation on eHealth/Health IT has been updated as mHealth has developed, with the last identified 
update being March 2016 [152]. However, it was noted that the FDA is developing its regulations 
more quickly [151]. To the best of my knowledge, while more costly and time-consuming, the FDA 
represents the state-of-the-art in specific mHealth evaluation policies due to their ability to address 
developments in the mHealth field in their regulatory policies more quickly than other countries. By 
understanding the differences and common challenges, e.g., evolving connectivity of devices, security 
and privacy concerns, etc., between mainly the EU and the US helps us as researchers to determine the 
gaps and unmet needs of evaluation attempts. 
Second, guidelines were constantly changing in attempts to evolve in parallel with app development, 
making it difficult for stakeholders to keep up. Toward the beginning of the mHealth boom, the FDA 
took what some considered a “hands-off” approach to app regulation. In their draft guidance in 2011 
and final guidance on mobile medical apps release in 2013, the FDA states only apps that were 
comparable and could be defined as mobile medical devices, presenting a high risk to the user, would 
be regulated, and not those that presented low risk [153]. Amendments were added in 2015 and 2019 
to reflect changes in the mHealth environment and definitions related to mHealth [145]. Even 
organizations that attempted to address the issue of silos, such as the European Commission, who 
called on all member states to contribute to mHealth and telemedicine quality guidelines, still fell 
victim to the need to constantly change their discussions and recommendations [154-156]. 
Finally, enforcement of guidelines was limited. One problem is that many guidelines are “not legally 
binding,” while others require developers to identify what is relevant for them through an 
overwhelming number of regulatory documents [157]. The intention with these guidelines was that 
with quality assurance, consumers would be more likely to use the validated apps – if patients 
demanded validated and tested apps, then developers would have to comply in order to stay relevant 
and maintain their market share. Larger developers who look toward the future interoperability and 
growth of their app do attempt to follow regulatory standards and achieve certification, e.g. through 
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self-certification models [158]. However, assurance of quality did not always outweigh or outpace the 
convenience of the online-available apps for consumers, and the struggle continued to provide 
regulatory influence on the mHealth app environment [159].    
2.5.2 Governance of patient-operated mHealth 
The patient-operated mHealth technologies exist under the FDA’s purview, i.e., “premarket review 
and post-market regulatory requirements, including but not limited to registration and listing and 
premarket notification requirements” [160]. The FDA has released an updated guidance document that 
outlined how mHealth apps would be regulated in 2015 and again in 2019 [145]. In this document, 
they announced their oversight of mobile medical devices. Those that are considered “devices,” intend 
to 1) “cause smartphones, computers, or other mobile platforms to impact the functionality or 
performance of traditional medical devices”  and 2) “diagnose, cure, mitigate, prevent, or treat a 
disease or condition” [paraphrased] [161]. Figure 5 illustrates the main differences between those 
devices that will be actively regulated and those that will not be, i.e., those that research has the most 
difficulty evaluating due to the lack of specific requirements and guidance. 
*Paraphrased from the FDA guidance document [160]
Figure 5 Hierarchy of mobile medical devices identifying the focus and scope of this thesis – patient-operated 
mHealth technologies for chronic illness self-management (copied and edited from Paper 2) 
The guidance emphasizes that the level of evaluation and independent review should be commensurate 
with the risk posed. It encourages manufacturers to use continuous monitoring to understand and 
modify software based on real-world performance [162]. 
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However, there are no specific instructions for which methods and measures should be used for their 
evaluation. Several attempts were made by health researchers to evaluate this sub-group of mHealth 
technologies.  
2.6 mHealth intervention research 
In this section, I describe more aspects of mHealth to which research could respond. The focus is on 
the research practices that have the potential to evaluate the technologies that have the least specific 
guidelines to follow and, therefore, the most potential and need for research innovation, i.e., those 
considered under the FDA’s enforcement discretion. The overall aim of mHealth research can be to 
bridge the gap between the commercial and medical systems and between HCP and patients. This can 
be achieved if we appropriately and equally address the unique aspects of mHealth and the needs of 
stakeholders related to chronic condition care. I aim to describe how methods and approaches of 
mHealth evaluation are building upon – not replacing - the traditional health research toolbox 
(Appendix A). 
2.6.1 The existing “Black Box” of intervention research 
There are limitations to the depth and breadth of evidence that mHealth research can provide and, 
subsequently, what changes could be enacted in real-world settings. Appendix A provides an 
overview of the traditional methods, data, and data analysis approaches available for researchers to 
choose from when designing an mHealth study. Here I describe the limitations of the traditional pre-
post measure study design, which introduces the challenge of the “Black Box” of unknown actions 
and experiences during an mHealth research intervention (Figure 6). 
Figure 6 Illustration of the “Black Box” concept of pre-post research study designs 
The concept of the “Black Box” is most familiar in the research fields of sociology, technology, and 
engineering, referring to a process in which you can only control the input and observe the outcome, 
but not what occurs between the two [163]. In the tradition of pre-post health studies, and randomized 
control trials (RCTs), research has largely been confined to the “Black Box” approach in its focus on 
merely finding an input that, ideally, improves the output of an intervention. In 1996, Vickers noted 
that “a useful analogy for the RCT might be the black box: all sorts of completed things might go on 
inside the black box…the RCT does not answer all questions of interest in healthcare” [164]. For 
example, researchers could introduce an intervention whereby the input is the addition of a treadmill 
and a 6-month exercise regimen to the self-management routines of those with COPD. The observed 
outcome would, hopefully, be a decrease in symptoms and hospitalizations of the participants. 
However, the researchers would not necessarily know what happened during that 6-months because 
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they only took measurements before and after. They could only answer what and how much a 
measurement changed after the intervention study concluded.  
While this is an adequate level of knowledge for the efficacy of new medications or, more recently, 
medical device functionalities, the impact of which are supported by established biological truths, 
mHealth for patients self-management brings to light more human-driven factors that determine the 
efficacy and success of these new health interventions. 
 “To see the world as a self-contained mechanical realm compounded of sets of point-to-
point linear cause-effect sequences is out of date in theoretical physics (Capra, 1982), 
and it is odd that it should still have any claim in the scientific basis of therapeutics… 
What we need is a research method which devises models of and looks at patterns of 
interaction among variables, and thinks in terms of the interactive effects of mental 
expectation and physical treatment” – John Heron [165]  
However, mHealth not only relies upon more factors than standard prescription or adherence but also 
produces more unpredictable and diverse outcomes, for which there are few and unspecific standard 
methods of measurement and interpretation. A criticism by Heron succinctly described why we need 
to adapt and to look at more factors than a pre-post design in intervention research: that the controlled 
and stringent structures of medical trials tend to produce “limited and misleading view of the 
multidimensional reality within which practitioners and their patients live, work, and participate in 
therapy” [165]. 
Pre-post, longitudinal and randomized control trials are gold standards for producing reliable evidence 
thanks to their strict and unbiased designs. But – Is “what” has changed the only important factor for 
patients, clinicians, and researchers? Because mHealth technologies require evidence to be produced 
quickly and processes to be flexible enough to adapt to the ever-changing nature of these devices, and 
the different uses by patients, RCTs may no longer be the feasible or most appropriate option [166]. 
Some of the RCT characteristics that do not always fit with the needs of mHealth are i) control groups, 
as patients who enter into an mHealth trial can be disappointed if they do not receive the intervention, 
and make both healthy and unhealthy choices as a result of this, ii) because the same mHealth app, for 
example, may be used in so many different ways, those assigned to the intervention group may be too 
heterogeneous in their use for accurate analysis, and iii) the study design, exclusive recruitment 
criteria, and intervention designs are often so specific and controlled that they do not mirror real-world 
situations for end-users [167]. We might need to combine qualitative and quantitative methods of 
evaluation, without abandoning traditional standards or “reinventing the wheel”, and identify more 
continuous, iterative, and patient-involved measures to truly understand not only what mHealth 
technologies impact but “how” and “why”. 
“How” and “why” changes occur are more relevant for the HCPs, patients, and the researchers who 
are designing interventions. These two questions refer to a patients’ motivations, capacity, internal and 
external facilitators of their health self-management. While these factors do affect patients’ use of any 
health technology, there are no prescribed standards or ideal ways for how to use them [168]. The 
patient’s choice is the determining factor when it comes to how the mHealth technology will be used 
for health self-management and how effective it will be for that individual patient. These “how” and 
“why” factors have always been present, and we have simply lacked the ability to access them in 
interventions – in the “Black Box” of pre-post study designs.  
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2.6.2 Growing pains: adjusting research practice to mHealth 
While public organizations and entities attempted to direct answers to consumers [105, 164], health 
researchers have and continue to work in the background. These consumer-directed solutions are in 
effect an initial defence or Band-Aid to evaluation challenges. Researchers, on the other hand, are 
taking the longer approach of developing evidence-based evaluation methods, working to bridge the 
gap between the consumer facing world and the medical. In 2011, the American National Institute of 
Health (NIH) organized the mHealth Evidence Workshop, calling for ways in which research can 
adapt and develop new approaches to evaluate mHealth [169].  
mHealth evaluation in health research is a tall order. Challenges in research now include questions 
about i) how can we, as researchers produce a broader set of information for a more diverse set of 
stakeholders, and ii) how can we produce this evidence efficiently enough to rival the rapid 
development of mHealth technologies in the market. Many initial attempts chose to focus on one 
health area or one aspect of evaluation to avoid drowning in the diversity of uses and designs of 
mHealth technologies. Literature reviews published within the previous 10 years have focused on the 
following: barriers and limitations of two-way mHealth communication for those with diabetes, 
calling for more patient-driven research [170], functionalities and features, calling for more guidance 
and structure for evaluating reliability [171], and evidence of mHealth interventions’ impacts on 
diabetes health, with a call for a greater quality in the production of evidence [172]. Those preceding 
these approaches focused on balancing the generalizability of mHealth evaluation with the specific 
nature of mHealth technologies.   
The Mobile App Rating Scale (MARS), published in 2015, had the aim of providing evidence of an 
app’s functionality, visual appeal, information quality, user engagement, and subjective quality [173]. 
Use of this measure has shown promise because of its quick and easy procedure [174]. A strength was 
that it could be used during app development to ensure its quality before the app was released to the 
public. There was also a user-version for individuals (uMARS) [175]. However, there was some 
question regarding the diversity of apps it could be applied to as it has only been used to evaluate 
specific types of apps [176, 177]. Some studies had to supplement the scale with additional measures 
of mHealth impacts, including behavior change. While thorough and comprehensive in their approach, 
this initiative still lacked two key needs of mHealth evaluation. The first is speed - by the time these 
evaluations are completed, the technology is often outdated or has been changed significantly based on 
consumer demands. The second is patient-involvement and measures of their use, perspectives, and 
needs. As described above, the questions of “how” and “why” patients use these technologies, in 
particular, are just as important as, and even determine, clinical health change, yet is often not 
addressed.   
With the aim of providing even more accurately tailored evaluation approaches, alternative study 
designs have been proposed to meet the flexibility needs of mHealth evaluation. As opposed to 
providing one single, static intervention and study model, Micro-randomized trials (micro-RCTs) 
using mHealth technologies provide users immediately, or “just-in-time,” support for their given 
health condition based on the users’ demonstrated behavior [178]. The Continuous Evaluation of 
Evolving Behavioural Intervention Technologies (CEEBIT) approach addresses the need of a study 
intervention, i.e., the tested technology, to be changed at any time during the study. This allows the 
study to adapt to mHealth technology development as well as what is working and what is not during 
the intervention [179]. Sequential Multiple Assignment Randomized Trials (SMART) organizes a 
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study into a series of stages in which one major impact of the intervention is addressed. The outcomes 
of each stage provide information about mHealth impacts that aid future developments of the mHealth 
intervention [180].  
These adaptive study and intervention designs provide an environment that more accurately reflects 
real-world situations– with constant changes in patient needs and technology developments. However, 
these efforts resulted in partial answers regarding effectiveness and relevant information. Given the 
traditional measures, e.g., static, objective measures of physical and mental health, researchers 
struggle to measure continuous behavior change and understand how an app is used and why.  
We need to take a step back and, given what we know about how most mHealth is developed, 
consumed, governed and evaluated, ask, “Why are we not getting the answers that we aim for?” 
Perhaps what we aim for does not fit the mHealth dynamic. Therefore, if what we have been looking 
at are the effects, perhaps we should look more toward the root of our understanding. Perhaps we 
should be asking, “What should we aim to understand? How should we go about it? What resources 
should be used to gain knowledge about this field?” These questions point to the purpose of scientific 
inquiry, so that is where this discussion will lead – given the overview of mHealth as described above, 
what approach to inquiry fits the needs of mHealth intervention research? 
2.7 The purpose of science: a paradigmatic approach to 
inquiry 
The purpose of a scientific inquiry changes what and how questions are asked and which approaches, 
methodologies and specific methods and measures are used. After all, if there was only one purpose to 
research, e.g. only qualitative or only quantitative, we would be left without understanding of the 
probability and representability of our qualitative outcomes, or without real-world context and 
explanation for the quantitative outcomes of intervention groups. However, simply acknowledging the 
methods and measures used and arguing that one or the other will give us the best understanding, does 
not adequately describe the aim or purpose of research. To explain how and why we as researchers 
choose certain methods, measures and study designs, I will introduce research’s philosophical roots, 
i.e. the different logical, ontological, epistemological perspectives and specific paradigms used to 
approach knowledge generation and understanding.  
A paradigm is a “set of beliefs that guide action” [181]. It encompasses a set of values, beliefs, 
attitudes and methodologies that reflect assumptions about i) what the researcher believes is valuable 
and ethical (axiology) [182], ii) what is the nature of reality, or what is real or true (ontology), iii) the 
nature of how one knows what they know (epistemology), and iv) how one can and should go about 
discovering that knowledge (methodology an associated methods).  
Here I will focus on three relevant paradigms and discuss how these shape the assumptions about the 
purpose, nature and approaches to diabetes mHealth intervention research. The three paradigms of 
positivism, pragmatism and constructivism can be described as existing on a spectrum – with 
positivism at one end, constructivism at the opposite end and pragmatism lying somewhere in the 
middle (Table 1) [183]. Although the most widely accepted view of these paradigms is that they are 
mutually exclusive, I acknowledge that it is possible to complete qualitative research using a positivist 
paradigm. For example, from an epistemological point, it is possible to describe regularly occurring 
relationships between distinct factors in a non-statistical way [184]. However, such practice is not 
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common. Acknowledging the traditional and distinctive paradigms that have been accepted for 
quantitative (positivism), qualitative (constructivism) and mixed-methods (pragmatism) research [185] 
can help us to distinguish between the main characteristics of these different approaches to 
demonstrate the scope, limits, values and future needs of these approaches when it comes to mHealth 
interventions research. While several other paradigms exist, I will focus on the comparison of these 
three paradigms in parallel to the characteristics of the mHealth self-management realm for diabetes, 
as described above, in order to illustrate why the paradigm of pragmatism is best suited to this thesis. 
Note that while this table is a simplification and stereotype, it allows us to compare the ways in which 
most research is performed and from which dominant perspective so that we can more clearly identify 
the best combination of approaches for this pragmatic thesis. Again, these paradigms are, in fact, not 
mutually exclusive but exist on a spectrum from radical positivism to radical constructivism.  
Table 1 Illustration of the continuum of research approaches by explaining three established research paradigms 
 
2.7.1 Positivism: the objective, quantitative approach to measuring a 
single reality 
Each approach to research has its place, especially in the field of mHealth for diabetes and other 
chronic illnesses. As described in the previous sections, traditional research within medicine is largely 
quantitative and based on established, repeatable and largely generalizable patterns of biological 
occurrences, i.e. the natural sciences. In medical research, positivist approaches aim to provide 
evidence that has minimal bias and risk of misinterpretation. The outcome is largely traceable and 
relationships between intervention and outcome can largely be predicted and applied to general 
healthcare practices. The role of the positivist inquiry is to identify reliable patterns that we can, in the 
case of healthcare, base our decisions and actions upon in order to provide the most benefit to the most 
people. Its value is reflected in the progress and understanding of biological sciences and the 
successful improvement of patient care.  
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For diabetes, objectively measured relationships between, e.g. insulin, carbohydrates and blood 
glucose has provided significant benefit to individuals in their self-management practices. 
Understanding of insulin sensitivity factor and e.g. the rules of 500 and 300 have allowed for 
evidence-based yet person-specific and practical ways in which individuals can understand their own 
needs for insulin in response to carbohydrates, in order to achieve healthy blood glucose levels. A 
literature review of current knowledge of insulin sensitivity and dosing calculations demonstrates that 
the more data gathered about a phenomenon can lead to a more accurate understanding of that 
phenomenon [186].  
Deductive reasoning or logic was and still is appropriate for drug trials and other interventions 
whereby the “behavioural” portion of the intervention is limited to the individual performing or not 
performing a prescribed task such as following a medication regimen. Common positivist practices 
within research within medicine include RCTs, standardized questionnaires and surveys [185]. These 
types of studies reflect the positivist paradigm whereby objective measurements, deductive reasoning 
and the acknowledgement of one, knowable and universal reality exists [185]. It is relatively straight 
forward and expected to objectively measure “what” has changed. Physical changes can be measured 
using specially developed technologies such as BP-cuffs, professionally calibrated weight scales, or 
blood tests. While it may be easiest to associate these largely quantitative methods with such 
measurements of observable and objective results, the Positivist paradigm also acknowledges ways in 
which subjective measures, such as wellbeing and self-efficacy, can be objectively accounted for. 
Psychological changes can be measured using understanding of human behaviours, often measured via 
standardized questionnaires or surveys, which are based on established theories of societal dynamics 
and human instincts [187].  
This mentality spread from research approaches to evidence to healthcare education and practice 
[188]. The positivist paradigm is a means to make objective and evidence-based decisions – based on 
research - in care practice that can do the most good for the greatest number of people. “What” has 
changed, as the result of a health intervention, is most relevant for HCPs’ decision-making when 
treating or guiding a patient. These changes would trigger the HCP to consult their library of learned 
knowledge or established clinical protocols to determine if that course of treatment is working or not. 
It is a cycle of how healthcare practice and research continue to reflect and impact one another, which 
explains how the positivist approach became the gold standard and foundation for today’s approach to 
both chronic illness, including diabetes, care and self-management. In fact, Wilson provides a pointed 
summary of his opinion that health education and exploration traditionally has operated from a set of 
assumptions whereby health is independent of a person: 
The definition contains several implicit assumptions. Firstly, the idea that disease can be 
considered as separate from the person with it, like other naturally occurring 
phenomena. This implies that apart from the doctor's biological interventions, a disease 
will continue to run a well-defined course, quite independent of the patient's context or 
beliefs. Secondly, the inherent logic is one of simplistic cause-and-effect: substance A will 
act on substrate B, causing effect C. Thirdly, the doctor is expected to remain ‘distant’ 
from the patient, rather like a natural scientist. This implies that the interaction between 
doctor and patient would have no influence on the outcome of the disease. The ‘detached 




Wilson continues to explain how these assumptions are incorrect and inapplicable to the research of 
chronic illnesses today. While positivism’s strengths were objective, and seemingly universal truths 
about disease function in response to traceable intervention components, positivist (quantitative) 
approaches to research on mHealth interventions do not give concise and actionable results. The 
understanding of more social sciences, in addition to natural sciences, is required for mHealth and 
diabetes care. The following aspects of diabetes and mHealth demonstrate this need: i) behaviour is a 
significant determinant in both type 1 and type 2 diabetes, ii) motivation, intention and ultimate action 
affects the benefit of mHealth, and iii) the diversity of mHealth technology uses clouds, to a certain 
extent, any cohort study (i.e. the basic assumptions of positivist approaches and objectivity, i.e. that 
reality is only that which can be observed by human senses, do not hold). In other words, positivism 
tries to focus on more objective factors than individuals’ motivations, intentions and beliefs. 
Positivism can lead to the identification of patterns within observations but does not seek to 
understand why they are happening. For non-communicable chronic illnesses, including diabetes 
which is by definition is an illness dependent upon behaviour, this traditional doctrine, on its own, 
does not begin to scratch the surface of describing how diabetes care is or should be treated. 
2.7.2 Constructivism: a subjective, qualitative approach to 
understanding different realities 
While the positivist approach can provide a solid foundation of “what” can change, the interpretivist 
or constructivist paradigms, with their inductive reasoning, came about – yet only gaining popularity 
recently in the 1960’s and 70’s- as a response to the limited knowledge of “why” something has 
occurred [185]. Constructivism, characterized by qualitative approaches to inquiry, is more 
appropriate when the purpose of the research is to understand, for example, satisfaction with 
healthcare services and potential improvements to better engage individuals. It is the belief of 
constructivists that by understanding an individual’s perception and experiences of, for example, their 
diabetes health, researchers can better explain and/or explore patterns in individual’s behavior, e.g. 
motivations. In practice, constructivist researchers put this ontology and epistemology into practice 
using more interactive methods than positivism suggests, such as interviews, focus groups and/or 
observation of participants’ every-day lives. This allows for previous assumptions and knowledge to 
be questioned, reassessed and updated given the more recent contextualized findings [185]. Within 
diabetes and intervention research, it is only through the qualitative approach that previously 
unaccounted for factors can be brought to light, and the impacts of which on the topic of inquiry 
explored.  
Such qualitative inquiry and social science perspectives were considered a revolution to the health 
sciences when they were argued for in 1995, as an alternative to quantitative methods for 
understanding health [190]. While healthcare professionals considered RCTs as the gold standard - a 
valued positivist tool in medical research - many found it difficult to apply the RCT interventions and 
achieve the same outcomes as were demonstrated in published studies. In the case of diabetes, 
although a technology such as an insulin pump or continuous glucose monitor has been validated for 
its biological effectiveness, its ease of use and practicality affect an individual’s willingness and 
ability to use it. So regardless of any beneficial impact it has shown from the positivist perspective, 
from the constructivist approach, a person’s decision to use the tool and how they use it has the 
greatest impact on the technologies’ effectiveness. Like the positivist paradigmatic approach to 
understanding health outcomes, constructivism applied to mHealth research does not give concise 
results. However, it can lead to new knowledge and actionable outcomes when, more or less, 
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generalized by identifying technical patterns from lay accounts of stakeholders’ experiences, 
“constructing models of typical meaning” [191] or theories to explain a situation, i.e. the use of 
mHealth in diabetes consultations, which can then be further explored.  
On the other hand, pragmatism as a “middle ground” focuses on how best to approach the field and 
formulate the research questions, without loyalty to one of the aforementioned paradigms. More 
importance is placed on exploring a situation or phenomenon instead of coming to a conclusion about 
that phenomenon. The pragmatist paradigm encourages researchers to approach a situation with the 
assumption that there is a single reality that periodically changes with time, which is possible to 
observe and interpret from different perspectives [192]. I continue this section by exploring the middle 
concept of the pragmatism paradigm and its appropriateness for diabetes and mHealth intervention 
research using mixed-methods. 
2.7.3 Pragmatism: a mixed-methods approach to gaining knowledge 
about mHealth intervention research for diabetes 
This thesis uses diabetes as a case, via the FullFlow Study, to explore how mHealth can help 
researchers adapt to the rapid change in technology used for individuals’ own chronic illness self-
management. mHealth technologies for self-management is a relatively new and unexplored field; 
systematic reviews have not led to a consensus about the medical impacts of, e.g. smartphone apps and 
wearables. Even while some systematic reviews suggest the potential medical benefits of using 
mHealth apps in conjunction with regular diabetes care coordinated via an HCP, they still do not 
answer how these can be accomplished in real-world practice [110]. Whereas positivist and 
constructivist paradigms have been most commonly seen as mutually exclusive- focusing on different 
phenomenon- I side with Johnson in his 2011 article describing Pragmatism as “dialectical pluralism”  
[193]. In this perspective, mixed-methods researchers can combine approaches to understand, not 
conclude on a single truth to explore multiple perspectives, accepting contradictions and basically 
living the phrase “it depends” through their practice and interpretation of research. Research fields or 
disciplines do not, and should not, “own” certain methods. If so, then researchers are deprived of 
resources when they are prevented from looking beyond the current trends in their own field of 
expertise. The benefit, Johnson argues, is that by approaching research in such a way, it is possible to 
bridge understanding between the varying values of different ontologies, epistemologies and methods. 
However, an important concept to keep in mind is that, due to the pragmatist assumption that reality 
changes with time, researches’ ability to generalization outcomes is affected by time. In other words, 
generalizations may become less relevant or outdated given changes in the context and/or the 
progression of time. 
In this section, I will explain how pragmatism reflects the needs of such research by separating out the 
three main concepts: i), mHealth interventions research, ii) mixed-method research, iii) diabetes self-
management, care and research (Table 2). I will use the background of these three concepts, as 
described until now, to demonstrate how the pragmatist approach from the perspective of dialectical 





Table 2 Summary of how the characteristics of Pragmatism paradigm from the perspective of dialectical pluralism 
is an appropriate lens through which to understand the three main concepts of this thesis: mHealth, mixed-














• Aids patients in understanding their 
own health from perspectives of 
BG levels, impact of activities and 
decisions on health etc. 
• Aids healthcare providers in 
understanding their patients’ self-
management status more 
continuously 
• Exploratory 
• Explanatory  
Requires understanding 
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can explain why, 











decisions and actions 
on health status 
The success of 
treatment requires: 
• Deductive reasoning 
based on clinical 
measures 
• Inductive reasoning 
based on a person’s 
experience of their 
health to determine 












• Recording BG, diet and other 
quantitative measures in a standard 
way is objective.  
• Reflecting on these measures allows 
for individuals subjectively judge 
the appropriateness and success of 




and measures explored 
via e.g. triangulation 
• Disease is objective 
• Illness is subjective.  






















• Patients, healthcare providers and 
authorities, informal carers and 
developers have different agendas 
and perceptions of what is needed 
to support diabetes care (including 
differences within groups).  
• The purpose and intention of app 
use changes with time and a 
person’s increased knowledge/ self-
efficacy and their provider’s 
understanding of the patient’s 
situation and the technology  
• While people may use the same 
app, they may use it in a different 
way.  
• Different geographical regions and 
other contexts either support or 
challenge individuals' use of 
mHealth, which affects their 
experience.  
• Interdisciplinary 
research teams are 
often used  





• Triangulation of 
interpretation of data 
from related yet 
different studies 
• Health influenced by 
behaviour 
• Illness is a personal 
experience affected by 
available resources, 
personal beliefs etc.  




• Experiential learning  
• Generalization has 
been practiced in the 
clinic yet is being 
questioned as the 
appropriate approach 






Use the most 
appropriate 






• The different functionalities allow 
for a variety of different uses. 
• Patients, and to some extent 
providers, can choose to use 
mHealth in the way that best fits 
their needs, i.e. heterogeneous 
intentions. 
Different ways in 
which qualitative and 
quantitative measures 
can be used and 
interpreted depending 
on the study and 
research questions 
• Self, health and 
technology efficacy 
based on experience.  
• Tailorable approaches 
to care being 
promoted in clinical 
treatment  
 
Pragmatism for diabetes research 
Annemarie Jutel describes it clearly and distinctly when she writes “disease is diagnosed, illness is 
not” [194]. Instead, “illness is the personal experience of sickness” in which a person experiences 
disruption to personal function as a part of society. As such, this concept of illness is affected by 
culture, external resources, self-efficacy etc., whereas, in the traditional biomedical model, disease and 
diagnosis are reflective of measurable biological dysfunction. This distinction between terms will help 
us to differentiate between what healthcare providers and individuals aim to achieve through self-
management of an individual’s illness, disease or both. This acknowledges that the distinct yet 
interconnected roles of patients and providers in the reality of diabetes care, which must act and exist 
separately and together. This complex adaptive system clearly calls for the ontology of Pragmatism, 
which can compensate for the diversity of moving parts and influencing factors in order to determine 
the needs of both parties separately, i.e. self-management and clinical care, and together, i.e. as a 
collaborative team in consultations (a goal of healthcare as described above). Both in clinical practice 
and self-management, the abductive logic of Pragmatism describes how patients and providers can use 
deductive reasoning to assess the individual’s health status using, for example, blood glucose levels 
and HbA1c values, respectively, as well as inductive reasoning to understand if a suggested self-
management recommendation or change is feasible given the individual’s personal situation.  
Understanding the concept that all input is considered differently yet equally is necessary when 
considering the various stakeholders, their priorities, needs and roles in diabetes care that are required 
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to work together to achieve interacting goals, the modalities to which evolve as technology and 
knowledge evolve. For example, while all may share the goal of improving an individuals’ diabetes 
health, their motivations may vary from personal, e.g. the individual hopes to feel better and regain 
their loss of social function or wellbeing, to systemic, e.g. health authorities wish for those who can 
effectively self-manage on their own to do so in order to reduce the burden on health services. 
Given the variety of medical, mHealth, social media and other channels of support, the Pragmatist 
epistemology of “use what works” is most appropriate when patients and providers make these 
recommendations. For example, the generalized treatment recommendations and “approved practices” 
historically have only been to prescribe insulin to those with T1D and not those with T2D. However, 
healthcare providers have found that more tailored approaches are called for to fit the needs of those, 
in this case, with insulin dependent T2D, which are reflected in The Standards of Medical Care of 
Diabetes – 2020 [195]. 
As described by Maarouf [192], “The Reality Cycle” is a reflection of the ontology of pragmatism 
whereby knowledge is both built and evolves with time based upon new realizations and experiences. 
This cycle parallels the assumptions of diabetes self-management; the meaning and intention of an 
individual’s diabetes self-management, use of health aids and healthcare services change with time. 
Examples of this change are a (hopefully) increased knowledge and self-efficacy as well as an 
improvement in their provider’s understanding of their situation. Diabetes is their reality - which has 
measurable and theoretically predictable patterns of change, i.e. how diet or insulin affect blood 
glucose levels - but which is also experienced differently - it is shaped by a person’s internal and 
external context.  
Pragmatism for mixed-methods research 
Mixed methods research values i) the complementarity and utility of multiple methods but also 
paradigms as well as iterative applications of inductive and deductive logics, ii) a range of research 
scopes from the empirical to conceptual, iii) acknowledging that the phenomenon in question are also 
living things – not static or universal [193]. Contexts that more commonly call for mixed-
methodologies include health services research as a whole and more specifically . These represents 
“complex adaptive systems” of interconnected actors and influences, of which diabetes care is an 
example. Mixed-methods are becoming more common for diabetes self-management research as the 
qualitative understanding of an individual’s behaviour, also through the aid of mHealth technologies, 
is seen as just as influential to understanding the impact of an intervention as quantitative clinical 
knowledge is about biological function. 
A quick search through PubMed database using the search string [review AND diabetes AND mixed-
method*] revealed few literature reviews for mixed-methods studies of adults with diabetes within the 
past 20 years found n=14 articles [196] and n=59 studies [197]. This demonstrates that while there is 
potential of understanding the addition of input and knowledge from “patient experts” to diabetes care 
research, it is not commonly practiced. Of the14 studies performed, it was found that the majority of 
mixed-method studies focused on the nursing profession, i.e. more patient experience related, rather 
than the medical profession, i.e. more clinically relevant information. This suggests that knowledge 
generated through mixed-method studies does not include nor is it transferred to clinicians. The lack 
of clinician participation and focus has a significant impact on how clinicians approach diabetes care; 
it perpetuates the lack of information and knowledge transfer about patients’ experience and its impact 
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on diabetes care, to clinical practice and education. Instead, this suggests that the majority of the 
information that clinicians use for their evidence-based practice remains positivist, objective and 
quantitative.   
Pragmatism for mHealth research 
mHealth exists in a constantly changing world, and is affecting the world of health practice. The fact 
that these technologies were developed outside of the traditionally objective and positivist realm of 
medicine contributes to the need for research to develop “knowledge” instead of searching for 
“answers”. Pragmatists believe that the ability of something to function in a way that helps the user to 
achieve their purpose or goal [198] parallels the diversity of potential uses of mHealth technologies 
which are based on the intention of the user. Dewey, a prominent philosopher of pragmatism, valued 
the understanding of the relationship between actions and consequences – another concept that is 
reflected in one of the primary purposes of mHealth, as a learning tool. The epistemology of 
pragmatism is that knowledge is based on experience [199] also parallels the idea that individual users 
of mHealth technology are “experts” in their own right, similarly to the expert knowledge of HCPs. 
Users can gather evidence of their self-management and reflect upon consequences of those actions. 
Individuals, as well as their care teams, can then learn from those decisions and outcomes in order to 
make better, more effective decisions in the future. As such, users of mHealth for diabetes can be 
described as pragmatists; they decide the best action to take to optimize beneficial consequences or 
outcomes based on their experience, i.e. gathered knowledge about their situation.  
3 The Ph.D. setting, objective, research questions 
The main objective of this thesis was to explore how we as researchers can adapt our inquiries about 
the use and impacts of mHealth, with the goal of providing more relevant and practical knowledge that 
is useful for mHealth stakeholders. Ultimately, I hope that this thesis will bring understanding to the 
conversation of mHealth in medical research and, subsequently, health care. 
3.1 The thesis: part of a larger mHealth intervention project 
In this thesis, I explored relevant approaches, methods, and measures that could be used during health 
intervention research to understand the impacts of modern mobile health (mHealth) technologies. 
These works were completed as part of a larger project, Flow of health data between patients and the 
health care system (FullFlow). The FullFlow Project was funded by the Norwegian Research 
Council’s IKT Pluss program and coordinated through the Norwegian Center of E-health Research  
(NSE). The Full flow project acted as an environment in which I could test specific approaches 
methods and measures to determine what effects we could measure and information we could gather 
from introducing patient-gathered app data to diabetes consultations.  
The FullFlow Project itself aimed to design, develop, and test a system for sharing patient-gathered 
diabetes data from patients’ mHealth devices to their healthcare providers (HCPs during consultations. 
The intention was to design and test a system that would enhance collaboration between patients and 
their providers related to diabetes treatment and self-management decisions by identifying and 
presenting relevant data to act as the basis for discussion.  
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The approach of both my thesis and the activities of the FullFlow project (2016-2020) was to explore 
how mHealth could be used as part of the intervention as well as a means of data collection through a 
series of smaller research activities followed by tests of learned concepts as larger studies. Included 
were the challenges and opportunities that mHealth brings to medical research and services. In doing 
so, we aimed to systematically understand the complex, fast-paced and interdisciplinary nature of 
sharing patient-gathered data (PGD) from mHealth technologies. Concepts that were found to be 
feasible and sustainable in this environment were pursued in the central FullFlow Project activities.  
My Ph.D. included four central studies, detailed through the four main, chosen papers: a literature 
review to gain a basic understanding of this area and use three cases. I tested theories for how 
researchers can utilize mHealth approaches and resources to address the opportunities and challenges 
of evaluating medical and health research interventions. These followed the sequential exploratory 
strategy. 
The introduction of mHealth technologies, approaches, and resources has certainly affected 
expectations and opportunities of research for chronic illness health interventions. With diabetes as a 
use-case, I will exemplify how these technologies answered patients’ demands for support and how 
this, in turn, presents opportunities for the medical system to adapt, which evidence research should 
and could produce.  
3.2 The setting of Ph.D. activities 
In this section, I describe the regional setting of the Ph.D. activities with a focus on the population, 
health status, and healthcare access. I aim for this information to provide context to the 
generalizability and limitations (described below) associated with living with T1D or T2D or similar 
chronic conditions.  
Tromsø, Norway: a region of northern Norway, situated north of the Arctic Circle with a population of 
approximately 167,000 (2019). Approximately 65% of the population is between the ages of 15-64 
years old [200].  
Population: Residents of Norway enjoy a relatively high average income compared to other EU 
countries. Employment rates are steady, with only a -0.1% decrease from 2018-2019. In Norway, 80% 
of employees in the fields of “human health and social work activities” were female, with nearly 
12,000 employees in Tromsø between the ages of 15-74 as of 2019, showing an 800 employee 
increase since 2016 [201].  
Health overview: When compared to EU statistics, Norwegians fare significantly better with regards 
to mortality rate, unmet healthcare service and support needs, and health status. Norway also has the 
highest life expectancy of 82.7 years, compared to the EU average of 80.9 years (2019). A contributor 
to this is a decrease in risk factors, including alcohol consumption, smoking, and obesity in the past 20 
years. While these are still less than the EU averages, poor diet and tobacco use are associated with 
15% of deaths, each, in Norway. Leading causes of death in 2016 were noted as COPD and heart 
disease. Following the global trend, obesity is also a growing concern among children (16%), and 
adults (14%) [200].  
General access to care: All residents have access to public healthcare services and resources with 
universal care in Norway. Healthcare is referral based, meaning individuals must go through their 
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assigned general practitioners (GPs) in order to seek specialist care. Within this sector of services, 
patients pay an annual maximum of just over 2,000 NOK before receiving care free-of-charge. Out-of-
hours and emergency services are also available. Individuals may have access to private specialist care 
more quickly if they are willing to pay out-of-pocket [202]. Care for those with chronic conditions 
accounts for 28% of total care spending, which is significantly higher than that of other EU countries 
[200].  
General healthcare providers: Each GP office has from 2-10 GPs practicing at any time, each 
operating as individual economic entities, with the addition of nurses in some surgeries [200]. While 
patients are assigned to a GP, they have the option to change GPs.  
Specialist and hospital HCPs: Prevention rates for chronic illness complications in Norway is second 
only to Denmark, meaning less unnecessary hospital admissions [200]. Hospitals work as a network, 
with one central hospital in each region surrounded by hospitals with more capacity for acute care. 
Waiting times are still an issue for elective procedures [200]. 
3.3 Objective 
In this thesis, the purpose of mixed-method research is to measure changes and reasonably explain the 
correlations between, as well as differences, deviations and variations of outcomes. The way in which 
the methods and results are presented should of course be detailed in such a way that others can 
replicate the activities and draw their own conclusions to contribute to the foundation of knowledge 
that research, or in some cases, draw conclusion about the positive and/or negative impacts of a health 
intervention. However, the aim of this thesis is not to conclude upon or disprove the effectiveness of 
other research methods or health interventions, based on the paradigm of pragmatism. The aim of this 
thesis is instead to contribute to the foundation of knowledge – of understanding – upon which we 
base our future research and questions and actions related to mHealth interventions for diabetes self-
management. 
3.4 Research questions 
RQ1. What information, support, and functionalities do patients, general practitioners, and specialists 
who work with diabetes, need and expect from mHealth tools?  
RQ2. What approaches, methods, and measures are being used to collect data for the evaluation of 
mHealth interventions for chronic illness self-management?  
RQ3. Can mHealth usage-logs and patient-centred analysis be used to provide more evidence and 
information about what, how, and why changes occur during an mHealth intervention? 
RQ4. How can mHealth approaches and resources supplement traditional methods and measures in a 
protocol describing how to measure impacts of an mHealth intervention on patients and HCPs? 
The structure of this thesis is to first present the methods that were used to address the research 
questions. In the Methods and Materials, I will describe the main purpose of each method and how it 
was used in this thesis. In the Results, I present the outcomes of utilizing mHealth approaches and 
resources in these methods via four papers. These papers describe the major results of our use of 
trialled methods. The discussion and conclusion cover how these works contribute to our 
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understanding of how intervention research can incorporates mHealth approaches and resources to not 
only address the challenges and opportunities that mHealth technologies present to patients and HCPs, 
but also to researchers and health authorities. 
The works described in this thesis (Table 3) illustrate a step-by-step process through which I i) explore 
what both patients and HCPs deem important and relevant, ii) identify the state-of-the-art for how 
researchers are evaluating modern mHealth interventions, and iii) trial two ways of incorporating 
mHealth approaches and resources into the evaluation of an mHealth intervention for sharing patient-
gathered diabetes data, which aimed to meet the needs of patients and HCPs. 
Table 3 Corresponding methods and results that address each Research question 
 Research question Methods used Results published 
in…  
RQ1 What information, support, and 
functionalities do patients, general 
practitioners, and specialists who work with 
diabetes, need and expect from mHealth 
tools?  
- Patient survey and HCP 
workshop 
Appendix C 
- Co-design workshops Paper 1 
RQ2 What approaches, methods, and measures 
are being used to collect data for the 
evaluation of mHealth interventions for 
chronic illness self-management? 
- Grey literature review Appendix D 
- Scoping literature review Paper 2 
RQ3 Can usage-logs and patient-centred analysis 
be used to provide more evidence and 
information about what, how, and why 
changes occur during an mHealth 
intervention? 








RQ4 How can mHealth approaches and resources 
supplement traditional methods and 
measures in a protocol describing how to 
measure … 
Development of a mixed-





…impacts of an mHealth intervention on 
patients and HCPs? 
Feasibility study results Appendix G-J 
Appendix L-O 
3.4.1 Candidate’s contributions to thesis studies and papers 
Each of the smaller and more iterative studies described in this thesis culminated in larger studies to 
confirm and expand upon the results found during the smaller studies. These larger studies are 
described in the thesis Papers 1-4, while the smaller studies are detailed in the appendices. My 









































X N/A X X X X X X X 
Paper 1 X X X X X X X X X 
Appendix 
D 
X X X X X X X X X 
Paper 2 X X X X N/A N/A X X X 
Appendix 
E 
 N/A     X X X 
Appendix 
F 
 N/A     X X X 
Paper 3 X X X    X* X** X 
Paper 4 X X X X  X X X*** X 
Appendix 
G-J**** 
X N/A X X X X X X X 
Appendix 
K 
X X X X N/A     
Appendix 
L-M**** 
X N/A X X X X X X X 
Appendix 
N 
X N/A X  X     
Appendix 
O**** 
X N/A X X N/A X X X X 
Appendix 
P 
X X X X N/A X X X X 
Appendix 
Q 
X X X X N/A X X X X 
*Cleaning only 
**Guided by second author of the paper (I contributed approximately 40% of the analysis) 
***Data analysis and interpretation of data as a result of the study protocol provided in Section 6.5  
**** All of these activities were part of the mixed-method feasibility study (the protocol for which is described 
in Paper 4) 
 
Journals allow us to designate (via symbol in the author list) who contributed to the study and 
manuscript. According to the Vancouver rules, those who contributed to the study and/or manuscript 
should be offered co-authorship. However, it is not always possible to differentiate which persons 
contributed to the study vs. the manuscript. In the manuscripts included herein, many of the co-authors 
contributed primarily to the study design and coordination and therefore are listed as contributing 
equally, and, yes, were involved in approving and editing the manuscript but were not equal 
contributors during that process compared to myself and co-authors listed in more senior positions of 
the author list. That being said, I am sole first author for all four manuscripts included in this PhD 
thesis and include details in Table 5. 
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journal (role of 
corresponding 
author***) 
1 X X X X X X 
2 X X X X X X 
3 X X X X X**** X 
4 X X X X X X 
*Co-authors for each manuscript were invited based upon their expertise in that particular field to guide the
appropriate and clear methodological approach
**Included: requesting and incorporating input from co-authors for each major draft of the manuscript as well as
editing the manuscript in response to journal reviewers’ and editors’ comments.
*** Included: securing and coordinating publication funds and being solely responsible for all tasks of
submission and publication once accepted
****Drafts and confirmation of figures used in Paper 3 were secured through second author of the paper
4 Materials and Methods 
I present the type of information that can be obtained by using mHealth-enabled research approaches 
including a) involving end-users throughout a research project, b) utilizing data and associated 
information that end-users gather by using mHealth and c) using a mixed-method approach to more 
comprehensively understand how an mHealth intervention can affect patients and providers together. 
Based on the description by Onwuegbuzie and Combs (2010), this project involved analytical 
techniques of mixed-methods research that are applied iteratively, largely following pragmatism as my 
research paradigm. I use the purpose/rationale of i) triangulation of the data (using multiple sources 
and analytical approaches, often involving an interdisciplinary team to increase 
credibility/applicability of research outcomes, i.e. understanding of a phenomenon from multiple view 
points by comparison and integration of quantitative and qualitative results gathered from different but 
related studies) [203], and ii) exploration (understand a phenomenon and test propositions resulting 
from earlier qualitative phase, in a “Sequential exploratory strategy” [204], which is often used when 
designing a new tool or intervention. We followed the design type, as described by Subedi as a multi-
phase design [205], following the phases of i) deciding an overall project objective, ii) performing a 
qualitative study (or studies), which informed iii) another qualitative or quantitative study, which 
informed iv) a mixed-method study (Figure 7).  
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Figure 7 Details of the sequential exploratory strategy of inquiry for the presented thesis 
The aspects of pragmatism that are reflected in this thesis include subjective researchers, involvement 
of end-users in the iterative design and testing of the intervention, basing the design and purpose of 
subsequent studies within the project on end-users’ needs and priorities in diabetes care, flexible and 
exploratory study designs, the intention of applying gathered knowledge to an eventual possible 
solution to the initially identified problem. 
4.1 Co-design workshops 
A series of co-design workshops were arranged to understand the end-users’, i.e., both patients and 
HCPs, needs for a system to share diabetes app data during consultations. These activities aimed to 
answer RQ1 and were carried out as part of the FullFlow Project.  
Co-design, or Experience-based co-design (EBCD), is a participatory research method whereby those 
who would be the end-users of a product or service are invited to help design and develop said product 
or service [206]. By addressing specific users’ needs and understanding their expectations, co-design 
aims to produce something that will be used sustainable and perform the way in which the end-users 
need.  
In the case of the FulFlow project, it was intended that the data-sharing system be operated by both 
patients and HCPs, together. The design and development of the system itself needed to be informed 
by i) both HCPs’  and patients’ reported needs related to diabetes care, and ii) which questions and 
activities could be used during the workshops to empower these two end-users to offer input and 
constructive ideas about how mHealth could meet those needs.  
4.1.1 Patient survey and co-design workshops with HCPs 
The series of co-design activities aimed to address these points began in 2016 with an anonymous 
survey, which was accessible via a link posted on various patient Facebook groups in Norway. 
Questions were multiple choice and addressed i) the patients’ ideal consultation discussion, given the 
chance and time to share their own app-gathered data, and ii) their experienced diabetes self-
management challenges. Patient responses were then presented to HCPs during a workshop. HCPs 
were called upon to i) comment on these responses in general and ii) imagine how a system for 
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sharing patient-gathered diabetes app data should function during a consultation to address the 
reported needs of the patients and clinical practice of GPs and specialists in diabetes care. The HCP 
workshop was audio-recorded, transcribed, and translated into English for analysis.  
4.1.2 Co-design workshops with both patients and HCPs 
The results from the separate patient and HCP co-design activities were used to inform the design of 
joint workshops. Building upon these results, we held two final workshops: one in 2017 for patients 
with T1D and diabetes specialists, and one in 2018 for patients with T2D and general practitioners. 
Each workshop consisted of three sessions: one for patients and one for HCPs in the mornings and a 
joint session, including both parties in the afternoons. By conducting joint sessions – an uncommon 
approach due to the typical hierarchy experienced during clinical consultations - we aimed to 
demonstrate the amount of information that could be gathered by encouraging both patients and HCPs 
to discuss opportunities, challenges, and solutions for an mHealth data-sharing system, together.  
The discussion guide for the separate sessions included an introduction and ice-breaker, followed by a 
series of rapid-fire and discussion questions. Rapid-fire questions allowed participants to establish 
their own opinions, without interference from others, before group discussions. Discussion questions 
allowed participants to reflect upon their own and one another’s responses. Included questions 
addressed a) participants’ perceptions of their roles and responsibilities in diabetes care and mHealth 
and b) the potential of sharing patient-gathered data during consultations. 
The discussion guide for the joint session allowed patients and HCPs to collaborate on the design of a 
system for sharing patient-gathered data during diabetes consultations. Participants were asked to 
summarize the main points from their separate sessions to one another and discuss their ideas and 
designs for the ideal mHealth data-sharing system. Activities were structured in the same way as the 
separate patient and HCP-sessions, rapid-fire, or “post-it note,” questions followed by discussion 
questions. However, the topics of these questions now focused on ideas for what, how, and when the 
ideal system for sharing patient-gathered mHealth data with HCPs during diabetes consultations 
should be conducted. Finally, we invited participants to “Design-It-Yourself” and design a paper 
prototype. We provided paper representations of functionalities, information, and technologies that 
they could use to build their own paper prototype of such a system. Each session was audio-recorded, 
transcribed, and translated from Norwegian to English for analysis. 
4.1.3 Analysis of workshop transcripts 
An abductive approach [207] was taken to thematic qualitative analysis, which was performed on each 
of the seven transcripts (one for the HCP only workshop and six for each session of the separate and 
joint patient and HCP workshops). Narrative summaries were created for each transcript and shared 
amongst the participating researchers to ensure a common understanding of patients’ and HCPs’ 
perceptions and expectations of mHealth and data-sharing. The abductive approach allowed us to 
deductively answer the research questions posed prior to the workshops by identifying broad themes 
and then inductively build more specific and emergent topics [208]. While there is no standard for 
how to perform an abductive approach to thematic qualitative analysis, the inductive approach was 
applied as independently from the deductive approach as possible; several weeks were taken between 
the generation of seams and more detailed review of the transcripts to identify emergent topics. Codes 
were generated for each time someone spoke. Common initial codes were grouped into secondary 
codes, i.e. pertaining to more than one code, and then sub-themes. These sub-themes were then 
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assigned to the most appropriate theme that was generated from the deductive approach. Paper 
prototypes were paired with their associated quotations from patients and HCPs that described which 
and how data should be presented, discussed, and used by both patients and HCPs during diabetes 
consultations. 
4.2 Literature reviews 
Literature reviews aimed to answer RQ2. While the FDA provided requirements for how to assess 
those mHealth technologies that qualified as “actively regulated,” they did not provide clear 
expectations for how to evaluate those under “enforcement discretion” (Figure 4) [160]. For mHealth, 
evaluations are not confined to medical or health research environments, and different, relevant 
information can be found in both scientific and grey literature. Both forms of the review were 
conducted with the intention of identifying all approaches, resources, methods, and measures being 
used by professionals in a variety of fields to understand the impacts of mHealth technologies on 
stakeholders, with a focus on patients and HCPs.  
Scientific literature is produced by researchers, and published and controlled by commercial journals. 
Within the scope of mHealth for self-management, this literature describes how researchers choose to 
structure an evaluation and which questions to ask to answer a specific question about a health 
intervention. A scoping review of the literature specifically aims to provide a foundational 
understanding of a novel field of research, or one in which limited information has been published 
[209]. 
While scientific literature produces results of research activities, grey literature includes documents, 
websites, and other forms of information generated by government or business organizations, industry, 
or academia [210]. In attempts to comprehensively address the large-scale, i.e., regional or national 
impacts of mHealth technologies, independent organizations developed evaluation frameworks, 
guidelines, and services to meet the information and evidence needs of app consumers.  
4.2.1 Grey literature review 
Grey literature reviews are used to identify reports, research project outcomes or results that have not 
been published in scientific journals, government documents, website information, news or social 
media articles and other forms of information surrounding medical research and practice both 
including and not otherwise found in scientific databases. While there is no one standard protocol for 
performing grey literature reviews, “databases of media reporting” and “internet search engines” are 
likely places to find grey literature [210].  
A 2017 grey literature search was conducted to identify reports, government websites, statutes, and 
policies, published and available online in English between 2013 and 2018 that address activities 
related to the evaluation of mHealth technologies within the EU and were ready and available for 
immediate use by stakeholders. GoogleScholar, Google and PubMed were searched using iterations of 
the following terms: [activity-performed] evaluation, evaluate, assessment, validat*; [type of 
technology assessed] “mobile health”, mHealth, eHealth, app*, tablet, wearables, sensors; and 
[resulting recommendations] framework, checklist, service, report, strateg*, toolkit, model, guidance, 
process, recommendations. Focus was placed on working frameworks i.e. those that are already 
implemented, final and published evaluation plans, guidelines and statutes. Ongoing research and 
development studies aiming to design and evaluation framework were excluded, as these were not yet 
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ready for implementation or to be used by stakeholders. Two authors reviewed the identified 
documents independently. Only initiatives and frameworks describing nonmedical devices (see Figure 
5) were considered.  Press releases or initiatives that had been cancelled by the time the search was
performed were excluded. Data were extracted on the following topics: framework type, name,
country of origin, responsible organization, target audience, mHealth criteria assessed (e.g., usability,
privacy, etc.).
4.2.2 Scoping literature review 
A scoping review was conducted in 2019 to identify the methods and measures that health intervention 
researchers had used to evaluate the impacts of mHealth apps and systems. While systematic and 
meta-analysis literature reviews focus on combining and curating outcomes of health studies, scoping 
reviews are meant to provide overviews for new or relatively new field, to provide better 
understanding of some aspect of that field, which mobile health is [209]. As noted in one scoping 
review of diabetes management and mHealth technologies, “Alternative study designs and more 
rigorous methodologies are needed” [196]. To provide a foundation of where current research is on 
this topic, we aimed to gather an overview of current approaches to measuring the impact of mobile 
health technologies.  
We focused our search on the period 2015-2019 based upon the, at the time, the most recent update of 
the relevant FDA documents describing the expectation and information needs regarding mHealth 
evaluation [160]. We chose to explore a sub-section of mHealth intervention studies, i.e., those that 
employed always-available technologies intended primarily for patients’ self-management of six 
major chronic conditions. In doing so, we could represent both the approaches to patient self-
management of chronic illnesses through mHealth technologies as well as how researchers have 
approached the testing of mHealth technologies that did not fall within the purview of actively 
regulated medical devices by healthcare authorities and certifying bodies. 
Table 6 describes the search strategy used to identify scientific literature describing the evaluation of 
the lower-risk, patient-operated mHealth technologies that were used for the self-management of 
chronic non-communicable diseases (NCDs). We searched PubMed, ProQuest, Medline, and 
GScholar for literature published between 2015-2019, in English. 
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Table 6 Scoping review search strategy 
 
Inclusion criteria were that studies described interventions that: 1) were intended primarily for adult 
patients to use for the self-management of their own chronic NCD, 2) allowed patients to register and 
review their data on “always available” devices, and 3) aimed to evaluate, test or assess an mHealth 
intervention.  
Titles and abstracts were screened for information that met the inclusion criteria. We extracted 
information regarding which methods and measures were used to evaluate mHealth app or mHealth 
system interventions. Data extraction also included the name of the intervention (if applicable), 
included technologies, study design and duration, health condition, and the participants. 
4.2.3 Analysis of literature reviews 
For the grey literature review, two co-authors reviewed the identified documents and extracted data 
independently. Due to the observed heterogeneity of the identified documents, all co-authors discussed 
what would characterize similar frameworks and distinguish other frameworks from one another. Each 
identified framework was distinguished based upon the type of evaluation described, i.e. a framework 
for how to evaluate a system’s readiness for mHealth implementation, for how to evaluate a single or 
groups of mHealth technologies, or how an organization performs evaluations as a service. Extracted 
data were then discussed, synthesized and organized into the agreed upon three different types of 
framework and then reported according to a structure agreed upon by participating researchers. 
Information regarding which stakeholder(s) each framework were intended to be used by (patients, 
researchers, developers, policy makers or healthcare professionals) was either explicitly noted by the 
authors of the framework or described within the evaluation tasks to be completed by stakeholder. As 
the terms used for evaluation criteria were largely homogeneous, these were simply noted and tallied 
for each framework.  
For the scoping literature review, we intended to perform a descriptive analysis of the results, thereby 
giving an overall picture of how researchers are approaching mHealth evaluation, and which resources 
they are using to do so. Single device, e.g. app, interventions present a lower risk to patients than those 
interventions involving multiple data sources, technologies, and potentials for error, i.e. system 
interventions. Therefore, we compared those methods and measures used to evaluate “app 
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interventions” against those used for “system interventions”. We also reported which methods were 
used to gather different measures as well as which combinations of methods and measures were used 
by the identified intervention studies.  
As was described in another publication, the use of different terminologies by each author to describe 
the similar methods and measures, some of which have numerous different definitions, made the 
categorization of methods and measures difficult [211]. Therefore, it was our job when performing 
data extraction and analysis to structure information about what was measured in and evidence-based 
i.e. definition-based, way. While not included in the attachments of published Paper 2, Table 7 below 
details the connotations, based off definitions, where possible from the online Cambridge Dictionary, 
and descriptions of authors of reviewed literature, of each disputable measure-category described in 
the appendices for Paper 2. The intention of highlighting discrepancies between these categories is that 
there is much heterogeneity within definitions and specific information can be used differently. For 
example, efficacy, effectiveness, and efficiency are sometimes included under the definition of 
usability. However, measuring how quickly someone can perform a task, i.e. efficiency, may not be 
someone’s intention behind their assessment of a device’s usability, and by grouping of all of these 
concepts under one definition can misrepresent the measured impact of an intervention and make it 
difficult for the accurate comparison of study outcomes. 
Table 7 Explanation of the connotations for each category of measure used in the scoping literature review 
(Paper 2) 
Category of measure Explanations of definitions and connotations  
App features and/or 
quality 
App features refers to any description of included functionalities, display, other physical characteristics 
are included in the evaluation process of the mobile health intervention. The term “quality” with regard 
to the medical device industry has been defined as the following by the international organization for 
standardization (ISO), the degree to which devices “meet customer and applicable regulatory 
requirements” [212].  
Efficacy/effectiveness  The degree to which a device is associated with a beneficial outcome [213], which can be defined 
differently based on who is being asked, e.g. satisfaction as perceived by the patient vs. clinical 
efficacy as determined by a medical professional.  
Efficiency How quickly, i.e. with minimal waste of time [214], users could perform tasks, i.e. interactions or use 
of a certain intervention or device functionality as prescribed, instruction or observed by the research 
team.  
Engagement/motivatio
n in self-management 
Engagement relates to the level of which someone is involved with something, physically or mentally 
[215]. This can also be seen as a patient’s actual behaviour or perspectives related to health compared 
to ideal or agreed-upon behaviour or perspectives internally, i.e. an agreement or goal for one’s self to 
perform a certain way, or externally with another.  
Healthcare utilization 
and impact 
Indications or measures of a person’s use of formal healthcare services.  
Interactions (via app) The number and/or type of physical interaction a user had with different functions of a device, e.g. 
button pushes, swipes etc. that caused the device to respond or change accordingly, which can also be 
to initiate or end data entry (i.e. patient-gathered self-management data).  
Intervention 
experiences 
First-person description or account, mainly represented in interviews or free-response options, of what 
or how something occurred between the participant and any aspect of the studied intervention. 
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Lifestyle Specific to health-related habits, or activities or actions that a study participant performed, that were 




Any information or data directly input into the app by the user or via a connected device that 
automatically measures relevant measures of a patients’ health.  
Patient-reported app-
use (non app) 
Any information about how and how often the user reported using the intervention or app that was not 
directly measured by analysing information within the app but instead via a questionnaire or verbally 
stated by the user.  
Patient-reported 
health (non app) 
Any information about health measures, symptoms or other indications of physical or mental health 
that were not directly measured by analysing information within the app but instead via a questionnaire 




Any information about what activities, which were either prescribed or suggested by a reputable health 
information source specific to the management of their disease case, or how and how often these were 
performed and then reported by the user via a questionnaire or verbally stated by the user. 
Perceptions, opinions, 
suggestions 
Any subjective statements made by participants about the intervention itself or study. 
Physical/clinical well-
being 
Measures taken by standardized protocols and/or medical tools related to a person’s physical health, i.e. 
related to the tangible body [216].  
Psychological well-
being 
Measures taken by standardized protocols, e.g. psychological diagnostic questionnaires, related to a 
person’s mental or psychological health, i.e. related to their feelings or experienced emotions [217] 
related to their disease case.  
Quality of life A person’s reported measurable perception of the quality of their life, especially as it relates to their 
health and disease case.  
Security The degree to which the intervention or any of its components can protect an entity, in these cases 
mainly of personal health information (PHI), from unauthorized/unpermitted access, abuse, 
manipulation or change of that entity by an outside party [218]. 
Self-efficacy A measure of an individual’s belief in their ability to perform a task [219], in this case use of an 
intervention or any of its components to ideally improve their health.  
Study engagement compliance , adherence to program, engagement (attendance) , intervention fidelity, number of sessions 
attended, number of participants who completed assigned intervention condition, fidelity (if having to 
do with intervention itself) 
Task performance The degree to which, or how well, a study participant completed a task, i.e. interactions or use of a 
certain intervention or device functionality, compared to the ideal, i.e. research team-prescribed or 
instructed performance [220].  
Usability/ Feasibility The degree to which an intervention or any of its components were easy-to-use [221], possible, i.e. 
feasible [222], to use from the perspective of the user themselves. If pertaining to the expected usability 
or feasibility, for example by a third party, this can relate to the overall, theoretical and/or perceived 




4.3 Approaches to usage-log data analysis 
With the aim of answering RQ3, usage logs from completed studies were explored to understand what 
information could be gained from what, how, and when patients choose to use a diabetes app for their 
self-management. For the purpose of this thesis, usage-logs refers to each interaction and piece of 
information that an individual chooses to register in their mHealth device. Most data collected in a 
study, including usage-logs, are compared based upon the patient’s originally assigned intervention 
group, i.e., intervention 1 vs. intervention 2 or control. However, it is well established that each patient 
is unique in how they approach their self-management and, subsequently, app use.  
4.3.1 Usage-logs from the “Tailoring Type 2 Diabetes Self-Management” 
project 
This retrospective analysis was performed on app usage-logs data collected during the 6-month cross-
over RCT, Tailoring Type 2 Diabetes Self-Management [223]. Two versions of an app were used, the 
regular and the tailored versions of the Diabetes Diary app. Those who were randomized to the control 
group (n=16) used the regular app for 3-months. Those in the intervention group (n=25) used the 
tailored version of the app for the full 6-months. Participants were able to record measures of BG, 
medication, nutrition, and physical activity. Along with demographic information, participants 
reported upon which topics their goals focused, with options corresponding to each registration type in 
the app. HbA1c was taken at baseline, 3- and 6-months at the clinic. Continuous and non-continuous 
number of months that the app was used was measured for each participant.  
4.3.2 Usage-logs from the RENEWING HEALTH Project 
Preliminary findings from the original study 
This retrospective analysis was performed on usage-log data collected during the 12-month RCT 
study, RENEWING HEALTH [224]. The original purpose of the study was to determine how patients 
used the Diabetes Diary app for their health self-management, both with (n=50) and without (n=51) 
health counselling, compared to a control group that received normal care (n=50).  The app itself 
allowed patients to register and review measurements of their self-management, i.e., BG levels, diet, 
and physical activity, as well as related goals and static information included with the app.  
Originally, results reported measures taken at baseline, 4- and 12-months focused on reported 
aggregate change of HbA1c and total usage of the app within and between each originally assigned 
intervention group. This study and analysis was performed prior to this thesis. The results 
demonstrated no significant difference in the change of these measures within or between the groups 
[225]. Therefore, the retrospective analysis for this thesis was based on the usage-log data of 
participants who chose to use the app; of the 101 patients in the two intervention groups, only 79 used 
the app.  
Developing and testing a novel structure for data analysis 
In the scoping review conducted as part of this thesis (Paper 2), several studies reported collecting 
and analysing usage logs [226]. While this retrospective study did not allow us to change the methods 
of collecting the data, studies identified in Paper 2 did provide us an understanding of the variety of 
approaches used to analyse the data. Some studies noted, for example, grouping all interaction data by 
week, including recorded values [227], or describing analysis based on rolling retention, return rate – 
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in other words, based on duration or use over time – as well as registration of own-gathered measures 
and navigation of certain functionalities [228].  
Working from (close to) scratch, we performed a preliminary analysis to understand what was possible 
to gain from these data as well as how to develop an evidence-based structure for the comparison of 
the usage-logs. Our challenge was to determine a) if the original patient groups were appropriate for 
mHealth analysis, b) in what period of time to group the data, and c) how, if possible, to compare 
mHealth-gathered app data to clinical measures, such as lab tests.  
Acknowledging that BG levels do not exist in a vacuum, we incrementally compared the other 
registered data that was available (physical activity and diet). We began by searching for theories that 
could help us understand individuals’ health self-management choices and the time it took to establish 
a new habit so that we could group the data accordingly. We referred to relevant, yet previously un-
consulted fields, reassessed assumptions about patient behavior during a study and in every-day life 
and established medical knowledge. Finally, we identified several theories that not only worked in 
parallel with one another but also provided a means to both structure and interpret the data. In doing 
so, we established one way in which we could learn more about how, and potentially why, health and 
behavior changes occurred during this study.  
Usage-log data from this study consisted of registrations, e.g., recorded measures of BG levels, and 
navigations, i.e., how and when a participant used and interacted with the app. These categories of 
information identified and summarized for each participant. Data was structured in two separate ways 
based on i) duration and level of app-usage, e.g., long- vs. short-term users, and ii) emergent groups of 
patients characterized by their combination of usage-log types, i.e., registrations and navigations, via 
K-means clustering. 
4.3.3 Analysis of usage-logs 
Retrospective analysis of data from the Tailoring study focused on the relationships between baseline 
goals and use of the app as well as use of the app and change in HbA1c. Total number of 
measurements registered, for each type of data, were tallied and grouped by month. Correlation 
analysis was performed between the number and type of registered data vs. value and change in 
HbA1c at baseline, 3- and 6-months. Repeated Measures ANOVA was performed on the usage-log 
data within and between months. The number and topics of baseline goals were compared to the 
number and types of registered measures taken in the app during the intervention as well as to the 
duration of app use. Comparisons of these data were also performed between groups.  
Retrospective analysis of data from the RENEWING HEALTH RCT was based on emergent app-
usage groups. Clustering is the process of identifying groups based on similar outcomes, i.e. discovery 
of discover the natural grouping(s) of a set of patterns, points, or objects [229], in this case usage-log 
patterns based on which functions were most used by the participants. This followed Bayesian logic, 
as options for outcomes are identified based on the options that are offered. The specific analysis 
method of K-means clustering was selected by the invited statistician who consulted and helped 
perform the secondary analysis of the data based on the fact that this is a commonly used clustering 
method [229]. Our intention was to identify profiles of use via secondary analysis of previously 
collected RCT data on participants’ use of the mHealth device. This means that by treating 
individuals’ data within originally assigned interventions groups as the same is ineffectual; the results 
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would be too heterogeneous and therefore skewed to accurately determine a common impact of the 
device. Therefore, RCTs, which perform analysis based on originally assigned intervention groups, do 
not apply to interventions that base their findings off of mHealth usage-patterns. Repeated Measures 
ANOVA was performed within and between each emergent group to quantify differences and trends 
in app-usage patterns. Correlations were reported between emergent usage groups and change in 
HbA1c. 
4.4 A mixed-method evaluation of an mHealth intervention for 
diabetes 
With the aim of answering RQ4, a mixed-method feasibility study was designed with the aim of 
supplementing traditional methods and measures with mHealth approaches and resources. The aim of 
a mixed-method study is to select approaches, methods and measures from both quantitative and 
qualitative research in such a way that would provide a comprehensive and explanatory insight into an 
intervention’s outcomes [230]. In combination, quantitative measures can explain what changes over 
time - with patterns of such measures explaining how these change - and qualitative measures can 
explain why they change.  
4.4.1 Designing the mixed-method feasibility study protocol 
This mixed-method protocol aimed to evaluate the impacts of an mHealth system, for sharing patient-
gathered app data during diabetes consultations, on both patients and HCPs. Our objectives in 
designing the protocol were as follows: i) identified an intervention design that would meet the needs 
of the patients and HCPs, i.e., the duration, coordination of activities from recruitment and training to 
follow-up to using the data-sharing system during the intervention, ii) identified traditional methods 
and measures that would address the main possible outcomes, i.e., on the patient, HCP, and their 
relationship during consultations, ii) identified how mHealth approaches and resources are 
incorporated or supplement the traditional methods and measures.  
The outcomes from the scoping review (Paper 2) and co-design workshop (Paper 1) revealed that 
while such mHealth resources as usage logs and patient experts are indeed being used to supplement 
traditional and clinical quantitative data to assess the impact of mHealth diabetes interventions, there 
are still unanswered questions and address needs of end-users. A literature review of mixed-method 
studies provided a more focused exploration of how quantitative and qualitative methods and data 
were combined in diabetes and mHealth research [196], e.g. how qualitative interview data were used 
to explain quantitative usage log  data. These reflected the different analysis approaches, or rationales, 
described in the pragmatism paradigm, i.e. mixed-method approach [204]: exploration, 
complementarity, triangulation, and explanation. Because we aimed to thoroughly understand how 
mHealth and share patient data during diabetes consultations affected both patients and providers, 
triangulation was found to be the most appropriate means of analysing the quantitative and qualitative 
data, which is described in the analysis section below. 
The intervention 
The intervention itself involved patients using and gathering data in the Diabetes Diary app for 6-
months. The intention was that patients gather data on any of the following measures: BG level, 
physical activity, diet, medication, weight, and personal goals. They would have the choice to share 
and discuss their gathered data with their HCPs during one or more consultations in the intervention 
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period. Depending on how much and which data the patient chooses to share, the web-based system 
displays graphs, figures, and summaries of, for example, the patient’s registered measurements, 
progress toward their goals, and even relationships between their different measurements.  
We invited diabetes specialists (endocrinologists and diabetes nurses) and GPs in the Troms and 
Finnmark areas to participate in the study and recruit patient-participants. Patients with both T1D or 
T2D, 18+ years, and willing to use an mHealth app were included. 
Methods and measures 
The structure of the intervention, methods, and measures chosen had to address clinical practice, 
individual self-management, patient-provider cooperation, and technology. Through the Diabetes 
Diary app, we had the opportunity to track patient-gathered self-management measures and users’ 
interactions with the app. By focusing recruitment on HCPs, we aimed to ensure their engagement and 
thereby reliable collection of clinical measures. Our choice of such measures was based on the 
duration of the study, i.e., likely relevant biological changes that would change in 6-months. We 
aimed to identify patient-reported qualitative and quantitative methods that provided as much insight 
as to what, how, and why measures changed during the intervention, as opposed to only what had 
changed between baseline and study end, i.e., the Black Box of pre-post study designs (Figure 6). We 
used the list of standardized questionnaires that were identified in the scoping literature review (Paper 
2), as a selection pool. Focus groups were also considered as supplements to these measures with the 
aim of elaborating or clarifying participant responses.  
The intention behind the search for measures was that the clinical measures and patient-registered 
usage-log data could provide an overview of the quantitative changes over time, based on patients’ 
choices, while psychological questionnaires and study-end focus groups would allow participants to 
specifically explain why they chose to register data and use the system in the way that they did. We 
chose standardized questionnaires and discussion guide questions that would not only provide an 
insight into the impact on patient self-efficacy and self-management habits but also related to concepts 
relevant to health authorities, e.g., usability and feasibility of the technology itself. Following our 
objective of encouraging interdisciplinary research, we invited researchers in the field of psychology 
to develop the discussion guide with us. Together, we aimed to inform the questions and activities 
with psychological theories and frameworks related to human behavior, motivation, and decision 
making. As a result, the order and content of the questions, as well as their eventual analysis, were 
based upon consensus reached between these researchers after several iterations [231].  In doing so, 
we could theoretically provide a more complete and comprehensive understanding of the impacts of 
mHealth than traditional methods and measures alone.  
Study-management 
For the study design, the efficiency of study management was a priority given the speed of 
development of mHealth technologies. There was also the challenge of ensuring complete data 
collection. As our location, Tromsø, Norway, proved a challenge for both recruitment and participant 
follow-up, a remote study-administration approach was taken. Previous experience with a remote 
study-administration platform (study platform) demonstrated the importance of participant follow-up 
and support, the role of goal setting, and the need to connect data collection databases so that data 
structure and analysis would be performed more automatically and efficiently [232]. These informed 
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improvements to ensure even more complete data-capture as well as dynamic and personalizable 
follow-up with our end-users during the FullFlow feasibility study. 
The study platform provided access to the automatically collected usage-log data from the patients’ 
diabetes diary apps, including an account of patients’ continuous interactions with their apps, e.g., 
which functionalities were used and when, as well as their registered self-management measurements, 
e.g., BG levels.  
4.4.2 Analysis of mixed-method feasibility study 
For this mixed-method study, we plan to provide our experiences with the study administration 
platform, recruitment and HCPs’ responses to the pre-study perception of the data sharing system, 
with a focus on the main outcomes of the study, i.e. descriptive comparison of the participants’ 
experiences and perceptions measured before, during and after the study.  
Information regarding HCPs’ specialties as well as their unique and raw responses to the pre-study 
questionnaire on the perceptions of the data sharing system will be translated from Norwegian to 
English. To explain participant’s experiences, we chose to present the three main interactions that 
were described in the study protocol, i.e. patient interaction with the app, patient-provider interaction, 
and user interaction with the data sharing system, as case studies. Case studies are often chosen as an 
approach to understanding a multifaceted or complex intervention [233]. As much of the data from 
healthcare providers and patients were collected separately yet pertained to a shared experience I 
believed it helpful to both illustrate and describe in text all of the relevant data for the three main 
interactions that occurred during the study. Figures allowed me to present both quantitative and 
qualitative information together and objectively. Analysis of standardize questionnaires were 
performed based on the protocols described by the authors of the standardized questionnaires: 
patients’ perceptions of intervention usability (System Usability Scale –SUS) [234], own diabetes 
empowerment (Diabetes Empowerment Scale-Short Form- DES-SF) [235], own wellbeing (WHO-5 
Wellbeing Index) [236], and the therapeutic relationship with their HCPs (Health Care Climate 
Questionnaire- HCCQ) [237]. We will illustrate, chronologically, each patient’s and HCP’s progress 
through the intervention. This will include usage-logs from patients’ apps during the 6-months; the 
data patients chose to share through the Full Flow System and HCPs’ post-consultation survey 
responses. We performed a qualitative analysis of the transcripts from the study-end focus groups. To 
demonstrate the feasibility of using these methods and measures to provide a comprehensive 
understanding of the impacts on the FullFlow System on both participant groups, for the purpose of 
this thesis, I analysed data related to two of the eight participants (n=1 T1D, n=1 T2D) and their 
respective HCPs.  
5 Ethics 
The FullFlow Project activities, including the co-design workshops, usage-log analysis, and mixed-
method feasibility study and their associated preceding activities, were found exempt by the 
Norwegian Regional Committee for Medical and Health Research Ethics (REC), and instead 
acknowledged by the Data Protection Officer (Personvernombud) at the University Hospital of North 
Norway (Appendix B). The study administration platform followed the same regulatory approval 
process. We strived to reach gender equality during each study. Data was kept safely stored as per 
requirements by both REC and Personbernombud. All participants of these activities provided signed 
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informed consent forms prior to the start of each activity. They were informed of their right to 
withdraw themselves and their data from inclusion in the study and analysis at any time.  
6 Results 
6.1 What diabetes patients and HCPs need from mHealth  
With the aim of answering RQ1: “What information, support, and functionalities do patients, general 
practitioners and specialists who work with diabetes, need and expect from mHealth tools?”, 
Appendix C [238] describes the activities and results of the online patient survey and HCP workshop 
that informed the first prototype designs for the FullFlow data-sharing system. Paper 1 [239] 
describes the results of the co-design workshops, including the suggestions for how a data-sharing 
system should function to respond to the information needs of patients and HCPs together in practice. 
Results from the co-design activities are all based on the concept of patients self-managing their 
diabetes with mHealth technologies and their choice of sharing that data with HCPs during 
consultations.  
6.1.1 Patients’ needs and perceptions of mHealth  
Of those who completed the 2016 anonymous online survey regarding self-management challenges 
and ideal consultation discussions, 15 were diagnosed with T1D, and 9 had T2D [238]. The most 
commonly reported challenge between both groups was motivation to exercise (60% o T1Ds, 89% of 
T2Ds). However, those with T1D reported greater challenges with eating healthy (47%), and those 
with T2D reported more challenge with reducing their weight (67%). The most desired topic during a 
consultation discussion was dealing with stress (60%), amongst those with T1D, with the least desired 
topic of the best exercise for me (7%). Amongst those with T2D, the most desired topics were tied 
between dealing with negative thoughts/feelings (44%), the best exercise for me (44%), and reasons 
for variability in their blood glucose levels (44%). The least desired topic amongst those with T2D 
was personal goals (11%).  
Four individuals with T2D participated in the 2017 co-design workshop, which also involved GPs. 
Five individuals with T1D participated in the 2018 co-design workshop, which also involved 
specialists in diabetes care [239]. All participants with T1D and T2D acknowledged that the 
availability of such mHealth devices that enabled them to take on greater responsibility, 
understanding, and control of their diabetes health. Differences between individuals with T1D and 
T2D were noted under each of the major themes: 1) patients’ and providers’ need for more specific 
and detailed information in diabetes care, 2) mHealth technologies’ impact on patients and providers, 
and 3) data-sharing. These differences were consistent with the inherent differences between 
diagnoses. Overall, those with T1D are required to closely monitor and understand how to react to 
immediate changes in BG levels. However, most with T2D would benefit from recalling their 
historical actions, over a period of time, to explain symptoms that appear sometimes days after its 
cause. They also often have comorbidities that their GPs must focus on as well, which means less time 
during consultations to discuss each health issue. Differences in feedback during respective workshop 
sessions were reported; those with T1D focused more on detailed information and feedback whereas 
those with T2D were focused more on gaining motivation and understanding their general health 
trends. This accounted for differences in when those with T1D and T2D needed feedback, i.e. more 
immediately when issues arise vs. after data had accumulated to provide evidence of reoccurring 
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symptoms. Both noted that apps provide some of this feedback, which is especially appreciated given 
the participants’ reported lack of support from HCPs when and where they needed it, i.e., in their 
every-day lives, when their symptoms arise. While the individuals with T1D and T2D were frustrated 
with this situation, they still noted their own inability to see all answers in their app data and highly 
valued their HCPs’ ability to identify and explain unseen issues within their self-management habits 
and health measures. However, those with T2D did note that GP’s understanding of diabetes was 
limited - understandably so- by their lack of time and specific training. Suggestions regarding 
alternative diabetes support services included diabetes nurses (DNs). 
While they were independent in their app use and self-management, they were eager to share that data 
with HCPs. Both those with T1D and T2D wanted to share their data before consultations, believing 
that the HCPs would have more time to review it and then explain the patients’ diabetes health to them 
during the consultations. However, they were unsure about which data the HCPs needed or wanted to 
see in order to provide such input. 
6.1.2 HCPs’ needs and perceptions of mHealth 
One endocrinologist and two GPs participated in the 2016 HCP workshop that reviewed patients’ 
responded to the online survey and provided ideas for how a system should present patient-gathered 
app-data during consultations [238]. Both agreed that HCPs function as guides to their patients in the 
diabetes care process, with consultations giving patients and HCPs the opportunity to learn from 
health and app-gathered data. However, the participants explained that there were main differences in 
their practice that needed to be acknowledged before designing a system to introduce any new data. 
The GPs were most concerned with gaining an overview of the patient’s situation quickly (1-3 mins), 
given the GPs’ need to cover not only diabetes but other health concerns as well during a shorter 
consultation. The specialist reported having more time, and therefore a priority, to discuss diabetes-
related health issues in-depth. If patients shared their own-gathered data, the GP preferred to see 
summaries of the data and the patients’ personal goals, while the specialist preferred to view detailed 
graphs and trends from multiple self-management tools. Both agreed that if patients intend to share 
their app data, they should come prepared with discussion points and any technology solutions to 
display that data should avoid data noise and overload.  
Three GPs participated in the co-design workshop held in 2017, together with patients with T2D. Two 
endocrinologists and a DN attended the 2018 co-design workshop, together with patients with T1D 
[239]. These results were similar to those reported by the participants in the 2016 workshop, involving 
only HCPs. In the 2017 co-design workshop, GPs reported that the technology acts as a learning tool 
for individuals, with the potential to help patients see issues within their health habits and correct them 
without requiring consultation time from the HCPs. All participating HCPs (2017 and 2018 co-design 
workshops) saw their roles in diabetes care as guides or teachers, with the patient taking the most 
responsibility for the actions determining their health.  
Both agreed that when presenting data, it should be summarized and structured in a way that 
highlighted patients’ ineffective habits or reoccurring issues. HCPs main concern was being 
overwhelmed, on both the individual HCP and healthcare resource management levels, if the patients 
chose to send great amounts of data to the HCPs. GPs especially reported their incapacity to review 
data before each consultation, and only wished to see the data when something had changed, either in 
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the patients’ self-management habits or as the result of changing, for example, medication. Without 
such a context, GPs did not view receiving data as useful for their case as HCPs. 
While specialists agreed with GPs, that context is important; they were more specific in their 
preferences for data-presentation. They suggested that if a patient was to present a short period of 
intensive data-collection, it would be representative of a person’s self-management routine and its 
effects on their health. While one specialist preferred to see “fluctuations over 24-hours” to identify 
specific issues that arose for that patient, another wished to rely on algorithms to indicate when an 
issue occurred and provide a suggestion as to why.  
6.2 Methods and measures to mHealth evaluation  
A grey literature review and scoping literature review aimed to answer RQ2 from both the 
organizational level and research levels: “What approaches, methods and measures are being used to 
collect data for the evaluation of mHealth interventions for chronic illness self-management?”, with a 
subsequent question being “are end-users’ needs being addressed in evaluations?”. The grey literature 
review (Appendix D) [240] included methods and measures that government and independent 
organizations are using to evaluate mHealth technologies. The scoping literature review (Paper 2) 
[226] described the mHealth approaches and resources that were used that supplemented or were 
incorporated into traditional methods and measures. 
6.2.1 Government and organizations’ mHealth evaluation initiatives 
Three main categories of evaluation frameworks were identified: i) implementation frameworks 
(n=20), ii) assessment frameworks (n=28), and iii) service frameworks (n=13) (Table 8) [240]. 
Table 8 Descriptions of the three main types identified mHealth frameworks 
 
These frameworks primarily target health authorities, researchers, and mHealth developers, with few 
providing guidance for, or involving individuals or patients. Instead, app directories were the only 
resource for individual users. The most commonly evaluated topics were measures of privacy, 
effectiveness, usability, and data security. While comprehensive in relation to governmental 
regulations, most frameworks did not cover transparency, reliability, validity, and interoperability of 
mHealth technologies [240]. In other words, the identified topics represent some of the 
aforementioned priorities of stakeholders, but not those of individual patients.  
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Decisions about which methods should be used to provide evidence of mHealth’s effects on 
individuals’ physical and mental health, connected technologies, and the medical system were diverse. 
Information was not mentioned regarding factors mHealth technologies impact and whom they 
impact, and how to measure and report these impacts [169]. The scientific literature review 
demonstrated how health intervention researchers are attempting to answer these methodological 
questions.  
6.2.2 Scientific evaluation methods and measures for mHealth 
interventions 
The search identified 3912 records, which were narrowed by removing duplicates and applying our 
inclusion/exclusion criteria [226]. App interventions were described in 15 studies, and system 
interventions were described in 16 studies. One study described both intervention types. It was found 
that both traditional and mHealth-enabled methods, i.e., mHealth approaches, and measures, i.e., 
mHealth resources, were used together in mHealth intervention studies.  
Most studies were also able to achieve their objectives, and in some cases, produce more information 
than expected because of their inclusion of mHealth resources, i.e., mHealth as a data-collection tool. 
Ten studies reported more than they intended [228, 241-249], three of which were able to do so 
through the use of mHealth as a data-gathering tool as well as part of the intervention [228, 245, 249]. 
One of these studies [250] was not able to produce the intended outcomes of cumulative time on an 
app due to technical errors. 
The most common methods amongst both app and system intervention studies were the Evaluation of 
usage-logs (n=21) and Standardized questionnaires (n=18). Ad-hoc questionnaires were the third most 
common method used (in n=15 studies), which were often (n=14 ad-hoc questionnaires) based off of 
standardized questionnaires, or used in conjunction with standardized questionnaires but included 
questions that the standardized questionnaires did not cover. The least common methods used were 
Download count (n=1), followed by Attendance, Medical record entries, Observational tests (in a lab 
setting) with two citations each, and Quality guidelines (n=3). 
Measures were gathered directly from patients 29 of the 31 studies. HCPs participated in many of the 
interventions and reported Perceptions, opinions, suggestions (n=4), and Usability/feasibility (n=4) 
most often. Interactions with the tested system were also reported by HCPs in two studies [251, 252]. 
Most quantitative measures were gathered from the intervention’s app or system. mHealth, including 
the central app as well as connected medical and wearable devices, provided the platform for 
collecting data, e.g., Interactions (n=8 in app studies, n=11 in system studies), followed by Patient-
gathered self-management data (n=6 in app studies, n=8 in system studies), for 3 of the 14 identified 
methods including evaluation of usage logs, collection of additional device data, and download count.  
6.3 Analysis of app usage-logs  
With the aim of answering RQ3: “Can usage-logs and patient-centered analysis be used to provide 
more evidence and information about what, how and why changes occur during an mHealth 
intervention?”, analysis of the Tailoring project’s usage-logs identified non-significant yet telling 
relationships between patients’ pre-determined goals and use of app functionalities (Appendix E and 
Appendix F). Analysis of the RENEWING HEALTH usage-logs (Paper 3) [253] identified 
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relationships between HbA1c, a formal clinical measure, how long and for which functionalities 
participants chose to use the app. 
6.3.1 Usage patterns of short- vs. long-term users 
First, we differentiated those who did and did not use the mHealth app. Those that used the central app 
for three continuous months were considered short-term users (n=11). Long-term users were those 
who performed at least five interactions per month for three continuous months (n=61). There were 29 
participants who did not interact at all with the central app during the intervention. There were no 
significant differences between these groups in terms of their demographics, including age, duration of 
disease, and education. However, while not significant, non mHealth users had a higher baseline 
HbA1c (8.4 mmol/L) than the short-term users (7.9 mmol/L) and long-term users (8.1 mmol/L), while 
short-term users had the lowest number of SMBG measures (5.5 per week) compared to the non-
mHealth users (7.2 per week) and long-term users (9.4 per week). There was a significant difference 
between these groups related to HbA1c at baseline, four and twelve months between the non, short 
and long-term users (F(2, 74) = 3.794,P= .027, η2 = .093), with long-term users demonstrating the 
greatest reduction in HbA1c (-0.86%), a clinically but not statistically significant reduction. However, 
none of the groups achieved the Norwegian goal of <7mmol/L during the study (Figure 8). 
 
Figure 8 Changes in HbA1c between users grouped by duration of app use (Paper 3) 
Among the 61 long-term users, there was a significant decrease in use after the first annual quarter, 
with a decrease of 64.91 interactions on average (t = 9.234,P< .001), with the greatest increase 
occurring after the first month of 212.25 interactions from 461.2 total interactions ((t = 5.022,P< .001, 
effect size = .643). BG registrations were the most consistent app function used during the study, 
which was shown by the least difference in these interaction types between quarters.  
Using K-means clustering, we identified two patient app-use profiles, i.e., their emergent groups or 
“clusters” based on the usage-pattern analysis. Cluster 1 was characterized mainly by Diet/exercise 
registrations and navigations (n=16), while Cluster 2 demonstrated mostly Blood glucose registrations 
and navigations as well as Navigations overall (n=40). Those that fell into two smaller clusters were 
not included (n=5). The two main clusters differed in all comparisons except BG navigations and 
Information navigations in total, over the 12 months and between quarters. For all participants in these 
two Clusters, it was found that there was a significant difference in change in HbA1c over time (F(2, 




Figure 9 Changes in HbA1c of groups based on usage patterns (empty circle= diet/exercise users, filled 
circles=BG users) (Paper 3) 
While not statistically significant, there was a medically significant change in HbA1c found between 
baseline and 12months for those in Cluster 1, but only between baseline and 4months for those in 
Cluster 2. 
6.4 Comprehensive design of an mHealth intervention protocol 
With the aim of answering the first part of RQ4: “How can mHealth-based data-collection and 
analysis be combined with traditional research methods and measures to produce more comprehensive 
information about what, how and why changes occur during an mHealth intervention?”, Paper 4 [254] 
describes a mixed-method study protocol. This protocol suggests a way in which an mHealth resource, 
app usage-logs, and mHealth approaches, e.g., the end user-driven structure of analysis, study, and 
intervention design, can supplement traditional methods and measures. 
6.4.1 Intervention study design 
The developed intervention was a system for sharing data between a patient’s app and their HCPs 
during consultations. It was designed and chosen because it allowed for both patient and HCP 
understanding and use as well as characteristics of measurement for the potential of mHealth: impacts 
on patients, HCPs and consultation structure. We designed a 6-month mixed-method feasibility study 
to measure these impacts. Before the study start, patients were sent a questionnaire both to their email 
and the Diabetes Diary app. Patients were encouraged to use the central app to collect data about their 
BG measures, medication doses, diet, weight, physical activity, and goals, in any manner that they 
choose. Monthly reminders sent as set follow-up messages through their email and app related to 
possible app functionalities to use etc. The follow-up message at month 5 instructed patients to 
schedule a consultation, during which they were meant to share their choice of collected data. HCPs 
were instructed to complete a post-consultation questionnaire after each time a patient shared data 
with them. Patients were then sent a study-end questionnaire after the research team had confirmed the 
HCP post-consultation questionnaire had been completed, thereby confirming the patients’ 
participation.   
6.4.2 Integration of mHealth resources in measures chosen 
We selected continuous and pre-post quantitative and qualitative outcomes that complement one 
another to be able to answer the questions: what, how, and why more fully. The complete set of 




Figure 10 Illustration of what and when data was collected. 
We chose the following standardized questionnaires, quantitative measures based upon a goal of 
measuring a balance of wellbeing, motivation, and health behavior change theories, and technological 
possibilities. Standardized questionnaires distributed at baseline (Appendix G) and 6-months 
(Appendix H) measured patients’ perceptions of intervention usability (System Usability Scale –SUS) 
[234], own diabetes empowerment (Diabetes Empowerment Scale-Short Form- DES-SF) [235], own 
wellbeing (WHO-5 Wellbeing Index) [236], and the therapeutic relationship with their HCPs (Health 
Care Climate Questionnaire- HCCQ) [237].  
Study-specific questionnaires allowed us to gather information that was specific to our research 
questions but were not part of the included standardized questionnaire. Appendix F includes the study-
specific questions for patients at baseline, which were distributed with the aforementioned 
standardized questionnaires. To measure the impacts of the data-sharing system on HCPs, we asked 
them to complete a pre-study survey (Appendix I) related to their impressions and expectations of the 
data-sharing system. After each consultation with a patient participant, we also requested that they 
complete a survey of which shared-data was discussed, which of the system’s functionalities were 
used (Appendix J).  
Quantitative changes in patients’ health were measured by comparing the HbA1c and BP levels 
available in the medical records from lab tests. Usage-logs provided quantitative information about 
both what had changed by collecting own-gathered measures of health and self-management tasks. 
These also demonstrated how these data had changed by demonstrating longitudinal patterns 
throughout the intervention in the logged data. 
Study-end focus groups provided a means to collect more information about how participants acted 
during the intervention and why they chose to use the technology in the manner that was recorded via 
the usage logs. We invited both patients and HCPs to separate sessions. The meetings were designed 
to allow participants to elaborate on their questionnaire responses and provide more context for their 
perceptions of and actions during the intervention. The focus group discussion guides were the result 
of a joint effort of FullFlow Project team members and three psychology researchers. Questions were 
based upon psycho-social theories of behavior change that were not available or being used in 
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comparable studies (Appendix K) [231]. Questions were chosen that addressed the following: the 
traditional measure of technology interventions, i.e., user-experience, as well as users’ intentions, 
perceptions, and motivations related to using mHealth for sharing patient-gathered data during 
consultations, as well as patient-HCP collaboration (Appendix L and Appendix M). These were 
audio-recorded, transcribed, and translated from Norwegian to English for analysis. 
6.4.3 Use of the mHealth study-administration platform 
While it was possible for this platform to perform nine functionalities (Appendix N) [255]: 1) recruit, 
2) send and collect informed consent, 3) randomize participants, 4) send and receive questionnaires, 5) 
track and 6) follow-up participants as they moved through the study, 7) gather and 8) provide basic 
summaries of data and 9) perform study closure. However, for this project, patient recruitment was 
performed through HCPs, who were themselves recruited in person, and randomization was not part of 
the study design.  
Users within the research team would be able to access project information through a secure web-
based interface. From here, it was possible to track participants as they moved through the study from 
informed consent to the reception of follow-up messages to the delivery and reception of 
questionnaires. We initially created one follow-up message for each of the six months of the 
intervention as well as a study-end “Thank you” to ensure engagement and support was provided to 
participants. Each of these was sent and tracked manually through the platform.  
It was then possible to access collected data from three data-sources: LimeSurvey [256], the app data 
server, and Piwik (now called Matomo [257]) for usage-logs. LimeSurvey also allowed us to create 
questionnaires for both patients and HCPs in the study. Within the FullFlow data-sharing system 
landing page, the HCPs could access the post-consultation questionnaire. Piwik automatically 
uploaded participants’ interactions with the app regularly, when they were connected to the internet.  




Figure 11 Illustration of the flow of data from the participants to the research team using the study 
management platform in the FullFlow mixed-method study. 
6.5 FullFlow mixed-method study: preliminary results 
With the aim of answering the second part of RQ4: “How can mHealth-based data-collection and 
analysis be combined with traditional research methods and measures to produce more comprehensive 
information about what, how and why changes occur during an mHealth intervention?”, the mixed-
method study results demonstrated the information that was gathered from the selected traditional 
methods and measures, with supplemental mHealth resources. While these results have not yet been 
published, examples of this analysis are presented below. In general, it demonstrates the feasibility and 
potential of using such an approach. 
6.5.1 Study admin platform 
Three researchers were provided unique and secure usernames and passwords to coordinate these 
activities: the principal investigator to oversee all activities, myself to assist in creating follow-up 
messages and to manage their deployment throughout the study and a researcher who focuses on 
programming to coordinate and structure data collection between the three main data-sources.  
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Both predefined and ad-hoc follow-up messages were required for participants experiencing different 
issues including not updating their app to the version required for us to collect data, not answering a 
questionnaire or scheduling the necessary consultation with their HCP, or when we saw a participant 
had not used the app in some time. Appendix O [258] describes the lessons learned from using this 
platform during this study.  
6.5.2 Recruitment 
Recruitment began in October 2018 and ended in June 2019. The principal investigator contacted and 
held information sessions to educate the HCPs on the system. All HCP recruitment efforts for the 
feasibility study are presented in Figure 12. The research team contacted a total of 26 offices and 
organizations (first column in Figure 12) to inquire about their interest in joining the project. We 
requested times to present the project and introduce interested HCPs to the intervention, i.e. including 
a walk-through of the system’s functionalities (yellow circles in Figure 12). Often, the research team 
had to initiate contact and follow-up several times throughout the recruitment period to, for example, 
provide more information, recruitment material or check on the status of patient recruitment. 
 
Figure 12 Illustration of the main HCP recruitment efforts for the FullFlow Feasibility study, i.e. initial contact (blue 
rectangle), presenting the project (yellow circle), agreement from HCPs to participate (green circle) and final 
reminders sent to HCPs. 
At offices #13 and #24, one HCP in an office would recommend we present the project to colleagues, 
in which case more than one project presentation was made (multiple yellow circles in a row). More 
than one HCP agreed to join at office #12 and #21. Study presentations concluded with a survey 
inquiring about their expectations of how the system could function with their patients. Seventeen 
(n=12 GPs, n=4 DNs, n=1 nutritionists) completed a pre-study survey, agreed to enter the study, and 
inform their patients with T1D or T2D about possible participation. Reasons for not being able to 
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recruit patients to the study included not having time to participate in an information session about the 
project, having too few patients who they thought would be eligible, and having too hectic a schedule 
to follow-up during the study.  
Eight patient participants with T1D (n=4, n=2 Female) and T2D (n=4, n=2 Female) entered the study. 
Participants with T1D were between 38 and 65 years old, had been living with diabetes for between 
four and 23 years. Of the four participants with T1D, two used five or more medical and commercial 
mHealth devices (e.g., apps and insulin pumps). Those with T2D were between 54 and 74 years old 
and had been living with diabetes for between one and 15 years. Of the four participants with T2D, 
one used a paper diary in addition to two or more mHealth devices before the study. 
6.5.3 HCP’s pre-study perceptions of the FullFlow system 
All 17 of the HCPs (n=1 nutritionist, n=4 DNs, n=12 GPs) participated in the pre-study survey after 
being given an hour-long session to introduce them to the FullFlow data-sharing system. Appendix O 
[259] summarizes these results, and Table 9 details the free-text results.  




Will the system be useful to 





• For those with android phones.  
•  For those who are interested in the 
technology. 
• Correlation between insulin and carbohydrate intake. 
• Associate the "Carbo and Insulin" for carb assessment in food, as 




• For those who already use the app. 
• Does the patient have the opportunity to enter the type of 
carbohydrate they eat (the number may not always be enough).  
• This system can be good for everyone but especially for patients 




• The Diabetes Diary app can 
replace written diaries.  
• Many of our patients use other 
apps and we are familiar with 
relating to these. 
• Under carbohydrates, does the patient have the opportunity to 




• Note from the consultation (short note) that could be entered in 
the Diabetes Diary app. 
5. GP 
Yes, 
• For those who are preoccupied 
with their diabetes. 




• Depends on the patient entering 
enough data 
• In addition to the information provided by the patient, would 
liked to have seen the distribution of slow and fast-acting insulin 
• Different colors on the columns that are slow-acting insulin. 
• In the overview: include a separate section for blood sugar values 
above 15 mmol / l and a separate section for severe 
values/symptoms (below 2.8 mmol / l). 
7. GP Yes • Desire to add lipids 
8. GP Yes  
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9. GP Yes 
• As much as possible, to allow automatic registration directly on 
Strava, blood glucose meter, insulin pen, etc. 
10. GP Yes  
11. GP Yes  
12. GP 
Yes, 
• Can be motivating for both the 
doctor and patient. 
 
13. GP Yes  
14. GP Yes  
15. GP Yes 
• Should support Apple phones 
• Should there be separate apps for type 1 and type 2? 
16. GP Yes  
17. GP Yes 
• Integrated in EHR, e.g. Noklus form.  
• Highlight changes, that can also be "journal-note-friendly".  
• Information [from the EHR] can be copied and adapted to the app 
so that measures are generated for the patient (can be followed up 
at the next consultation) 
 
All believed that that the presented system would be useful during consultations. One diabetes nurse 
though that it would be particularly useful as a replacement for the paper diaries, recognizing that most 
of their patients use apps and other technologies. Another DN believed this system would be more 
useful for patients who lived at a distance than those who lived more centrally. GPs’ suggestions for 
improvement included the desire to enter a note after the consultation, automatic registrations from 
medical devices. Nurses were more interested in specific outputs of information, such as cases of 
severe hypo- or hyper-glycemic events and correlations between insulin boluses and food 
consumption in order to more accurately understand each patient’s particular metabolism of food in 
response to insulin. The responses of two participants, in particular, i.e., a DN and a GP, are presented 
in detail below in use case 1 and use case 2, in combination with their associated patient-participants.  
6.5.4 App interactions, patient-gathered data, and pre-post questionnaire 
responses 
Eight participants completed the first questionnaire set, with five completing both questionnaire sets. 
All participants provided usage-logs, which included patient-gathered data, i.e., physical activity, BG 
values, calories/carbohydrates, and medication (e.g., insulin, oral medication), and the number and 
time of interactions with the app. Two attempts were made to recruit HCP and patients. Four patients 
(n=1 T1D, n=3 T2D) participated in the study-end focus group meeting. One nurse participated in the 
corresponding healthcare personnel focus group meeting. However, this nurse did not see any of our 
patient-participants.  
To demonstrate the ability of the measured outcomes to provide a comprehensive understanding of the 
impact of the mHealth app and FullFlow System, I chose two use cases (one with T1D, one with T2D) 
including patients’ app usage-logs, demographics, and pre-post questionnaires and the healthcare 
personnel’s responses and focus group results. These quantitative and qualitative data will be 
illustrated together, for each patient participant, in three diagrams: one diagram will depict data 
associated with the user’s health, app-use and self-management, one depicting data related to the 
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users’ perception of their patient-provider relationship and one diagram depicting the patient and 
HCPs’ reported experiences using the system for data-sharing during the study consultation. After 
each diagram, a brief text will summarize how the data was analysed to give a more complete 
understanding of each of the three main impacts: i) users’ health, app-use and self-management, ii) the 
patient-provider relationship and iii) use of the FullFlow data-sharing system. 
Use case 1: Qualitative and quantitative data related to a T2D user and his HCP 
T2D user’s health, app-use, and self-management 
Figure 13 illustrates the variety of participants’ data, i.e., demographic and reported self-management 
data, usage-logs, changes in self-efficacy via the DES-SF [235], changes in reported wellbeing via the 
WHO-5 Wellbeing Index [236] and quotations from the focus group meeting about their use of the 
app for self-management. Major trends within the usage-logs are pointed out in the graph. Based on 
these data, we can see what parameters this individual focused on as well as begin to understand how 
these changed during the intervention and some explanations for why this individual chose to engage 
in the manner that he did and why some parameters changed. Note that HbA1c for this participant was 
not inputted correctly and is, therefore, missing from this dataset. 
 
Figure 13 Quantitative and qualitative data related to T2D user’s health, app-use and self-management 
This T2D user focused on measuring his blood glucose using a BG meter and oral medication to self-
manage, but not goals. His motivation behind his focus on BG was reportedly to see how his lifestyle 
affected his BG levels. He chose not to set goals because, as he explained in the focus group meeting, 
he felt that goals were “unachievable” from the start. It appears that the user registered activity, BG, 
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and diet a few times during month #1 but showed a significant increase in his registration of BG 
values during month #2 and then a decrease until the BG registrations and interactions stopped after 
month #5. While there were no physical activity and a few diet registrations made in the app, this user 
explains that he exercised more and became more aware of what he ate. However, he expressed that he 
felt shame for eating poorly and, therefore, for example, during Christmas, would not register food. It 
is unclear why he performed so many more interactions at month #1, yet had few parameters 
registered. However, technical difficulties may have played a role; he reported that it was too easy to 
delete his data, including his diet, which may explain the large number of deleted measurements 
(n=178) in his usage logs. By comparing questionnaires collected at the beginning and end of the 
study, we can see that he felt more refreshed after waking up and calm after the study (WHO-5 
Wellness questionnaire) and experienced some improvement in his self-efficacy, including ways to 
overcome barriers and to stay motivated, with the exception of creating and accomplishing goals 
(DES-SF questionnaire). 
Patient-provider relationship: T2D patient feedback  
While the HCP responsible for meeting with this user did not attend the healthcare personnel focus 
group meeting, Figure 14 illustrates the patient’s report about what changed in their patient-provider 
relationship via the HCCQ questionnaire and more in-depth explanation of his preferences and 
frustrations with the HCPs shared during the focus group meeting, i.e., how and why he perceived 
changes in their patient-provider relationship. 
 
Figure 14 Qualitative data from the patient related to patient-provider relationship 
Based on his responses to the HCCQ, the T2D patient’s relationship with his GP did not change, 
except that he did perceive that his GP showed less confidence in his ability to make health changes. 
The patient was frustrated when he was first diagnosed because although he was diligent in using a 
paper diary to track his measurements, the GP did not spend time to look at it. However, he also 
reported that he has confidence in his GP because the GP gives him realistic self-management 
recommendations. He expressed how he would rather experience healthcare, i.e., by visiting his DN 
first to discuss the details of his disease and then to the GP and having a common database whereby 
his HCPs could coordinate his care. He also explained that he spent more time discussing the details of 
his diabetes and collected app data with his DN. 
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Use of the FullFlow System: T2D patient and HCP feedback 
Figure 15 illustrates what occurred during their use of the FullFlow data-sharing system during their 
consultation. The HCP reported discussing health measures with the patient as well as how they recall 
using the system and its effects on their clinical practice via post-consultation questionnaires. During 
the patient focus group meeting, this participant reported their experience with the system as well as 
how it was for them to share and discuss their data with their HCP and some explanation as to why 
these may have occurred. 
 
Figure 15 Quantitative and qualitative data collected from the T2D patient and his HCP about his expectations 
and use of the FullFlow data-sharing system 
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The HCP reported using five of the six main pages of the system. However, he would ideally have 
liked to integrate the data into his EHR system. He found that he understood more about the T2D’s 
situation after using the system, and it allowed him to provide the T2D patient with more specific 
recommendations.  
Use case 2: Qualitative and quantitative data related to a T1D user and his diabetes nurse 
T1D user’s health, app-use, and self-management 
This case describes how a T1D user experienced the app, system, and relationship with his HCP 
during the 6-month study. Just as with the T2D user, we will explore these data to see what parameters 
this user-focused on as well as begin to understand how these changed during the intervention and 
some explanations for why this individual chose to engage in the manner that he did and why some 
parameters changed (Figure 16). Note that HbA1c was not input correctly and is, therefore, missing 
from this dataset. 
 
Figure 16 Quantitative and qualitative data related to T1D user’s health, app-use and self-management 
This T1D user focused on measuring his BG, diet, and insulin, using a combination of medical and 
mHealth devices. While it was not possible for the CGM to transfer BG values to the app, the BG 
values that were registered gave a relative view of the percentage of time this user experienced hypos 
and hypers, since he mainly recorded those values. His registrations and interaction with the app 
appear consistent throughout the study, with the exception of month #5—his reported being motivated 
by the app – associating a better HbA1c with its use. The user expressed that while it is easy to use the 
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app, one does have to invest time to record enough data so that the app can have a useful level of 
information to help you decide, e.g., how many carbs were in your meal. By comparing questionnaires 
collected at the beginning and end of the study, we can see that he felt more refreshed after waking up 
and more active after the study (WHO-5 Wellbeing Scale) and experienced little change in his self-
efficacy – only a decrease in his understanding of which parts of his diabetes he is dissatisfied with 
(DES-SF). Data was gathered for five months instead of six because data-collection and structuring 
was not finished for this participant by the time this analysis was performed.  
Patient-provider relationship: T1D patient feedback only 
As was the case with the T2D user, this patient’s HCP did not attend the healthcare personnel focus 
group meeting. Figure 17 illustrates the patient’s report about what he typically experienced during his 
consultations via the HCCQ questionnaire, how he felt during the consultation, and why. 
 
Figure 17 Qualitative data from the T1D patient related to patient-provider relationship 
The HCCQ questionnaire showed that the T1D’s relationship with his HCP worsened; he reported that 
the DN gave him fewer options, showed less confidence and encouragement toward the patient, and as 
a result, understood less about how he (the patient) felt about his health. While he did report positive 
experiences with his DN, because they were able to explore the data together, it was unclear which 
HCP he was referring to in the HCCQ, i.e., GP or DN. These negative experiences may be because, as 
he mentioned, the GP demonstrated little knowledge about his self-management and app use and, 
therefore, should rely more on the DN. 
Use of FullFlow System: T1D patient and diabetes nurse feedback 
Figure 18 illustrates what both expected from the system prior to their consultation vs. what they 





Figure 18 Quantitative and qualitative data collected from the T1D patient and his diabetes nurse about their 
expectations and experiences. 
While the T1D patient-reported gaining a better understanding of his HbA1c and BG, not feeling 
anxious sharing his data, and improving his focus on his disease and discussion of specific cases with 
his HCP, he also reported a very poor usability score for the system. Specifically, he believed the 
system was too inconsistent and cumbersome and slightly agreed that he would have benefited from 
learning more before using the system. On the other hand, the DN said that the system, including the 
presented information, was very useful and noted using all of the pages of the system. She (DN) said 




The aim of this Ph.D. was to explore (Papers 1-3) and then test (Paper 4 and the mixed-method 
study) a combination of both traditional and modern mHealth approaches and resources with the aim 
of providing a more comprehensive understanding of how mHealth technologies affect patients and 
HCPs. The lack of methodological standards for how to structure mHealth intervention studies is a 
blessing and a challenge. As such, we have the opportunity to evolve how we approach and conduct 
research – we can be more relevant, more user-oriented, more creative, and more comprehensive in 
how we produce knowledge. 
This thesis has taken an exploratory role within the research evaluation of mHealth interventions. In 
addition, I would like to take the opportunity to dive into the potential impact or implication of these 
works – from the limitations of outcomes from pragmatic research to the generalizability of lessons 
learned about study administration. This chapter is separated into sections. Section 7.1 summarizes the 
outcomes of each of the studies and describes the limitations unique to those studies, while 7.2 
discusses the limitations to generalizability of the overall FullFlow Project and thesis outcomes. 
Section 7.3 then discusses what is generalizable, or useful information and insights, for fellow 
professionals working with mHealth technologies for diabetes intervention research and the like.  
7.1 Insights and outcomes summarized 
7.1.1 How mHealth data-sharing can address patients’ and HCPs’ needs 
RQ1: “What information, support, and functionalities do patients, general practitioners, and specialists 
who work with diabetes, need, and expect from mHealth tools?”  
The results of the HCP workshop, which was informed by the online patient survey, responded to 
RQ1 by providing insight as to what patients wanted out of a consultation, i.e., their ideal consultation 
discussions, that could include their app gathered data. As both activities were conducted in 2016, the 
HCPs’ feedback about the needs for EHR-integration of the patient-gathered data (Appendix C) was 
still a focus on many stakeholders, including the research team of the FullFlow Project. Perhaps the 
un-reported assumption of the HCPs was that patient-gathered data could inform clinical decisions. 
This perception shifted during the project duration, as EHR-integration lost its appeal and feasibility. 
This shift also matched the sentiments of our vendor partners in the project, as this ambition of the 
EHR integration of a mHealth data-sharing system was too far ahead of the practical possibilities of 
the time. The loss of appeal of EHR-integration for some HCPs could be seen during the joint co-
design workshops of 2017 and 2018 (Paper 1); as HCPs, especially GPs, had over time became more 
aware of the details of mHealth, the potential breadth of data that patients could gather, they became 
more concerned with data-overload and the liability of trusting erroneous data. However, in another 
published work, we describe how time also played a role in HCPs’ readiness and willingness to accept 
mHealth app data. HCPs began to see a different potential to use patient-gathered data to understand 
their patients and recommend more tailored self-management recommendations, with no mention of 
how they would change their clinical recommendations (Appendix P) [260]. HCPs’ cautious 
optimism about relating to PGD during consultations was reiterated during the joint-co-design 
workshops.  
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One major outcome of the joint co-design workshops was the breadth and depth of information that 
was known and suggested by both our patient and HCP participants. A significant point that was made 
by both was that mHealth information is out there, but limited to a few stakeholders. Our specialist 
and DN, in particular, had experienced different patients coming with different mHealth devices, such 
as apps, and asking the HCPs to interpret the data or even help with technological errors. This was 
certainly not included in their medical training. HCPs noted that the only information about patient 
health devices that they receive semiregularly is from device manufacturers, who are often large 
corporations contracted with that clinic. These cover clinically approved devices such as insulin 
pumps and CGMs, not apps. This later informed the mixed-method study design (Paper 4) by 
highlighting the HCPs’ need for a thorough training session prior to the study start, as they would not 
have gained enough knowledge or understanding of an mHealth data-sharing system elsewhere.  
The joint co-design workshops responded to RQ1 by also producing an outcome related to the 
structure of the participant sessions. Choosing to involve both patients and HCPs together proved to be 
a greater benefit than challenge, despites concerns about this arrangement. Participants were able to 
resolve or correct assumptions that either group had - there and then. As observing researchers, this 
provided us with concepts for the designs of both our FullFlow data-sharing system and mixed-
method feasibility study, that were agreed upon by both end-user groups. In other words, we were able 
to move forward with concrete, realistic and common ideas for the intervention as opposed to trying to 
coordinate misunderstandings and erroneous comments from both sides. For example, in the joint 
session of T2Ds and GPs, by discussing patients’ assumption that HCPs could review all of their data 
before the consultation, GPs were able to comment that this was unrealistic and alternatives should be 
sought to meet the patients’ needs of specific and thorough responses. In fact, in the T2D session, 
patients demonstrated their ingenuity and understanding of both the GP’s limitations when they 
suggested seeking answers from DNs, or others who know more about the technology and specific 
situations in diabetes.   
As patients are becoming their own experts in mHealth and self-management, we have to ask, “s 
research answering to the needs of our primary mHealth end-user, patients?”, “Are we looking at all of 
the information or using all of the resources that we can to provide evidence?” Patients are now asking 
HCPs such detailed questions based on their data as, “how did this specific combination of foods, 
while I was hiking two days ago, affect my blood glucose today?” or “why am I so tired all of the 
time, with swinging blood glucose levels, even if I follow the recommendations that you, my doctor, 
gave me? Here, can you look through my data to tell me why?” and “what information should I be 
gathering that is relevant to you, my doctor so that we can discuss my situation more effectively? 
Similarly, HCPs’ questions were, “how are we, or anyone in healthcare services, expected to provide 
these kinds of answers given such unstructured data and little to no evidence of this app’s reliability 
and effectiveness?” As researchers, we have to ask, “can we help HCPs feel more comfortable with 
these data?” The answer – partly. We cannot immediately change the EHR and other proprietary 
systems to be more open and accessible, but we can listen to our end-users when we develop 
something new and perform any research on their behalf. 
We can develop the most innovative technologies, taking advantage of advancements in connectivity, 
wireless technologies, sensors, and artificial intelligence, but if we do not answer to the needs of our 
end-users, these technologies will essentially be useless. We need to address more specific questions 
and take into account the broader environment in which patients use mHealth and other available 
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health resources. Our research team also conducted a related work whereby we compared patient 
reported-needs to what information was being produced by mHealth app and social media 
interventions. The results showed that research is producing general information, e.g., about usability 
and feasibility of these technologies, but not necessarily the specifics that patients are asking for, e.g., 
what resources are available to effectively support personal self-management (Appendices K and Q) 
[231, 261]. The results of these co-design workshops also support the conclusion from the scoping 
literature review (Paper 2), i.e., it is not feasible for one group to produce all of the information, and 
collaboration is needed. Patients need to be part of study designs and the selection of methods and 
measures to ensure that their needs are being addressed and valued when it comes to producing 
evidence of mHealth’s effects on them and their overall lives. 
Limitations of the co-design workshops 
While much preparation and theory was put into developing the discussion guide questions and 
activities, participants reported being confused by some of the more introspective questions, and why 
it was suggested that they write their answers on post-it notes prior to discussing their answers. The 
sessions with patient participants were also held in Norwegian, led by the project manager, while I 
observed the best I could, with limited Norwegian language proficiency. Coming from an American 
style of research, with the tradition of more formal and, perhaps, over-detailed explanation of activities 
to participants, I saw an opportunity not taken to explain more thoroughly before the start of the 
workshops. There was also a lack of balance between men and women in each of the workshops, i.e., 
more men than women. As HCPs vary in their practices, and individuals differ in their self-
management and lifestyles, I would have preferred to have more specialists and female patients.   
7.1.2 How mHealth evaluations are being approached 
RQ2: What approaches, methods, and measures are being used to collect data for the evaluation of 
mHealth interventions for chronic illness self-management? 
The grey literature review responded to RQ2 with evidence of the mHealth technology criteria that 
governmental and independent organizations were focusing on in their evaluation efforts. These 
criteria aimed to cover categories of apps or an mHealth system for regional or national integration. 
The evaluation processes that are described are largely publically available and concrete. In other 
words, they are published in such a way that others can use them. With the exception of evaluation 
services, which aim to generate profit for their services, governmental reports, guidance, and 
frameworks are intended for hospital systems, regions, or entire countries to follow in order to 
understand the impacts of mHealth at scale. Processes described ensuring not only the success and 
feasibility of the technology in and of itself but also the readiness of the medical facility and network 
in question to ensure the sustainability of the technologies’ practical integration. Like traditional 
medical systems, these evaluation approaches are meant to offer an explanation for how these mHealth 
technologies can deliver the most positive impact to the most people.     
Whereas the grey literature review described the broader, more publically-facing approaches to 
evaluation, the scoping literature review provided an overview of evaluation efforts in controlled and 
clinically informed structures, looking at specific questions about mHealths’ impact. The scoping 
review paper (Paper 2) aimed to answer RQ2 by collecting information about what researchers’ 
intentional study approaches were and how they chose to evaluate patient-operated mHealth 
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technologies. Unlike the grey literature review, the research processes described in the scoping review 
are controlled and are meant to be built upon with additional evidence from fellow researchers.  
By comparing traditional vs. mHealth approaches and resources, we discovered that these two 
categories are not mutually exclusive. Researchers are using a combination of traditional and mHealth 
approaches to explain, more comprehensively, how mHealth technologies affect patients and HCPs. In 
doing so, they acknowledge that each category of information alone has its own strength and 
weakness, but together they form a more complete picture.  
While usage-logs and patient-expert feedback are valuable and informative, we still have a way to go 
when it comes to validating such mHealth-related resources and measures. Researchers demonstrated 
much creativity regarding how they collected, structured, and analyzed these data within the reviewed 
studies. However, these strategies were unique to each study, making them difficult to compare, form 
a meta-analysis, and thereby provide reliable and useful evidence.  
There have been attempts to create evaluation frameworks, scales, and scoring systems for these 
technologies. The WHO and the mHealth Technical Evidence Review Group’s (mTERG) mobile 
health evidence reporting and assessment (mERA) checklist, represents a research-facing strategy for 
identifying information about an mHealth app or system [262]. It urges studies to produce results on 
topics ranging from the financial impact, user feedback and accessibility, clinical impact, and delivery 
at scale, among others. But have these studies followed these strategies? Partly. Unintentionally or 
intentionally, researchers have, of course, covered the user-facing and medically-related outcomes that 
such checklists call for. However, to the best of our knowledge, there is little to no solid evidence in 
the scientific literature that researchers have been able to, or choose to, produce business and 
operational evidence.  
Limitations of the scoping literature review 
As was pointed out by our reviewers, we could have included more types of NCDs. While our 
narrowed selection of intervention types was based on public trends in mHealth and up-to-date 
regulations posed by health authorities regarding mHealth evaluations, we could have included a 
broader selection of technology and intended uses. For example, we could have included interventions 
based on SMS, an established and effective means of providing self-management support, especially 
in more limited socio-economic areas. 
7.1.3 How usage-logs can illustrate what is happening during an 
intervention (inside the Black Box) 
RQ3: Can usage-logs and patient-centred analysis be used to provide more evidence and information 
about what, how, and why changes occur during an mHealth intervention? 
Finding a balance between the mHealth resources that we now have access to, the patient voice, and 
the clinical interests of HCPs seems like a pipe dream. Yet, this is what we tried to illustrate in Paper 
3 by analysing patient participants’ mHealth app usage patterns, from a year-long RCT study. With 
data that told us when users interacted with the app, which screens they accessed and which health and 
behavior data they entered, we had the opportunity to provide more information about how patients 
chose to use the app for diabetes to meet some of their own self-management needs, during an 
intervention. If that sounded like a long, complicated task, and sentence, then you would be correct.  
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In health studies, the typical approach to data analysis is to compare results before and after the 
intervention, between pre-assigned intervention groups and control groups. The traditional analysis of 
these study groups represents differences in the assigned intervention groups, not differences in the 
individuals. This is an example of Weinstein’s criticism – back in 1974 - that clinical trial 
methodologies “obscure, rather than illuminate, interactive effects between treatments and personal 
characteristics” [263]. The analysis presented in Paper 3 proposes a more patient-driven approach at 
data analysis by structuring analysis, only after it was found that there were no significant differences 
between intervention groups, on how patient-participants chose to use the mHealth app. In doing so, 
we acknowledge that patient-choice has more of an impact on the outcomes of app usage than 
assigned groups. Focus on these emergent groups contested the traditional pre-post evaluation of 
health intervention studies and acknowledged patients’ choices of app usage just as much as clinical 
outcomes. Justification for this approach came when we saw that there were no significant differences 
between control (n=50) and intervention (n=51) groups (in app-use or health outcomes), yet there was 
much heterogeneity amongst those who chose to use the apps. Some focused on physical activity and 
diet behaviors and data entry (Cluster 1), whereas the other main group focused on BG and reviewing 
previously recorded events (Cluster 2). By comparing the usage-logs in addition to traditional clinical 
measures, between these two groups, we found that these two app-use strategies did have an impact on 
how much their HbA1c changed; Cluster 1 lowered their HbA1c more than Cluster 2. We also noticed 
that there was a relationship between how long patients used the app and clinical change – not after an 
entire year as one would expect, but instead after 4-months. This suggests that perhaps individuals did 
not have to use the app for a long time to experience benefits; perhaps it mattered more how they used 
an app, not how long.  
The outcomes of this analysis demonstrated that not only do end-users have a greater impact on the 
outcomes of a study than the group assignments made by the researchers; they also demonstrated how 
usage-logs provide context and some explanation for changes in before-and-after studies, using 
traditional and clinical measurements, such as HbA1c and self-efficacy. This was a test of a new way 
of structuring data for analysis and has the potential to help HCPs and researchers structure patient-
gathered app data for future practice and health interventions to answer questions about patients’ self-
management strategies and impacts on their health. Had we only depended on the original analysis, 
based on comparing intervention groups, we would have been forced to accept the results of “no 
significant differences, i.e., no significant impact, was found” and a conclusion that, simply, “more 
and different forms of research are needed”– something we find in very many of the research papers in 
this field. With the new approaches that we tested, we not only produced more information about the 
impacts of the intervention and which factors were at play, we also produced more actionable 
questions for future research. Instead of a general call for “different forms of research,” we were able 
to generate questions such as, “what impact did motivation play, or why did they choose to use the app 
in that way?”, “what other services or guidance would support patients to make more effective use of 
the app, given their collection of these data sets, e.g., what kind of help could an HCP add?”, “how 
long do patients really need to use an app, and in what way, to achieve physical or psychological 
changes – and what kind of changes are these?” Not only has mHealth technology and patient-driven 
research provided us the opportunity to understand what changes occurred during interventions, but 




Limitations of usage-log analysis 
Due to the K-means clustering method, used to identify similar usage patterns amongst participants, 
resulting clusters that were compared had few individuals included in the analysis. Also, five 
participants were excluded from the analysis due to their irregular or dissimilar usage patterns. 
Similarly, we did not include short-term users in our analysis. It has been proposed that individuals 
may not have to use an mHealth intervention sustainably or for long periods to experience benefits. As 
proposed by a specialist participant in the co-design workshops, intensive use of an app to record 
detailed self-management habits and health changes could also be very informative to the HCP but 
also to the patient-user. The short-term users may have chosen to use the app as more of an 
informational tool or to answer a specific question about an issue they were experiencing within their 
self-management. It would not necessarily require more than three months of use to gain the answers 
and support they needed –usage logs from whom could also be informative. 
Bias in clustering 
This analysis method was selected by the invited statistician who consulted and helped perform the 
secondary analysis of the data based on the fact that this is a commonly used clustering method [229]. 
Our intention was to identify profiles of use via secondary analysis of previously collected RCT data 
on participants’ use of the mHealth device. Clustering is the process of identifying groups based on 
similar outcomes, i.e. discovery of discover the natural grouping(s) of a set of patterns, points, or 
objects [229], in this case usage-log patterns based on which functions were most used by the 
participants. 
Clustering has been used to identify and make decisions related to, for example, “natural 
classification” such as those used to classify similar biological organisms into phylum. It should be 
noted that this is different from a case-control study in which controls and cases, e.g. disease exposure, 
are matched based on a common features, e.g. age, sex or education, and then retrospectively 
compared to identify if there are inherent differences that could have contributed to their different 
outcomes, i.e. no disease exposure vs. disease exposure; in k-means clustering, the individuals are 
being treated as a group because of their similarities and their usage-logs are described to gain a 
detailed understanding of what those patterns include, e.g. ratios between different functions used, 
duration of use of these functions, when the device was more or less frequently used. In the case of 
this usage-log analysis, it allows us to interpret the results from a participant-driven perspective, based 
on their decisions, not our third-party, and observably incorrect, presumptions that all use the 
technology in the same amount or way. However, there are biases related to the following parts of the 
“partitional” approach to clustering, i.e. the K-means cluster analysis: i) the researcher decided on the 
cut-off number of 5 individuals as this would allow for more meaningful statistical comparison 
between groups, ii) “hard assignments” of a data point to one group or another do not, by definition, 
allow an individual to be part of more than one cluster at a time, even though could share a low level 
of similarity to another cluster than the one they were assigned to; while this eases statistical 
comparison between emergent groups, it does not allow for interpretations of just how similar 
individuals are between the “hard assigned” groups just that they are “different enough” to be assigned 
to different groups, iii)  identification of the emergent clusters and decision that a data point, or 
participant, is more similar to one group than another is somewhat subjective based on the researcher’s 
interpretation and decision, which is often difficult as cluster clouds can be different and vague in 
terms of density, size and shape [229], and iv) clusters were assigned based on a certain set of data, 
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without consideration of age, gender and other potentially relevant factors. We can therefore not form 
conclusions related to differences in usage patterns between older and younger individuals who may 
have used similar functions but in different variations within an assigned cluster, which again was 
based on the most commonly used functions. Differences between people within the assigned clusters 
based on these factors were not explored and therefore should be considered upon future analysis of, 
ideally, larger participant populations. 
7.1.4 How mHealth can be used as a resource for traditional health 
evaluation methods and measures 
RQ4. How can mHealth approaches and resources supplement traditional methods and measures in a 
protocol describing how to measure impacts of an mHealth intervention on patients and HCPs? 
The design and the test of the protocol answered the first part of RQ4, related to how mHealth 
approaches and resources could be used to supplement and complement the traditional methods and 
measures. Combining standardized pre-post questionnaires – measuring both psychological and 
physical wellbeing and patient-provider relationships – with usage-logs, focus group feedback, and 
usability questionnaires from both patients and HCPs. We believed that these combinations of 
measures would allow us to answer not only what had changed during the intervention for both 
patients and HCPs, but also how and why. However, these results only demonstrate, not prove, the 
possibility of mHealth as a resource for health intervention research. While we have the opportunity to 
broaden research’s perception of what is relevant and what impacts the medical community, we do 
have to take these results with a grain of salt and take into account before our next studies that both 
mHealth and traditional research have their strengths and weaknesses. 
Traditional methods and measures are specific, validated, and make it possible to replicate studies and 
build upon the same evidence as others in the field. However, they attempt to measure cumulative 
change reported at a single moment, such as the Healthcare Climate Questionnaire (HCCQ). The 
responses may fall victim to memory error or mood that day for the patient, which may not accurately 
reflect their experience during the whole intervention. This may have been the case with the second 
case (T1D) analysed as part of the feasibility study, in which the participant responded that they felt as 
though their DN had less confidence in him, even though they both reported positive effects of using 
the system together. Situations during an intervention, especially interpersonal ones, are much more 
complex than can be measured by one method applied only a few times during the study, typically 2-3 
times. While our focus group meetings helped to elaborate on the T1D patients’ side, it was not 
possible to clarify any miscommunications from the DN’s side, as she was unable to attend the HCP 
focus group meeting.  
mHealth technologies reinforce and facilitate the concept of patient-centred and patient-driven 
research. mHealth for self-management puts individuals in the driver’s seat of their own health 
decisions. When we acknowledge patients’ decisions in our research activities, e.g., usage-log 
analysis, we are also forced to acknowledge that individuals use apps differently – just looking at the 
heterogeneous data of the RENEWING HEALTH study demonstrated that one size does not fit all. It 
forces us to rethink our questions, our interpretations of the data, and our assumptions of patient needs, 
priorities, self-management practices, and barriers to doing so. With the help of mHealth technologies 
and empowered patients, we can more effectively expand the impact of research by expanding the 
conversation and focus of healthcare practice to include that of the patient.  
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As demonstrated by the mixed-method feasibility study, usage-logs can also be complementary to 
traditional measures. These logs refer to each interaction that a user has with an app or other mHealth 
device [264]. Researchers can refer to “usage patterns” to describe a patient’s journey through a study, 
e.g., their engagement with the intervention as well as participation in the study or when they were 
most and least engaged [265]. By comparing these data to other data collected during a study, we 
could theoretically begin to explain why these changes in usage patterns occurred. We can also begin 
to ask more questions than we have been able to measure before, e.g., when did that user change 
which type of data they collected and used in their self-management routines? These could be 
followed by more qualitative questions that elaborate or explain these responses. Analysis of usage 
logs and usage patterns is also a very new concept in medical and health research, with most cited 
studies occurring in the last 2-3 years. As such, the same questions apply to this form of data as 
patient-generated health data, e.g. how to structure the data, how trustworthy and reliable these are etc.  
The results of the feasibility study demonstrated that the mHealth-focused resources and measures 
helped to explain why and how the experiences, relationships, and wellbeing changed during the 
intervention period. For example, focus-group input explained some patient participants’ motivations 
behind not only collecting but also sharing data. Patient participants seemed to give honest and direct 
feedback about technical errors that they had with the system and frustrations with the healthcare 
system and their HCPs that were correlated with, e.g., missing data for the T2D user, and T1D’s 
decreased satisfaction with his patient-provider relationship.  
mHealth could provide an approach and the resources to conduct studies that lead to more in-depth 
and foundational questions about not only what but also how and why patients, and even HCPs, 
engage with an intervention in the manner that they do. Perhaps by using mHealth approaches and 
resources, the future publications of our research works could conclude with concrete suggestions for 
what information needs to be explored next, as opposed to the very popular phrases “more research is 
needed to…”.  
 
Figure 19 Illustrating how mHealth can help to open the “black box” of health intervention research. 
We can continue to ask: what information should we aim to produce, for whom, and how should we 
go about this for mHealth intervention evaluations? In doing so, we can use mHealth to open the 
“black box” of research interventions and identify not only what has changed but also how and why 
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these changes occurred during an intervention using a practical case, diabetes self-management 
interventions (Figure 16). 
However, patient-generated data, such as usage logs, are prone to technological and human error. The 
analysis for these data has not yet been standardized and therefore are difficult to replicate and 
validate. Case and point, while the structure of the usage-logs for analysis was based on 
interdisciplinary theories, this process has only been performed a few times; it has not been performed 
or validated outside of the present research team, i.e., during the Tailoring and RENEWING HEALTH 
projects, and therefore requires more validation and, of course, data.  
Reflections of the pragmatism paradigm in the study design and administration 
Loudon et al. provide a means to assess the level of pragmatic approach that a study has built into its 
design and performance [266]. Based on 9-domains of a study design and performance, the study 
could be scored from 0 (explanatory, positivist and evidence driven) to 5 (pragmatic and knowledge 
driven). I performed this analysis on the FullFlow feasibility study will benefit from recalling Figure 
20.  
 
Figure 20 PRECIS-2 Score for the FullFlow Feasibility Study 
I provide detailed explanation for how I concluded on these scores for each PRECIS-2 domain, based 
on specific decisions made in the protocol and administration of the FullFlow Feasibility study, in 













 Individuals who were 18+years, with T1D or T2D, lived within the Troms/Finnmark areas, 
interested and willing to try to use the intervention were considered eligible 
 Providers were identified based on our own research network and colleagues’ contact within the 
Troms/Finnmark areas 
 Because this excluded those who were not interested in mHealth technologies, from both the patient 
and provider side, or those who lived outcome of the Troms area, scores of 4 or 5 were not justified 
 However, no limitations were placed on HOW the intervention would be used, only described the 
possibilities of the various ways in which it could be used, so use-related decisions were meant to be 
based on participating users’ level of technology interest and ability, which justified a score of 3 
Recruitment 4 
 All patients with T1D or T2D were recruited through their providers, who had already agreed to 
enter the trial 
 Recruitment materials were given to those who attended an appointment at the clinic or mailed to 
those whom the provider perceived as potentially interested 
 A score of 4 is justified because, outside of eligibility, the process of recruitment used existing 
workflows and protocols, which did not require much more work than a provider would normally 
perform to contact patients  
Setting 4 
 Part of the intervention occurred in the typical setting of a consultation for the purpose of diabetes 
care between the patient and their normal provider in their office setting  
 While the research team encouraged patients to schedule these in order to try to use the intervention, 
it was unknown which of these were regular appointments or which were scheduled because of the 
study, which is why the score of 5 is not justified 
Organization 3 
 Patients were not trained but were provided with access to online resources to assist them in 
deciding how they would like to use the system 
 The system was made available online so that anyone anywhere could access the patient's data 
(including themselves) as long as the patient provided the access key and initiated data 
transmission. Therefore, this could be made available during normal clinical consultations as long 
as the secondary user had access to the internet and consent from the patient (the ideal and hoped-
for setting of our study) 
 Participating providers were trained on the system for 1hour, which would, the in real world, require 
outside support and technical assistance 
 Additional assistance is a rather large barrier to real world use, which is why the score is only 3 and 






 Participating patients were encouraged to schedule an appointment with their provider to discuss 
their data after a 6month period of time (via a message sent to their smartphone app and on e-mail) 
 Patients decided when and if they would indeed do this and follow-up reminders were provided only 
twice if they did not decide to do so (data limitations were expected to result) 
 Providers were instructed to click the link in the intervention system, which automatically led them 
to a questionnaire page associated with the consultation of the individual who shared the data, after 
each consultation to provide research feedback so that the experience was fresh in their minds and it 
would reduce the need to remember later.  
 Patients were sent the link to a 6-month questionnaire about their consultation via a message to the 
intervention’s app on their smartphones and on email 
 Patients and providers drove the conversations together and questionnaires only asked what they 
talked about instead of dictating what they should talk about or how they should use the system 
 While the research team did encourage use of the system, the freedom provided to patients and 




 Researchers sent follow-up messages each month to encourage and inform participants of the 
different functionalities that were available on the app 
 However, these messages did not direct the patient about how to perform self-management or what 
information to record, only encouraged them to explore the possibilities of the technology that they 
believed would be useful for them (tailorability) 
 More administrational follow-up messages included instructions for how to participate, i.e. up to 2 
reminders for the start-up registration of their device to the research system so that we could 
remotely collect their data, baseline questionnaire, 6-month consultation scheduling and post-
consultation questionnaire 
 These would not be available in real life, which is why this is not a score of 4 or 5. 
Follow-up 1 
 As mentioned under “Flexibility: adherence”, we performed significant efforts of follow-up after 
each consultation throughout the duration of the study and provided email support whenever they 
needed.  
 The score for “Follow-up” is low because such support would not be available in the real-world 
setting. We did not expect healthcare providers to be able to do so given their already overwhelmed 
schedules, and if they would like to include this in their practice, they would most certainly have to 





 Outcomes were largely based on the previous studies (described in the Methods and Results 
sections), provided by both healthcare providers and patients 
 To ease reporting by patients, outcomes were gathered by response offered via a link in a message 
from us to their smartphone app/email to a set of questionnaires. Usage-log data was remotely 
captured (which did require some effort from the individual participant who had to enter a code in 
order to allow our system's access to their logs) 
 Patients and providers were also invited to study-end focus group meetings, through which they 
could express their experiences, frustrations, and overall perceptions of their experience and the 
intervention's impact. 
 Because outcomes were based on end-user input and the flexibility in which they could be reported 






 We did not exclude or limit the data available if the participant stopped using the device, did not 
complete questionnaires or did not schedule with their providers. we simply viewed these as results 
reflective of real-world situations  
 Missing data were seen as valid results of either the participant's experience in the trial or use of the 
intervention (although we did not know which one), which is why the score of 5 is justified for this 
criteria 
 
Limitations of the feasibility study outcomes  
The main limitations of the feasibility study as a whole included geographical location, recruitment, 
and technological challenges. Because this study focused on collaboration between patients and HCPs, 
we needed HCPs to be engaged, and therefore we needed to recruit prospective patient-participants 
through them. The Troms and Finnmark regions occupy a large geographical area, with a small 
potential participant pool from each clinic. As a result, we were only able to recruit eight patients. This 
led to the inability to comment on the statistical change or comparison of the usage-logs or 
questionnaire responses within and between patients during the study. There were also limitations 
regarding the amount of quantitative data we could gather through the app due to the connectivity 
challenges with not all users being online 24/7. As such, we also have limited ability to comment on 
the usage data of app interactions. As a result, we would not have continuous interactions and patient-
gathered measures data to provide insight into behavior change during the study. However, all patient-
registered measures were recorded and will be included in later analysis. 
Due to the risk of participant burn-out, known as respondent or participant fatigue [267], we were 
limited in the number of standardized questionnaires we could include. While the patient focus group 
meeting did provide more understanding of their situation, we may have improved our ability to 
understand the responses more thoroughly by reflecting their questionnaire responses in the discussion 
questions that were asked in addition to basing questions off established theories.  
The patient study-end focus group, fortunately, was held before city closures were enacted due to the 
COVID-19 crisis [268]. Unfortunately, only one HCP – a DN who did not participate with a patient in 
the study, and used a system called Diasend [269] instead of the tested data-sharing system – was 
willing and able to attend a virtual interview. The rise of the COVID epidemic only highlighted an 
existing research challenge - recruiting HCPs. While we did pay GPs for their time, these HCPs do not 
have the same funding and flexibility as hospital staff to participate in research. Therefore, the only 
understanding of how the HCPs who met with patient participants felt about the use of the system was 
based on questionnaires. 
7.2 Limitations of the Pragmatism Paradigm 
In addition to the practical study-specific limitations that affect the generalizability of this thesis, as 
was mentioned in the background section, the pragmatism paradigm comes with its own perception of 
generalizability that must be discussed.  
COVID-19: prime example of how a global change affects generalizability 
Circumstances change how we perceive and respond to our environments. As we can see from the 
world’s ongoing experience with COVID-19, perceptions and realities evolve with time and are highly 
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affected by the tangible and intangible factors that surround individuals. In one of our own articles 
(Appendix P) [260] we noted that while clinicians’ willingness to support their patients’ use of 
mHealth and receive patient-gathered data had increased between 2013-2017, healthcare authorities 
had not provided sufficient daily recommendations for how to successfully and safely accomplish this. 
Today, the need for healthcare services despite social distancing measures of the pandemic have 
forced healthcare authorities such as the CDC to offer official guidance and recommendations about 
how healthcare providers and facilities should react [270], and even provide information regarding 
insurance coverage, something that mHealth technologies have not yet achieved [271]. These changes 
happened over a matter of months in response to the rapid spread of COVID-19. There are also the 
intangible influences such as the stress of being isolated and defeated during the pandemic, i.e. 
COVID or Pandemic Fatigue, for everyone and/or the exhaustion and anxiety of being a healthcare 
provider. These symptoms of mental stress can manifest in many different ways from frustration with 
simple tasks and short tempers, to depression and loss of occupational productivity [272, 273]. While 
these may not seem to affect the use or perception of mHealth think of how frustrated we can normally 
get when our phones or internet is not working – an overly simple example yet one we can all relate 
to. Now add the stress of needing to connect online, perhaps with your doctor about some worrying 
symptoms you are experiencing from your diabetes, and not being able to. If we had the capacity to 
interview the HCPs and individuals with diabetes who participated during the FullFlow Project, it is 
within reason to expect that their perceptions of mHealth and/or the need to share patient-gathered 
data in-person would have changed. The functionalities of the system that we developed during the 
presented project would then also need to change to support social and “medical distancing” where 
possible. 
Self-selection bias 
The generalizability of our findings is also limited by a common bias – self-selection bias. This is 
exactly how it sounds; while recruitment information may have been made public via pamphlets or 
social media etc., individuals who choose to enter a study inherently skew the data that are recorded 
because they are willing and able to participate. As such, they may not represent the larger population. 
The negative impact of self-selection bias can be larger or smaller given the study design and purpose. 
In the FullFlow Project, we aimed to build upon existing and used mHealth technologies for diabetes 
and therefore the purpose of our findings not only expected but relied on self-selection; we aimed to 
recruit and analyse the specific needs of those who have or were willing to have experiences with 
diabetes apps and data-sharing. Our recruitment activities reflected this need by posting recruitment 
messages on our research group’s Facebook page (Diabetesdagboka), via our research app and 
through healthcare providers themselves, who had a population very specific to the geographical 
region. However, the danger of selection-bias for this project is evident in the interpretation and 
application of these findings to other circumstances. Factors, such as prevalence of smartphone use 
and internet coverage, accessibility of health information and support prior to study-start, could have 
influenced individuals in the described studies to present as more or less motivated or have greater 
internal locus of control than other populations. These results cannot be compared to or expected to 
appear, if the same intervention were used in a geographical area with less access to useful 
information and other support. A systematic review also noted self-selection bias as a challenge of 
interpreting results from mHealth studies [274]. An example from the FullFlow project is the 
secondary analysis of an mHealth intervention’s usage-log that was performed as part of Paper 3. The 
results are highly biased because the use of the intervention technologies was entirely up to the 
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individual participants, i.e. as part of our secondary analysis, they self-selected their groups by using 
the app for shorter or longer periods of time and using different combinations of functionalities. As an 
RCT, individuals were assigned to a control, intervention or intervention with counselling group; 
while these factors and other measured demographic data were possible to account for in the statistical 
analysis of the usage-logs, the behavioural component within was not part of the original plan. In the 
primary results of the study, it was reported that there was no significant differences between groups 
or within groups over time [225]. Upon review during our secondary analysis, based on use-duration 
and clustering, we observed that n=29 participants did not even interact with the app, i.e. introduced 
non-response bias which has similar effects as self-selection bias; these participants’ usage-patterns 
pulled the averages and other measures of use down. Due to small group sizes, the lack of identified 
significant differences between these self-selected groups as part of the secondary analysis (Paper 3) 
[253] cannot be taken at face value. Similarly, the statistics show a change over time and difference 
between groups associated with HbA1c, these numbers cannot be generalized to other individuals or 
cohorts. This is because comparisons were the result of k-means clustering. As mentioned above, 
clustering is highly affected by the statistician’s interpretation, which is influences by underlying 
biases like background, previous knowledge of the intervention, disease and cultural influences that 
affect perceptions of study participants’ behaviour.  
Other limitations to generalizability: technology and geography  
The activities described in this thesis do not address all types of mHealth, nor will they answer all of 
the needs of mHealth evaluation. In order to improve upon these works and direct future studies, we 
must acknowledge the limitations of the described thesis activities with regards to what mHealth 
intervention evaluations can tell us. 
This thesis uses patient-operated mHealth technologies as a use case. Evaluation of these technologies 
assumes that patients’ use of these technologies, and thereby their health impact, are equally 
dependent upon the patient’s daily self-management decisions as much as those of the HCP’s clinical 
judgment and recommendations. However, there are health technologies that can still be described as 
mHealth that are used by HCPs to monitor their patients. In these cases, use is prescribed, and patients 
may not have access to their data. Therefore, an evaluation may not need to rely as much on 
understanding the patients’ varying motivations for using the technology, their health literacy, nor 
their diverse patterns of use, as these are directed by their HCP. In addition, there is a slew of other 
types of mobile technologies that are not included in the “patient-operated mHealth” category, 
including short-message-service (SMS) and consultations via Skype. As such, the findings in this 
thesis may not be as applicable to those who live in lower-income areas and/or only have access to 
SMS-based services and/or video conferencing tools.  
The mHealth technologies chosen for most of the thesis activities, i.e., the Diabetes Diary app and 
FullFlow data-sharing system, are in-house developed and tested technologies that we use as a 
research platform. As a research platform and not a commercial product, we do not have the funding 
or capacity required to pursue extensive development, e.g., those who pursue connectivity, advanced 
computational abilities, and functionalities. In addition, due to timing and policy constraints during the 
course of the FullFlow Project, our original aim to incorporate patient-gathered data into HCPs’ EHR 
systems was not reached. As many HCPs in our previous works have expressed the desire to have data 
incorporated into the patient record in a clinically informative way, this may have affected recruitment 
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of participating HCPs as well as their ability to use yet another electronic system to meet their patients 
– an addition that they have specifically said was undesirable.
This thesis’ generalizability is also limited by geography. In Norway, residents have relatively high 
access to healthcare, good health, education, disposable income, as well as a low prevalence of 
reported unmet needs in healthcare. This means that participants in these presented activities represent 
highly educated individuals and HCPs with the access and disposable income needed to receive 
treatment as well as preventative and palliative care when it is indicated. While this may be 
comparable to some other medical systems and countries that have fully or partially socialized 
medicine, this is a unique situation compared to other high-income countries, such as the US, without 
socialized healthcare, not to mention low-income countries.  
7.3 Contributions to the field of mHealth diabetes intervention 
studies 
This thesis focused on how to approach studying the impacts of mHealth on patients and providers 
related to diabetes care. My intention was to explore and understand the concepts related to study 
design, methods, what and how to measure these impacts whereby the purpose of the outcomes of 
each study being to indicate the depth and breadth of knowledge and understanding that could possibly 
be generated by these approaches. Therefore, while the specific results of research based on the 
pragmatism paradigm may hold little potential for generalizability, there are elements of these 
research activities that contribute to the relatively new and largely unknown field of mHealth.  
As described in the background, many intervention studies involving mHealth for diabetes describe 
limited outcomes and often end in the conclusion that further research is needed to, e.g. better 
understand the impacts of other factors that make “it difficult to demonstrate the efficacy of apps” 
[109]. The importance of exploratory research efforts (e.g. those performed during the FullFlow 
Project using a sequential exploratory strategy) in a burgeoning field is to identify what more needs to 
be known, e.g. compared to health technology intervention research, what can be known and how it 
can be known.  
Building upon previous knowledge: the pragmatist paradigm and pragmatic research 
In the 1970’s, qualitative methodologies were found to be necessary to build upon, contextualize 
and/or explain quantitative findings; for such chronic illnesses as diabetes, researchers and healthcare 
providers acknowledged that a patient’s understanding and behaviours related to their diagnosis was 
just as impactful to their health as was the biological impact of medications. What we are seeing 
today, i.e. identifying what can be known about the new field of mHealth using traditional and largely 
pragmatist approaches vs. what more is needed to know in order to optimize its use, parallels the shift 
from quantitative to qualitative methodologies in the 1970’s. Research into mHealth interventions for 
diabetes self-management requires a shift from a dichotomous approach of performing separate 
qualitative and quantitative research to the dialectic pluralism approach of the pragmatism paradigm. 
This means holding both positivist, quantitative methodologies and constructivist, qualitative 
methodologies as equally important and often mutually dependent. As described by the HCPs in the 
co-design workshops (present in the transcripts but not included in publication), continuous glucose 
monitors are considered the gold standard in Norway for those with T1D. However, they are more 
effective if they are worn continuously; in reality, individuals often have interrupted and inconsistent 
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use patterns. Using this as an example, the evidence of the CGM’s efficacy (established via positivist 
quantitative methodologies [275]) is not feasible in the real-world unless used optimally, which means 
we need to understand why individuals take breaks in using these tools. In other words, by applying 
constructivism and qualitative methodologies, we can begin to understand barriers and reinforce 
facilitators that contribute to the optimal efficacy of, e.g., CGMs.  
While CGMs have a protocol for how best to use them – whether it is used correctly or not – mHealth 
in general has no such guidelines; downloaded diabetes apps for self-management can be (and are) 
used in almost uncountable different ways. This means that outcomes from most studies that aim to 
prescribe a certain type of use are not as generalizable as other health technologies studies, such as 
those for CGMs. Theoretically, to understand the impacts of mHealth (well enough to judge its safety 
and efficacy to the point of, e.g., CE-marking and FDA approval), we as researchers would have to set 
up studies that mirror the “almost uncountable different” uses of mHealth for diabetes self-
management. I think we can all agree that this is unrealistic. Applying the pragmatism approach to the 
study of mHealth interventions for diabetes self-management can help us narrow down the factors that 
should be measured and explained; emergent factors and ideas that impact one’s use of mHealth 
technologies point to the next question to be asked in future studies. As demonstrated by the outcomes 
of the PRECIS-2 assessment of the FullFlow feasibility study’s administration, we can systematically 
identify which parts of a study can be more or less expected in the real-world application of an 
intervention – a criticism of quantitative outcomes that led to the popularity of qualitative approaches. 
It is also important to note that the factors that were measured, i.e. the primary outcomes and primary 
analysis which were given a score of 5 on the PRECIS-2 assessment in the FullFlow feasibility study, 
were generated from smaller studies which produced understanding of end-user needs and priorities 
through the sequential exploratory strategy of mixed-methods research.  
Using pragmatism paradigm in the thesis: a best fit for mHealth diabetes mixed-methods 
intervention research? 
The activities of this thesis followed a sequential exploratory strategy within a pragmatism paradigm: 
each study informed the design and provided the research questions for the subsequent studies, with a 
focus on reflecting and understanding real-world situations. Figure 21 illustrates how each separate 
study was dependent upon preceding studies. The blue diamonds represent the thesis activities, the 
dark blue rectangles represent the outcomes of these activities (either published as a conference paper, 
poster or publication), the green rectangles represent the questions that arose upon completion of the 
previous outcomes, i.e. the questions that prompted subsequent activities (i.e. the blue diamonds). 
Activity outcomes (dark blue rectangles) also generated ideas (orange rectangles) that would help 




Figure 21 Overview of the relationships between activities, outcomes and subsequent questions in this thesis' 
pragmatic sequential exploratory strategy 
 
88 
7.4 Implications of the Pragmatist FullFlow Project for future 
research 
What I have learned from participating in FullFlow Project activities, the expressed needs of different 
stakeholders in the care of chronic conditions, as well as my own experiences with healthcare services, 
has impacted how I intend to pursue a career in research, described in details in the sub-chapters 
below. 
7.4.1 Does mHealth call for a new paradigm or just a new way to 
measure impacts? 
Rapport and Braithwaite provide a description for the shift in thinking, or paradigm shift, as a lens 
through which we can view these changes in the diabetes research environment.  In their 2018 paper, 
Rapport and Braithwaite introduce the concept of a shift between the “Third” and a proposed “Fourth 
Research Paradigms” in medical and health research, which build from the “First” or quantitative 
positivism paradigm and “Second” qualitative constructivism paradigm [276]. The Third paradigm of 
research embraces mixed-methods research, i.e. a combination of both quantitative and qualitative 
approaches and methods. It is important to note that what Rapport and Braithwaite mean by “a shift in 
paradigms” is not really a pure shift but an evolution; it builds upon the advancements in 
understanding that came before, but does not seek to replace them. This Fourth paradigm is described 
as being one that is distinctly different than the Third paradigm; while the Pragmatist Third paradigm 
still uses established and standardized methods and measures, the Fourth acknowledges the need to 
incorporate the more continuous, real-time gathered data into research (Figure 22). However, they do 
not answer “how” we as researchers can achieve this in practice. 
 
Figure 22 Illustration of Rapport and Braithwaite’s [276] proposition of the ongoing evolution from the third to 
fourth paradigms of research, with the question of how to achieve this evolution practically. 
While this is a newly proposed concept, with few references, the point they make is sound and one 
that this thesis supports, in part. The way in which the Pragmatism paradigm applies qualitative and 
quantitative methods, as well as interprets these outcomes, is in a more flexible manner than that of 
Positivist and Constructivist approaches. However, the methods and measures themselves are still 
consistent with those used in these other two paradigms; Pragmatists still rely quantitative measures 
that are validated, established and structured and qualitative measures that are collected and analysed 
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in established ways, e.g. semi-structured interviews and analysis via identification of themes by 
researchers, independently, within a team. However, Rapport and Braithwaite point out that mHealth 
data presents different characteristics that are beyond those of established methods, i.e. patient-
gathered data is continuous, unstructured, arbitrarily gathered by individuals. But do mHealth data call 
for a shift in paradigm or simply a way in which to capture, structure and perform analysis on 
collectable data? I argue that this thesis supports the proposal by Rapport and Braithwaite, but only in 
part, because a paradigm is built from more than just a new method or measure. The Pragmatist 
paradigm already addresses the axiology, epistemology and ontology that mHealth embodies. Even 
the “Reality Cycle” proposed by Maarouf [192], to describe how knowledge is generated and evolves 
in a cycle, is comparable to the “Experiential model of learning” for health self-management – the 
foundation for Diabetes Self-Management Education - which describes how a person can learn from 
previous experiences to improve upon previous actions or maintain their habits to achieve health. So, I 
suggest that what we, additionally, need to explore further and eventually decide is how we could, or 
should, perceive mHealth data.  
As demonstrated in Paper 3, usage-logs can be quantified and analysed similarly to measures taken 
from the Positivist perspective. Part of the positivists paradigm is the belief that even emotions, 
feelings or motivation can be measurable, e.g. standardized questionnaires about self-efficacy or 
wellbeing. The frequency, duration, type and amount of interactions can all be perceived as, of course 
not standardized, but distinctly measurable accounts of a person’s self-management habits and, in turn, 
possibly their health foci and progress. The main divergence from this paradigm is the interpretation, 
which is more in line with the Pragmatist approach. Usage-logs reflect a single reality - living with 
diabetes-, which calls for at least some of the four primary parameters to be measured. However, 
usage-log analysis in this study also acknowledged that individuals do not perceive or act upon that 
reality in the same way. Especially when compared to the qualitative feedback from the study-end 
workshop, we were able to interpret the usage logs through the lens of the individual’s preferences and 
capacity. As is the purpose of science, the way in which this measure is analysed and interpreted 
depends on the research question and intention of the researcher. Future research should explore the 
lengths to which mHealth usage-logs and patient-gathered data can be treated as either qualitative or 
quantitative measures of the impact of mHealth, patients’ self-management, engagement or otherwise.  
7.4.2 The importance of collaboration and multidisciplinary approaches 
This process has opened my eyes to the heterogeneity of those living with chronic illnesses. Most of 
us have become familiar with the phrase “one-size-does-not-fit-all” in relation to fashion and other 
commercial industries, politics, education, and health care. Especially for the medical system, and we 
as researchers who aim to provide evidence for practice, this ideal of tailored care has yet to be 
realized at-scale [277]. Research is traditionally set up to describe cohorts or groups of people who 
demonstrate relatively similar characteristics. What research is not as prepared or set up to doing on a 
large scale, is combining comprehensive data sets to describe each person as their own cohort. We 
have, to a large extent, been educated and trained to specialize – to focus on either qualitative or 
quantitative methods, to focus on clinical changes or psychological impacts, to base our approaches on 
one or just a few fields of knowledge. As such, we are limited in our ability to bridge the gap between 
the ideal of personalized care and the reality of generalized research approaches and outcomes. 
Specialization historically allowed societies to grow, each group focusing solely on their skill with a 
limited understanding of other fields [278]. While it is true that one group or person cannot do 
everything, specialization has met its limits in today’s age of research where more involved 
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connection, collaboration, interoperability, and interdisciplinary endeavours are favoured [279]. While 
it is important for groups, e.g., HCPs, patients, health authorities and device manufacturers, to have 
their unique competencies, it is now more important than ever to find common grounds and objectives 
in order to achieve the ideal of personalized, empowering and clinically effective health interventions. 
7.4.3 Challenging the common terms: changing the language can 
change perspectives 
Words have meaning. They can confuse or effectively educate. Here I will describe two situations in 
which a common set of terms could have facilitated a more unified, open perspective and common 
understanding, and thereby, more efficient and effective work. The first is from the overall project, 
through which this Ph.D. was conducted. The second is a more widespread use of phrases related to 
“patients,” users or individuals living with a chronic condition in research and healthcare settings.  
The first situation was at the research project level. In the FullFlow Project, our team was comprised 
of those with clinical, engineering, programming, and marketing backgrounds. When it comes to 
collaboration between groups, we continuously experienced the challenges of, for example, agreeing 
on what “usability” meant. These differences were also experienced in other projects, e.g., developing 
a global framework for mHealth assessment [280]. It was difficult to move forward through the 
project stages because we were speaking, effectively, different languages. We spent hours, over the 
course of days, to agree upon how to proceed based on our background and understanding of relevant 
terms. However, after we agreed, and in some cases, agreed to disagree on minute (inconsequential) 
details, we were able to collaborate to design a working prototype in each of these projects.  
The second group of situations is more systemic to the healthcare environment. The use of the words 
“shared” and “centred” in terms such as patient-centred, shared decision-making, adherence, and hard-
to-reach patients, may lead us to believe that individuals are treated as equals in their involvement. 
However, it often means that the assumptions of patients’ needs are addressed. The words “diabetics” 
and “patients” imply that a person is –or at least is largely - their illness, while “adherence” and “hard 
to reach” imply a negative judgment on individuals, i.e., that they are not meeting others’ 
expectations. What these phrases have in common is that they often describe events that lack patient 
input and perspectives. These phrases are commonly used to describe different aspects or groups of 
people in research and healthcare practice. I, too, am guilty of this habit; it has always seemed easier 
and universally understood. However, these words strongly affect our perceptions of the individuals 
whom we aim to help; they apply the stigma of the fault and propagate the inaccuracy of our 
involvement of individuals in medical and health research. We have become numb to using these 
words, but now, with the advent of mHealth and patient-empowered movements and societal foci, it is 
time to stop using these phrases and instead try to use more inclusive, non-judgemental and open-
minded words to describe those who are living with chronic health conditions. 
Just as medical services and approaches to the care of chronic conditions have been turned on their 
heads, so too have research approaches. People living with health challenges have become partners in 
research as well as decision-makers in their own health care. Methods that originated from other 
fields, such as business and marketing, have been incorporated into intervention design and 
development in order to address all end-user needs, not just those with an official acronym.  
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7.4.4 Changing perspectives can lead to the spread of equal 
collaboration and empowerment in healthcare 
We can and should challenge our assumptions and perspectives of one another. Not just within 
healthcare but in society. This brings to mind a quotation from the movie Finding Nemo in which the 
predators, the sharks, are in the process of changing their perspective of their prey, the fish: 
“I am a nice shark, not a mindless eating machine. If I am to change this image, I must 
first change myself. Fish are friends, not food” –Bruce, the Great White Shark [281].  
The same must happen in healthcare: “patients are people, not symptom clusters.” Just as the sharks 
are fighting their instincts, we have to fight our formal education. While we in research and healthcare, 
of course, do not set out to view people as such, our training and education urge us to embrace the 
more objective and emotionally distanced practices of care and research. The aim of this approach is 
not to be callous or unfeeling, but to be effective to the greatest number of people – of those whom we 
serve in the medical system. Instead, I argue that by embracing what mHealth encourages, e.g., 
empowering the individual to become experts of their own health, and personalizing heterogeneous 
health solutions for chronic conditions, we, as equal stakeholders in the healthcare system, can be 
more informed, communicative and effective.  
When we acknowledge one another’s competencies, we can enact more strategic change. We need to 
challenge the assumptions that we make of one another. For example, one of our HCP participants in 
the co-design workshop expressed that he believed patients were not interested in discussing the 
specifics of their health. This implied an end to this conversation, as there were no alternatives 
provided.  Alternatively, those in the patient co-design group described that they understood GP’s 
limitations in time and schedule to be able to answer their specific questions related to technology and 
mHealth-aided self-management. Instead of ending the conversation, this allowed for further 
discussion that could address these specific limitations, and several participants ended up suggesting 
alternatives.  
To change our assumptions, our perspectives, we need to ask questions and communicate between 
groups. By treating individuals as equals in true, shared decision-making practices in healthcare, and 
as partners in the design of research endeavours and intervention evaluations, we have the opportunity 
to produce knowledge, devices, and practices that are relevant, useful, and sustainable for patients and 
HCPs.  
Ultimately, to achieve greater understanding and provide the basis for correcting assumptions, we 
have to communicate. However, the platforms through which different stakeholders communicate are 
generally very much separated. This is especially where having field-specific vernaculars limits 
understanding across fields. 
7.4.5 Tailoring communication to spread knowledge: “the 
democratization of knowledge” 
As the results of this project and other research have demonstrated, most patients living with chronic 
conditions want to know more – about their condition, about options, and even about research or 
developments in the pharmaceutical and medical device fields. Unfortunately, they are not always able 
to access this information. Relying on scientific publications to disseminate research knowledge is not 
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ideal if the aim is to educate all relevant stakeholders. The Norwegian government, among other 
authorities throughout Europe, have made disseminating research results in a more publically 
accessible way a primary goal [282].  
Just as the traditional hierarchy of medical care is coming to an end, so is the habit of collecting health 
knowledge in scientific silos, such as scientific journals. While, yes, having a medical and health 
researcher agree with a programmer on what the finite points of “usability” means, may hel p those in 
the scientific community communicate, those outside of these fields are not interested in the specifics 
of words. They want to know what “usability” means for them. The trend toward “the democratization 
of knowledge” is a consequence of progress in information and communication technology (ICT), 
such as access to information on the internet [283]. Individuals no longer have to wait for a book on 
advancements in diabetes treatment to be printed in order to access it. However, they do have to know 
which online platform to look in.  
Unfortunately, most results of these innovative and to-date studies are secluded in research journals. 
Outcomes of tested technologies or new strategies for health treatment are mainly published in 
literature via subscription-based forums, in a scientific vernacular, and directed to our peers. However, 
the accessibility of online information has contributed to the greater focus on open-access literature 
and even popular science articles to reach all, not only some, of the interested parties [284]. Everyone 
has a right to knowledge. Popular science articles are accessible, direct (to-the-point), and focused on 
informing a general audience about advancements in health care knowledge. Only when we have 
interdisciplinary collaboration, transparency, and truly accessible knowledge can we hope to produce a 
complete set of mHealth impacts that can effectively inform decision-making in research approaches, 
clinical practice, and self-management. 
As those who develop and produce knowledge, we have to consider more diverse options for 
dissemination. Popular science, social media, blogs, and newspaper articles address the masses [285]. 
Professionals in the healthcare fields have begun to take advantage of a more inclusive and accessible 
language and a more direct voice used on these platforms to appeal to a more socioeconomic and 
educationally diverse audience [284, 286]. By continuing to do so, we have the opportunity to come 
full circle -- to facilitate patient-empowerment, self-efficacy, and health literacy, which will, in turn, 
enable people living with health challenges to be informed and active participants in their own health 
care process. 
7.5 Future research 
As the results presented in section “6.5 FullFlow mixed-method study: preliminary results” only focus 
on two of the eight participant cases, our research team will focus on publishing not only the usage 
logs, questionnaire and focus group results and analysis, but also the method in which we designed the 
study-end focus group meetings.  
One major limitation of not only mHealth intervention research but also medical and health research, 
in general, is who we are able to recruit. My experience as a researcher in the field of mHealth, patient 
engagement, coupled with my recent works of this thesis, has opened my eyes to those who are and 
are not, engaged and represented in medical research and care. The focus on patient-empowerment 
and personalized care grows, and with it more detailed and comprehensive understanding of those who 
participate in research studies. However, these participants are seldom representative of individuals 
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living with chronic illnesses who need the most help and support. The public is told, by organizations 
such as the WHO, that there are large percentages of those in the population with chronic illnesses, 
who are underserved and/or remain undiagnosed. No matter how well we, as researchers, HCPs, and 
health authorities, prepare, explore and discover how to improve healthcare outcomes, if we are unable 
to reach those who would benefit the most from this knowledge, then our efforts eventually hit a glass 
ceiling. Those who are not reached and experience poor health experience high costs – physically, 
mentally, socially, and financially - and eventually require unnecessarily costly and resource-heavy 
healthcare treatment. Whether it be socioeconomic disparities, gender, differences in priorities, or 
disinterest – I am interested in why individuals choose not to or cannot engage in their health. We 
know that the tradition of one-size-fits-all has been, and continues to be, challenged. By identifying if 
such factors as limited resources, lack of motivation or incapacity, play a role in those who experience 
poor health and are unengaged in their healthcare, we can begin to understand what we need to add or 
adjust within interventions or how we as researchers and HCPs can adjust our practices to reach these 
individuals. I aim to apply for a Post-Doctoral research grant in order to study these factors in the 
coming years. In doing so, the lessons learned and insights gained from such works can further inform 
our exploration of both those who are already engaged, yet are unable to achieve their ideal health, as 
well as those who are not yet engaged but would benefit from more personalized health interventions. 
8 Conclusion  
Evolution is inevitable. How we perform research is no exception. The intention of these thesis 
activities was to continue discovering using pragmatism paradigm to research as a scaffolding. Two 
important parts of this were i) using new and relevant resources that have more recently become 
available , i.e. mHealth tools and services and ii) constantly asking questions that build upon the 
knowledge base of previous research and dig deeper into concepts that could provide more actionable 
insight into clinical practice, in our new situation where use of mHealth is increasing rapidly.  
These Ph.D. activities describe some of the research means that we have at our disposal for use in 
mHealth intervention evaluations. The literature reviews and usage-log analyses described the breadth 
and depth of what kind of information can be provided by traditional and mHealth resources. These 
activities responded to two of my research questions (RQ2 and RQ3) by forming a sort of library from 
which I proposed methods, measures, analyses, and intended outcomes for the mixed-method 
feasibility study. While not the primary focus, the different study structures also demonstrated the 
breadth of information that was possible to collect. Study administration, e.g., participant follow-up 
and reducing the efforts needed to participate, also seemed to play a significant role in the efficacy of 
the methods and reliability of the outcomes based upon end-user engagement and decisions in how 
they used the intervention tools. This was confirmed in our experience during the mixed-method 
feasibility study.  
The integration of end-users in the design of the intervention technology, as well as their input into the 
formation of the associated feasibility study, responded to my two other research questions (RQ1 and 
RQ4) by demonstrating the depth and breadth of contribution patients and providers can have in 
research. Without this input, our selection of features for the data-sharing system, questionnaires, or 
discussion guide questions may not have responded as directly to end-user needs or answered more 
about the rationale and motivation behind patients’ use of mHealth or the patient-HCP use of the data-
sharing system. However, these outcomes have to be taken with a grain of salt. They do not concretely 
 
94 
answer how these mHealth technologies should be used to ensure the greatest impact, only how the 
Diabetes Diary app and FullFlow data-sharing system were used by this small group of patients and 
providers. While the HCPs who participated in the co-design workshops and pre-study survey 
suggested that they would use patient-gathered data more to inform their recommendations for 
changes in self-management or lifestyle, not clinical changes in, e.g., medication. While these 
outcomes are situationally limited, they do demonstrate the depth, breadth and complementarity of the 
quantitative and qualitative data gathered throughout the thesis studies.  
The complexity of diabetes care networks calls for diabetes intervention studies to be flexible. The 
addition of mHealth technologies and concepts that have been newly introduced to these networks 
only services to support this call. By acknowledging the added opportunities for data-gathering and 
analysis that mHealth brings, we as researchers can combine our knowledge from different 
backgrounds, and utilize mixed-methods to determine how to best coordinate the use of these novel 
resources and structure the analysis of their impact. As summarized in Figure 21, we have 
demonstrated that the necessity, ability and feasibility of research to structure mHealth diabetes 
intervention studies in such a way that allows us to adjust our focus, questions and methods to fit the 
ever changing needs of mHealth for diabetes. As such, the sequential exploratory strategy of 
performing mixed-method studies through the lens of the pragmatic paradigm is an appropriate way of 
combining the strengths and benefits of traditional, positivist, quantitative approach to research with 
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How mHealth can facilitate collaboration in
diabetes care: qualitative analysis of co-
design workshops
Meghan Bradway1,2* , Rebecca L. Morris3, Alain Giordanengo1,4 and Eirik Årsand1,4
Abstract
Background: Individuals with diabetes are using mobile health (mHealth) to track their self-management. However,
individuals can understand even more about their diabetes by sharing these patient-gathered data (PGD) with
health professionals. We conducted experience-based co-design (EBCD) workshops, with the aim of gathering end-
users’ needs and expectations for a PGD-sharing system.
Methods: N = 15 participants provided feedback about their experiences and needs in diabetes care and
expectations for sharing PGD. The first workshop (2017) included patients with Type 2 Diabetes (T2D) (n = 4) and
general practitioners (GPs) (n = 3). The second workshop (2018) included patients with Type 1 Diabetes (T1D) (n = 5),
diabetes specialists (n = 2) and a nurse. The workshops involved two sessions: separate morning sessions for
patients and healthcare providers (HCPs), and afternoon session for all participants. Discussion guides included
questions about end-users’ perceptions of mHealth and expectations for a data-sharing system. Activities included
brainstorming and designing paper-prototypes. Workshops were audio recorded, transcribed and translated from
Norwegian to English. An abductive approach to thematic analysis was taken.
Results: Emergent themes were mHealth technologies’ impacts on end-users, and functionalities of a data-sharing
system. Within these themes, similarities and differences between those with T1D and T2D, and between HCPs,
were revealed. Patients and providers agreed that HCPs could use PGD to provide more concrete self-management
recommendations. Participants’ paper-prototypes revealed which data types should be gathered and displayed
during consultations, and how this could facilitate shared-decision making.
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Conclusion: The diverse and differentiated results suggests the need for flexible and tailorable systems that allow
patients and providers to review summaries, with the option to explore details, and identify an individual’s
challenges, together. Participants’ feedback revealed that both patients and HCPs acknowledge that for mHealth
integration to be successful, not only must the technology be validated but feasible changes throughout the
healthcare education and practice must be addressed. Only then can both sides be adequately prepared for
mHealth data-sharing in diabetes consultations. Subsequently, the design and performance of the joint workshop
sessions demonstrated that involving both participant groups together led to efficient and concrete discussions
about realistic solutions and limitations of sharing mHealth data in consultations.
Keywords: Patient-gathered data, Data-sharing, Co-design, mHealth, App, Health care providers
Background
As a medical society, we have increased our knowledge
about diabetes beyond managing the cornerstones of
self-management: blood glucose, physical activity, medi-
cation and diet. We have recently unmasked the effects
of less well-known factors as sleep, stress or even
temperature, on blood glucose levels [1]. While it is the-
oretically ideal to understand all factors that affect a dis-
ease, in order to effectively treat it, it also inadvertently
puts added pressure on healthcare providers (HCPs) and
patients to not only track these factors but also under-
stand and react to them. In fact, it was only 50 years ago,
with the invention of the first commercial glucose meter,
that patients were given the ability to check their blood
glucose at home [2]. Since then, medical devices for dia-
betes have been developed alongside the necessary sys-
temic changes to the medical system that are required to
effectively use such new technologies. However, this
trend has shifted as commercial technology, such as mo-
bile health (mHealth) apps and devices, now offers pa-
tients the ability to easily track all of the indicated
disease factors that are expected of them, often without
oversight from medical professionals [3].
Lately, the use of mHealth technologies has become
common practice for diabetes self-management [4]. For
example, by connecting one’s smartphone app to a blood
glucose meter and wearable activity tracker, one can
automatically combine blood glucose levels with how
physically active they are as well as manually entered
food and medication intake. Such measures are consid-
ered patient-gathered data (PGD) and allow a user to
track how their self-management activities affect their
health outcomes [5]. With this stored history, the next
time an individual chooses to undergo a similar combin-
ation of activities, they could easily identify, for example,
how they chose to eat or what dose of insulin was effect-
ive or not for that situation. However, this information
is only effective if used correctly; not everyone is able to
process and make connections for all of this information
on their own. Therefore, while mHealth provides clear
potential benefits, there is only so much most individuals
can understand without the complementary medical
knowledge of the disease itself. This is where the poten-
tial of sharing one’s own data from their mHealth tools
with HCPs can benefit both the patient’s understanding
of their own health and the provider’s understanding of
how to best practice personalized and evidence-based
medicine.
Unfortunately, when it comes to introducing mHealth
and PGD in the clinic, both parties have differing ideas
as well as concerns and unanswered questions. Providers
have noted concerns about data overload and how to re-
late to the data for clinical decision-making [6]. Patients
are concerned with how providers can effectively use
this information to give personalized health recommen-
dations [7]. Despite a growing effort to research these
technologies, most research focuses on exploring the
topics of technical possibilities, feasibility, usability and
policy issues [8], with little focus on how both patients
and providers can use PGD together. This is not only
due to the concerns and questions mentioned above but
also because the gap in disease knowledge between pa-
tients and providers has traditionally been too great [9].
This gap has lately been shrinking thanks to mHealth,
which adds a new dimension of diabetes management –
enables greater self-efficacy, disease understanding, espe-
cially among technology savvy people. In fact, in the field
of mHealth, patients’ have become vastly more
knowledgeable, and are even considered “experts” by
some [10]. By gaining insight into their own disease self-
management, patients are now more capable of bringing
this understanding and PDG to consultation discussions
with their healthcare providers [11, 12]. Therefore, there
is a need for data-sharing systems to be able to transfer,
structure and present this data in a way that facilitates
collaborative discussions and shared decision-making in
diabetes care. Previous studies in the field of health tech-
nology have provided knowledge regarding the needs of
data integration and patients’ and HCPs’ expectations
and their needs from data-sharing technologies. The ma-
jority of these studies have gathered information from
patients [13] and providers [14] separately. However,
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other studies also show that when both end-user groups
were engaged together in development discussions, more
concrete and realistic solutions can be identified [15].
Experience-based co-design (EBCD) (hereby referred
to as co-design) allows patients, and providers to impose
their collaborative insights on the design and develop-
ment of the tools and services that they are eventually
meant to use [16]. “Happenings become experiences
when they are digested, when they are reflected on,
related to general patterns and synthesised” [17]. This
describes the general use scenario of those who use
mHealth technologies for chronic illness self-
management; recording, reviewing or reflecting and syn-
thesizing an understanding of their health experiences.
Unfortunately, many “patient-centred” research efforts
do not always involve patients or other end-users in
such design, and/or development [18, 19]. By consider-
ing patients as “experts” in their own self-management
and providers as, of course, experts in the disease me-
chanics, we acknowledge that both parties can bring
complementary knowledge and skills to diabetes care.
Ideally, this is considered the process of shared decision-
making, which is characterized by providers and patients
collaborating to make decisions about the patient’s
health, with a balanced focus on both hard clinical evi-
dence as well as the patient’s priorities and values [20].
This suggests the necessity of engaging both main end-
users in co-design to design and develop the technology
that they will use, together [21].
In this paper, we present the qualitative analysis of
transcripts and paper-prototypes from two co-design
workshops involving both patients and HCPs regarding
the design of a system to share patient-gathered self-
management data during diabetes consultations. These
workshops were conducted as part of a larger research
project to create and test a system for sharing PGD be-
tween patients and providers, called the “Full Flow of
Data Between Patients and Healthcare Services” project
(2016–2020) [22]. Previous workshops within the same
research project reported the differences in self-
management foci and challenges between those with
T1D and T2D, as well as differences in how specialists
and GPs meet their patients and their clinical practice
needs. These results were published elsewhere [23]. In
this paper, we build upon this knowledge, and the input
from co-design, to design a system for sharing PGD dur-
ing diabetes consultations. We focus on our end-users’
intentions for the use of, needed functionalities, ideal
discussion and collaboration that can and should be gen-
erated from sharing PGD.
Objective
By arranging two co-design workshops, where patients
and HCP together discuss expectations and design ideas
for an mHealth data-sharing system for diabetes, we aim
to understand how a system can present patient-
gathered mHealth data and be used effectively by both
parties to facilitate shared-decision making and collabor-
ation in diabetes care.
Methods
Two co-design workshops (N = 15) were conducted with
the aim of inviting both stakeholder groups to discuss
the concept of sharing and using patient-gathered self-
management data during diabetes consultations. The
first involved patients with type 2 diabetes (T2D) (n = 4)
and GPs (n = 3) (2017) and the second involved patients
with type 1 diabetes (T1D) (n = 5), diabetes specialists
(n = 2) and a nurse (2018). The workshops were held in
Norwegian, the participants’ native language.
Recruitment
Participants were invited to attend the workshops at the
Siva Innovation Centre in Tromsø, Norway. Conveni-
ence sampling was used to expedite recruitment and
draw from a population with experience or interest in
the particular field of mHealth for diabetes self-
management. Patients were recruited by messages sent
through the Diabetes Diary app [24], which is available
on Google Play app store. At the time of recruitment,
there were approximately 7000 downloads of this app in
Norway. Patient participants had to be 18+ years with ei-
ther T1D or T2D and be willing to travel to Tromsø,
Norway for the workshop. All who expressed interest
and met inclusion criteria were invited to participate. All
participants presented a signed consent form prior to
the workshop. HCPs, who currently see patients with
diabetes, were recruited via e-mail requests. Participants
were given the option to withdraw their participation at
any time.
Discussion guides and workshop activities
During each daylong workshop, patients and clinicians
were split into their respective groups in the morning.
Following a common lunch, all participants took part
in a joint session in the afternoon. The intention of
joining both groups was to allow participants to
present their views to each other and to discuss and
correct assumptions and expectations regarding
mHealth technologies and data-sharing during consul-
tations. A moderator used a semi-structured discus-
sion guide, which was developed by the co-authors
(see Additional file 1).
Two story-boards, describing T1D care and T2D care,
were split into three main sections illustrating the fol-
lowing: experiences and topics surrounding patients’
own self-management, the healthcare providers’ clinical
practice and experiences, and the consultation between
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both patients and providers, which was used only during
the joint session. In both of the separate patient and pro-
vider sessions, participants filled out post-it notes in re-
sponse to questions, presented them orally to the group
and then placed the notes on the story-board that corre-
sponded to each of the three situations. This allowed
them to form their own opinions before engaging in
group discussions. During the joint session, participants
were asked to create, and then describe how to use, his
or her own paper-prototype of an ideal data-sharing sys-
tem. Paper cut-outs that represented functionalities and
features of the system’s interface were provided. These
included cartoon representations of data sources, such
as mobile phones, wearables and sensors, data types,
such as blood glucose and physical activity, how to dis-
play data, such as graphs, arrows and scales, and com-
puter screen, through which the system is meant to be
accessed.
Thematic analysis
After each workshop, single-page summaries were made
by the research team, within a month following each co-
design workshop, and sent to all participants. Partici-
pants were encouraged to correct these reports, com-
ment or ask any additional questions before further
analysis was performed.
All sessions were audio recorded, transcribed and
translated into English by a native Norwegian speaker,
and de-identified. As not all in the research team were
present during all sessions, before more detailed analysis
took place, narrative summaries for each of the six co-
design sessions were created. Co-authors discussed the
summaries to ensure collective understanding of the
transcripts, e.g. what was produced that was directly re-
lated to the research questions and what unexpected yet
relevant additional information was provided. To iden-
tify patterns within and across the participants’ feedback
while also addressing the research questions, a thematic
analysis was used. As it is difficult to separate one’s self
from their research experiences and background know-
ledge, this thematic analysis included iterative use of de-
ductive and inductive reasoning to structure and report
the transcripts, i.e. an abductive approach [25]. The de-
ductive approach first generated themes, based upon dis-
cussion guide questions that participants responded to,
from a small selection of the transcript, which are de-
scribed as “analytic inputs” by Braun et al. [26, 27].
These themes then direct the combination of emergent
salient concepts, i.e. the inductive approach; while emer-
gent concepts were identified and grouped as primary
and secondary codes, relevant codes were selected and
combined into sub-themes and assigned, based upon
reasonable association, to agreed-upon themes [28]. An
example of this process is provided in Table 1.
Quotations will be formatted with brackets indicating
omitted words, e.g. “it”, “they”, that are replaced with the
words to which these articles refer.
Results
Demographics
Seven individuals attended the first co-design workshop,
related to T2D (Fig. 1), and eight individuals attended
the second workshop, related to T1D.
While it was not required for participants to offer
these information, as the focus was on development of
the data-sharing system, some did offer some personal
information when asked introductory and ice-breaker
questions. The available details are provided in Table 2.
HCPs offered only basic information about themselves
before offering their opinions of mHealth and data-
sharing (Table 3).
Main themes identified
Across the workshops, the following three main themes
were identified: 1) patients’ and providers’ need for more
specific and detailed information in diabetes care 2)
mHealth technologies’ impact on patients and providers,
with subthemes concerning a) both groups’ use of
patient-gathered data and b) roles and responsibilities,
and 3) data-sharing, with subthemes concerning a) ex-
pectations of sharing and receiving PGD during consul-
tations, b) what and how to share PGD, c) electronic
health record (EHR) integration and d) concerns. Be-
cause each session focused on allowing the participants
to drive the discussion, each theme and sub-theme var-
ied in the amount of feedback participants’ provided.
Therefore, for the themes and sub-themes that gener-
ated lengthy and diverse feedback, tables are provided
for each-sub-theme to summarize and differentiate be-
tween responses of each group. Additional quotations
from the transcripts, and details about responses for the
sub-themes, are provided in Additional File 2.
Theme 1: patients’ and providers’ need for more specific
and detailed information in diabetes care
At the beginning of each workshop, participants were
prompted to describe their overall self-management and
clinical practice, respectively. Responses about sub-
theme 1A: What and how information is needed are ex-
emplified in Table 4.
Both those with T1D and T2D had similar experiences
with healthcare providers – lack of specific feedback and
information. Differences in self-management and care of
T1D and T2D were evident in the details, for example,
when individuals needed specific support from their
healthcare providers. For those with T1D, support is
needed when a challenge or symptoms arise because
their symptoms and challenges occur more frequently
Bradway et al. BMC Health Services Research         (2020) 20:1104 Page 4 of 20
and immediately. However, those with T2D experience
more delayed symptoms, making it difficult to identify
the cause leading them to need to accumulate informa-
tion over time and then seek guidance or answers about
how those decisions affected their health. GPs and spe-
cialists agreed in the importance of specifying their rec-
ommendations based on a patient’s situation, but noted
that this also requires patient engagement. Specialists
mentioned that mental health and a patient’s knowledge
and skills affect their expectations of their patients with
T1D and how they approach diabetes care. The partici-
pants’ background with diabetes care allowed us to iden-
tify potential needs for mHealth and data-sharing
support for both individuals and healthcare providers
during consultations.
Theme 2: mHealth technologies’ impacts on patients and
providers
As one participant stated concisely, “diabetes doesn’t
happen in a container. There are other things around it.”
[T1D_P3].
Subtheme 2A: purposes of, and challenges related to,
mHealth and patient-gathered data Participants were
promoted to discuss how they used mHealth technolo-
gies and patient-gathered data for self-management and
during clinical practice. Both groups of T1D and T2D
participants used their own-gathered data to find pat-
terns by comparing their self-management actions to
their resulting blood glucose levels. However, differences
emerged regarding what kind of information they as-
pired to understand, how much data, and over how long
a period, these comparisons were made. Responses
about sub-theme 2A: Purposes of and challenges related
to mHealth and patient-gathered data are exemplified in
Table 5.
Those with T1D tend to look at information related to
daily experiences. In contrast, T2D requires less frequent
measures, which is consistent with both patients and
GPs’ focus on longer-term health control and expect-
ation of less data. These differences between patient
groups point to how much information either group
would gather and possibly present during consultations
as well as their driving health goals. It was also evident
Fig. 1 Story-board and post-it notes generated during the first co-design workshop, illustrating the T2D patients’ and GPs’ situations and their
expectations of a system for sharing patient-gathered data
Table 1 Abductive approach to analysis process of categorizing quotable text from the transcript into codes, followed by the
grouping of codes into progressively higher-level themes
Deductive Analysis → ←Inductive analysis













Initial codes Example from transcript
• Research questions asked
• Impressions of major topics and
concepts presented in the















• Preference to see
selected/relevant
data
“Could you possibly assimilate so much
data?...How much data can you
incorporate into a [15-min] consultation?”
(Specialist2)
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that the ability of those with diabetes to collect much
data has affected what healthcare providers expect of
their patients.
Subtheme 2B: roles and responsibilities Within the
formal healthcare setting, those with T1D and T2D note
that the value of healthcare providers is based upon their
ability to understand the patients’ everyday reality of liv-
ing with diabetes. They also share similar frustration
with healthcare providers’ lack of such specific know-
ledge and answers, when the patient needs it. However,
during consultations, the role of authority figure is dif-
ferent in either case (Table 6).
Those with T1D appeared to place themselves in the
role of authority and decision makers. In these cases,
healthcare providers – mainly diabetes nurses - are seen
as sources of suggestions and information about unique
situations that an individual may face in their daily lives,
yet the individuals are the ones to use of the data and
make the final decisions about their health. This division
of responsibility and roles within T1D care also seemed
unanimous and expected amongst healthcare provider.
Specialists stated that outside of the consultation,
patients were expected to be active in using and under-
standing the data they generate. While, in the previous
sections, those with T2D established that they value
mHealth and its ability to help them to better under-
stand their health, in the formal healthcare setting, indi-
viduals with T2D place more authority in the healthcare
providers. Also, they make a distinction about which
healthcare provider is better prepared to answer their
specific questions.
Theme 3: The data-sharing system
Subtheme 3A: expectations of sharing and receiving
PGD during consultations With regards to their expec-
tations of sharing data with their healthcare providers,
participants with T1D and T2D were similarly con-
cerned with receiving specific and relevant answers. Just
as with the theme of roles and responsibilities, differ-
ences between expectations of those with T1D and T2D
centered on the level of detailed feedback from their
providers, who to contact and overall goal of the consul-
tations when sharing data (Table 7).
Participants had experienced the expected benefits of
sharing their own-gathered data, i.e. more personalized
self-management recommendations. However, even with
data, others experienced the limitation of interoperability
problems of healthcare technologies. Participating spe-
cialists expect that those individuals who use health
technologies, including both medical and mHealth de-
vices, pre-digest the data to identify self-management
problems before coming to the consultation. However,
specialists also explained the diversity of experiences and
expectations in their clinical practice, including the fact
that many either do not use these technologies or do not
use them optimally.
Table 3 Demographics of participating HCPs in both co-design
workshops














Reported technology used Reported self-management foci
T1D_Patient#1 F 40–50 N/A N/A N/A
T1D_Patient#2 M 20–30 2 Apps, insulin pen Physical activity, BG
T1D_Patient#3 M 50–60 30 Insulin pump, CGM, app BG, physical activity, insulin, carbohydrates
T1D_Patient#4 M 40–50 38 Insulin pen, app BG, insulin
T1D_Patient#5 N/A Insulin pen, app, BG, physical activity, sick days, insulin, diet
T1D_Patient#6 M 60–70 8 Smartwatch, insulin pen Physical activity, insulin, BG
T2D_Patient#1 M 60+ 12 Paper diary, app BG, physical activity, diet
T2D_Patient#2 M 60+ N/A* BG meter, insulin pen, paper
diary, app
Diet, medications (non-diabetes related), insulin,
physical activity
T2D_Patient#3 M 60+ 3 BG meter, apps Diet, physical activity, well-being
T2D_Patient#4 M 60+ N/A** BG meter, paper diary BG, input from doctor
*Participant stated “a good amount of time ago”
**Participant stated that they were “in the introduction phase” of their diabetes
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The expectations and experiences of those with T2D
and GPs reflected a different dynamic between individ-
uals, the technology and their providers than those with
T1D and specialists. While those with T2D did want
specific answers, they were first and foremost concerned
with the concept of communication and responsibility;
when to communicate and with whom, in order to
receive the type of answers they wanted. Participating
GPs also acknowledged the challenge of providing spe-
cific feedback to their patients in the absence of data.
Like those with T2D, GPs were also interested in com-
munion but more specifically, shared decision-making
and believed that specific data would lead to specific and
realistic goals for the patients.
Table 4 Summary of responses about what and how information is needed by patients’ and providers’ regarding diabetes self-
management and clinical practice, respectively





Answers about specific challenges in their self-
management
“[What is important is] not what we struggle most with on
average but what we need to do in specific situations and





Answers in the form of recommendations from HCPs
about why specific self-management challenges occur
and how to respond to them
“[Most healthcare providers] too far away from the specific
situation … You get answers after a day or two … but that
is not when I am in the situation … I don’t want to disturb
doctors and nurses with my small problems, but maybe they
are not so small if we acknowledge what they really are”
(T1D_P3)
“More appointments more frequently … and maybe get




• To differentiate patients based on situation and
needs
• To understand patient’s mental state to effectively
guide them
“For example, I cannot expect this one man to get a perfectly
controlled diabetes. I would be happy if his hba1c came
down to 9%, whereas another patient who is themselves a
doctor, I can expect him to have an hba1c around 7% or
even below 7% without hypoglycaemia” (Specialist2).
“Separate the patients in two groups - the ones who have
hba1c higher than 8.5 or 9 who are the higher risk ones,
[and] the ones with lower than 6–8% who still have
problems … different problems” (Specialist1)
“A person’s mental state and resources, of course … gives






It is the responsibility of the patients to collect and
share information as well as provide explanation of
their situations.
“[Patients must] take the responsibility [themselves]” in order
for the HCP to be able “to understand diabetes and insulin






• To understand how lifestyle choices affect health (i.e.
BG)
“I was better in the starting phase to note down drinks and
food … but it has faded, and I don’t today. Need more
motivation” (T2D_P2)
“I have injured knees and shoulders, so motivation is lacking”
(T2D_P1)
“I kind of feel like I don’t self-manage because … I think it
goes a bit slow when I test my blood sugar. It’s usually high






Disease-specific knowledge from HCPs “[Healthcare providers] could be more specific. They are pretty
diffuse and say “you can do this”, but they need to be more
specific and say “you need to do this”, and then tell me the
things I need to be doing” (T2D_P2)
GPs What
information
• Information about specific challenges,
• To understand and treat all of a patient’s health
challenges
“If [the patients] have reliable information, we use that more
than medical history because things happen along the way”
(GP1)
“Patients don’t just have diabetes. Many are mixed with a lot
of other things and I feel that can be confusing because they
high blood pressure, maybe are overweight, maybe have low





Health measurements and patient recollection/
evidence of challenges to then discuss together
“Things I find important focus on how it has been since last
time. Any hypos? Are they in okay shape? Anything wrong?
Sometimes I check blood pressure, but not always. I usually
check hba1c … then we make an appointment and discuss
the plan” (GP1)
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Subtheme 3B: what data to share and how to display
it Referring to their own developed paper prototypes
during the joint session, participants were able to explain
how their ideal system would function to generate a dis-
cussion (Table 8). For quotations that detailed both what
and how the data should be displayed, cells within the
table are merged.
Participants’ comments converged on the end goal of
information exchange - generating discussions. Both pa-
tients and providers acknowledged that each had rele-
vant and desired information to exchange, and an
opportunity to do so with mHealth, that was not com-
monly used at the time. A comment from one specialist
summarizes what all seemed to hope for from a data-
sharing system – to facilitate information exchange;
“One thing is data sources another thing is information.
Because the information is generally the communication
with the patient at the site there and then” (Specialist1).
However, both those with T1D and T2D independently
identified a challenge that should be addressed within
this type of information exchange.
Suggestions from both patients and providers were
similar in that they would like a system that summarized
the PGD, with the option of choose which data to
explore further, if trends or outlier points were identi-
fied. Those with T1D wanted answers about specific
challenges that they experienced and documented.
Those with T2D wanted an overview of their progress
and feedback about how to progress. One GP expressed
the value of a diverse data-set while another expressed
that, for some parameters, exact values were not as im-
portant as bringing correct and representative data. Fig-
ures 2, 3, 4 and 5 illustrate examples of paper prototypes
designed by the participants.
Subtheme 3D: electronic health record integration
Specialists and GPs preferred different ways of accessing
and integrating the data into their everyday practice
(Table 9).
Subtheme 3E: Concerns.
Despite participants’ optimism and the potential that
they saw with sharing PGD, providers consistently noted
their concerns (Table 10).
As mentioned above, specialists were specifically con-
cerned with healthcare service priorities and resource
management. Specialists were also concerned with how
and where they should go to learn how to use these
technologies, because they lack the time and support to
Table 5 Summary of responses regarding purposes and challenges experienced by patients and providers when they encountered
or used mHealth devices or patient-gathered data
Groups Codes Summary Example quotations
Participants
with T1D
Purpose • To identify similar situations
• To identify relationships between
parameters, e.g. BG and diet
“Similar situations … I rarely eat ice cream so I can go back and look at how much
insulin I took then and how my blood glucose was after” (T1D_P5)
“Seeing patterns about what I ate and did in relation to my blood glucose” (T2D_
P2).
Challenge Lack of support/guidance to interpret
data
“The lack of support from the healthcare system”, asking “where is the course where
I can learn as a patient? I take more responsibility for my own health when using
mHealth tools … [and get] a better overview … But even though I know a lot … I
want to know more and I want to do better” (T1D_P1).
Specialists Purpose For technology to support patients’
self-learning
“Use of technology needs to create patient action … We want these sort of [patient-
gathered] data to be self-learning technology” (Specialist1).
Challenge Limited capacity “The number of consultations in our out-patient clinic has increased steadily during
the last years. And I remember when I started there almost 20 years ago we had so
much more time for patients” (specialist2).
Participants
with T2D
Purpose • To understand long-term effects of
lifestyle choices on diabetes health
• To spend less time worrying about
their health and more time living
“[I look for] the results for stress level, drinks and such … to find the causes for high
blood glucose” over “days, sometimes a month sometimes three months, between
the evaluations” (T2D_P1).
“spend less time and energy on self-management” (T2D_P2)
Challenge • To understand relationships between
parameters,
• To trust in technology to function
properly,
• Cost (in some cases)
“I document blood glucose in the Diabetes Diary app. Plus, I have it on paper too. I
don’t trust electronics. I do double” (T2D_P1)
“I stopped the electronic way because I was abroad and it cost a lot. But I record
manually” (T2D_P2).
GPs Purpose Not specifically stated N/A
Challenge Inconsistency in and lack of patient-
gathered data
“They just test three days before, but then stop testing for half a year, and then
come back with three lost test-days. Some are testing every day, four times a day …
Some have blood pressure monitor at home, that they show me” (GP3)
“I rarely see [paper] diaries with lots of measurements … many of them have Fitbit
but I haven’t seen the results from them” (GP2).
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engage with these types of new medical and mHealth de-
vices technologies. Those with T1D shared the pro-
viders’ concerns of data-overload. Both healthcare
providers and patients expressed a desire to share rele-
vant and discussion-worthy information during diabetes
care, but these barriers highlighted reasons that some




The co-design workshops focused on options for inte-
grating mHealth as a supportive tool for diabetes care –
designing a system for sharing patient-gathered mHealth
data during consultations. Common design features that
were identified included a) the presentation of PGD in a
summary on the first screen of the system, with the op-
tion to select more detailed views and combinations of
information on subsequent screens, b) graphs and charts
were popular choices for visual representations, espe-
cially when comparing different data types, c) visual in-
dications of change such as arrows or symbols related to
each data type based on desired and undesired clinical
values, e.g. blood glucose values in high (yellow), accept-
able (green) or low (red) ranges, d) presentations of data
that is relevant to the patient and e) efficient to use.
While both those with T1D and T2D believed that shar-
ing data remotely or before the consultation would allow
them to receive answers and guidance during challen-
ging situations and save time for both patients and pro-
viders, most providers were sceptical of this idea noting
that patients must be present during the discussion in
order to share and explain their data effectively. With
these design features, both parties would be able to
choose which data to look at, and then agree upon feas-
ible solutions together.
These design features support the concept of “shared-
decision making”. While this term was meant to refer to
patients and providers discussing and sharing the re-
sponsibility of deciding the best course of action for both
self-management and medical treatment options to-
gether [20], much of the literature refers to HCPs mak-
ing the final decisions in a “paternalistic model” [29, 30],
have cited the challenges of or referenced the lack of
Table 6 Summary of which roles and responsibilities patients and providers perceived of one another given the introduction of
mHealth into diabetes care
Groups Codes Summary Example quotations
T1D
participants
Own role Have control and responsibility for own
health
“You have to take responsibility for the things not being done by healthcare …
you have to follow up yourself” (T1D_P3)
Specialists’
role
Nurses support patients with answers to
specific questions
“[Want] more specific answers on situations and questions when I am meeting
with the nurse. I sometimes have questions about different situations … and
two similar situations can become two completely different ones. [And the
nurses] never has any good answers” (T1D_P5)
Specialists Own role • Advisors
• To distinguish between what kind of
support different patients need
“Task is to be advisors. We can’t change anything, we can just give advice. The
data by itself needs to help the patients to do the best thing” (Specialist1)
“We have to start differently and expect differently from our patients. This is




• Have responsibility and are decision-
makers for own health
• Must be the one to initiate contact with
HCPs when needed
“To make the appointments, and to bring some own generated data”
(Specialist2)
“Be prepared for the consultation. Because we have so little time” (Specialist1)
T2D
participants
Own role Informed data-collectors “My role [in sharing data] could be to be more exact in documenting
information, such as diet, physical activity … that can help the GP confirm
where I am in the process” (T2D_P2).
GP’s role • Interpret patient-collected data
• Authority figures, but GPs may not be the
best HCP to answer diabetes questions
“It is interesting … with input from doctor from more examinations and closer
follow-up... I miss that, and I am uncertain” (T2D_P4)
“[GPs] really lack the knowledge in which we diabetics struggle with [because
they] do not have enough education to cope with those specific health issues”
(T2D_P2).
“There are also diabetes nurses … they can maybe give more input about what
you should do and not do … let the doctor take the more serious, while nurses
help along the way” (T2D_P1).
GPs Own role • Teachers of patients
• To give advice
“[Patients] are our pupils, and we are their teachers so when they do
homework, of course I want to see what they’ve done. And then … I can begin




Have main responsibility for health “You take care of your own disease, not me. I will help you on the way. It is
your responsibility, and you have to have some sort of a motivation for it”
(GP2).
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Table 7 Summary of patients’ and providers’ experiences and expectations of sharing patient-gathered data during consultations
Groups Codes Summary Example quotations
Participants
with T1D
Experiences • Without data, feedback is too generic
• With data, discussion is more practical
“[Without data], often I feel like the meetings I have with them, it’s
like – “how do you feel” and [I say] “I feel its fine”. I don’t get that
much out of [the consultation]” (T1D_P2).
“[I get] specific tips with things [the doctor] extracts through the
data which I don’t feel like I saw myself. I’ve gotten advice that
works” (T1D_P2).
Expectations • More specific feedback based on own-gathered data
• Interoperability will limited HCPs in their ability to
interpret data
“[Healthcare providers could] Interpret data with the knowledge
they have and then give specific tips and feedback about the
data” (T1D_P2)
“Maybe [HCPs] can help me more if they see that there’s a
reoccurring problem … if I’m high during the evening...we can try
to talk more specifically” (T1D_P3).
“The [insulin] pump has all this data, so when I come to the nurse
she puts the pump into the computer then she runs through and
program and sees everything, and … it doesn’t turn into much
… with having a lot of data … [its] because of the tools [the
HCPs] use” (T1D_P3).
Specialists Experiences • Not all patients use, or want to use, these
technologies
• Some patients do not use the technology as HCPs
would like
• Those who understand the potential benefit of the
technology use it correctly
• CGMs and pumps are the most common
technologies seen, few apps
“They can come with all sorts of data, because it’s automatic. But
they haven’t made a diary or sort of explained why was it like
this, why did I get a hypoglycaemia … saying “oh these are my
measurements” and “ohh no, I haven’t looked at them” then it’s
so useless” (Specialist2).
“They check a lot of blood glucose and they actually write it
down for me because they realize that when they come with their
small booklet then we can talk about it together and see”
(Specialist1).
“When we are talking about new technology, it’s mainly based on
CGM. Because that’s the new technology the past 10 years”
(Specialist1).
Expectations • Patients will pre-digest data before consultations,
then present it to HCPs
• Patients who use mHealth are adept enough to use
it correctly
• Too difficult to understand all of the diverse health
technologies
“Patient X comes in and she has her measured blood glucose …
on her device, whether it’s a telephone or not. You get it on the
doctor’s screen … and then you see if it’s high in mornings and
so on, and you see how much insulin you use. You have the
patient already before the consultation – trusting in her
responsibility and her interest in doing better” (Specialist1).
“[Use of mHealth] requires some technological insight and of
course some intelligence in a way or - you understand me -
stamina” (Specialist2)
“Less than 50%” of their patients bring their own data to the
consultations, either written in a book or via an app...[and] I don’t
know how many of my patients would like to use the Diabetes
Diary app - maybe 5–10% - because it’s too much!” (Specialist2).
Participants
with T2D
Experiences Frustration with GPs not being able to answer specific
diabetes questions
“GPs are busy with work, so … it would be better to get an
appointment at the hospital with a diabetes nurse, maybe once a
year, and discussed your case with your data. And if you are way
off with your values, you could also discuss with a doctor and
then come to a conclusion” (T2D_P1)
Expectations Perceives that the GP wants patients to come to
consultations with an agenda/questions and
corresponding data
“I think what doctor expects is that you bring your blood glucose
measurements, at least from the last week [with] notes about
diet, physical activity, [if I] ate too much or drank too much.
Compare my own measurements” (T2D_P2).
“As I see it with the GP, you go to them when you have a specific
problem. If you have [an annual check-up] with diabetes, [you are
not going because of] a specific problem” (T2D_P3).
GPs Experiences • Without specific questions or data, the consultation
discussion is “boring”
• Wishes for the patient to explain their situation in
more detail
“I think it is a bit boring. “This doesn’t look pretty good, go home
and be better”. We need to know how you have been doing,
what has happened. That’s what’s going to start a discussion”
(GP2).
Expectations • That the patient-gathered data must be easy to
understand, will save time and result in specific and
realistic goals for patients
• Patients and providers will discuss data together
“[It is possible] if the patient comes with [PGD] and it is easy to
understand” (GP2)
“[Patients need to] understand how to get there. To say getting
HbA1c down by doing X. Very specific. In that case, say “you
won’t have blood glucose under that and that, and you will walk
5000 steps each day”. Specific feasible goals from day to day”
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specific suggestions for how to achieve this ideal [31,
32]. Even when shared-decision making is used in its
truest intended way, it still faces challenges such as pa-
tients’ lack of understanding of their disease and the
providers’ unwavering focus on clinical measures [33].
The results of these workshops suggest that patients and
HCPs see that potential collaborative point between
their areas of expertise – providers’ medical knowledge
and the patients’ mHealth self-management experience
an PGD– can lead to true shared-decision making and,
subsequently, feasible health goals for individuals.
Collaboration and understanding
The shared aim amongst patient and healthcare provider
participants of displaying these data was to facilitate dis-
cussion and shared decision-making. Patients and pro-
viders independently and consistently described the
value of discussions, exchanging valuable and useful in-
formation and for improved communication, not just
about the data itself but about expectations and inten-
tions. For example, both those with T1D and T2D
wanted to know which data healthcare providers were
interested in or needed in order to provide specific feed-
back and recommendations. While patients hoped that
providers could relate to and interpret PGD, providers
were quick to explain that it is an unrealistic expectation
because the healthcare system does not provide re-
sources to teach providers about how to discuss the vari-
ous mHealth technologies in care practice.
Participants also expressed an understanding of their
counterparts’ situations within diabetes care in general.
For example, those with T2D understood that GPs may
not be the only, or even the most knowledgeable, source
of answers for their diabetes-specific questions. This was
expressed with empathy, not judgement. Instead it
prompted discussion about realistic alternatives such as
going to visit hospital nurses or reputable internet sites.
Specialists were particularly concerned with understand-
ing the unique situations of their individual patients.
While in some cases their comments were not directly
related to the question being asked, it forced us to take a
step back in the discussion and understand the reality of
diabetes care. For example those with T1D, where one
specialist urged us to keep in mind that treatment is
about the individual person and their specific situation -
a concept which should be more prominently addressed
in our mHealth research; addressing those with T1D as
a group is not actionable given the unique needs of each
person. The other specialist emphasized that providers
need a comprehensive understanding to effectively guide
an individual, i.e. understanding their mental state, re-
sources and intentions in order to generate a realistic
goal for their diabetes. A participant with T1D also rein-
forced this from the patient perspective by explaining
that they would rather have a conversation with their
HCP about which data to share in relation to a certain
situation so that the consultation could be more pro-
ductive and targeted.
It is also important to note that the participating indi-
viduals with T1D portrayed the need for data-sharing as
very straight forward – seeing the situation from the
perspective of someone who already is familiar with, and
uses, medical and mHealth technologies; i.e. they present
their data and the healthcare provider can identify pat-
terns. However, participating specialists made it clear
that their perceptions and expectations of sharing data
during consultations is much more complex. While
some patients can come with a well-prepared agenda,
providers also have to prepare to relate to those who
only use paper diaries as well as those who try, but do
not manage to use the technology as specialists would
hope.
Data sharing and information exchange
Specialists were very aware of the impact of accurate
and complete data sets because collecting data is useless
if the user is unable to determine meaning from what
they measure. They expressed several times that each
decision about a patient’s case not only had to be in-
formed by their sense of the individual’s personal
Table 7 Summary of patients’ and providers’ experiences and expectations of sharing patient-gathered data during consultations
(Continued)
Groups Codes Summary Example quotations
(GP2).
“What happened to that resulted in these data? What has
happened here? Good and bad. Why is it like this?” they could
“make a plan to reach a goal - make a decision together …
because it is the patient who has to go through with it and
follow it up, regardless of what we write... it has to be feasible”
(GP3).
“I think you go through data in together. Look at it together, both
and points and trends, both hard data and stories … specific
information will save us time, instead of trying to make people
tell us” (GP1).
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situation, e.g. other responsibilities in their life and well-
being, but also the accuracy of the representations of
their diabetes health, e.g. blood glucose levels in relation
to insulin doses. GPs, however, were not as concerned
with where the data came from as expected. While they
did emphasize that the data was representative of the pa-
tient’s situation, because, as some explained, they did
not intend to alter medication or clinical treatment plans
based on this data, the exchange of information was
more important. Instead they believed that they could
use PGD as an indicator for the patient’s progress and a
basis for which patients and providers could together de-
velop self-management recommendations.
A significant distinction between the meaning of
“data” and “information” emerged from these discus-
sions. Data is useless on its own. Individuals need to
Table 8 Summary of patients’ and providers’ ideals about what and how a data-sharing system would present patient-gathered
data during consultations





• Indications of specific problems in
their self-management
• Concerns about what data to share
“We could get a sign on the graphs … maybe statistics on how the blood
glucose is … in the evenings or afternoons” (T1D_P5)
“What I need is different than what you need as a doctor” (T1D_P4)
“Summaries of my every-day [data] in such a way that we together can discuss
where the problems are” (T1D_P4).
“I have a lot of data and my ideal situation is that I get a mail from my nurse
saying I want your data, or a reminder. Or I upload my data in my program
and share with my nurse and then I get the question “Can you note this week






• Graphs, e.g. showing trends during
different times of day
• Symbols to indicate change of a
data type over time
• Provide specific data as requested
by healthcare provider
Specialists What data to
share
• Fluctuation and trends
• Indication of what patient’s
problem/challenge is within the
data
• Representative data-sets
“First, I would like to see the fluctuation [of blood glucose] over 24 h - it’s the
most important for me. Then have a look at some data because there was
something special going on” (Specialist1) (Fig. 2).
“An intensive period [worth of data], maybe some days or weeks before they
come to me, because I want to see variation. And document pretty carefully
… Then we can see the context … So these very like, these short, tiny, detailed
periods is very valuable for me even if it’s not representative for the long life”
(Specialist1).
“The last week or 14 days … where you can see meals, calibrations - to see
that you calibrate correctly - physical activity and illness … to explain why you
are high the whole night, and of course insulin doses. Additionally, if the
algorithm can pull statistics and say “ok, you are always low after correcting




• E.g. algorithm or statistics
• Ability to choose which






• Overview of own situation
• Status of self-management habits,
i.e. each data type gathered
• Concerns about what data to share
“Having summaries of the data, and then [you can] click on blood to get
[more details] … what you’ve done that day and time and all. Everything in a
submenu of the main” (T2D_P2) (Fig. 4)
“I can collect irrelevant data - I can gather data about my own situation that
may not be relevant for doctors” (T2D_P4)
“You have green and red and yellow zones. I might not need all the values,
but you could see if you are safe or not. Like the weight it is pretty much too
high all the time. Physical activity is maybe not so good.... And then you could
choose, and get out the exact values, as a table” (T2D_P3).
“A diagram with levels - level for goals, level for what was completed.... With
remarks and blood glucose data and diet” (T2D_P2)





• Diagrams or graphs with colours or
indications of change
• Comparison of self-management
habits vs. goals
• Ability to choose which data-types
to explore from a summary
GPs What data to
share
• Challenges or issues within a
patient’s self-management habits
• Detailed data for challenges
“I tried to get in everything at once [to] see a correlation if you have [different
PGD] together … You won’t bother to plot it every day, but rather have a
marker of some sort if it was something special...like if [the situation is]
suddenly changing- the values go up or down, their health situation is getting
worse or something- it could be okay to have more values, to see what is




• Summary via, e.g. Graphs
• Indicators to show if “something
special” (challenges) happened
• Correct and representative data
“Type of compressed summary...Instead of having to look at a thousand
measurements” (GP3)
“If you get graphs and stuff it is easy to relate to and you can get quick glance
of what has changed. But if you get the whole [data set] in reverse and just
scroll and scroll, then it’s not very useful” (GP2).
“With physical activity, having it correct, so maybe step counter for example. It
says something about changes. Useful if you have these watches. They are not
necessarily very reliable, but it says something about your development. Instead
of you saying you went for a walk, or half an hour, which doesn’t really tell
me much” (GP1).
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have a purpose, intention and questions in order to dir-
ect what data to collect as well as how much and what
information, evident from the whole collection of data
types, can be identified and presented to their healthcare
provider. Healthcare providers may be interested in spe-
cific data points when “something special is going on”.
However, again, participating providers believed that in-
dividual data points, or even a collection of one data
type, are useless without context.
Issues that data-sharing can and cannot solve
By comparing participants’ backgrounds, i.e. general self-
management and clinical practice experiences and needs,
and their ideas about sharing PGD through a dedicated
system we were able to generate a better understanding
of what they believe can and cannot be addressed,
let alone solved, with sharing data from mHealth de-
vices. While the primary aim was to gather input about
the design and functionalities a system should have,
participants provided additional information about is-
sues surrounding the use of the system. Especially those
with T2D expressed that they often did not know why
their blood glucose values were changing so drastically.
This was an example of a solvable issue because their
ideal solution was that a data-sharing system could not
only identify a patient’s challenge areas but correlate the
concerning blood glucose values, for example, with their
food and medication. Issues that needed to be addressed
before such a system could even be realistically imple-
mented were mHealth technology training and support
for healthcare providers. Both specialists and GPs
expressed their limited knowledge and frustration with
not having the resources they need to become aware of
or optimize use of mHealth and PGD during clinical
practice. For example, specialists repeatedly emphasized
their concern about resource management, when tech-
nologies required nurses to provide more time and sup-
port for a small group of CGM users, and technology
training in general, because there are too many different
types of technologies to familiarize themselves with.
Proposed data-sharing system vs. state-of-the-art
We aimed to address what it would take to make the
collaboration between patients and healthcare providers
using PGD possible and useful for all users. Some of the
unique design ideas and purposes for the system that re-
sulted from these discussions were the overwhelming
agreement that the system should generate discussions,
and more importantly, shared decision-making. The sys-
tem should be flexible and present an overview of
patient-relevant data, and give the patient-provider team
the option of further exploring certain data at their dis-
cretion. These options and intentions differ from many
commercial options or other tested interventions avail-
able at the time. Typically, the responsibility and ability
to interpret the data and make decisions is one-sided -
either skewed toward patient self-management, such as
apps found on app stores, or clinical monitoring and
oversight of only one parameter such as CGMs [34]. For
example, an individual with T1D can use an app to track
how each type of food affected their BG levels to meet
their goals, whereas an HCP may prefer to see summar-
ies of data such as medication use and response, which
can then be compared to lab results. However, partici-
pants of these workshops agreed that the potential bene-
fit of using a data-sharing system that would allow both
parties to explore the data together, would be to foster
mutual understanding and discussion of the data, which
could lead to feasible recommendations. The presented
users’ feedback support the notion that patients and pro-
viders working separately, e.g. with separate agendas for
the consultation and poor communication, is not as
Fig. 2 Specialist 1’s paper-prototype for an ideal data-sharing
system display
Fig. 3 Specialist 2’s paper-prototype for an ideal data-sharing
system display
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Fig. 4 T2D Patient2’s paper-prototype for an ideal data-sharing system display
Fig. 5 GP1’s paper-prototype for an ideal data-sharing system display
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effective as identifying common needs of both parties
and designing systems to support those.
Reflections on the research method
With respect to the research method itself, it is import-
ant to note that these presented results highlighted a sig-
nificant difference, and challenge, of mHealth research
compared to traditional research. Traditional research
on medical tools and services follows a thorough, fo-
cused and lengthy process. Spending much time on
these interventions options is expected and healthcare
providers, thanks to the validated and trusted methods
of inquiry, accept the results. However, research on
mHealth tools and services requires a more user-
involved, comprehensive and rapid approach. It calls for
not only validation of the technology – which still lacks
a standard process, but at the same time, the validation
of feasible options for integration into medical system
workflows. Therefore, we as researchers must re-
evaluate how best to perform research that answers trad-
itional questions, e.g. hard health outcomes, as well as
those that are unique to mHealth and personal health al-
ternatives, e.g. ways of gathering and displaying data that
both healthcare providers and patient, as experts in their
own health, can understand. This includes taking advan-
tage of new resources, e.g. expert patients in mHealth
and social media, and more actively collaborating with
healthcare authorities and organizations to determine
feasible health service options to support mHealth inte-
gration for both patients and practitioners. Many co-
design workshops do involve patients and HCPs. How-
ever, they do so most commonly in separate sessions
[35]. In research practice, the interpretation of the
resulting participant feedback, often would have to be
inferred rather than explicitly stated. In other words,
there is usually limited or no possibility for participants
in different groups to correct one another’s assumptions.
We hope that by demonstrating how patients and HCPs
can discuss solutions together, we can encourage others
to use the EBCD method more in the mHealth and per-
sonal health field.
Lessons learned
With regard to the methods and approaches used to
conduct these co-design workshops, we have generated a
list of “lessons learned” (Table 11). Planning of the
workshop sessions and activities were generated itera-
tively over months to ensure that all participants felt
prepared and safe to share their perspectives and that
we as a research team would receive the feedback neces-
sary to design an end-user-based system for sharing
data. We experienced the need for a research team to be
flexible, inclusive and have an open agenda when invit-
ing end-users to participate in directing the research.
Study limitations
Geographical region
Limitations of these workshops resulted largely from the
convenience sampling from a specific geographical loca-
tion – Northern Norway. The relevance of this is that
Table 9 Summary of responses to perceptions of mHealth and patient-gathered data being integrated into healthcare providers’
electronic health record (EHR) systems
Groups Codes Summary Example quotations
Specialists Preferences • Automatic data transfer
• Visual summary of specific data types within patient-
gathered data
“Automatically getting the continuous glucose values for the
last week, into my electronic diabetes journal system... and the
use of insulin or automated data easily, visually presented”
(Specialist1)
Risks • Data-overload
• Capacity of personnel and resources
• Personal liability of not identifying indicators of dangerous
habits and symptoms
“The other thing that comes to my mind when you say
[integrating technology] is “Please stop it!” because I if you are
the patient and I get your data continuously for your whole life
on my screen, then I am responsible because if something
happens to you, if you go into your car and have a traffic
accident with hypoglycaemia it’s my responsibility because I
should have seen that last week you had several
hypoglycaemias … but we do not have the resources for this”
(Specialist1).
GPs Preferences • While prefer no integration, alternatives could include
automatic and simple data-transfer that do not require the
provider to perform additional tasks
• Rely on entering own notes into EHRs about a patient’s
status
“We don’t need to load [PGD] into the EHRs, because there are
many problems and overload of information. And, why should
we keep it?” (GP3).
“If we would to have it on our computers, partly via a journal.
Not extra software! Then [the patient] can have [their] phone,
plug in USB, and I have it, okay, we could do that … a
compromise - But not one manually!” (GP3).
“Instead, I prefer] to type [notes about PGD] myself … write it
short. Reminder [to focus on this] for next time” (GP3).
Risks • Data-overload
• Overloading the provider with additional tasks
“It’s always a chance of overload … a whole lot of data. We
can’t relate to it” (GP1)
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the typical culture of the medical system is less hierarch-
ical. This can sometimes extend to the relationship be-
tween patients and their healthcare providers. The
consequence is that the use of a joint session in the co-
design workshops and gathered feedback therein may
not be representative of the type of feedback, e.g. the un-
abashed correction of assumptions, that could be gath-
ered in other cultures or geographical regions.
Gender balance
Another limitation was the lack of gender balance
amongst our participants. The relevance of this is that,
in general, there are differences between genders with
and without the use of technologies. These differences
stem from their daily responsibilities and cultural roles
that research should be addressing and that impact the
outcomes and application of scientific findings in health-
care practice [34]. While we aimed to recruit equal num-
bers of each gender, few female or non-gender-binary
participants expressed interest in participating, e.g. dur-
ing the T2D patient session in which there were only
men. The consequences of this are that there was an
overrepresentation of suggestions about how technology
should function that suit men, e.g. the ability to collect
and share types of data that may be more or less import-
ant to other genders. To ensure more balanced partici-
pation in future studies, we could allow for a longer
response time during the recruitment process, and/or
advertise the study in different media.
Participants’ level of technology experience
The convenience sampling also relied on recruiting pa-
tients who used the in-house developed Diabetes Diary
app and were therefore already engaged in mHealth for
diabetes. The relevance of convenience sampling for
mHealth studies is to recruit those who have experience
and therefore experience-based suggestions for how to
address the call for mHealth integration into clinical
Table 10 Summary of responses to perceptions of mHealth and patient-gathered data being integrated into healthcare providers’
electronic health record (EHR) systems
Groups Codes Summary Example quotations
Participants
with T1D
Concerns • Data overload
• That healthcare providers still would not be
able to use data to generate personalized
recommendations
“Giving up all of my blood sugar measurements is very much
information” (T1D_P4)
“[I shared] a lot of data … I got little use out of meeting the diabetes
nurse...Last time she said it wasn’t much she could help me with” (T1D_
P3)
Specialists Concerns • Priorities of healthcare providers would be
hindered
• Healthcare providers’ capacity, i.e. time required
to use and knowledge about how to use
technology
“The CGM technology is very good, but our nurses – it means that 80%
of their time is working with the functional learning patients and
[complaints about] “it doesn’t work”, “how can it do it and change”. So
instead of actually talking to the patients about “how are you” – we are
dealing with problems about “I can’t fit it” (Specialist1)
“10% [of patients] use the CGM. Then those patients get much more
consultations with the nurses because they need to be taught the CGM
and they need follow-ups. So this small group … maybe they use 80%
of the nurses’ time” (Specialist2). Also, continuous data transfer poten-
tially meant the need “to have a diabetes nurse continuously, 24 h-a-
day, checking on continuous glucose monitors (CGMs), like we do with
hospital patients. We don’t have resources for this” (Specialist1).
“There is a lot of different technology now. It is Freestyle and it is CGM
and it is 640 G and Freestyle Libre. Of course patients are oriented about
this because they talk to other patients, search on internet and so on.
But the doctors have very little possibilities … so, we have little time to
learn these new systems and to understand how to optimally use them”
(Specialist2).
“During this 30mins where I am also supposed to have nice
communication with the patients and also do blood pressure and
check their feet and check if they have been to the eye doctors,
checking and requiring lab measurements and prescribing insulin– I
need to get these data in. That’s a problem of time. The other thing is
the problem of methodology of how to get the data presented in a
way so that it is not time consuming for me” (Specialist1).
Alternatives • PGD could complement and be used together
with EHR systems, if it were to be integrated
automatically
“I work in an [electronic health record system] so there we have a lot
established already. And what I want is a new screenshot showing
blood glucose...and the insulin. It has to happen automatically, either
with pen or pump. And then something about physical activity. And
then something [about] food, and short [remarks] about stress and
questions for the doctor … And then we look at it on the screen
together. Then it is easier to see and explain, and with things already in
[the electronic health record]” (Specialist1).
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practices; such a group would be likely to consider shar-
ing their app data with their HCPs and would be more
likely to know what they would want from a system de-
signed to do so. However, we do acknowledge that these
participants were not representative of all patients with
diabetes. As the specialist participants echoed, they only
meet a small percentage of patients who use medical de-
vices and mHealth technologies. The consequence of
Table 11 Lessons learned about conducting a co-design workshop between individuals and their healthcare providers
Aim Lessons learned Recommendations
1. Address topics relevant to the design of a
data-sharing system.
Participants have their own agendas when
participating in a workshop, e.g. specialists spent
more time explaining the situation in their
clinics and their views of what patients need in
general, than expected and often did not
respond directly to the question asked.
Plan for participants to take time to explain their
situation. This provides more context for their
perceptions and expectations of the situation,
allows the research team to better understand
their needs, and may provide additional and
unexpected relevant information.
2. Explain intentions, e.g. explain how to use
participants’ feedback
Know your audience - What you see as
important to the core purpose of the project
may not be relevant for the participants.
Do not overwhelm participants with
information, especially at the beginning when
their priority is to get settled in and
comfortable. Test out your explanation on
someone completely unrelated to the project,
e.g. a family member or friend, and ask that they
point out the confusing or unnecessary details.
3. Encourage participants to produce as much
input about their needs and ideas as possible.
Engaging and creative activities were planned
based off of research and online “toolkits”
available from several difference organizations.
Despites attempts to make instructions as
straightforward and clear as possible,
participants felt the need to clarify several times
because the instructions were either too
detailed and complicated or not
understandable.
• Use other researchers or staff in other fields,
e.g. product development, as resources for
activity ideas
• Participants may have a different interpretation
of the instructions or may miss instructions, in
which case it is best to adjust yourself as a
researcher to their interpretation instead of
trying to correct them as this may be
discouraging
4. Create a comfortable and inclusive
atmosphere to bring forward honest feedback
We posted signs and reiterated verbally that
there are no small or silly comments; all insights
and feedback would be welcome.
Disagreements were of course welcome but we
encouraged respect in the verbal discussions.
Before the workshop, reinforce within your team
that this is about the participants’ experiences,
not about your own assumptions or
preconceived notions of what is happening or,
especially, what should happen. Do not take
sides if there is a disagreement but encourage
participants to explain - ask “why do you feel
that way?” or “why do you believe that”.
5. During the joint sessions, ensure that both
patient and healthcare provider participants feel
comfortable and safe to share their opinions,
despite the difference in perceived “authority
level”.
We expected to need to reiterate that
everyone’s opinion is their own and should be
respected. However, possibly due to the less
hierarchical cultural structure in Norway, we did
not need to reinforce this concept. Participants
were respectful and listened without having to
be directed.
• Make sure that none of the participating
healthcare providers were the clinicians of
participating individuals with diabetes.
• During the lunch break between the separate
morning and afternoon joint sessions, invite all
participants to eat together.
• Suggest ice-breaker activities, within and be-
tween groups?
6. Creating an engaging and creative
atmosphere
We chose large rooms and posted the three
situations that we aimed to understand (self-
management, clinical practice and consultations)
on wall-sized poster boards as visual aids. These
included pictures and space for participants to
draw, write and tape their ideas to.
Introduce each situation and allow participants
to familiarize themselves with the posters before
starting the activities. Allow them time to
brainstorm and encourage physical interaction
with the visual aid materials. If participants know
what is planned, they can mentally prepare
themselves for the day, e.g. develop ideas
throughout and know what is expected of
them.
7. Allow for the participants to drive the
conversation and tell the research team what
they need and ideas for the systems’ design
Some participants seemed unfamiliar and
uncomfortable with suggesting creative
solutions for a future system. Instead they
wished for us to present prototypes and then
form a discussion based off of existing ideas.
• Expect that different participants have had
different history with workshop activities and
different expectations going into the workshop
• Clarify the expectations of the researchers and
participants at the beginning
• Participants could also help to plan the
workshop and select activities that their
believe will allow them to most accurately and
completely share their opinions
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this is the potential to widen the digital divide by fo-
cusing on further development of modern technolo-
gies instead of focusing on how existing technologies
can be more inclusively developed and supplied. In
the future, all interested and eligible (18 years +) par-
ties could be included to ensure that feedback about
mHealth represents not only additional and advanced
functionalities but also improvements on existing
functionalities to lower the barrier-of-use and increase
the benefits of personal technologies for diabetes self-
management.
Focus of the discussion guides
Further, discussion guide questions focused on data-
sharing, use of mHealth and healthcare consultations,
not on the demographics of the participants. This led to
an incomplete data set, i.e. lack of information about
duration of diabetes, exact age, HbA1c, education and
other potentially relevant factors. While the primary
focus of these workshops was to explore the impact of
participants’ experiences and preferences on the design
and potential use of a data-sharing system, the conse-
quence was a lack of consideration for what younger vs.
older individuals would need from such a system or how
they would experience sharing their data with healthcare
providers. This can be overcome in future studies, with-
out affecting the workshop time, by the simple addition
of a demographic survey at the beginning or prior to the
workshop start, perhaps as a part of the informed con-
sent process.
Conclusion
Those related to T1D care emphasized the need for a
system that identifies instances of health issues from
individuals’ registered data, facilitates patient-provider
discussion, fulfils the information needs of individuals
for their self-management and makes it easy and effi-
cient for healthcare providers to view the same data
in different ways, e.g. reviewing different time periods
or combining different data types. Participants related
to T2D care expected that mHealth technologies to
motivate patients to track their health and be able to
learn more effectively and direct the consultation con-
versation in a more proactive way. Both those with
T2D and GPs hoped that sharing this much more
representative data during consultations would pro-
vide evidence of trouble areas in the individual’s self-
management that they could both discuss and find
solutions for, together.
To benefit both of these end-user groups, the system
should structure the data in a relevant and usable way,
and be flexible enough to present different levels of in-
formation, i.e. summarized and in-depth, and be under-
standable for both patients and providers in order to
generate collaborative and tailored discussions. This
argues that there should be a single flexible systems
is influenced by the healthcare providers’ preference
for fewer additional technology solutions and the fact
that some individuals with T2D also visit HCPs in
the hospital, not just those with T1D. Specialists and
GPs agreed that they would prefer not to install, and
have to learn, yet another technological system in
their practice.
To address healthcare providers’ concerns of their
own preparedness and workload capacity, healthcare sys-
tems should consider developing support services and
resources surrounding mHealth and PGD integration,
such as topic-specific education. The verified feedback
from these co-design workshops have demonstrated the
importance and value of including both patients and
healthcare professionals in designing a system for inte-
gration of PGD during consultations.
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Additional File 1. Discussion guide for the Co-design Workshops 
The Full Flow research project 




Patient session (9-12) 
Welcome & Ice breaker: 
Year of the Coin 
- Welcome & return/fill in signed informed consent
forms while fill up coffee/tee
- Introductions of everyone by first name (name tags)
o Describe research team roles so participants are
aware
 Discussion moderator (EÅ)
 Agenda facilitator (AsGr)
 Observers and helpers (MB and AG)
- Ice breaker: Year of the quarter (tell what you were
doing during that year)
o 7 coins, one for each patient participant and
researcher
A: Common understanding of 
what we want to achieve 
from workshop 
P: Working within the scope 
of the project without 
limiting creativity and input 
Description of project 
purpose and aim 
- Introduction to the mHealth environment:
o We are speaking about patients in general - the
average patient may not have so much experience
with technology but are interested in using it
therefore we must address their needs as well.
o So, participants can educate us about what is
important, what works for them and where they
need more assistance/support in managing their
diabetes.
About the research project:
Mention briefly the aims and actors involved, and
the main test we aim for.
- Purpose:
o Want to know how mHealth and patient-collected
data can be used in clinical consultations
o Help patients and clinicians make better plans for
managing their own diabetes
o All of this will help design a system where you and
your clinician, together, can view the health data
that you collect yourself.
(Visually displaying the ideal situation that we hope to 
achieve – put this in the center panel of the landscape) 
- Overview of the day and agenda:
o So for today, we will get to know how you interact
– or wish to interact - with your apps and self-
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collected data and then, in the afternoon together 
with clinicians, what you would need from a 
system that helps you to share and discuss your 
data during consultations 
A: Common understanding of 
how to conduct one’s self 
during the workshop  
 
P: Encouragement and 
comfort of ALL participants, 
establish safe environment to 
share own ideas and receive 
others’ ideas 
Workshop rules 
Refer to the large printed: “YOUR ROLE, YOUR NEEDS”   
- Everyone’s opinions are valid 
- We ask that you only focus on YOUR ROLE and YOUR 
NEEDS as a patient/clinician – try not to assume what 
the other patient/clinician believes or is trying to do, 
this is why we invited both  
- Everyone should feel comfortable and not judged:  
- everyone wears different hats, experiences 
situations differently and we need to respect their 
opinions but feel free to ask clarifying questions 
or respectfully disagree 
- Enthusiasm is great but gentle reminders will be given 
if we get off track 
- Sessions will be tape recorded but it can be turned off 
upon request 
- Everything in the room will be confidential – no 
names please 
- No identifiable information will be recorded  
- Honest feedback is best to improve research and the 
system – no need to “save face”  
- No treatment advice will be discussed during this 
session 
- If questions of medical issues arise, please note 




P: Reassure that all ideas 
have value and no idea is 
stupid, breaking the tension 
and making the atmosphere 
more casual 
Warm up activity: Worst 
Possible Idea exercise 
Practical notes: White pieces of paper to draw on or write 
ideas on (enough for all 7 participants, researchers 
included)  
 
- Purpose is to reinforce that no such thing as a bad 
idea because everything leads to something useful: 
umbrella 
- Rules: 
o Both research team and patients will participate 
o Everyone should get a chance to talk, but okay if 
there are no ideas 
-  “Worst Possible Idea” exercisei 
o Think of the worst design for an umbrella  
o Write down as many ideas as you can on 
separate white sheet in 2 minutes 
o Pass them to the person next to you and 
elaborate on their bad idea – go through as many 
separate ideas as possible for 2 minutes X 2 
rounds  
o Then read out loud and place them on a board 
visible to all 
o Now propose the best design – no limits (gravity, 
legal issues, reality etc.) 









- Start audio recording of the session  
- Explanation: we will brainstorm and write down some 
things on our own and then discuss together for most 
of today – this way, in case we are not able to cover 
everything, you are still able to provide your input!  
- Introduce the landscape: Explain what the landscape 
is and how we will use it during the day 
o Fargelegg Landskapet: Egen behandling, Møte, 
klinisk diabetespraktis (MB put up graphics to 
illustrate this) After each question you will be 
given a few minutes to brainstorm 
- This is just brainstorming, you can keep writing down 
ideas as we go so don’t think that 2mins for 
brainstorming 
- Feel free to post it yourself or hold it up and we will 
come get it from you  
A: Which parameters patients 
gather, their baseline 
motivation level and measure 
of activation on a non-
standardized level 
 
P: Understanding what 
patients prioritize in their 
self-management, which will 
primarily inform the 
functionalities of the system 
and secondarily enable 
clinicians to be aware of 
patients’ perspectives 
Discussion: Do you feel 
like you self-manage your 
diabetes? Why do you 
self-manage the way that 
you do? 
Practical notes: Audio only + cotton balls to initiate 
conversation and set precedent for equal participation 
- Cotton ball method: each person gets 3 and “uses 
one up” each time they speak. 
- Follow-up & examples to use if the conversation 
stalls  
o why do you choose to spend more time on one 
thing than another  
o Impacts of the disease? 
o Realizations, habit changes? 




o Overall perceptions of how well they self-
manage?  
 
1. What do you focus 
on? Do you have a 
goal for any of these 
or do you just track to 
find trends or 
patterns? 
 
2. What data are you 
saving/collecting? 
 
Practical notes: Yellow post-its to write or draw on in 
response to each question (1-2minutes per question)- 1 
verb and 1 noun 
- Instructions: mark each post-it as # to reference the 
question we are on and try to use only 1 verb and 1 
noun for each feedback 
- Follow-up questions & examples to use if 
conversation stalls 
o Are you gathering: BG, physical activity, diet, 
medication? 
o Routines, following a schedule, preparations? 
- Place responses on white board or wall under heading 
“Egen behandling” 
 
A: What tools and support 
patients use to aid their self-
management 
 
P: Depicts possible areas 
besides health measures 
3. Do you use any 
mHealth apps or 
medical tools and 
which kind? And 
what is good and/or 
bad about them? 
Practical notes: Yellow post-its to write or draw on in 
response to each question (1-2minutes per question) 
- Instructions: mark each post-it as # to reference the 
question we are on and try to use only 1 verb and 1 
noun 
- Follow-up questions & inspirational ideas 
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that the system 
can/should address  
(else it will just be a 
survey) 
 
o Smartphone app, smartwatches, BG meters 
- Place responses on white board or wall under heading 
“Egen behandling” 
Participants place post-its 
on board in area drawn 
MB reads out loud to begin discussion and allow people to 




Discussion: How do you 
use these tools to help 
you?  
Practical notes: Audio recorded only, no additional 
supplies or preparation needed 
 
- Follow-up questions 
o why are they effective or why not? 
o how could they be more effective…”its good but” 
4. What challenges do 
you have with self-
management? 
 
5. How do you (or could 
you) overcome that? 
 
Discussion question: ask 
them to comment on 
these suggestions – lets 
focus on the solutions or 
any other ideas given 
other tools etc. that could 
help solve the 
challenges? 
Practical notes: Yellow post-its to write or draw on in 
response to each question (1-2minutes per question)- 1 
verb and 1 noun 
- Instructions: mark each post-it as # to reference the 
question we are on and try to use only 1 verb and 1 
noun. Post suggestions for 4 and 5 next to each other 
- Place responses on white board or wall under heading 
under “Egen behandling” 
A: Determine how patient 
participants interpret their 
responses. 
 
P: To engage participants 
throughout the activities. 
Allow them to take 




Practical notes: MB at board to organize 
 
- Instructions: now that we have some ideas on the 
board, we should organize them so that it will be 
easier to reference these in the coming activities 
(because we will be using your suggestions in the 
future) 
- Follow-up questions & examples to use if 
conversation stalls 










A: Which data displays are 
easiest for patients to relate 
to. Baseline understanding 
and engagement in diabetes 
data and disease knowledge. 
 
P: Understanding how 
patients interact with 
their registered data, 
6. How do you use your 
data to self-manage 
 
Practical notes: Audio only 
 
- Instructions: looking at what we wrote for questions 
1&2, let us discuss this. 
- Plan B: Give example situation to respond to 




thereby setting a basic 
or baseline way of 
displaying data in the 
system 
o How would you use your data to make a change 
or decision in self-management? 
A: Which data do patients 
want to share and what 
answers do they need from 
their clinicians to understand 
their data and act on it in 
self-management 
 
P: The expected scope of the 
systems functionalities that 
will facilitate discussion, 
initiated by patients 
7. What are clinicians 
helping with? 
8.  What could they help 
with?  
9. What should they 
help with?  
 
Discussion: Have you 
presented your own data 
or app data to your 
clinician? When did you 
or think that you should 
present your data? What 
worked/was successful or 
easy and what didn’t 
work or you both had 
trouble discussing?  
Practical notes: Yellow post-its to write or draw on in 
response to each question (1-2minutes per question)- 1 
verb and 1 noun 
- Instructions: mark each post-it as # to reference the 
question we are on and try to use only 1 verb and 1 
noun. 




A: Generate ideas to facilitate 
joint discussion 
 
P: Prepare participants for 
joint session – thereby saving 
time and establishing 
concrete topics to discuss 
Prepare for lunch break:  
Given this new situation 
where you gather data 
yourself… 
 
10. How do you think this 
changes yours and 
your clinician’s roles 
during the 
consultation? 
11. Does it change what 
you bring to the 
consultation or how 
you prepare to talk to 
your clinician? 
 
Practical notes: Brainstorm-write down or draw (if they 
want) ideas on post-its (can take them during lunch) 
- Instructions: because there is no such thing as a free 
lunch, we would like you to think through these 
questions and jot some things down because we plan 
to come back and discuss consultation during the joint 
session. Place responses on white board on line 
between “Egen behandling” and “Møte” - when you 
return from lunch 
 
 
(Stop audio recorders) Patient Lunch (12:00-13:00) 
 
patient participants to 
lunch in cantina at 
12:00 
- Preparation tasks for research team 
o Workshop rules Bring lunch in the room for the 
clinicians and 3 researchers - eat when we prep them 
and MB and AG can help describe the purpose and 
project etc.  
 




- Welcome and introduction: First Names and Experience 
with diabetes patients  
A: Common understanding 
of what we want to achieve 
from workshop 
 
P: Working within the scope 
of the project without 
limiting creativity and input 
Description of project 
purpose and aim 
Overview of what was 
done in the patient 
session 
- Current situation of mHealth and EHR data 
o Purpose of the day and project – making the most 
out of this situation 




 o Make clear what the patients have done before they 
arrive and what kind of input we want in this 
workshop  
o Make clear what will help a safe environment – no 
judgement and no assumptions of how patients 
perceive and think about their diabetes 
o Generally about the FullFlow and actors by EÅ 
- Ask if they are comfortable with MB and AG introduce 
Full Flow project in English: 
o  MB and AG, 2-3 sentences about purpose of Full 
Flow and the fact (no details) that we are PhD 
students, and what they want feedback on. 
o Visually present the ideal situation that we hope to 
achieve 
 
- (Refund formalities – if not already done by AsGr) 
- Opportunities for future involvement 
o This is a large project and we hope to include you in 
the future if you are interested – what would we 
need in order to recruit? And approximate interest 
from these participants? 
- Purpose of this workshop is to generate concrete 
suggestions using post-its AND fruitful and concrete 
suggestions and feedback during discussions that we can 
use to design this ideal situation (above) 
- Explain the landscape poster: This is what was produced 
during the patient session, i.e the yellow post-its on the 
boards. We will be doing the same thing in this session. 
Please keep in mind that our aim is to cover this whole 
landscape today together 
A: Common understanding 
of how to conduct one’s self 
during the workshop  
 
P: Establishing a safe and 
comfortable environment 
for ALL participants to share 
own ideas and receive 
others’ ideas 
Basic workshop rules 
plus clinician session-
specific rules  
Refer to poster on wall that says “YOUR ROLE, YOUR NEEDS” 
- Everyone’s opinions are valid 
- We ask that you only focus on YOUR ROLE and YOUR 
NEEDS as a patient/clinician – try not to assume what the 
other patient/clinician believes or is trying to do, this is 
why we invited both  
- Everyone should feel comfortable and not judged:  
- everyone wears different hats, experiences 
situations differently and we need to respect their 
opinions but feel free to ask clarifying questions or 
respectfully disagree 
- Enthusiasm is great but gentle reminders will be given if 
we get off track 
- Sessions will be tape recorded but it can be turned off 
upon request 
- Everything in the room will be confidential – no names 
please 
- No identifiable information will be recorded  
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- Honest feedback is best to improve research and the 
system – no need to “save face”  
- No treatment advice will be discussed during this session 
Clinician session specific rules 
- During this session, feel free to speak about your 
perceptions of patients, but during discussions with 
patients, we ask that you only focus on YOUR ROLE and 
YOUR NEEDS  
o E.g. of acceptable phrasing: “ideally it would be good to 
get X amount of information from the patient”- 
objective and general in comments  
- Suggest functionalities that might be used in a good way 
– do not focus on barriers, focus on what you need and 
how you would do it regardless of how much time it 
takes because the technology is intended to help this 
A: Baseline of how clinicians 
conduct their consultations 
and interact with patients  
 
P: Same as previous 
1. How do you start 
the consultation? 
(as separate Post-it 
sessions?) 
 
2. What do you cover 






from memory, written 
or apps) that a patient 
presents does and does 




Discussion: How can 
patients’ use of 
mHealth and patient-
gathered data be 
beneficial in the 
consultation? 
Practical notes: Green post-its to write or draw on in 
response to each question (1-2minutes per question)- 1 verb 
and 1 noun 
 
- Instructions: mark each post-it as # to reference the 
question we are on and try to use only 1 verb and 1 
noun. 
- Place responses on white board or wall under heading 
“Klinisk praksis”  
 
A: When clinicians believe 
shared decision making is 
appropriate.  
 
P: Brainstorm situations in 
which the Full Flow might be 
more useful for GPs and 
T2Ds 
3. When would data-
sharing be useful or 
appropriate, i.e. in 
which situations? 
 
Discussion: Have your 
patients ever brought 
you data on or from an 
mHealth app? Do you 




(don’t want written for 
patients to see) 
Practical notes: Green post-its to write or draw on in 
response to each question (1-2minutes per question)- 1 verb 
and 1 noun 
- Instructions: mark each post-it as # to reference the 
question we are on and try to use only 1 verb and 1 
noun. Your responses can be theoretical or reality that 
they have experienced. 
- Place responses on white board or wall under heading 
“Clinisk praktis” 
- Follow-up questions & examples to use if conversation 
stalls 




(Stop audio recorders) Break (12:55-13:00) 
 
(start audio recorder) Joint Session (13:00-15:00) 
A: Common understanding 
of how to conduct one’s self 
during the workshop  
 
P: Establishing a safe and 
comfortable environment 
for ALL participants, 
establishing that all input is 
equal and valued 
Ice breaker activity: Year 
of the Coin 
Different coins with different years than the morning 
session 
- Something that happened in your life during this year 
Reiterate workshop 
rules  
Refer to poster on wall that says “YOUR ROLE, YOUR 
NEEDS” 
- Everyone’s opinions are valid 
- We ask that you only focus on YOUR ROLE and YOUR 
NEEDS as a patient/clinician – try not to assume what 
the other patient/clinician believes or is trying to do, 
this is why we invited both  
- Everyone should feel comfortable and not judged:  
- everyone wears different hats, experiences 
situations differently and we need to respect their 
opinions but feel free to ask clarifying questions or 
respectfully disagree 
- Enthusiasm is great but gentle reminders will be given if 
we get off track 
- Sessions will be tape recorded but it can be turned off 
upon request 
- Everything in the room will be confidential – no names 
please 
- No identifiable information will be recorded  
- Honest feedback is best to improve research and the 
system – no need to “save face”  
- No treatment advice will be discussed during this 
session 
A: Presentation and 
common understanding of 
the “resources”, i.e. 
common tools and ideas, 
that we can use or refer to 
during the discussion.  
 
P: Ensure that ALL 
participants are aware of 
what we have to work with 
and each other’s ideas. 
Activity will limit group think 
and allowing all to contribute 
even if they are not 
comfortable being vocal. 
 
 
Present where we are in 
the landscape:  
- Introductions to the joint session: This is what we have 
produced together so far today and we can use these 
during the discussion if they are useful  
o - The morning session produced these – briefly review 
o - the lunch session produced these- briefly review 
- The overall goal is: to discuss together, how to meet both 
of your needs that you have brainstormed during your 
separate sessions, to be used during the consultation. We 
want to produce concrete suggestions on post-its AND 
fruitful and concrete suggestions and feedback during 
discussions 
- Allow time to ask questions and discuss or clarify these 
before beginning the activity 
Participant review of the 
landscape themselves 
- Instructions: now we should take a few minutes to all of 
us go up and physically look at what we have produced 
together – both your own and the other part. Please tell 
us what you agree with (endorse the idea) by placing a 
*check mark* (or red page marker) on the post-its that 
you truly agree with and you think should be 
highlighted in the coming discussion Each get 3 pieces 




Describe activity and 
then Present the Data 
Sharing Story Board  
- Instructions: Our intention is to colour in this landscape 
by filling in the important components/aspects of the 
situation whereby we can all discuss and agree on what 
is important for data-sharing. Once each person has 
described “why or why not” during the post-it phase, 
then we can open up and ask “who had similar 
suggestions, any comments? Arguments?” 
Describe how the 
activity will be 
conducted 
- Everyone should write down on post-its their ideas 
before presenting them out loud/discussing so that 
everyone has a chance to contribute and discuss. After 
discussion, the post-its are placed into the landscape 
- Cotton Ball method: each person gets 3 and “uses one 
up” each time they speak. 
A: When/how/what 
mHealth data should be 
shared? 
 
P: To establish a 
foundation for the 
discussion which will 
direct how and when 
the Full Flow system 
should be used, which 
will inform which 
functions are 
appropriate for each 
use case. 
1. When would it be 







(more than today) 
Practical notes: Respective post-its to write or draw on in 
response to each question (3minutes per question)- 1 verb 
and 1 noun 
- Instructions: mark each post-it as # to reference the 
question we are on and try to use only 1 verb and 1 
noun. Each person will be allowed to read theirs out 
loud and explain their perception. Please be prepared 
to say why or why not they wrote that on the post-it 
during the discussion 
- Discussion & Cotton ball exercise:  
o the point of this exercise is to allow everyone a 
chance to speak and then we can open it up once 
all cotton balls are used up or everyone speaks that 
wants to.  
o is anyone willing to say why or why not there is an 
appropriate time to share self-gathered info/data? 
o Does anyone have any additions or comments to 
this? 
- Follow-up: (Once cotton balls are all used) 
o E.g. to use if silence: When the patient has specific 
questions? 
o When there is sufficient data?  
o During the planning phase during diagnosis and 
then agreed upon thereafter for specific changes in 
self-management? 
o Why is the suggestion effective?  
- Place responses on white board or wall under heading 
“When” under “Møte”, once the discussion has come 
to an end or we have reached the time limit then 
everyone should place their post-its. 
2. What self-gathered 
information and 
data would be useful 
to share during 
consultations? (refer 
to examples that 
both brainstormed 
in separate sessions: 
suggestions for self-
management were 
XYZ and suggestions 
for what clinicians 
Practical notes: Respective post-its to write or draw on in 
response to each question (3minutes per question)- 1 verb 
and 1 noun 
- Instructions: mark each post-it as # to reference the 
question we are on and try to use only 1 verb and 1 
noun. Each person will be allowed to read theirs out 
loud and explain their perception. Please be prepared 
to say why or why not they wrote that on the post-it 
during the discussion 
- Discussion: is anyone willing to say why or why not 
these data should be shared during the consultation? 
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need to know for 
their clinical practice 
were ABC- MB can 
present some of 
these)  
o Does anyone have any additions or comments to 
this?  
- Follow-up: How much information should be shared? 
Very details or overview?  What should not be shared 
or it is not necessary to share during consultations? 
3. How can each of you 
use this information 
to a) either make a 
joint decision about 
self-management or 
treatment or b) 
make own decisions 
about how you will 
use this information 
in self-management 
or your clinical 
practice? 
Practical notes: Respective post-its to write or draw on in 
response to each question (3minutes per question)- 1 verb 
and 1 noun 
- Instructions: mark each post-it as # to reference the 
question we are on and try to use only 1 verb and 1 
noun. Each person will be allowed to read theirs out 
loud and explain their perception. Please be prepared 
to say why or why not they wrote that on the post-it 
during the discussion 
- Discussion: is anyone willing to say why or why not 
these data should be shared during the consultation? 
b. Does anyone have any additions or comments 
to this?  
Follow-up:  
Refer back to main 
idea of the project: 
data sharing system  
Then ask 
participants: do you 
have any good ideas 
about how to 
visualize your data?  
- Draw on a blank 
paper 
c. Now we have gone through what you need and 
what questions and purpose you have for the 
consultation. With these ideas in mind, we want 
to now figure out HOW a system should work 
and what pictures or graphs or information the 
system should have that visual triggers the 
discussion of what you need to know 
d. Present the wireframes of graphs and plots that 
they can draw on if they want AND graphics for 
inspiration 
e. One white sheet and one with some wire 
frames on it 
i. MB and AG: print out several copies 
pictures and descriptions of these that 
they can draw on or pull out to refer to 
Allow for some time to ask questions and clarify or give 
initial thoughts 
- Prompt them to draw ideas: Before we present our 
sketches and ideas, we want to give opportunity to 
brainstorm how to go about sharing data and how it 
should look 
o Reinforce that it is okay if no one has any ideas, this 
is what the next activity is for  
Briefly present the 
concept of the data 
sharing system in a 
bit more detail than 
previous sessions: 
explain Introduce 
research team’s ideas 
for core components 
of the system and 
rough sketch:  
- Use all ideas 
provided to suggest 
Practical notes: MB to put three scenarios, one for each 
situation on the landscape in the middle area (MB to print 
the scenarios – computer screens with headings) 
- Introduction of researcher ideas: To be more concrete, 
here are some things that we have played with and 
discussed amongst ourselves (MB to put up wire frames 
and graphics etc. 
- Explain the purpose of the system in more detail: the 
stepwise treatment approach/the fact that the system 
should progress or evolve with the patient and disease, 





f. Present wireframe components ALONG WITH: 
pictures AND their own graphs that they can 
now place in the scenarios.: 
o Wire frames 
o Goal setting and progress tracking 
o Presenting only the data that patient gathers and 
decides to share 
o Options for what data types are possible to collect 
during the study 
o Ability to ID trends and possible problem areas 
- Three situations: Imagine that this is implemented 
already- how should it look like when….  
o Shortly after diagnosis 
o Learning to self-manage and understand disease 
o Today 
Describe that these are example scenarios to illustrate the 
progress of the system in different situations 
 
A: How should: 
1) the system look (i.e. 
level of detail and 
functionalities) at each 
individual stage of the 
disease and patient’s 
self-management 
2) data be displayed 
3) the system facilitate 
follow-up from one 





P: How the system can 
display information in a 
mutually understandable 
way that also facilitates 
continued and collaborative 
care 
i. 5.a. Consultation in 




ii. 5.b. Consultation 
during your “learning 
period” – months or 
years into self-
managing the disease 
- Instructions: Now we will present the scenario from the 
two perspectives and give you some time to 
brainstorm, just as before, some notes and ideas about 
how this should look. Please write down or draw your 
ideas and then we will post them on the board and 
discuss together. 
- Scenario 1 & 2 Consultation shortly after diagnosis and 
in the middle of disease management: you first hear 
that you have diabetes and clinicians, you have given 
them information to review on their own. Imagine that 
you both have had previous meetings that go over 
some basic information and. Now, you are both back to 
continue planning treatment and discussing the future.  
- Follow-up questions to patients: Thinking back to the 
first months or years of your diagnosis. Knowing what 
you know now about self-managing, what works for you 
and support you need – 
o What should the system display as options for the 
consultation discussion – meaning you have 
gathered some data, how do you want to show it 
so that it makes sense for you? 
o what kinds of images and what should they include 
that could be helpful to you? 
o What other information should the system provide 
to help plan your treatment? E.g. goals for how to 
start self-management or data gathering options so 
that you can select where to start? 
- Allow participants to write down additional thoughts on 
post its, wireframes (either drawn on or not) before 
proceeding – 5 minutes to brainstorm 
- Follow-up questions to clinicians:  
o what do you look for in the small/large amount of 
data that you have instructed your patients to 
gather?  
o What helps you determine the progress that your 
patients are making?  
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o What problems or indicators of challenges might 
you look for? 
- Allow participants to write down additional thoughts on 
post its, wireframes (either drawn on or not) before 
proceeding – 5 minutes to brainstorm 
- Referring to the story board, have participants place the 
post-its on the board in the appropriate location – 3 
minutes 
- Ask if anyone would like to describe their placement of 
the ideas 
- Researcher can say aloud what seems to be important 
for the system from patients’ and clinicians’ via the 
post-it notes 
- Allow participants to discuss what is shown before 
moving to next situation – 15mins 
Break (as needed) 
iii. 5.c. Today’s 
consultation  
- Scenario 2 Today’s consultation: Think of the last 
consultation that you had as an individual – you have 
been working with your diabetes for some time and 
have learned more about yourself and what helps you 
manage your health and how to interpret your data. 
And clinicians: you are now meeting with a patient who 
has had the disease for a while and has been collecting 
data. 
- Follow-up questions to patients:  
o what data did you bring? What questions did you 
have for your doctor?  
o If the system were there to display your data, what 
kinds of graphs or progress or activities would it 
show? What should the graphs indicate (e.g. highs 
and lows of BG, each individual registration or 
summaries of your data, calculations of X? (E.g. 
Single events, daily and weekly trends) 
o Describe how you would show this to your 
clinician? Where do you start? Does anything need 
to change? 
- Follow-up questions to clinicians:  
o If you were to use this system, ideally, how much 
data do you need to understand your patient’s 
situation and suggest improvements or 
explanations?  
o What should the graphs or figures show – how 
much detail do you need and what kind of detail, 
e.g. averages, calculations, medication adherence, 
indicators of change in their habits/goals or health 
progress?) 
- Allow participants to write down additional thoughts on 
post its, wireframes (either drawn on or not) before 
proceeding – 5 minutes to brainstorm 
- Referring to the story board, have participants place the 
post-its on the board in the appropriate location – 3 
minutes 




- Researcher can say aloud what seems to be important 
for the system from patients’ and clinicians’ via the 
post-it notes 
Allow participants to discuss what is shown before moving 








Summing up and closing remarks (15:00-15:15) 
A: Common understanding 
of what was covered, how 
research team will 
incorporate these ideas into 
the next stages and future 
steps of the project 
 
P: Inform participants that 
their input was valued. Also 
that there are future 
opportunities to participate.  
Sum-up what we have 
all done together and 




- Reiterate the purpose of the project and why this 
research is important 
- Researchers emphasize their thanks to all participants 
- Have a description ready for exactly how this will inform 
the study and how we will test it out during the Run-In 
period 
- Tell them that we will send out additional information 
for future study opportunities WITH summary and 
follow up questionnaire about their experience with the 
co-design and any other ideas they may have (2-3 
weeks after)  
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Additional File 2. Additional information and quotations extracted from the co-design workshop 
transcripts 
 
We believe that context is of equal importance to design features when understanding how mHealth can impact end-users. The following 
additional information provides a foundation of understanding of priorities, experiences, challenges and wishes individuals with diabetes have for 
themselves and from their healthcare providers about diabetes care. In doing so, this information contextualizes and provides background for the 
input gathered about experiences, expectations, preferences and concerns about using patient-gathered data during diabetes consultations. This 
feedback helps us – as researchers, healthcare providers and health authorities – understand if and how mHealth technologies and sharing patient-
gathered data can address these factors and facilitate a beneficial change for both end-users, i.e. patients and healthcare providers. The following 
additional quotations and description of the discussion (i.e. summary) are separated into the identified themes and sub-themes presented in the 
main manuscript. The codes provided are those that were identified in the original qualitative analysis.  
 
Theme 1: Patients’ and providers’ need for more specific and detailed information in diabetes care 
Table 1. Additional quotations, grouped by codes assigned during qualitative analysis, from participants with T2D about their diabetes self-management 







“Wholeness and well-being is the focus. The goal is well-being” (T2D_P2) 








“Diet and physical training or exercise – at least at my age exercise is the most important in addition to diet. The goal is to stay as low 
[blood glucose] as possible, maybe satisfy the doctor’s wish” (T2D_P3) 
“I use internet and read about diabetes. Every time I eat something new, I can search it up. See how the specific food is built and 
contains, and if there are any objections about it” (T2D_P3) 
Motivation 
 Symptoms as 
external 
motivators 
 Peer support 
“Abnormal warm and sweating and thirsty, then I measure blood glucose extra, to see my value. If I am tired, I also measure, and 
normally have low blood glucose. Have to add sugar of some sort, juice is the best. The excuse being you can eat chocolate if you 
want. I use my feelings, then measure, then take action” (T2D_P3) 
“I am in a work out group circle, once a week….If not for that I would give up the diabetes battle, considering I feel like go to the 
doctor every week and get feedback about blood sugar. It always varies. So basically you rely more on physiology than on your own 




“I try to read online magazines, but there are so many articles contradicting each other” (T2D_P4) 
 
Table 2. Additional quotations, grouped by codes assigned during qualitative analysis, from participants with T1D or T2D about their experiences with diabetes 
healthcare providers 
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 Experienced less support
than had hoped for
 Unsure about whether to
contact HCP or not
“I suppose I can call my diabetes nurse but she has never called the healthcare service in the 30 years I have 
had diabetes to solve a situation today. I have called the diabetes line a few times but they are too far away the 
specific situation, so they tell me to go further to someone else and then you get answer after a day or two, but 
that is not when I am in the situation. So being able to solve the situation that you are in…  I don’t want to 
disturb doctors and nurses with my small problems. But they are maybe not so small if we… acknowledge what 








 Rely on healthcare
providers to tell them the
status of their health
 Experience discussion
with GP about patient-
gathered data
“I go to yearly controls and take many blood tests. If I don’t hear anything, I assume everything is fine” 
(T2D_P2) 
“My GP helps with control and coping and looks through the Diabetes Diary [app] on my phone…and then we 





 Experienced lack of
training/ support/
knowledge
 Experienced little use of
healthcare services
 Limited contact with
HCPs
“The experience I have with the doctor’s office is that GP usually is not there, so always a substitute, which it 
has been the last three years….I feel like my general practitioner doctor that they really lack the knowledge in 
which we diabetics struggle with. Patients are just a case, do not have enough education to cope with that part 
of public health” (T2D_P2) 
 “After I was diagnosed with diabetes, I haven’t gotten any advice… I got an appointment at a nurse. I got a 
note on how to react on insulin and increase doses eventually. [I was trained] to use the syringe. And three 
months after to check, and then he was satisfied with HbA1c. After that, I haven’t talked to anyone about 




Desire more guidance 
“I have little contact with healthcare professionals in relation to diabetes. I was diagnosed three years ago. 
Was two-three times at my GP. After that, I have felt like I had enough control myself for it not being a 
necessity. But now I feel like I can use some more contact and input. So a question being if an app which gave 




Understand HCP’s needs 
and limitations 
“I don’t think GPs have the time it requires to get familiar with it…. It’s not so easy you know; the GP have 
1000-2000 patients” (T2D_P3) 
Table 3. Additional quotations, grouped by codes assigned during qualitative analysis, from healthcare providers’ experiences with patients with diabetes 




 Positive toward mHealth
 mHealth can be easy to relate
to 
 Experience mostly with
medical devices (CGMs)
 Use of mHealth with EHR
systems
“We are very positive about [mHealth and diabetes care], because we have been in the field for a long 
time. And we see that it’s a revolution. It’s fantastic. The fall of late complications in enormous” 
(Specialist1)  
“Some of it is very easy - in using the DIPS journal system or NOKLUS [the national diabetes registry]. 
Ideally when a patient comes to me, I can automatically - by Bluetooth or something - get the continuous 
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glucose values for the last week into my electronic diabetes journal system, with insulin taken and glucose 
measured, so I could have it on the screen and then I could have a look at it” (Specialist1) 
mHealth 
(negative) 
 mHealth is a challenge to 
clinical practice capacity 
 HCPs do not have time to learn 
the new technologies 
“In our business where we are only measured after how many patients we see every day. So if we go to 




 Learning about mHealth: 
literature 
 Experience with mHealth as 
learning strategy 
 Prefer learning by experience 
than by industry “sales pitches” 
“When we are talking about new technology, it’s mainly based on CGM. Because that’s the new technology 
the past 10 years” (Specialist 1) 
“[Instead], we generally read scientific literature…and experience from all of my diabetes nurses and sort 
of accumulating clinical experience from the use of these devices… which means we see the problems much 





 Coordinate resources 
 Achieve the greatest good for 
the most people 
 Provide support for those who 
need it 
“CGM is very costly, not only to buy it for... but also costly because it uses all of the time resources for our 
diabetes nurses” (Specialist1)  
“As to resources and as to budget costs, it is much more helpful or much more saving money and saving 
pain for people to bring these people here with HbA1c of 10% down to HbA1c of 8%. That is really an 
advantage for everybody” (Specialist2) 
Perception of 
patients 
 Perception of patients’ 
concerns and motivations 
 Patients’ locus of control in 
diabetes  
 Some do not communicate all 
symptoms to avoid being 
hospitalized 
“Of course we want that to be more around 7% but many patients don’t want to go that low because they 
fear hypoglycaemia and they think it would cost too much work and they don’t understand why they should 
be lower, because they think the late complications are far away” (Specialist2) 
“I think the main responsibility is what [Specialist 2] says, is to make them communicate with us because 
that’s a big problem. That patients don’t want to come and communicate with us and they find it 
bothersome so they go to their general practitioner and get an insulin prescription once a year [to avoid 
hospital admissions]” (Specialist1) 
“This is in general about health and psychology like locus of control -. Is the locus of control of my health 
within in myself or am I just behaving healthy because you and you and you tell me to – that’s a general 






Typical consultation experience 
with someone with T2D 
“Many diabetes controlled are mixed with a lot of other things and I feel that can be confusing because 
high blood pressure, maybe overweight, maybe low back pain, maybe a lot of other things. I measure the 
blood pressure, I listen to the heart and lungs, we talk, if they have any problems with the medic since 
diabetes medicines often has side effects, so we discuss that” (GP3) 
mHealth 
(positive)  
mHealth technologies as 
motivation 
“When I think of some of my patients, [I see that] they are so fed up with diabetes” (GP3) [and mHealth 




Theme 2: mHealth technologies’ impacts on patients and providers 
Subtheme 2A: Purposes of, and challenges related to, mHealth and patient-gathered data 
Table 4. Additional quotations, grouped by code, from participants’ experience with mHealth and/or patient-gathered data 







 Use of mHealth helps 
with/ motivates self-
management 
 Use of multiple devices 
 Reliance on app for self-
management 




“Data collection gives you experience…if you track the data” (T1D_P3)’ 
“When I have it on my phone it is easier to plot insulin and have data on a specific time, amount insulin, blood 
glucose, and maybe food, if I bothered to” (T1D_P4) 
“I registered them in Diabetes Diary app, but there I also note the physical activity. I tried registering in the new 
version my medicine, but I gave up because I had to keep up 13 different tables every day. …also I use, and 
another app [step counter] from Samsung where it was nagging that I am not physical active enough in day 
time…. If you try to be independent of your mobile phone, you won’t be able to follow anything.  (T2D_P3).  
“[I collect] a lot of blood glucose measures…too much…I only measure in the morning to see the value [which] 




 Change: additional 
interoperability 
 Future use: collecting 
data to present to HCP  
“To start, I would want that my measurements and phone should talk together….if I don’t bother [to collect data 
consistently] it would be nice for a period – a week- before I have a consultation. Blood glucose for several 
months is available but food and insulin I take for a set period can be gathered. I don’t picture me register all of 




 Patients do not want 
data-overload 
 Automatic data-
gathering is necessary 





 Who uses mHealth 
 CGMs perceived as 
mHealth 
 Patients gather a lot of 
data but do not always 
reflect on it 
“I think some of them are younger or older, the people in the middle don’t have time for all of this. Because they 
are early in their careers and they make a family and they have children so they have got time for all of this and 
then if they the CGM people –they can come with all sorts of data because its automatic but they haven’t made a 






 How mHealth could 
change diabetes 
consultations 
 Expectations of GPs 
related to mHealth 
“It ends up with the doctor often being a conversationalist. Of course they want to help you but I experience that 
they don’t have time” (T2D_P2). When asked by the researcher facilitating the discussion if they thought sharing 
their patient-gathered data would change this, the participant responded, “I don’t know, could have compared 
data, and told me what I should do. As you say, maybe not the GP should be the one, but a different healthcare 









 Reliance on data from
patients for information
 Observation of which
data-types patients
collect/bring
 Reliability is important
“If they bring their books, and they’re clever sometimes they just test three days before and then stop testing for 
half a year, and then come back with three lost test days. Some are testing every day, four times a day…Some 
have blood pressure machine at home, then they show me…. I rely on my patients [for information]” (GP3) 
“Glucose meter yes. Usually bring it yes. And the books, usually blood sugar values, some people bring blood 
pressure tests” (GP1) 
“If they have some information that we can rely on, a book, writing their values, few of them is quite clear to 
remember. If they have reliable information, we use that more than medical history because things happen on the 
way” (GP1) 
Theme 3: Data-sharing system 
Subtheme 3A: Expectations of sharing and receiving PGD during consultations 
Table 5. Additional quotations, grouped by code, from participants’ about their experiences and expectations about sharing and receiving patient-gathered data 
during diabetes consultations 




mHealth with HCPs 
 HCPs understand patients’
situation
 Positive experience discussing
mHealth data with HCP 
“I have good help in my diabetes nurse because I can talk with him [about own-gathered 





 Wish for HCP to see data during
consultations 
“I wish that [HCPs] could see it when I’m at checkups….maybe [HCPs] can help me more 
if they see that there’s a reoccurring problem…if I’m high during the evening...we can try 




Consequences if patient is not 
prepared to explain own-gathered 
data 
“[The doctor] is going to be the person who is solving all the patient’s problems” 
(Specialist2) 
If the patient has not reviewed or attempted to understand their own-gathered data before 
sharing it with the doctor, “then it’s useless” (Specialsit2) 
Recommending 
medical devices 
 Technology not appropriate for
everyone
 Support technology use for
specific groups of patients
“For some individuals, I put a [continuous glucose monitor] on them and say “you are 
supposed to use it” while others, I keep it away from them” (Specialist2) 
“We also have a lot of compliant patients who try their best. So those in the group below or 
around 7% are compliant and they meet for consultations and want the new insulins and 







“Better communication about your situation if you have your data and can evaluate from 
it…. As I see the GP, you go to them when you have a specific problem. If you have control 







 GPs should not have to use new 
technology if patient comes 
prepared 
“If you need the GP to go to seminars to learn about it they will do it- they may not 






 Patient-gathered data could help 
streamline discussion 
 Patient-gathered data could 
provide more specifics and 
evidence of patients’ self-
management 
“The discussion with the patient could at least be more to the point. Now we ask “Have you 
been exercising lately?”, and they say “Yes, I have been every day”, and then “Okay”. 
Instead – “I see you have not been exercising every day or at all last week”. So we could 
discuss it, and more specific” (HCP_GP2) 
 
 
Subtheme 3B: What data to share and how to display it, and when 
Table 5. Additional quotations stated while participants presented their own paper prototypes, grouped by code, about what data to share, how to share it and 
when to share it 
Group Code Summary Quotations 
Participants 
with T1D 
How to share 
data 
 Wish for HCPs to have access to 
patient-gathered data 
 Possibility of remote data-sharing 
 Preference to remotely conduct 
consultations when symptoms/ 
challenges happen 
“This is what I want and what I want my doctor to get access to, or nurse…. At least that my 
doctor to have easy access to my blood glucose. And I want him to get HbA1c and possible to see 
activity. Insulin at night if I bothered to” (T1D_P4) 
“If I could say that now I’m struggling with something, and question if you [the HCP] could 
connect up and see the data…easier than booking an appointment” (T1D_P2) 
When to share 
data 
 Prefer remote transfer of data  
 Prefer to be able to share data when it 
is needed, outside of consultations  
 Remote transfer of data outside of a 
consultation could allow HCPs to 
review it when they have time 
“Or I upload my data in my program and share with my nurse and then I get the question “Can 
you note this week what you put of insulin in the given period and then I get the data from you.” 
And then I don’t really have to meet up on this…and [I still] get specific answers on it, because 
then I feel I save a lot of time [for both myself and the nurse]. She can do it when she has the 
time for it…That is my dream situation” (T1D_P3) 
Specialists 
What data to 
present 
 Specific information patients should 
provide: insulin doses 
 Data should be accurate 
 Clinical changes depend on accurate 
data  
“They should know how much insulin they have taken per day, the last week at least or the last 
month and not give only an approximation because in case we are going to give them any advice 




 Patient must collect data  
 Patient must be proactive/ prepare to 
present data 
 Sharing data can lead to better 
communication 
 Patient engagement can lead to better 
communication 
“You have the patient already before the consultation – trusting in her responsibility and her 
interest in doing better. Kind of her personal responsibility for it. As opposed to if a patient 
comes and has not gathered any data at all and the HbA1c was measured three months ago, and 
you don’t know how much insulin the patient uses and so on. So it will be a proactive attitude 
from the patient wants to better the communication and make the whole situation better. Both for 






 Patients afraid to communicate – fear 
losing “privileges” 
 Communication is needed if provider is 
to offer guidance 
“In Denmark, there is this one study that has shown that after these rules [about how many 
instances of hypoglycaemias means a person is unfit to drive] were implemented then the 
patients with diabetes type 1 do not report their actual hypoglycaemias because they are afraid 
to lose their driving licence…it’s a problem of communication and openness and frankness 
between the patient and the doctor… I [would] not be able to give him any advice” (Specialist2) 
Participants 
with T2D 
When to share 
data 
 Preference to send data to GP prior to 
consultation 
 Pre-sharing data could be more 
efficient 
“Data already be shown for the doctor before a consultation, so we have a 
baseline….To not waste time” (T2D_P1) 
 
How to use a 
data-sharing 
system 
 Use of the system changes based on 
diabetes duration  
 Assume HCPs do not want to store 
patient-gathered data 
 Information also about what data to 
present and how to present it  
“I have set up these symbols, because you got to have something. When you get diagnosed with 
diabetes, [have to know] what you have to be aware of, and so [that information] is there about 
what you can do. Eventually get graphs and register schemas in and things. We have talked 
about the possibility of getting a compressed report that we could take to the doctor, since they 






What to share 
Participants clarifying assumptions about 
one another  
Participant with T2D: “Everything regarding medicines should be in doctor journal, so don’t 
think it’s important, it is self-measurements and blood glucose and physical activity and diet and 
what affects the blood glucose” (T2D_P1)  








 Thought process about how to relate to 
data-sharing system 
 Present data and discussion according 
to patient’s duration of diabetes (time 
since diagnosis) 
 Alternative information sources when 
first diagnosed 
 Must consider time restrictions when 
discussing patient-gathered data 
“I drew it as if the paper prototype] was my computer at my office, because I think I would like 
this to be pretty easy in the start. Explain the high blood glucose, where are the limits, health 
consequences. The day you get diagnosed I think you blank out, and you don’t really know 
anything. So I would [present the data] very simply, and I would give them the website to 
Diabetes Association, where there is a lot information. And if [a patient] came to me and I have 
20 minutes, [we would] look at blood glucose. I don’t have time to inform about [patients] about 
everything, so they have to look into it themselves. [We could] talk about physical activity, a bit 
on diet, what is good and not good. But don’t start with the apps or something at once – [do it] 
step by step. I would try to make it simple. [I would schedule] a new appointment pretty soon 
again – about 3 weeks. Then [we could] get into it a bit more and give it more thought” (GP1) 
Design of data-
sharing system 
 Needs to be simple 
 Synchronising data-exchange would be 
helpful 
 Ability to use data-sharing system on 
patients’ own computer 
“[I drew a] simple front page. [Maybe have] a synchronization with an app to phone and 
patient’s own computer. Same possibility for both. Simple front page, maybe a bit more thorough 
here. For example have an exercise diary with possibility to save data” (GP3) 
What data to 
share 
Wellbeing 
“Wellbeing factor – yes useful…you get a greater understanding of the changes [of the other 
data types]” (GP2) 
How to share 
data 
Patient must be present to share data 
“Without the patients, it is not useful. The patients should be there to use it for discussion and 
planning…knowing what’s going on” (GP2) 
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When to share 
data 
Do not want patients to share data prior 
to consultation 
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Background: Despite the prevalence of mobile health (mHealth) technologies and observations of their impacts on patients’
health, there is still no consensus on how best to evaluate these tools for patient self-management of chronic conditions. Researchers
currently do not have guidelines on which qualitative or quantitative factors to measure or how to gather these reliable data.
Objective: This study aimed to document the methods and both qualitative and quantitative measures used to assess mHealth
apps and systems intended for use by patients for the self-management of chronic noncommunicable diseases.
Methods: A scoping review was performed, and PubMed, MEDLINE, Google Scholar, and ProQuest Research Library were
searched for literature published in English between January 1, 2015, and January 18, 2019. Search terms included combinations
of the description of the intention of the intervention (eg, self-efficacy and self-management) and description of the intervention
platform (eg, mobile app and sensor). Article selection was based on whether the intervention described a patient with a chronic
noncommunicable disease as the primary user of a tool or system that would always be available for self-management. The
extracted data included study design, health conditions, participants, intervention type (app or system), methods used, and measured
qualitative and quantitative data.
Results: A total of 31 studies met the eligibility criteria. Studies were classified as either those that evaluated mHealth apps (ie,
single devices; n=15) or mHealth systems (ie, more than one tool; n=17), and one study evaluated both apps and systems. App
interventions mainly targeted mental health conditions (including Post-Traumatic Stress Disorder), followed by diabetes and
cardiovascular and heart diseases; among the 17 studies that described mHealth systems, most involved patients diagnosed with
cardiovascular and heart disease, followed by diabetes, respiratory disease, mental health conditions, cancer, and multiple illnesses.
The most common evaluation method was collection of usage logs (n=21), followed by standardized questionnaires (n=18) and
ad-hoc questionnaires (n=13). The most common measure was app interaction (n=19), followed by usability/feasibility (n=17)
and patient-reported health data via the app (n=15).
Conclusions: This review demonstrates that health intervention studies are taking advantage of the additional resources that
mHealth technologies provide. As mHealth technologies become more prevalent, the call for evidence includes the impacts on
patients’ self-efficacy and engagement, in addition to traditional measures. However, considering the unstructured data forms,
diverse use, and various platforms of mHealth, it can be challenging to select the right methods and measures to evaluate mHealth
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technologies. The inclusion of app usage logs, patient-involved methods, and other approaches to determine the impact of mHealth
is an important step forward in health intervention research. We hope that this overview will become a catalogue of the possible
ways in which mHealth has been and can be integrated into research practice.
(JMIR Mhealth Uhealth 2020;8(4):e16814) doi: 10.2196/16814
KEYWORDS
mobile health; apps; self-management; chronic disease; noncommunicable diseases; interventions; patient-centered approach;
patient-operated intervention
Introduction
Need for Mobile Health Evaluation
Health research is yet to agree upon a framework for evaluating
mobile health (mHealth) interventions. This is especially true
for tools, such as apps and wearables, that are intended primarily
to aid patients in health self-management. Traditionally, the
evaluation of mobile medical devices has been based on clinical
evidence, and it can take years to bring these devices to the
market. The continuous glucose monitor first came onto the
market in 1999, but it was not until 2006 that the next version
was available [1]. Similarly, the pulse oximeter struggled for
decades to become a standard mobile tool for measuring blood
oxygenation [2]. Because there are increasingly easy-to-use
patient-operated mHealth technologies available on the market,
patients are no longer willing to wait for a lengthy evaluation
process. Instead, patients often use apps without assurance of
quality or guidance from their health care providers [3].
Always-Available Self-Management Technologies
Individuals are more empowered to take greater responsibility
for their health, and currently, they enthusiastically seek out
mHealth apps and other devices for self-management. For
chronic conditions in particular, health challenges occur
continuously, not just when it is convenient or at a doctor’s
office. Technologies for self-management must allow individuals
to register and review the measurements that they input into the
app or system at any time. Connectivity to devices, such as
medical or commercial sensors and wearables, adds to the utility
of an app. A report by Research2Guidance [4], an organization
that provides market research on digital health, emphasized the
central role of patient-operated mHealth apps in the
“connectivity landscape” of electronic health technologies [5].
However, their diverse functionalities and intended uses pose
great challenges to researchers.
Challenges of mHealth Evaluation: Single Apps Versus
Multiplatform Interventions
The amount of assessment and testing that is necessary for health
technology is directly related to its potential risks and benefits
[6,7]. For example, medications based on patient-gathered health
data are associated with higher health risks than those in patients
with type 2 diabetes who seek motivation from an activity
tracker for weight management. Although multiplatform (ie,
system) interventions serve to increase the benefits (eg,
automatic and less burdensome operations), they increase the
risks related to data safety, integrity, and reliability [8,9].
Researchers must adapt their approaches, methods, and measures
for patient self-management interventions involving single
mHealth apps and those involving multiplatform systems.
Evaluation Framework: Coverage
There are two main categories of mobile medical or mHealth
devices associated with the amount of oversight health
authorities will show; those that are “actively regulated” and
those that fall under “enforcement discretion.” These categories
are described in the 2015 Guidance for Industry and Food and
Drug Administration Staff [10] and are echoed in the updated
2019 Guidance [11] and included in the terms of The European
Economic Area Certification (CE) Mark [12]. Devices that are
actively regulated are required to undergo an evaluation and
meet security and effectiveness standards for use in health care.
On the other hand, many patient-operated technologies fall
under “enforcement discretion,” and they pose less risk to patient
safety and health. For individuals aiming to assess the usefulness
or safety of these technologies, there are no evaluation
frameworks or guidelines to follow. The year 2015 marked a
relevant change in the mHealth arena, which we are still
exploring today (connectivity between different device types,
development on different platforms, and marked focus on
mHealth integration into clinical practice) [13].
Although there have been many strategies [14-17] for the
evaluation of this subset of mHealth (eg, National Institute for
Health and Care Excellence [18]), there is no agreement about
which qualitative or quantitative measures should be addressed
or how they should be evaluated [19]. Evaluation frameworks,
such as the World Health Organization (WHO) mHealth
evidence reporting and assessment (mERA) checklist [20],
suggest that traditional health research measures and methods
are not sufficient. For assessing the comprehensive impacts of
such patient-operated mHealth approaches, research needs to
look into additional factors. This can be achieved by producing
evidence that is relevant for both patients and clinicians.
Additional Factors for mHealth Evaluation
Although clinical evidence is essential for the evaluation of any
health aid, the two major concepts of time and human behavior
must also be addressed in mHealth evaluation. As “always
available” technologies are being used continuously and
uniquely by patients, it is uncertain how much time is needed
to produce an effect and what changes in self-management
behavior will occur. Traditionally, medical devices rely on
established biological knowledge, have fewer alternatives in
the market, and do not offer frequent updates. However,
patient-operated mHealth approaches require the consideration
of patients’ motivation, health beliefs, and resources for
self-management. They must also compete with hundreds of
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other mHealth apps and devices that are continuously developed
and updated. In recent years, clinical research has attempted to
keep pace with mHealth by employing methods that aim to
expedite the research process and produce more tailored
knowledge for the field of mHealth [21].
Stakeholders associated with chronic health and care
(researchers, individuals, health care providers, and health care
authorities) have been calling for evidence related to the personal
use of mHealth technologies for many years [22-24]. Regardless
of the beneficial or harmful outcomes, we need to know their
potential. Without such evidence, people in the health care field
will not be able to effectively support and guide individuals in
the use of these technologies for health self-management. This
evidence must be obtained with appropriate questions and
methods.
Recent scoping reviews of mHealth technologies for chronic
conditions focused on evidence as it relates to a specific age
group [25], the development process [26], or clinical outcomes
[27] and not on how the research was performed or which
resources were used in the evaluation. The purpose of this
scoping review was to identify which methods were used and
which qualitative and quantitative data were measured to assess
patient-operated mHealth devices for the self-management of
chronic noncommunicable diseases (NCDs). As evidence for
health authorities and health care providers, quantitative clinical
outcomes have historically been considered the primary target
for evaluation [28]; however, given the growing trend of
mHealth, we included qualitative measures of participants’ use
of and experiences with the technology.
Research Questions
The research questions were as follows: (1) What methods are
used to evaluate patient-operated mHealth apps and systems
for self-management of chronic NCDs? (2) Which qualitative
and quantitative measures are used to evaluate the impact of




We performed a scoping review to document how researchers
have evaluated mHealth interventions for self-management of
chronic NCDs. Munn et al [29] stated that scoping reviews are
favored over other review types in cases in which researchers
are using an evolving set of methods owing to the novelty of
the field or where the purpose of the review is to inform future
questions about the field. We intended to provide an overview
of what methods researchers use and which qualitative and
quantitative measures were adopted to evaluate mHealth
self-management interventions. This review reports information
according to the Preferred Reporting Items for Systematic
review and Meta-Analyses extension for Scoping Reviews
(PRISMA-ScR) checklist (Multimedia Appendix 1).
Search Strategy and Databases
The scope of the search and definitions of mHealth were
discussed among the coauthors (MB, EG, EÅ, and MJ). The
databases searched for scientific literature were PubMed,
MEDLINE, Google Scholar, and ProQuest Research Library.
PubMed and MEDLINE were both included because PubMed
includes citations that are not yet indexed in MEDLINE [30].
We searched for articles published in English between January
1, 2015, and January 18, 2019, which were related to the
evaluation of patient-operated mHealth interventions for
self-management of chronic NCDs. The search string included
key terms describing the intervention’s intended use (ie,
self-efficacy, self-assessment, self-management, or
self-monitoring) and the intervention’s platform (ie, mobile
phones, wearables, sensors, or apps). The full search string was
used for titles and abstracts, and the format was adapted to the
database being searched (Multimedia Appendix 2).
Medical Subject Headings (MeSH) terms were not considered
because our search included articles published recently, which
may contain terminology that has not yet been indexed within
the MeSH database. The identified abstracts and titles were
collected in EndNote [31] and then uploaded into Rayyan [32],
an online “library systematic review service” that allows
researchers to collaborate on the organization, inclusion, and
exclusion of articles for literature review.
Eligibility Criteria
We aimed to include research efforts that may have addressed
new guidelines for mobile medical devices. Within our broad
search criteria for low-risk mHealth apps and systems, articles
were eligible for inclusion if they described low-risk
technologies consistent with the FDA and CE Markings’
description of mobile medical devices under “enforcement
discretion” [10-12]. Multimedia Appendix 3 describes the
specificities of this subcategory.
A preliminary search was performed, and a random selection
of 10 articles was reviewed for inclusion or exclusion by two
authors (MB and EG). Refinements were made to the review
criteria.
For this review, we included studies that evaluated interventions
involving (1) mHealth technologies for chronic NCDs, including
the primary NCDs listed by the WHO [33] (ie, diabetes, cancer,
cardiovascular diseases, chronic respiratory diseases, and
chronic mental health conditions); (2) mHealth technologies
for self-management (tasks which a person must perform in
order to manage the symptoms, treatment, physical and
psychosocial consequences, and lifestyle changes inherent in
living with a chronic condition, and efficacious self-management
was considered to encompass the ability to monitor one’s
condition and to affect the cognitive, behavioral, and emotional
responses necessary to maintain a satisfactory quality of life)
[34]; and (3) mHealth technologies that allow the patient to
choose which measures to register and review.
The details of the inclusion and exclusion criteria are described
in Multimedia Appendix 4, and they were used during the main
review search.
Data Extraction and Synthesis
After removing duplicate articles, reviews, and protocol articles
without evaluation results, two authors (MB and PJ)
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independently screened the titles and abstracts for eligibility
according to the inclusion and exclusion criteria. In case of
disagreement regarding eligibility, another author (EG) was
called to join the discussion until an agreement was reached.
Author MB reviewed the full-text articles and performed data
extraction.
The identified studies were classified as either those that
evaluated mHealth apps or mHealth systems. Interventions that
included a single app were grouped as mHealth apps, whereas
those that included services or devices connected to a central
app were grouped as mHealth systems. In this way, we could
more clearly assess the different approaches taken by researchers
when addressing the various impacts of these two mHealth
intervention types.
Abilities of Studies to Produce Results
For both groups, one author (MB) assessed whether a study was
able to produce the evidence that it aimed to obtain, using the
selected methods. This was performed by comparing the
objectives as stated by the authors of the identified articles to
the methods and reported results. The studies were judged
according to their ability to produce the information, and the
findings were reported as yes, yes and more than expected, no,
and cannot tell. The results of these comparisons are detailed
in Multimedia Appendix 5.
Results
Overview
Among 3912 records identified by the search criteria, we
reviewed 55 full-text articles and included 31 studies for data
extraction and synthesis. Figure 1 illustrates the process of
identifying the relevant articles for inclusion in data extraction.
Figure 1. Flow diagram illustrating the selection of studies for inclusion in data synthesis. NCD: noncommunicable disease.
Summary of Studies: Apps Versus Systems
Among the 31 studies chosen for data extraction, 15 were
categorized as those that evaluated mHealth apps and 17 were
categorized as those that evaluated mHealth systems. One study
evaluated both apps and systems [35] and was therefore included
in both categories. General information about the selected
studies that evaluated mHealth apps are summarized in Table
1 [35-49] and those that evaluated mHealth systems are
summarized in Table 2 [35,50-65].
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bRCT: randomized controlled trial.
cNot available.
dStudy evaluated both apps and systems and therefore will appear in both categories.
eCombination of cardiovascular disease, obesity, diabetes, high blood pressure, high cholesterol, osteoporosis, gastroesophageal reflux disease,
osteoarthritis, chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease, and bipolar disorder, major depressive disorder,
schizophrenia, or schizoaffective disorder [47].
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bSchizophrenia spectrum disorder, bipolar disorder, or major depressive disorder [52,58].
cN/A: not applicable.
dRCT: randomized controlled trial.
eStudy evaluated both apps and systems and therefore will appear in both categories.
App interventions mainly targeted mental health conditions
(n=7), followed by diabetes (n=3) and cardiovascular and heart
diseases (n=4), with one study evaluating multiple apps that
were used to self-manage multiple health conditions (Table 1).
Patients were included in all studies, and the studies had between
3 and 156 participants (median 36, IQR 15-87, maximum 156).
The exception was one study in which only researchers
evaluated patient-operated apps according to Google
recommendations and quality standards [35,39]. Although
studies tested single apps intended to be used primarily by
patients, two studies also explored the impact of patients sharing
their collected data with health care providers [35,42].
Six studies utilized single evaluations, either through a
cross-sectional design [35,37,39,45-47] or an analytic service
to analyze data available through the app store [41]. The
remaining studies evaluated the impacts of app use over time,
lasting between 4 and 72 weeks, with a mean period of 22.75
weeks (median 16 weeks, IQR 6-36, maximum 72). Of these,
four utilized prospective study designs, three were randomized
controlled trials (RCTs), and two used a retrospective design.
Among the 17 studies that described mHealth systems, most
involved patients diagnosed with cardiovascular and heart
disease (n=6), followed by diabetes (n=5), respiratory disease
(n=2), mental health conditions (n=2), cancer (n=1), and
multiple illnesses (n=1; Table 2).
As with mHealth app studies, all system studies, except one
[35], involved patients. The 16 studies had between 6 and 151
patients (median 30, IQR 14.5-51.5, maximum 151), with eight
studies involving health care providers. In these cases, health
care providers either provided input on the suitability of an app
for patient use or reviewed patient-gathered data during
consultations.
In 12 studies, patients were required to share data (n=6)
[50,51,57,60,62,64] or encouraged to share data (n=6)
[35,53,55,59,61,65] with their health care providers or peers as
part of the study. Data were also collected and transmitted to
the main app by medical devices [50,51,53-57,61,63,64] and
commercial wearables [35,52,53,58,60], demonstrating the
prevalence of connectivity in modern mHealth systems.
Few studies (n=3) used single evaluations. RCTs (n=4) lasted
longer (35.75 weeks on average) than cross-sectional studies
(mean 24.5 weeks, n=2) and prospective studies (mean 12.93
weeks, n=7). Overall system evaluations lasted a mean of 20.32
weeks, which is very close to that for app interventions, but
with a higher median number of 23 weeks.
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Most studies included a combination of qualitative and
quantitative methods of evaluation. Evaluation of usage logs
was the most commonly adopted method (21 studies), followed
by standardized questionnaires (17 studies; Table 3). Only two
studies adopted quality guidelines to evaluate mHealth
interventions; the Mobile Application Rating Scale was used
to evaluate multiple apps [35], and compliance with Google
standards for Android systems, in addition to other approaches,
was used to evaluate the HeartKeeper app [39].
Table 3. Categories of methods used to evaluate mHealth interventions.
Studies that evaluated mHealth systemsStudies that evaluated mHealth appsMethods (adopted approaches)





[35,53,62][35,41,43,45]Open feedback (ie, oral or written)
[54,56,57,60,62,64]N/AaCollection of additional device data (eg, medical device data)
[61,65][46,47]Field study and observation
[59,64]N/AFocus groups
N/A[45,47]Observational tests (in a lab setting)
[35][35,39]Quality guidelines
[63][42]Medical record entries
N/A[42,48]Attendance (intervention assigned activities/meetings)
N/A[41]Download count
aN/A: not applicable.
Among the 14 ad-hoc questionnaires used, four were developed
according to concepts or questions from standardized
questionnaires [47,58,61,62]. Similarly, two studies included
interviews, where the interview guides were based on
standardized questionnaires [40,45]. Some standardized
questionnaires were used in more than one study. Multimedia
Appendix 6 lists these questionnaires and illustrates the
combination of questionnaires used in each study. Compared
with traditional medical device testing, relatively few studies
included information gathered from medical record entries
(n=2), clinical outcomes (n=9), or observational tests (n=2).
Of note, some studies inferred more information from usage
logs than the count and type of app interactions and
patient-gathered data. For example, Triantafyllidis et al [50]
interpreted information from the evaluation of usage logs on
the usability of the device and participants’ engagement in the
study. The complete set of the types of data that were measured
and collected by the mHealth app and system intervention
studies are listed in Table 4.
JMIR Mhealth Uhealth 2020 | vol. 8 | iss. 4 | e16814 | p. 8https://mhealth.jmir.org/2020/4/e16814
(page number not for citation purposes)
Bradway et alJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
Table 4. Categories of qualitative and quantitative data that were measured to evaluate mHealth interventions.
Studies that evaluated mHealth systemsStudies that evaluated mHealth appsTypes of data measured
[50,52,53,56-59,62-65][36,37,40-42,44,45,49]Interactions (via app)
[35,52,53,56,58,59,61,62,65][35,37,39-42,45,47]Usability/feasibility
[50,54,55,57,59,62-64][36-38,41,45,49]Patient-gathered self-management data (via app)
[35,50,51,53,56,58,59,64,65][35-37,40,42,43,45,48]Efficacy/effectiveness
[54-57,60,62-64][36,40,42,48]Physical well-being

















Although a single method can often provide information
regarding more than one measure, over one-third of the studies
in this review used more than one method to collect information
on one type of measure [40,42,45,48,50,55-60]. For example,
two studies used both the collection of additional device data
and clinical outcomes to report physical well-being [54,64].
Multimedia Appendix 7 includes a description of which
measures were produced by each method. Several of the studies
collected information on twice as many types of data measured
as methods used to collect them (n=9) [35,41,44,49,58-60,65],
with two studies collecting three [51,52] and one collecting four
[39] times the number of types of data measured as methods
used to collect them. Only one study used four methods to
evaluate the most unique data types that were measured (n=10)
by utilizing information resources that mHealth technologies
make available (eg, automatically collected data from current
users in the Android app store) [41].
Conversely, measures can be reported using more than one
method. For example, usability/feasibility was the most common
measure (22 times in 17 studies), followed by
efficacy/effectiveness (20 times in 16 studies), interactions (via
app; 19 times in 19 studies), physical well-being (18 times in
13 studies), and patient-gathered self-management data (via
app; 15 times in 14 studies; Multimedia Appendix 7).
The study by Possemato et al [42] described the only app
intervention that measured health care utilization and impact
from these methods. Kim et al [56], Alnosayan et al [64], and
Sieber et al [63] described system interventions that measured
health care utilization or impact (ie, hospitalizations reported
by participating health care providers and hospitalizations
recorded retroactively). The remaining studies (n=5) collected
information regarding physical well-being from clinical
outcomes measured by researchers or health care providers
during follow-up [36,48,54,55,61].
More comprehensive mapping of methods and measures
revealed that the methods that were used to produce the most
diverse set of data were, as expected, interviews (n=9),
standardized questionnaires (n=16), and study-specific
questionnaires (n=13; Multimedia Appendix 7). However,
evaluation of usage logs produced nearly as many different
types of measures (n=8).
Objectives and Methods Versus Results
A comparison of the study objectives with the results
demonstrated that 30 of the 31 studies reported the results that
they intended. One study reported all but one of the intended
results described in the original objectives (ie, whether the
reviewed apps and systems had been previously validated) [35].
Ten studies reported more than they anticipated, some of which
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included the assessment of app [42,48] and system [50] usage
patterns, as well as comparisons with other outcomes [41,44].
Other unforeseen outcomes included the accuracy of the app’s
knowledge base, as evaluated by nurses [45]; usability according
to patients’ performance of predetermined tasks with the app
[47]; usability of connected devices in an mHealth system [53];
health care utilization [56]; and patient-reported symptoms [63].
Two studies stated that the objective was to develop mHealth
systems; however, their outcomes also included evaluation
results [50,51]. None of the studies phrased their goals as
research questions and some reported what they intended, but
the objective was not explicitly stated or detailed [40,63]. For
example, Velardo et al [62] stated their intention to evaluate
their intervention at scale. However, it was not clear how they
intended to “evaluate” their intervention.
Discussion
Principal Findings
We identified 31 studies that described evaluations of mHealth
apps or systems, with one describing evaluation of both
intervention types [35]. Our findings show that studies relied
mostly upon more continuous measures. Except for the
collection of additional device data used by system interventions
but not app interventions, there were no significant differences
between apps and systems with regard to their ability to produce
the intended outcomes, health conditions, or types of methods
or measures used within the studies. Overall, medical record
entries [42], attendance of meetings or activities assigned by
the intervention [63], and download count [41] were the least
used methods for gathering information about an intervention’s
impact on patients and providers. On the other hand, evaluation
of usage logs [36,38,40-42,44,48-50,52,54,56-59,62-64] and
standardized questionnaires [35-39,41-45,48,49,55-57,60,64]
were the most commonly used methods. These two approaches
(ie, one traditional and one mHealth) were also commonly used
together in the same studies, demonstrating that mHealth is
supplementing, not replacing, traditional research approaches.
mHealth Trends Versus Methods and Measures Used
Although clinical integration of mHealth technologies is on the
rise, only two studies described app interventions that were
meant to be used by secondary users (ie, health care providers
and family and friends) [35,42], with three involving health
care providers in the evaluation process [42,45,48]. Despite the
focus on data safety and security, as well as patient privacy, as
described by the new General Data Protection Regulation [66]
and established FDA [10,11] and CE marking [12] expectations
for health-related technologies, only two studies included
measures regarding security [39,51].
Need to Reassess Evaluation Standards
Health evaluation studies are meant to produce evidence and
understanding of how various interventions could affect patients
and providers in real-world health care settings. Traditionally,
studies have been classified within a hierarchy based on their
designs, methods, and measures used to evaluate health
interventions [67]. Health professionals consider high-level
studies to be those that use rigorous and strict study designs,
such as RCTs [68]. These studies provide an objective and
quantitative understanding of how an intervention would
influence patient clinical health measures, cost, or health care
resource use [69]. On the other hand, low-level studies are often
those that rely upon subjective and flexible study designs (eg,
qualitative studies of participants’perception of the intervention
or its impact on their lifestyle) [70].
Challenges of Quality Assessment
Health intervention researchers are not given instructions or
guidance about how to evaluate these mHealth apps or which
additional evidence is needed to determine their comprehensive
impacts on patients and providers. The recent addition of
connected technologies, such as wearables and sensors, has
introduced even more factors to the evaluation context.
Interventions now vary from recording exercise, to decision
support for patient self-management, to providing evidence of
a patients’ actions for health care providers, to review from a
variety of data sources. Because of these new information
sources, we cannot always anticipate all of the impacts of these
diverse networks of mHealth self-management technologies.
For example, 10 studies did not intend to obtain results related
to certain factors, such as usage logs and patient-reported
outcomes [41,42,44,50,53,63].
The assessment of a study’s success, validity, or quality presents
another challenge to traditional research practice. mHealth
resources consist of factors that make standard quality
assessments inconclusive for intervention studies. For example,
identifying patterns of patient self-management habits and
progress describes the impact of an mHealth intervention on a
patient’s behavior. However, the analysis of usage logs, as a
measure of intervention effectiveness, patient engagement, or
self-management practices, has been minimally investigated as
an appropriate method. As demonstrated by some of the
reviewed articles, usage logs, download counts, and online
ratings of apps were interpreted as indications of patient
engagement, self-management behavior, intervention reach
[41], effectiveness, and intervention utility [40] or feasibility.
Comparing Objectives and Results to Determine
Successful Use of Methods
As opposed to completing a formal quality assessment, we chose
to determine whether a study was able to produce the evidence
that it aimed to provide, using selected methods. Some studies
that performed usage log analysis were able to produce more
information than they anticipated. Possemato et al [42] stated
their intention to assess the fidelity of the PTSD Coach
intervention by comparing health care utilization and health
outcomes between those who used the app with and without
clinical support. They were able to provide evidence for the
effectiveness and fidelity of the intervention among health care
providers, symptoms, and clinical health parameters from
questionnaires. Moreover, they provided evidence for
participants’ patterns of intervention use from usage logs.
Thereby, they were able to discuss the relationship between
health care provider involvement and reinforced use of the app,
as patients may have felt more accountable for using the app to
self-manage their post-traumatic stress disorder.
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Among the 31 studies identified, one did not obtain all of the
intended information (missing one of the intended outcomes)
[35] and one was found to be inconclusive [53]. We found that
it was challenging to determine the specific objective of a study
when objectives were not stated as such or when they were
vague. This made it difficult to determine if a study was
successful in the use of its selected methods and study design
to reach its goals. For example, Velardo et al [62] stated that
they intended to evaluate the EDGE digital health system
intervention at scale; however, they did not state how they
intended to do so or provide a research question that they
intended to answer. Sieber et al [63] did not state the objective
of their study. Instead, they stated simply what was done (ie,
investigated the effects of usage profiles on hemoglobin A1c).
Without a stated objective, we are unable to judge the reliability
of intervention studies, whether it be through standard traditional
means or an alternative approach. Clear objectives must be
included in order to validate mHealth resources as trustworthy
and relevant measures for evaluating mHealth interventions.
Relevance
mHealth must work for health care providers as well as patients.
Patients are more engaged in their health, and they incorporate
mHealth into their self-management. Thus, patients are aware
of and can even influence how an mHealth intervention should
or could be used to influence the kind of impact that is relevant
for them. Understanding the potential risks and benefits of
patient-operated mHealth requires more continuous evidence
of not only technical and clinical outcomes but also personal
and psychological impacts. This review demonstrates, through
the use of such measures as mHealth interactions and
patient-gathered data via an app, that we as researchers have
the resources at our disposal and are beginning to use them.
A 2016 study by Pham et al [71] called for alternative or
additional methods and measures for mHealth clinical trials that
address the additional needs of mHealth. As most mHealth
technologies for chronic health self-management are intended
to be always available and continuously used by the patient,
research questions, approaches, and designs need to reflect the
real-world situations in which patients use these apps and
systems.
Several studies within the presented scoping review
demonstrated an attempt to meet this call by including more
flexibility in their intervention design. For example, the EDGE
digital health system [62], PTSD Coach app [42,43], and
HeartKeeper app [40] made the patient the “decision maker”
by allowing the patient to choose which data are relevant for
them to gather and share with their health care providers.
Further, two studies focused on reporting that patient
engagement improved as a result of using mHealth apps [36,52].
User engagement is a necessity for the success of any
intervention. It is paramount to consider patients’ intentions
when using these apps outside of the clinic; we should deem an
app’s ability to engage patients with their health as necessary
as clinical evidence. There are individuals who do not choose
to manage their chronic illnesses at all, for example, those
deemed “hard to reach,” who may benefit from merely
acknowledging their health challenge by using an app primarily
for education, without the expectation of performing
complicated and time-consuming self-management. Therefore,
when judging the success, usefulness, or potential benefit of an
evaluated mHealth intervention, there should be less of a
hierarchical gap between clinical health change or improvement
and patients’ experiences and change in self-efficacy.
Limitations
We believe our review covers most of the articles that were
published during the established period and dealt with mHealth
interventions for chronic conditions. This review reported on
patient-operated mHealth self-management and did not include
other potentially relevant interventions, such as SMS-based
interventions.
We chose to focus on self-management of chronic NCDs, as
defined by the WHO, in addition to severe mental health
conditions, according to the demand for solutions from two
fields (the medical system and public app development market)
[4,13,33,72]. As such, these health cases represented the most
potential for including state-of-the-art technology studies, with
chronically ill people consistently being the leading market.
However, exclusion of preventive treatments and other chronic
health challenges (eg, musculoskeletal diseases) may have
excluded a large proportion of cases that both involve the use
of self-management options and represent a relevant portion of
the chronic disease burden for individuals and health care
systems worldwide [73]. As such, this noninclusion may have
omitted conditions that could have provided relevant insights
into methods and measures used to assess motivational,
educational, and empowering mHealth technologies for
self-management.
Because we did not collect data on reported results for this
scoping review and did not perform a systematic methodological
quality assessment, we cannot comment on the usefulness or
effectiveness of the mHealth app and system interventions
presented in these studies.
Conclusion
Researchers are now using several mHealth resources to evaluate
mHealth interventions for patient self-management of select
NCDs. This is evident as studies relied mostly on more
continuous measures, including usage logs
[36,38,40-42,44,48-50,52,54,56-59,62-64] and patient-collected
data from medical devices [54,56,57,60,62,64], in addition to
pre-post measures, such as clinical health measures
[36,40,48,54-56,63,64] and standardized questionnaires
[35-39,41-45,48,49,55-57,60,64]. In doing so, they evaluated
the health status, engagement, and feasibility of mHealth apps
and systems. In this review, which focused on mHealth, we
found that only 20% of the included studies relied solely on
traditional study designs (eg, RCTs) and methods that measure
only pre- and postintervention health changes. The findings
illustrate that the tradition of focusing on “clinical effectiveness,
cost-effectiveness, and safety” [74] or health-related quality of
life and the use of health care resources [75] is not being
replaced, but is instead being expanded by taking advantage of
additional resources that mHealth provides to evaluate
interventions.
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There is still no clear standard for the evaluation of mHealth
interventions for patient self-management of chronic conditions.
However, because mHealth presents additional challenges,
needs, and resources to the field of health intervention research,
we have the opportunity to expand and maintain our relevance
to patients, providers, and health authorities. mHealth provides
new types of information that we can and should gather to
determine the impact of the interventions.
The presented results demonstrate that health studies have
started to take advantage of additional mHealth resources, such
as app usage logs and other patient-involved research methods,
to determine the comprehensive impacts of mHealth on patients
and other stakeholders. We are able to not only answer
questions, such as which tasks patients choose to perform during
interventions that may affect their clinical outcomes, but also
say more about the relevance of mHealth for various types of
users. This is essential in health intervention research, as the
call for evidence on mHealth continues to push for not only
traditional clinical health measures but also impacts on patients’
self-efficacy and engagement. We believe that to achieve a
compromise between the rigidity of traditional quality standards
and the push for more patient-relevant outcomes, the definition
of quality or meaningful impact, as well as available and
appropriate evidence should be reassessed.
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The Introduction of mobile health (mHealth) devices to health intervention studies chal-
lenges us as researchers to adapt how we analyse the impact of these technologies. For
interventions involving chronic illness self-management, we must consider changes in
behaviour in addition to changes in health. Fortunately, these mHealth technologies can
record participants' interactions via usage-logs during research interventions.
Objective
The objective of this paper is to demonstrate the potential of analysing mHealth usage-logs
by presenting an in-depth analysis as a preliminary study for using behavioural theories to
contextualize the user-recorded results of mHealth intervention studies. We use the logs
collected by persons with type 2 diabetes during a randomized controlled trial (RCT) as a
use-case.
Methods
The Few Touch Application was tested in a year-long intervention, which allowed partici-
pants to register and review their blood glucose, diet and physical activity, goals, and access
general disease information. Usage-logs, i.e. logged interactions with the mHealth devices,
were collected from participants (n = 101) in the intervention groups. HbA1c was collected
(baseline, 4- and 12-months). Usage logs were categorized into registrations or navigations.
Results
There were n = 29 non-mHealth users, n = 11 short-term users and n = 61 long-term users.
Non-mHealth users increased (+0.33%) while Long-term users reduced their HbA1c
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(-0.86%), which was significantly different (P = .021). Long-term users significantly de-
creased their usage over the year (P < .001). K-means clustering revealed two clusters: one
dominated by diet/exercise interactions (n = 16), and one dominated by BG interactions and
navigations in general (n = 40). The only significant difference between these two clusters
was that the first cluster spent more time on the goals functionalities than the second (P <
.001).
Conclusion
By comparing participants based upon their usage-logs, we were able to discern differences
in HbA1c as well as usage patterns. This approach demonstrates the potential of analysing
usage-logs to better understand how participants engage during mHealth intervention
studies.
Introduction
Standard approaches for evaluating research activities do not sufficiently address all aspects of
mobile health (mHealth) interventions. This is in part due to a reliance on hard clinical end-
points, and part because study designs often follow the ªBlack Box evaluationº method [1], the
aim of which is to answer «what» has changed, in retrospect, by comparing end- and baseline
measures. In doing so, these studies traditionally produce evidence of, for example, how a new
medication will predictably affect individuals with a certain diagnosis in real-world medical
practice. For pharmacology, this is acceptable. The usefulness of these results is clear; either
the drug is safe and efficient to use, or not. However, intervention studies for chronic illnesses
that utilized modern technologies often conclude that their results require further testing [2±
4]. This is, in part, due to the complicated nature of chronic illness self-management, requiring
individuals' to make daily health decisions in response to biological changes, such as their
blood glucose in the case of diabetes. Humans, their decisions and behaviours require greater
understanding than biology alone. Therefore, clinical research must adapt to look at how par-
ticipants choose to behave during the intervention in order to understand why an intervention
is±or is not±producing any effects. In other words, tracking and understanding participants'
behavior can allow us to understand what is going on inside ªThe Black Boxº during interven-
tion studies.
Today, many who live with diabetes rely on such mHealth devices as smartphones and
wearable trackers to aid them in their self-management. These tools can reduce the burden of
performing self-management by allowing individuals to more easily record and review their
self-management measures, i.e. blood glucose, physical activity, diet and medication at their
fingertips. Fortunately for clinical research, these technologies can also provide date-stamped
records of a user's self-management decisions through their interactions with the mHealth
devices, i.e. usage-logs, and registered health measures, lifestyle habits, and notes [5, 6]. How-
ever, due to the novelty of these technologies for health care, there is no standard for how to
assess these newly available data. Recent studies have, to a certain degree, incorporated analysis
of usage log patterns during clinical trials. Some have even included values of registered health
data [7]. However, most of these have only analysed cumulative measures such as total key-
strokes or hours interacting with a device [8, 9], and many are inconclusive and fail to contex-
tualize the data.
Methods for approaching diabetes app-usage logs
PLOS ONE | https://doi.org/10.1371/journal.pone.0203202 August 30, 2018 2 / 18
Europe WorkINg toGether for HEALTH
(RENEWING HEALTH) project (https://cordis.
europa.eu/project/rcn/191719_en.html), led by Lis
Ribu and Eirik Årsand. The Research Council of
Norway (norges forskningsråd, https://www.
forskningsradet.no/no/Forsiden/1173185591033)
funded the preparation of the manuscript and
decision to publish through the “Full Flow of Health
Data Between Patients and Health Care Systems”
project (https://ehealthresearch.no/en/projects/
fullflow) (grant number 247974/O70), led by Eirik
Årsand. The publication charges for this article
have been funded by a grant from the publication
fund of UiT The Arctic University of Norway
(https://uit.no/ub/forskningsstotte/art?p_
document_id=449104) (No. 551011), led by
Meghan Bradway. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Therefore, mHealth research calls for a toolbox of sorts±in addition to traditional measures,
a collection of concepts adapted to inform new possibilities for explaining the impact of
mHealth interventions. Approaches such as theory-driven evaluation [1], program theory eval-
uation using logic models [10], and logic analysis [11] have been proposed as alternatives to
ªBlack Box evaluationº. Traditionally, these approaches are used to evaluate e.g. an educational
program intervention. These programs consist of complex interactions between inputs and
outputs. Theory-driven evaluation is used to explain either part or the whole of these contexts
[12]. These approaches can inform the assessment of mHealth interventions because they aim
to explain the context of an intervention, such as participants' behaviour and decisions, rather
than to predict cause-and-effect, such as the effect of a drug.
For the case of mHealth interventions for diabetes, we must consider the context. Individu-
als are expected to continuously self-manage their diabetes through a cycle of trial and error.
The cycle is characterized by tracking, reflecting upon, reacting and repeating certain health
actions, which personifies the behavioural theories of Experiential Learning [13] and Health
Habit Change [14±19]. Therefore, the registered data and usage logs that track these actions,
available on the mHealth devices, can be interpreted as reflections of an individuals' engage-
ment in their health. This provides a much more detailed picture of how patients are relating
to mHealth over the course of an intervention.
In this paper, we present a preliminary study for applying human behaviour theories [13,
18±20] to structure and analyse usage logs. We used the use-case of the logs collected by the
mHealth intervention used in the REgioNs of Europe WorkINg toGether for HEALTH
(RENEWING HEALTH) Norwegian randomized control trial (RCT).
Objectives and aims
The overall aim is to provide evidence for how applying behavioural theories to usage logs can be
used to provide a better understanding of the context of mHealth interventions. In doing so, we
aim to inform the appropriate and effective design and administration of future mHealth studies.
Methods
Use case: The RENEWINGHEALTH RCT
To demonstrate the potential benefits of analysing usage-logs to explain the impact of
mHealth, we use the case of the European Commission funded RENEWING HEALTH proj-
ect's Norwegian RCT. The study was registered with Clinical Trials, with reference number
NCT01315756, and was approved by the Regional Committee for Medical and Health
Research Ethics in South-Eastern Norway (REK sør-øst).
This 3-armed study was conducted between 2011 and 2013 to test the impact of a mHealth
self-management intervention called the Few Touch Application (FTA) [21], including use of
a smartphone application (app) and glucose meter. The FTA intervention tracked when partic-
ipants registered and reviewed their blood glucose, diet and physical activity, goals as well as
accessed general disease information stored within the application. The app was Bluetooth-
paired with the OneTouch Ultra Easy blood glucose meter from LifeScan through a Bluetooth
adapter from PolymapWireless, enabling fully automated transfer of BG measurements to the
app. Originally, n = 151 participants were recruited and randomized into two intervention
groups: n = 51 used the mHealth intervention (referred to as FTA); n = 50 used the mHealth
intervention together with health counselling (referred to as FTA+HC); and a control group
(n = 50) (Fig 1). The FTA+HC group was followed up by the diabetes nurse five times,
remotely by phone, within the first 4 months. The diabetes nurse provided health counselling
with principles from motivational interviewing and supported patients' use of the FTA.
Methods for approaching diabetes app-usage logs
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Patients' own registered app data and app usage were continuously gathered and stored. More
detailed descriptions of the study design can be found in the protocol paper published else-
where [22] (S1 and S2 Files).
Training. Both intervention groups were trained on how to use the mHealth intervention
at the start of the study. Participants were provided both a paper and an electronic version
(USB memory stick) of the user-guide. Included were explanations and screen shots of all app
functionalities and step-by-step instructions for registering data using the provided mHealth
system, both manually and using the system for automatic data transfer when using the blood
glucose meter. The participants also had access to a technical support-service during work
hours (9 AM-3 PM), by phone, in the study period.
Previous analysis and results. The primary analysis results for this study have been
reported elsewhere [22±25]. These focused on comparing changes in HbA1c and question-
naire responses, with a coarse look at usage patterns. Of the 101 who received the mHealth
intervention, with and without health counselling, 79 completed the study. It is important to
note that the previous analysis was based upon the participants' completion of the primary
outcome (HbA1c level), and did not distinguish between their mHealth usage.
Previous results yielded only a significant increase in self-management related to ªskill and
technique acquisitionº in the FTA with health counselling group compared to the control
group. There was no significant difference in HbA1c or total usage of the mHealth devices at
4- and 12-months between those who received the mHealth intervention and the control
group [23, 26]. Recently, a follow-up analysis for this study, found that half of the persons were
in pre-action phase according to the stage of behaviour change, reflected in the physical activ-
ity and dietary-related usage patterns [25]. This demonstrates the potential of applying theo-
ries, related to the context of self-management, to the analysis of mHealth usage logs.
Fig 1. CONSORT flow diagram of the RCT.
https://doi.org/10.1371/journal.pone.0203202.g001
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An in-depth analysis of log-data
The mHealth usage logs from the RENEWING HEALTH study contained data and time
stamps related to use of blood glucose- (BG), physical activity-, diet- functionalities and access
to other disease information within the FTA smartphone app. In addition, the app automati-
cally recorded when and what users registered as well as when they reviewed their past regis-
trations or any other interaction with the app. By interacting with the app in these two ways,
the user personifies the cycle of experiential learning by performing active engagement and
self-reflection related to their self-management.
Population: Comparison of users vs. Non-users. As mentioned in the original protocol,
we focus on those who participated in the intervention [22]. Therefore, in this descriptive anal-
ysis of the usage logs, we focus on those who used the mHealth devices. Because there were no
statistical differences between the two FTA intervention groups, we consider all the 101 inter-
vention participants as one cohort. We were then able to a) identify those who actually used
the mHealth tools at any point in time during the study and b) explore and differentiate
mHealth usage patterns in this presented in-depth analysis (S3 File).
Participants were included based upon whether or not, and for how long, they used the
mHealth tools. To be considered as a user of the mHealth intervention, as opposed to one who
casually explored the functionalities but chose not to continue using the tools, participants
must have logged at least 60 interactions with the tool at any time in the 12 months, i.e. a mini-
mum of 5 interactions per month. To be defined as Long-term users, participants must have
used the FTA app for three or more continuous months, with at least 5 interactions per
month. Because participants used the separate LifeScan BGmeter with the adapter for auto-
matic transfer of BG measurements, only functionalities that required user-interaction with
the FTA smartphone app were included when categorizing the participants into the three
groups: those who did not use the mHealth tools once (ªNon-mHealth usersº), those who used
them for less than 3-continuous months (ªShort-term usersº) and those who used them for
three or more continuous months (ªLong-term usersº).
Of the 101 participants who received the mHealth intervention, 29 participants fell in the
ªNon-Usersº group, while 72 participants interacted with the mHealth devices at least once,
and 61 of those participants used the devices for a minimum of three continuous months dur-
ing the intervention period.
Measures: mHealth-usage logs. To describe how the theory of experiential learning was
used to structure and interpret the usage logs, we grouped usage logs into two basic types:
ªRegistrationsº, which are an individual's active interaction with their health through entry of
self-management recordings into the app, and ªNavigationsº, which are any non-registration,
or reflective, interactions with the app.
Due to an error in the logging routine, we were unable to distinguish ªGoal registrationsº
from navigations. However, the number of minutes spent watching the app's various screens
were collected by the system. The logs were therefore grouped as follows:
· Diet/Exercise registrations (D/E Regs): indicating when a user manually registers informa-
tion related to diet or physical activity.
· Diet/Exercise navigations (D/E Navs): when a user accesses previously registered data related
to diet or physical activity, thereby demonstrating actions relevant for self-reflection.
· Blood glucose registrations (BG Regs): when a user measures blood glucose levels via the BG
meter.
· Blood glucose navigations (BG Navs): when a user reviews previously measured blood glu-
cose values, thereby demonstrating actions relevant for self-reflection upon past BG levels.
Methods for approaching diabetes app-usage logs
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· Disease Informational navigations (Info Navs): when a user accesses disease information,
thereby demonstrating actions relevant for active learning behaviour.
In addition, minutes spent per screen were calculated for the following screens: Home
Screen, Data Navigations, and Goals (S1 Text).
Identifying emergent user subgroups. We used the FTA usage logs from the first three
months, i.e. the first quarter, to identify usage patterns. Of the six main functionalities the FTA
provided, a range of different usage patterns are possible (Table 1). We based the usage groups
on the two most frequently used FTA functions. Conceptually, a patient may use the FTA
mainly for registering self-management habits or also for reflections / navigating through pre-
viously registered health information. The FTAmay also be used mainly for diet / exercise
management, or blood glucose management. A range of other combinations is also possible.
To investigate this in our sample, we employed k-means clustering (S2 Text).
Statistical analysis
In the first part of our analysis, we compared app-users to Non-app users. In the second part
we focused the analysis on those who used the app for three or more consecutive months, i.e.
Long-term users. The details of extracting and analysing of the log data can be found in the
supplementary material (S1 Text).
To determine differences between participants based on overall duration of mHealth use,
demographics, baseline HbA1c as well as interactions and logged time spent with the interven-
tions' mHealth tools' usage were compared between Non-users (n = 29), Short-term users
(n = 11) and Long-term users (n = 61) (Table 2).
The remaining tests of these in-depth analyses focused upon investigating relationships
between patterns of app usage, and health outcomes from the Long-Term users (n = 61) (Fig













Registrations usage group X X







Goals usage group X
Inconsistent usage group Any combination of functionalities not otherwise described
https://doi.org/10.1371/journal.pone.0203202.t001
Table 2. Descriptives for the three FTA usage groups.
M (SD) Non mHealth users (N = 29) Short-term users (N = 11) Long-term users (N = 61) F-value P η2
Gender 17 female 5 female 37 female
Age 57.45 (12.97) 55.18 (12.86) 58.84 (11.26) .49 .62 .01
Duration (years) 9.69 (7.87) 11.27 (7.14) 9.25 (8.3) .30 .74 .01
Education (years) 3.72 (1.19) 3.91 (1.38) 3.61 (1.48) .25 .78 .01
SMBG (per week) 7.17 (7.315) 5.5 (5.11) 9.43 (10.46) 1.18 .31 .02
HbA1c at baseline 8.41 (1.11) 7.99 (.062) 8.08 (1.17) 1.01 .37 .02
: SMBG is self-monitoring of blood glucose
https://doi.org/10.1371/journal.pone.0203202.t002
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2). In addition to comparing usage patterns based on emergent groups, we also explored the
smartphone app's recorded blood glucose levels. Because the goal of blood glucose self-man-
agement (SMBG) is to keep BG levels within a certain range (4-10mmol/L), we chose to com-
pare the number of In-Range BG values both within and between quarters.
Pearson Correlation and Repeated Measures ANOVAwere used to compare change in
HbA1c and app-usage activities (total as well as individual Diet/Exercise and BG Registrations
and Navigations and Disease information Navigations) within and between groups, over the
12-months pooled into 3-month intervals (quarters of the year). Pearson Correlation analysis
and Linear regression were used to analyse relationships between interactions with app-activi-
ties and minutes used on each app-screen over the four quarters. We have chosen the pooling
into quarters as it reduced the number of missing values compared to a monthly or bi-monthly
analysis. The statistical package for social sciences (SPSS) version 19 software, and JASP ver-
sion 0.8.5 [27] were used to run the statistical tests.
Ethics
This study was approved by the Regional Committee for Medical and Health Research Ethics
in South-Eastern Norway (reference number 2010/3386). All patients provided signed
informed consent documents before participation in the intervention. If patients revoked their
consent, their data was removed from the database and not included in analysis.
Results
As seen in Table 2, there was no selection bias between those who did and did not use the
mHealth intervention tools for self-management.
According to a repeated-measure ANOVA among the 101 participants, time, i.e. the 12
months, did not affect HbA1c , F(2, 148) = .541, P = .583, η2 = .007. However, the Non-users,
Short-term and Long-term users differed in change in HbA1c, F(2, 74) = 3.794, P = .027, η2 =
.093. Among the Non-mHealth users and Short-term users were drop-outs, reducing the N in
this analysis to n = 9 for non mHealth users, n = 7 for Short-term users, and n = 61 for Long-
term users. The data does not change if one uses only the 0 and 4 months where there are
slightly fewer dropouts. To compare specifically which groups differed from one another, a
pair-wise comparison, or post-hoc test, was run. This showed that the only difference between
groups was between the Non-mHealth users, who increased their HbA1c by 0.33%, and the
Long-term users, who reduced their HbA1c by -0.86%, P = .021, Cohen's d = .311. Short-term
Fig 2. Diagram showing two approaches for analysing the usage logs. Five participants were grouped in two very small clusters and not considered for Analysis 2.
https://doi.org/10.1371/journal.pone.0203202.g002
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users did not differ from either of the other two groups. The interaction between time and
group did not significantly impact change in HbA1c, F(4,148) = 1.26. P = .288, η2 = .033 (Fig
3). Note that the participants, in general, did not achieve the target (Norwegian) of achieving
an HbA1c below 7mmol/L during the mHealth intervention.
Exploration of Long-term users' mHealth data and logs
We explored and compared the usage logs and data of the 61 participants who engaged in the
intervention for three or more continuous months.
Baseline self-reported SMBG did correlate positively with the number of BG registrations
(Pearson's r = .579, P< .001, CI [.383; .725]), BG navigations (Pearson's r = .436, P< .001 CI
[.207; .62]), D/E registrations (r = .339, P = .008, CI [.095; .544]), and Goals (r = .409, P = .001,
CI [.176; .599]), but not with D/E navigations (r = .229, P = .076, CI [-.024; .455]), made during
the study. In contrast, change in HbA1c did not correlate with number of interactions spent
on mHealth device functionalities, (all P> .15).
Use of the FTA differed significantly both within and between individual functionalities
over time. Fig 4 illustrates the results of a repeated measures ANOVA (Greenhouse-Geisser
correction for sphericity violation), which revealed that total use significantly decreased over
the four quarters: F(1.642, 98.528) = 45.02, P< .001, η2 = .429. Participants used the FTA
mostly for diet / exercise (D/E) registration and navigations. Post-hoc tests revealed that the
steepest decline is from first to second quarter with a decrease in 64.91 interactions on average
(t = 9.234, P< .001), and for navigations in general. Use overall plateaued after this first quar-
ter, with differences of fewer than 25 interactions between successive quarters (all P< .001).
However, BG registrations were more consistent over the 1-year intervention, with the greatest
difference was 21.51 BG registrations (t = 3.202, P< .05, effect size = .410) between the first
and second quarter, whereas for example, participants decreased their use of D/E registrations
significantly moreÐby 63.44 (t = 3.344, P< .01, effect size = .428)Ðover the same time. The
use of each of the six functionalities differed significantly from one another in total (F(1.62,
97.2), P< .001, η2 = .202), as well as from one quarter to another: F(3.213, 192.795) = 13.26,
P< .001, η2 = .181.The only functionalities that did not significantly differ were D/E Regs and
D/E Navs, and BG Navs compared to D/E Regs and D/E Navs.
Fig 3. Comparison of HbA1c between users grouped by duration of FTA use. Error bars denote standard error of
the mean.
https://doi.org/10.1371/journal.pone.0203202.g003
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Next, we looked more closely at the first 3 months to identify where the reduction in FTA
usage occurred the most (Fig 5). Overall, the same trends were found in use of the FTA
between months as between quarters. In other words, use of the FTA differed significantly
between these first three months (F(1.386, 83.14) = 23.545. P< .001, η2 = .282). Participants
used the functionalities the most in the first month (461.2 ± 63) with a significant drop by
212.25 interactions (t = 5.022, P< .001, effect size = .643) during the second month. This was
especially true for D/E navigations, which dropped by 35.374 interactions, on average, after
the first month (t = 8.158, P< .001, d = 1.044). The plateau in use of the FTA actually began
after the second month, as the second month did not differ from the third (t (60) = 1.379, P =
.519, d = .177). However, BG registrations and Disease Information navigations were stable
throughout the first 3 months with less than a 15 interaction difference between successive
months (P< .05, except Disease Information Navigations between the second and third
months). In addition, all functionalities differed from each other (all P< .01), with the excep-
tion of BG Regs and Goals which did not differ significantly.
Fig 4. Used functionalities of the FTA per quarter. Error bars denote standard error of the mean (SEM).
https://doi.org/10.1371/journal.pone.0203202.g004
Fig 5. FTA usage over the first three months among the 61 Long-term users. Error bars denote standard error of the
mean (SEM).
https://doi.org/10.1371/journal.pone.0203202.g005
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We explored the barriers and opportunities for analysis of patients' self-measured blood
glucose values by comparing the in- and out-of-range values to number of registrations taken
using the LifeScan blood glucose meter. Figure A in S4 Text demonstrates the great variability
in frequency of SMBG both within and between participants over quarters of the study. S1
Table displays the significant Pearson Correlations between in-range BG measurements and
goals functionality interactions for most quarters as well as in-range BGmeasurements and
HbA1c for three of the four quarters.
Identifying clusters and patterns frommHealth usage
The FTA offered six main functionalities and participants differed in their usage. Among the
61 Long-term users we performed a cluster analysis (k-means with at least N = 5 in a cluster)
of the six functionalities: BG registrations, BG navigations, D/E registrations, D/E navigations,
goals, and disease information. Cluster analysis yielded two clusters differing in their usage
patterns (Fig 5), one dominated by diet/exercise registrations and navigations (n = 16), while
the other cluster was dominated by BG registrations and navigations, as well as overall naviga-
tions (n = 40). Five participants were grouped in two very small clusters and were not included
in further analysis.
Repeated measure ANOVA confirmed that there was a significant difference between the
use of the individual functionalities: F(2.987, 161.325) = 59.79, P< .001, η2 = .392, as well as
use of each functionality over time between the clusters (F(2.987, 161.325) = 38.88, P< .001,
η2 = .25). As can be observed in Fig 6, the only interactions in which these two clusters did not
differ were for BG navigations, in total (P = .302) and between quarters (P = .129), and for Dis-
ease Information navigations, in total (P = .398) and between quarters (P = .689).
Not only did Cluster 1 use the mHealth intervention more than Cluster 2 throughout the
study, participants in this group also spent more time on interactions with goals functionalities
in total (F(1,53) = 54.54, P< .001, η2 = .507) and between quarters (F(1.815, 96.211) = 42.47,
P< .001, η2 = .241) (Fig 7). During the study, participants in Cluster 2 drastically decreased
their use of goals, disease information and registration of diet/exercise. However, Cluster 1
was more consistent in their use of all functionalities overall. This can be seen in S5 Table,
which details these changes in use over time by comparing percentages of functionalities used
per quarter between and within each cluster. Of note is that while Cluster 1 spends most
Fig 6. Comparison of the six interaction types between Cluster 1 (diet/exercise functionalities) and Cluster 2
(blood glucose functionalities and overall navigations) for the whole study period.
https://doi.org/10.1371/journal.pone.0203202.g006
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interactions on D/E activities, they still maintain their use of BG registrations, ranging from
between 10%-16% per quarter, and BG navigations, ranging from between 12%-16% per quar-
ter. On the other hand, while not statistically significant, Cluster 2 seems to increase BG activi-
ties while decreasing all other activities over the quarters.
Comparing the two groups, we found a non-significant group difference in HbA1c over the
duration of the intervention (F(1, 55) = 3.642, P = .062, η2 = .062) (Fig 8). There was a signifi-
cant difference between months (F(2, 110) = 5.043, P = .008, η2 = .084) but not between groups
over time (F(2, 110) = .298, P = .743, η2 = .005). While not statistically significant, the group
using the D/E functionalities of the FTA improved HbA1c over the course of the study,
whereas the group using mainly the BG functionalities showed improvement during the first
half of the year, but did not further improve in the second half of the year.
Fig 7. Distributions of functionalities used between Cluster 1 and Cluster 2 over the four quarters of the year. Error bars denote standard error of the mean (SEM).
https://doi.org/10.1371/journal.pone.0203202.g007
Fig 8. Comparison of change in HbA1c between Cluster 1 (D/E users, empty circles) and Cluster 2 (BG-users,
filled circles) over baseline, 4- and 12-months.
https://doi.org/10.1371/journal.pone.0203202.g008
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Adverse events
While there were no clinical adverse events reported during the intervention, participants did
report some technological issues. Of impact to this analysis were issues with the Bluetooth
transfer of BG registered measurements from the BGmeter to the Diabetes Diary app. This
may have caused frustration and additional psychological stress and time when participants
tried to engage in self-management during the intervention. While BG registrations were
among the more stable types of interactions, it was postulated by Holmen et. al. that this may
have discouraged participants from using that functionality or the FTA as a whole [26]. How-
ever, all participants were informed of these possibilities before the study began, including the
possibility to get support via phone.
Discussion
Theory-based evaluation is typically used to evaluate program interventions, such as education
or, business management programs [12]. In fact, theory-based diabetes program interventions
are common, but are characterized by structured instruction, external motivation and collabo-
ration with clinical staff or support groups [28, 29]. However, programs and individuals' diabe-
tes self-management are similar in that they A) involve complex interactions and B) require
that intervention evaluators acknowledge and understand these complex interactions. There-
fore, we argue that it is appropriate to consider this presented approach as a supplement to
hard clinical measures for mHealth studies. However, to the best of our knowledge, this study
is the first to approach analysis of mHealth usage-logs by grouping such data based upon beha-
vioural theories.
The insights from using the presented approach on this study are two-fold. The first is
related to patients' change in use of the mHealth intervention and the effect on their health.
The second is related to what was learned about the proposed methods and approaches for
analysing the impacts of the mHealth devices. As described below, additional data is required
to properly interpret the impact of mHealth in self-management intervention studies. There-
fore, the presented analysis should only be considered as a preliminary study of log data.
Main results
90% of an iceberg's mass is not noticed at first sight±the same can be said for mHealth inter-
ventions. First analysis of the data, based upon intervention groups, revealed no significant dif-
ference in change in HbA1c [30]. However, this additional analysis of actual and detailed
mHealth logs revealed that those who did not use the mHealth tools increased their HbA1c
over the course of the study while those who did use these tools significantly decreased their
HbA1c. For all FTA users, the observed decrease in HbA1c between baseline and 4 months
and the increase between 4- and 12-months suggests that the impact of using the FTA for 3
+ months actually occurs during the first 4 months. This is just a coarse preview of the kind of
relevant information that we can gain by categorizing users and reassessing outcomes based
on actual usage.
Analysis of usage-patterns, for all mHealth users, and the comparison of groups based on
functionalities used, revealed much more about how patients chose to engage in the interven-
tion and their health over time than originally thought possible. By splitting up participants
into similar groups based upon their own preferred use of the intervention, we were able to
better understand the opportunities and limitations of how mHealth logs can reflect realistic
and varied self-management habits. Comparison of how the functionalities were used by each
cluster confirmed that individuals did in fact use the functionalities differently, which should
be accounted or adjusted for in future analysis of mHealth interventions. Over the year, most
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patients fell into the blood glucose management cluster, and only 16 out of the 61 (or, when
considering all of the users involved in the study, 101) patients also used the FTA's lifestyle
functions, i.e. diet and exercise registrations and navigations, significantly. Similarities also
provide insights as to common approaches to treatment that may aid in adherence to clinical
recommendations. For example, both clusters were similar in their use of goals functionalities
in total±themain difference being when they used these functionalities (S2 Table). This infor-
mation can be used to design improved mHealth interventions that encourage experiential
learning by reinforcing the functionalities that patients already use and encouraging the use of
un-used functionalities.
Further consideration of temporal relationships between usage of each functionality
revealed that the number of interactions, and not time spent, with mHealth tools seem to be
more suggestive of sustained mHealth use, as was demonstrated by the analysis of mHealth
use related to goals (S3 Text). Those who did use the devices, their use significantly decreased
after the first months suggesting that the first month reflects the novelty-effect of a new device.
Therefore, the following months may have been more reflective of the realistic day-to-day use
of mHealth devices for self-management. However, the assumed more familiar functionalities,
such as BG registrations, were more consistent throughout the course of the study.
These logs not only provided insights about patients' self-management habits, but could
potentially provide a better understanding of how their health changes through their own-
recorded health measures in self-management. For example, self-recorded BG values are infor-
mative of a patient's health. However, inconsistency and lack of sufficient data limited our abil-
ity to suggest conclusive outcomes related to mHealth use and participants' health (S4 Text).
Further, we demonstrate how this approach to analysing usage logs can complement tradi-
tional measures. For example, the use of the goals functionalities suggested not only a relation-
ship on both HbA1c and number of In-Range BG values over time, but also future and more
sustained use of the mHealth functionalities (Table A in S3 Text).
Experiences and future directions
We don't know what we don't know. Unless we ask the right questions in research, we cannot
hope to achieve understanding of any endeavour regarding health interventions. In order to
successfully measure the impacts of complex interventions such as mHealth interventions, we
must look more deeply into how patients useÐand differ in their useÐof self-management
technologies.
Therefore, we endeavoured to explore new concepts related to usage log analysis in this
paper. In doing so, we aimed to provide accounts of practical and useful lessons learned and
recommendations for future mHealth interventions. In Table 3, we summarize the main
implications of the presented analysis for both research efforts and clinical practice.
Strengths and limitations
This presented analysis of the RENEWING HEALTH study is underpowered. However, barri-
ers, limitations and setbacks are only as negative as your reaction to them. In fact, limitations
experienced during this study provided greater insight for how to not only improve future
mHealth interventions but also how to approach their evaluation. Of those who received the
mHealth intervention, 29 participants (30%) did not use it once after the start-up meeting,
which rose to 45 participants not using it after the first three months. Furthermore, all partici-
pants reduced their usage of the mHealth tools significantly over time. This led us to question
where the barriers for sustainable use occurred and how we could address these in the next
iteration of mHealth intervention studies. Analysis of the usage-logs, such as those actions
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related to the manual entry of diet/exercise data, revealed that time-consuming or burdensome
usage-requirements discouraged many from long-term engagement with those functionalities.
However, those in Cluster 1, who used the FTA largely for diet/exercise management, also
reduced their HbA1c. While this is both encouraging and telling of how usage can be associ-
ated with health change, we cannot rely solely on statistical testing of small and diverse samples
to conclude on the impact of any mHealth intervention. Another point that is both positive
and negative for future studies is that this technology it still changing rapidly. In fact, the
mHealth devices used in this study had become almost outdated by the end of the trial, which
may have contributed to frustration and a steep decline in use over the year.
These trends raise two common plights of research interventions: 1) the desire or habit to
trust statistical output at face value, without scepticism and assessment of the reliability of the
data itself compared to real-world scenarios and 2) sustaining use of the intervention so as to
collect enough consistent and reliable data to produce conclusive results. In order to both
improve participants' experience during interventions and also ease the burdens of self-man-
agement instead of creating them, the use of mHealth technologies should be less time-con-
suming, more relevant and provide greater reinforcement of beneficial habits than standard
modalities. In relation, participants were not given long-term reinforcement for when and
how to use the devices. The benefit of providing such reinforcement could be two-fold. First,
participants may feel more supported and engaged. Second, we as researchers may be able to
Table 3. Aims, lessons learned and recommendations regarding analysis of usage-logs generated from the presented analysis.
Set Aim Lessons learned Recommendations
1 To suggest and test a way of grouping log-data
based on theories of human behaviour, to
improve upon the tradition of summative
analysis.
By grouping usage logs into ªregistrationsº and
ªnavigationsº we were able to more easily and
meaningfully identify how patients change their
interactions with the mHealth devices.
When combined with traditional measures, established
theories from complementary science fields, e.g.
psychology, should be used to provide additional insight
for mHealth intervention studies.
2 To explore what log-data can tell us about
patients' experience or relationship with the
intervention technologies.
· The reduction in usage after the first month
demonstrated the ªnovelty effectº of this technology.
· Sustainable use, past the novelty effect, are
dependent on relevant and easy-to-use functions.
· Analysis should consider and account for the ªnovelty
effectº as a ªrun inº period, during which patients
become more familiar with a technology before the
intervention begins.
· Automated functionalities, e.g. automatic registration of
physical activity via Bluetooth from a wearable sensor,
should be incorporated into the intervention when
possible.
3 To suggest how researchers can tailor
administration of the intervention to patients'
preferred use of the mHealth technologies.
The cluster analysis demonstrated that individuals
indeed use mHealth tools differently based on the
focus, or own priorities, of their self-management.
Reminders or recommendations for continued use and
self-management practice can be tailored based on usage
patterns of each patient during the first 3-months.
4 To propose a solution to achieve adequate
data-collection.
The variability both within and between participants'
use was expected, and can be seen as a realistic
representation of self-management amongst those
with Type 2 diabetes.
Suggest minimum mHealth usage requirements for
intervention studies to make data collection more
consistent and reliable.
5 To determine how research and analysis can
approach patient collected health measures.
Self-collected health data, such as BG values, diet and
exercise, can supplement health measures collected
at the point-of-care by providing details of health
change between consultations. However, consistency
and reliability of the data is required.
While lifestyle measures such as diet and exercise can be
episodic and without schedule, measures such as SMBG
should be done on a consistent schedule to ensure their
comparability over time and two other measures during
interventions.
6 To determine what more is needed to
understand not only what and how, but also
why patients choose to self-manage.
Usage logs are a valuable resource for understanding
how use of diabetes mHealth tools change during the
intervention. However, why changes occurred
during the intervention period were not clear.
Related and complementary questionnaires include, e.g.
Patient Activation Measure [31], Health Education
Impact Questionnaire [32], Patient Health Locus of
Control [33], which measure motivation and patients'
intention to engage in their health, as well as the Health
Care Climate Questionnaire [34], which may provide
insights as to the impact of the therapeutic relationship
related to not only engagement in self-care and health
outcomes but also mHealth use.
https://doi.org/10.1371/journal.pone.0203202.t003
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reduce variability and inconsistency in device usage, which would facilitate actionable statisti-
cal analysis and more insightful interpretation of the intervention results.
Conclusion
Today's mHealth technology can allow researchers and health-care practitioners to not only
better understand but also better reinforce patient's self-management behavioursÐbut we
need to adapt research practices to keep up. Analysis of quarterly accounts of usage-logs, dif-
ferentiated by functionality and purpose, illustrated that clinical research can benefit from
studying usage patterns in such a way that provide meaningful and actionable information
beyond the typical conclusion of ªfurther studies are neededº. This is evident in the compari-
son between previously reported results of the Renewing Health project versus the presented
study of log data. The previous study used total measures of logs based on originally assigned
intervention groups and demonstrated no difference in use of the app or HbA1c's between
intervention groups. However, in the present study using log data, by analysing the impact of
the app based on how individuals used the apps functionalities, we were able to identify for
which users the mHealth intervention yielded a significant improvement in HbA1c. We pro-
pose the presented exploratory analysis as a novel supplement to the traditional hard-measures
of diabetes health and self-management, and encourage others to use, comment, suggest and
discuss this approach. We also aim to apply this approach both retroactively to the now com-
pleted Tailoring Type 2 Diabetes Self-Management Study [35] data-set and proactively to the
design and testing of the mHealth data-sharing intervention in the Full Flow of Data between
Patients and Health Care Systems Project's [36].
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Background: There is rising demand for health care’s limited resources. Mobile health (mHealth) could be a solution, especially
for those with chronic illnesses such as diabetes. mHealth can increases patients’ options to self-manage their health, improving
their health knowledge, engagement, and capacity to contribute to their own care decisions. However, there are few solutions for
sharing and presenting patients’ mHealth data with health care providers (HCPs) in a mutually understandable way, which limits
the potential of shared decision making.
Objective: Through a six-month mixed method feasibility study in Norway, we aim to explore the impacts that a system for
sharing patient-gathered data from mHealth devices has on patients and HCPs during diabetes consultations.
Methods: Patients with diabetes will be recruited through their HCPs. Participants will use the Diabetes Diary mobile phone
app to register and review diabetes self-management data and share these data during diabetes consultations using the FullFlow
data-sharing system. The primary outcome is the feasibility of the system, which includes HCP impressions and expectations
(prestudy survey), usability (System Usability Scale), functionalities used and data shared during consultations, and study-end
focus group meetings. Secondary outcomes include a change in the therapeutic relationship, patient empowerment and wellness,
health parameters (HbA1c and blood pressure), and the patients’ own app-registered health measures (blood glucose, medication,
physical activity, diet, and weight). We will compare measures taken at baseline and at six months, as well as data continuously
gathered from the app. Analysis will aim to explain which measures have changed and how and why they have changed during
the intervention.
Results: The Full Flow project is funded for 2016 to 2020 by the Research Council of Norway (number 247974/O70). We
approached 14 general practitioner clinics (expecting to recruit 1-2 general practitioners per clinic) and two hospitals (expecting
to recruit 2-3 nurses per hospital). By recruiting through the HCPs, we expect to recruit 74 patients with type 2 and 33 patients
with type 1 diabetes. Between November 2018 and July 2019, we recruited eight patients and 15 HCPs. During 2020, we aim to
analyze and publish the results of the collected data from our patient and HCP participants.
Conclusions: We expect to better understand what is needed to be able to share data. This includes potential benefits that sharing
patient-gathered data during consultations will have on patients and HCPs, both individually and together. By measuring these
impacts, we will be able to present the possibilities and challenges related to a system for sharing mHealth data for future
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interventions and practice. Results will also demonstrate what needs to be done to make this collaboration between HCPs and
patients successful and subsequently further improve patients’ health and engagement in their care.
International Registered Report Identifier (IRRID): DERR1-10.2196/16657
(JMIR Res Protoc 2020;9(2):e16657)  doi: 10.2196/16657
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Introduction
How Patient Mobile Health Apps Are Changing
Consultations
Mobile health (mHealth) technologies originally were designed
for and used by patients to better understand and self-manage
their health. For those with diabetes, this means tracking and
understanding how many different factors, such as diet, exercise,
and medication, affect their blood glucose levels. As a result of
collecting and reviewing these data, patients are more
empowered and knowledgeable, eager to take control and
responsibility of their daily health, and more knowledgeable
patients are able to better understand how their actions affect
their diabetes health. Some information and subsequent
decisions are more evident than others after reviewing their
data. In other words, patients can only understand or explain a
portion of the data that they collect without the medical expertise
of health care providers (HCPs) to contextualize these data with
known disease processes. Patients have begun to bring these
data from their mHealth technologies to their health care
consultations, hoping that the HCPs can provide explanations
for the results seen in their gathered data [1].
Mobile Health Data Sharing
The expected benefits of mHealth integration and data sharing
are to decrease health care costs, increase patient engagement
and aid options, and improve clinical outcomes [2,3]. However,
HCPs have traditionally relied on scientifically proven,
professionally collected clinical data, such as laboratory test
results and biological measures taken at consultations, to
understand the patient’s health status. There is evidence that by
using these data to inform a clinical recommendation, HCPs
can be confident that they have provided a relatively accurate
diagnosis and that their treatment will produce a known clinical
outcome [4]. Ideally, presenting app-collected data to HCPs
would provide a greater understanding of the patient’s situation.
However, the data have not been collected, structured, or
validated in relation to disease status like traditional laboratory
data. The presentation and structure of the data (ie, dozens or
hundreds of data entries), including many different types of data
from a variety of different mHealth technologies, is a challenge
to relate to from the HCPs’ perspective.
Further, HCPs aim to use medical data in a slightly different
way than patients use their patient-gathered data. In other words,
each wants to know different things. The patient wants to know
if their daily decisions are having a positive effect on their
disease management, and the HCPs want to know how their
clinical recommendations and medications are affecting the
disease status. These priorities are complementary; as part of
daily self-management, diabetes patients need to observe,
understand, and respond to fluctuations in their blood glucose
[5], often instantly for those with type 1 diabetes. The focus of
HCPs is on the progress or trend to determine if a treatment
modality or approach is a practical choice for that patient in the
long run [6,7]. Therefore, for mHealth data sharing to be useful
for patients and HCPs, the information should be presented in
a way that both can understand, discuss, and use together to
determine how best to maintain or improve treatment and
self-management strategies. This is an example of shared
decision making.
The Potential of Shared Decision Making
Shared decision making describes the communication and health
care decisions made between patients and their HCPs [8]. When
used in such a way, shared decision making is key to successful
therapeutic relationships—those between patients and their
HCPs—and, ultimately, patients’ adherence and achievement
of treatment aims [8]. Several studies have demonstrated that
patients’ improvement in HbA1c (glycated hemoglobin) and
perceived diabetes competence are associated with a medical
environment where clinicians encourage patients’ autonomy
[9,10].
Sharing Mobile Health Data Enables Shared Decision
Making
With mHealth, individuals have been presented with the
opportunity to bring patient-relevant data to the conversation
during consultations, as opposed to relying on only patient
memory of their self-management and clinical test results. In
doing so, true shared decision making between the HCP and
patient is not only possible but necessary to effectively support
and validate patient decisions in their self-management. For
example, a patient may collect diet or exercise data that could
explain fluctuations in clinical test results, such as lipid levels
or imbalances between insulin and blood glucose levels during
those periods. Patient-gathered data could even bring to light
challenges that the patient faces in their self-management that
are not evident from clinical test results, such as dangerous
nightly hypoglycemic events. The result of bringing such
information to the consultation is, for example, that the patient
could provide concrete evidence of their challenges and
self-management activities, with specific questions that would
improve their understanding and ability to self-manage. Then
the HCP could explain why adverse outcomes are occurring
and give patient-tailored guidance about how to better deal with
such situations in the future. Therefore, patient-gathered data
from these devices could strengthen patient-clinician
collaboration in tailored diabetes treatment.
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How to Approach Mobile Health Intervention Research
The purpose of health intervention research is to develop and
test the ability of such things as a new device, system, or service
to improve patient health outcomes or experiences. To develop
a solution that facilitates shared decision making using mHealth
data, one must consider two main questions: (1) how to
effectively present the mHealth-gathered data during
consultations between patients and HCPs, and (2) how to
promote conversation about the patient-gathered data in a way
that leads to shared decision making. The goal of testing such
a solution is typically to determine if a system can successfully
convert patient-gathered data to a form that is understandable
and useful for patients and HCPs and shows that the use of the
data can produce positive clinical or experiential outcomes.
The Proposed Solution
To assess how mHealth data sharing comprehensively affects
patients, their health outcomes, HCPs, and their therapeutic
relationship, we must first have a suitable data-gathering and
data-sharing platform that can facilitate and validate this new
situation. As the data-gathering platform, we use a mobile phone
app, the Diabetes Diary, which has been tested in several studies
[11-14]. In the Full Flow of Health Data Between Patients and
Health Care Systems project, we aim to design, develop, and
test a system for sharing patient-gathered mHealth data with
HCPs during diabetes consultations by iteratively involving
both patients and providers throughout the research activities
[15].
The Diabetes Diary app is a research tool that allows patient
participants to register their self-gathered health measurements
(eg, blood glucose and physical activity) and review previously
registered data either as a summary or list (Figure 1). Patients
then have the option to select the data they want to share with
their HCPs, which is then displayed via the FullFlow System,
a platform for sharing and presenting patient data.
The FullFlow System’s Web interface allows both patients and
providers to view together selected summaries and preliminary
information about the set of shared data. This system also allows
users to choose the summary forms to view, which is intended
to be guided by the information about the patient’s progress on
their goals, measurements, and identified areas of possible
concern illustrated on the home screen (Figure 2). The
development details and initial clinical testing of the
data-sharing system are described elsewhere [16,17].
Figure 1. Home screen of the patient-operated Diabetes Diary app (English version).
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Figure 2. The FullFlow System’s Web-based home screen (English version).
Study Aims and Objectives
A working version of the system was developed in 2018 [17-19].
We now aim to comprehensively measure its impacts on patients
and providers and its role in encouraging patient-provider
collaboration in diabetes care. Further, by using diverse
measures (mixed methods) based on different research fields
(eg, psychology, medicine, and technology), we can better
understand which impacts mHealth can have on health care
services.
The overall objective is to understand and test the effects of
using a data-sharing system (exemplified by the FullFlow
System developed in-house [17,20]) for patient-gathered
mHealth data and the Diabetes Diary mobile phone app. We
hypothesize that sharing such data, in the form of mutually
relevant information, will enable patients and HCPs together
to generate more tailored and concrete self-management
recommendations for patients. This protocol includes a
description and justification behind why the selected measures,




This protocol describes a six-month mixed method study, which
is part of the larger Full Flow project [15], in which the FullFlow
data-sharing system is used to enable the sharing of
patient-gathered mHealth data during diabetes consultations.
The design of both the data-sharing system itself and mixed
method study structure (Figure 3) are based on developmental
studies and activities within the Full Flow project, described
elsewhere [16,18,19,21,22].
Traditionally, health studies report only the pre- and posteffects
of interventions, perhaps with some participant-recalled
experiences. However, human memory is prone to forgetfulness
and mistakes. Using mHealth technology that can provide
real-time recording of information about what patients did and
how their health responded to their self-management is an
invaluable resource for health studies. Therefore, in the
described study, we include a comprehensive set of measures
that take advantage of the reliability of clinical measures and
standardized questionnaires with the record of how patients
performed their self-management between consultations (see
Table 1). In doing so, we aim to understand not only the pre-
and posteffects of using such a system but also how patients
performed their self-management between consultations.
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Figure 3. Study design flowchart. HCP: health care provider; T1D: type 1 diabetes; T2D: type 2 diabetes.
Table 1. List of data types, their sources, and purpose for measurement.
When collectedPurpose: to measure...Data collection toolsa
Primary outcomes
Before study startHCPs’ first impressions of the system and their expectationsPrestudy survey to HCPsb
After each consultationFunctions of the system used, HbA1c
c, and blood pressure of patientsPostconsultation questionnaire
At each consultationWhat patients chose to share during consultationsData displayed by the FullFlow
System
After study endExperiences, perceived benefits, barriers to, and facilitators for using the
system
Study-end focus group meetingsd
After study endUsability of the system for patientsSystem Usability Scale [23]
Secondary outcomes
Before and after the studyPatient engagement (ability)Diabetes Empowerment Scale [24]
Before and after the studyPatient engagement (likelihood)WHO-5 wellness [25]




Patients’ self-measured health parameters: blood glucose, weight, diet,
physical activity, and medication
Patient-registered health data (app)
Continuously throughout the
study
Patients’ interactions with the Diabetes Diary appApp usage logs
a Norwegian versions of all questionnaires will be used. The five-question World Health Organization Wellness Index (WHO-5) is the only Norwegian
version of a questionnaire to be officially validated [27].
bHCP: health care provider.
cHbA1c: glycated hemoglobin.
dFocus group sessions will be held in Norwegian, audio-recorded, transcribed, cleared of all identifiable information, and translated into English for
analysis.
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Online Study Administration and Management
The online study management platform provides a real-time
overview of participants’ progress through the study. The
platform allows study administrators to deliver recruitment
material and collect informed consent electronically. After it is
confirmed that the patient has downloaded the app and entered
the code, we can collect their data. Each participant is assigned
an anonymous user ID, which is not directly linkable to the
user’s personal information (eg, personal email, sensitive
personal information) that is stored elsewhere. Electronic
questionnaires and direct follow-up messages can then be sent
to these user IDs, directly to the app, and registered personal
email. This direct channel with the app also allows the platform
to collect both registered measurements and usage log data from
the app. Preliminary and summative analysis is accessible via
the system as well to identify data gaps, such as possible
technology challenges that participants are experiencing that
study administrators can efficiently respond with follow-up
messages when necessary.
Study Population
We recruited general practitioners (GPs), diabetes nurses, and
individuals diagnosed with either type 1, type 2, or other types
of diabetes in the Troms and Finnmark region of Norway
between October 2018 and July 2019. Inclusion to participate
as a health care provider required that they had the ability and
willingness to use the FullFlow data-sharing system during their
consultation setting, which required an internet connection and
a Web browser on their office computer. Persons with diabetes
who were older than 18 years were eligible to participate.
Inclusion required that they have a mobile phone with an
Android operating system through which the Diabetes Diary
app could be downloaded and used for data collection.
Participants had to be willing to use the app to gather and share
data during consultations, and to consider participation in a
study-end focus group meeting. No restrictions were placed on
applicants’ disease duration or HbA1c level. Exclusion criteria
included any mental or physical illness that interfered with their
ability to fulfill study expectations.
Recruitment and Training
Health Care Personnel
We require sets of patients and their health care professionals
to agree to participate together; therefore, we will first approach
diabetes nurses and endocrinologists through our research team’s
current network, including the University Hospital of North
Norway and Hammerfest Hospital. A member of our research
team will identify potential GP participants and cold-call them
directly. Emails will also be used to request in-person
recruitment meetings. Two representatives of our research team
will give a brief lunch presentation to HCP offices accepting
such meetings. For those interested in participating in the study,
we will schedule one-hour training sessions to demonstrate the
FullFlow data-sharing system in more practical detail on the
HCP’s own computer. The HCPs will be asked to complete a
brief survey about their perceptions of the presented FullFlow
System after these in-person training sessions.
As GP offices in Norway do not commonly have agreements
or contracts with local or national research projects, we will
provide additional compensation for the time taken outside of
their regular work schedules for the training sessions for each
patient enrolled and for any additional time spent on the study,
such as study-end focus group meetings. These will follow
standard reimbursement schemes for health care professionals
in Norway.
Patients
When needed, we will also assist HCPs in identifying potential
participants from their diabetes patient lists. We will provide
both electronic and paper copies of the patient recruitment
materials. HCPs will provide patients the recruitment letters
and study information in-person during consultations, or they
will mail the letters to those not scheduled to meet for
consultation shortly after. Patients will be instructed to contact
us if they are interested in enrolling in the study. Patient
recruitment letters will contain a link to the study webpage
where interested patients will be able to read and sign the
informed consent form electronically (Multimedia Appendix
1). Patients who have not already downloaded the tailored
version of the Diabetes Diary app, including an associated
website and user guide [28], will be requested to do so to
participate. We will also inform patient participants of their
right to withdraw their data or participation from the study at
any time. Patients will be reimbursed for travel and consultations
if the meetings are scheduled in addition to their usual care.
All participants will be encouraged to participate in the
study-end workshop. The participants are informed that technical
support will be available via email or by visiting our office.
Patient recruitment ended on July 1, 2019.
Sample Size
We plan to approach 14 GP clinics, with an estimated one to
two interested GPs in each clinic, and two hospitals, with one
to three nurses and one endocrinologist in each.
The GPs in the Troms and Finnmark regions of Norway have
listed 1000 to 1500 patients [29]. The prevalence of type 2
diabetes is 4.7% [30]; therefore, our recruitment pool is expected
to be 1234 patients with type 2. The average expected response
rate is 15% (range 10% to 20%), and approximately 40% of
these patients are estimated to meet the inclusion criteria.
Therefore, we expect to recruit 74 patients with type 2 diabetes.
There are 511 patients with type 1 diabetes registered at
University Hospital of Northern Norway (UNN) Tromsø and
62 registered at Hammerfest Hospital in the Norwegian Diabetes
Registry for Adults [31]. With the same estimated response rate
of 15% and 40% of these meeting the inclusion criteria, we
estimate to recruit approximately 30 patients from UNN and
three patients from Hammerfest Hospital.
Intervention Description
Diabetes Diary Application—Tailored Version
Our research team previously developed a tailored version of
the Diabetes Diary app [32,33], which we will provide to all
patient participants. We developed the app over several years
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to act as the research platform for many projects [13,34,35].
The app itself allows patients to tailor the app to their diabetes
type and self-management foci, including the ability to register
and review the following data types: goals, blood glucose,
medication, physical activity, nutrition, and weight.
For the study, both registered measurements and usage log data
from this app will be continuously encrypted and transferred to
the project’s secure online study management platform [36],
which was used during two previous projects [34,37]. However,
for consultations, the patient will be able to control the data
they share with their health care team via the tested FullFlow
System.
The FullFlow Data-Sharing System
The FullFlow System will summarize and display information
based on the data provided. If patients do not share data, patients
and HCPs can plan goals together about which data to collect
and discuss during future consultations. We have designed the
dynamic, Web-based interface of the FullFlow System to
facilitate easy navigation of this information. The FullFlow
System will register the data that patients choose to share, which
we will then qualitatively analyze after the study. A more
detailed description of the FullFlow System itself is described
elsewhere [17].
Consultations and Self-Management
We will ask that each patient-clinician team schedule at least
one consultation by the sixth month of the study related to
diabetes treatment. To the best of their ability, HCPs and patient
participants should use the FullFlow System during these
consultations. HCPs are requested to report the functions that
were used, the usefulness of the FullFlow System, and the
patients’ HbA1c and blood pressure via a postconsultation
questionnaire (requiring three to five minutes).
We will send monthly messages to patients using the online
study management platform. These messages will appear both
in the participants’ email and the Diabetes Diary app. We detail
the scheduled messages (eg, reminders to schedule appointments
and register data throughout the study) in Multimedia Appendix
2.
Data Collection
We will administer questionnaires through LimeSurvey [36,38]
and our study management platform. Information about which
data was registered in the Diabetes Diary app will be collected
continuously through connection to our secure research platform.
We will request patient participants to report the following
before study start: age, gender, level of education, disease
duration, medication type, and delivery system (eg, pens, pumps,
pills). We will also request data, described in the Evaluation
Measures section and Table 1, about patients’ self-management
habits and perceived health status and challenges that they may
have with the self-management of diabetes parameters.
Evaluation Measures
We chose to include standardized and validated questionnaires
where possible, supplemented by measures specific to
impressions of the use of the technologies involved. The
combination of questionnaires was chosen to limit the number
of questions because we are also asking them to track several
other factors as part of the intervention on the mobile phone
app. Table 1 introduces an overview of the purpose and selection
of our data collection tools.
System Usability
We will assess the usability of the system with three data
collection tools: the prestudy survey to HCPs, the System
Usability Scale (SUS) [23], and the postconsultation
questionnaires. The reason for combining these to measure
usability is that responses from each build on one another. In
other words, we measure not just overall satisfaction or
dissatisfaction with the system, but information about how each
pair of patients and providers used the system during each
consultation.
The postconsultation questionnaires provide a specific indication
of the functions the HCPs and patients chose to use (ie, which
characteristics of the system contributed to their use).
Patient Well-Being and Health
Postconsultation questionnaires will also request that the HCP
provide the laboratory values for each patient’s HbA1c and blood
pressure. The participants’ own app-registered health data (ie,
measured values of blood glucose, administered insulin or other
medication, weight, physical activity, diet, and goals) will
provide a more continuous illustration of a patient’s
self-management foci and health. By comparing these recorded
values to the other measures mentioned, we aim to explain how
patient self-management habits contribute to measures of health,
engagement, and communication with their providers.
The World Health Organization Wellness Index (WHO-5) is a
five-question measure of an individual’s subjective health during
the previous two weeks using a six-point Likert scale [39]. We
chose this measure based on its simplicity, brevity, and ability
to cover a diversity of concepts related to well-being.
Patient Empowerment and Engagement
The Diabetes Empowerment Scale-Short Form (DES-SF) is an
eight-item questionnaire that measures an individual’s
psychosocial self-efficacy [24]. Self-efficacy refers to a person’s
belief in their own ability to perform the activities necessary to
achieve a specific level of performance; in this case, those
necessary to maintain or improve their diabetes health. Although
this is a measure of a person’s belief and not actions,
self-efficacy is strongly correlated to an individual’s self-care
actions in the case of diabetes [40,41].
The participants’ own app-registered health data are evidence
of their real-world self-management habits. Similarly, the
interactions with the app (ie, app usage logs) indicate time spent
using the app that includes not only time taken to enter values
but also the use of other functionalities (eg, reviewing previously
recorded materials).
Therapeutic Relationship
The Health Care Climate Questionnaire (HCCQ) is a six-item
measure of patient perception of whether their HCP supports
their autonomy [26,42]. In other words, the HCCQ measures
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the relationship between patients and HCPs. This questionnaire
is based on the concepts of self-determination or one’s ability
to choose their own actions [43]. The therapeutic relationship
supports one’s health self-management and has been shown to
significantly contribute to an individual’s health-related
outcomes [44]. These concepts describe a collaboration based
on mutual contribution to care decisions rather than a
patient-provider relationship based on a hierarchy of knowledge
and power. In combination with the other questionnaires listed,
we can better understand how, and possibly why, a system that
encourages communication, initiated by the patient’s choice to
share patient-gathered data, affects the patient’s motivation,
self-care actions, and health, as described previously.
Study-End Focus Group Meetings
We have chosen the presented questionnaires to limit “burnout”
from answering too many written questions; however, we still
expect there to be missing responses. In addition, as this is the
first time these measures have been used together in a study for
mHealth—to the best of our knowledge—we expect that we
will have follow-up questions and clarifications about the
patients’ and providers’ responses. Therefore, the study-end
focus group meetings will focus on elaborating the participants’
responses from the measures mentioned previously and
encouraging the participants to share their experiences and
opinions. We also aim to gather more specific input and
explanation of the system’s function, use, and suggested
improvements.
Data Analysis
Baseline measures will be described using descriptive statistics.
We assume that some variables will differ between participants
with different types of diabetes due to the limited size of the
study population.
Analysis of responses for all standardized tests will follow the
scoring guidelines provided with each measurement tool.
Postconsultation questionnaires will be assessed quantitatively
and qualitatively, depending on the question type. The
transcripts from the study-end focus group meetings will be
analyzed using inductive thematic analysis to contextualize the
quantitative results. Paired t tests will be used to compare all
quantitative baseline (0 months) and study-end (6 months)
measures. Correlation analysis will be used to assess




The protocol, questionnaires, interview guides, recruitment
material, and other adjoining study material have been submitted
to the Regional Committees for Medical and Health Research
Ethics for Northern Norway, who found the study exempt from
their purview of approval. Instead, the study was declared and
approved by the Personvernombudet (Personal Data Protection
Officer) at UNN.
Funding
This study is part of the first author’s PhD program and has
been funded through a larger project, entitled “The Full Flow
of Health Data Between Patients and Health Care Systems
(2016-2020),” by the Research Council of Norway (number
247974/O70).
Progress to Date
Recruitment for this six-month study began in October 2018.
As of September 2019, we recruited 13 GPs, two diabetes nurses
at two hospitals, and eight patients. We expect all results to be
collected by March 2020. We will then have results about patient
and provider usage of the technologies, collected automatically,
as well as their reported experiences. From these, we can
identify whether the tested system met their individual needs
and potential improvements needed to facilitate collaboration
in diabetes care consultations. Results will also include the
impact of collaborative use on the patients’ clinically measured
data from mHealth tools, as well as their measured health and
wellness.
Discussion
Collaboration Between Patients and Providers
The described Full Flow mixed method study is the final phase
of the Full Flow project. Previous phases of this project engaged
individuals with types 1 and 2 diabetes, and a variety of HCPs,
in iterative and experience-based activities to design the studied
FullFlow data-sharing system. During these initial phases, the
concepts of end-user perspective and collaboration between
patients and providers, not only in clinical practice but also in
research, was emphasized.
Although many studies and commercially available systems
involving shared patient-gathered data focus on the provider’s
interpretation of the information, we believe that it is not only
possible but necessary to encourage more collaboration between
and contribution from both parties in mHealth interventions and
care practice. Through our choice of methods and measures,
we aim to exemplify the importance of accounting for the unique
additional needs and opportunities of mHealth in research
practice.
True Shared Decision Making
Shared decision making is described as patients and their HCPs
working together to collaborate on the process of making health
decisions [45]. However, most interventions describe this
process with HCPs taking on the bulk of the decision making
[46]. Instead, the patient is queried about their goals and
preferences, acting mostly as an information source for the HCP.
This lack of a true, equal partnership between patients and HCPs
has been cited as mainly due to time constraints and lack of
patient engagement or knowledge of their health situation [47].
This highlights the importance of using a patient’s capacity and
willingness to contribute to this process.
Today, patients’ use of mHealth and the ability of these
technologies to enable collecting and sharing of patient-gathered
data make true shared decision making possible. Sharing
patient-gathered data allows for a more balanced and
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patient-initiated process of developing recommendations for
self-management (ie, tasks that are performed by the patient on
a daily basis).
Other Measures Are Needed
Within research, we must also adapt to the new situation that
mHealth creates. A major challenge of understanding the effects
of mHealth interventions is determining which traditional
measures are applicable and which others are needed. The World
Health Organization (WHO) is an example of several attempts
to develop a comprehensive set of information that is needed
from mHealth intervention studies. In addition to the traditional
usability reports for new health technologies, the mERA
(mHealth Evaluation, Reporting and Assessment) checklist also
calls for evidence of barriers and facilitators to participants’
access to the intervention (eg, “factors that may limit the users’
ability to use the intervention”) as well as its potential to be
implemented into clinical care [48]. The dynamic network of
interactions that mHealth represents calls for more than pre-
and postintervention measurements. In this context, where
patients can use several tools and services continuously in their
everyday lives, it is no longer sufficient to merely understand
what has changed and by how much [49]. This is our opportunity
to invite not just patients and their devices but also their HCPs
to participate in considering and understanding the interactions
within and outside of clinical practice.
Not only has mHealth provided researchers with a more
informed patient, it has also provided us with ways of tracking
how they use mHealth (eg, by analyzing app and system’s usage
logs) [50]. These allow us to more effectively observe and record
patients’ self-management tasks and health measures, their data
shared during consultations, and other factors that static
questionnaires are not able to collect. One of these factors, which
now plays an even more crucial role than before, is the
motivation to be more involved in the data collection and sharing
process. The relationship—now hopefully,
collaboration—between patient and provider is not only
something that can change but also something that can play a
role in patients’ motivation to engage in their health [51,52].
By including standardized psychological questionnaires with
the other measures of patients’ well-being, health, and
self-management activity, we can contribute to a better
understanding of this relationship. The planned study-end focus
groups will allow us to elaborate on why some of these changes
are happening and provide insight from all the participants about
the context of their decisions.
Conclusion
In this study, we aim to address and understand the nuances of
mHealth. By including measures of what has changed, including
how and why, we can begin to more effectively and accurately
explore the impacts of mHealth on not only the before and after
measures but also events during the intervention itself. In
addition to the relevant research communities, the information
gained from this study will inform our electronic health record
vendor partners and both The Norwegian Directorate of eHealth
and overarching Ministry of Health and Care Services [53],
which will better prepare Norway, and other countries, when
forming future health systems that support mHealth integration.
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Appendix A. A researcher’s toolbox 
1 Established resources, methods and measures of 
medical research 
In this section, I introduce established approaches, resources, methods and measures that we have to 
choose when planning any health intervention study. I present those that are relevant and commonly used 
for health interventions involving patients or HCPs for the treatment or self-management of a chronic 
illness. I will summarize the definitions, pros and cons of these research practices. In doing so, I aim for 
you, the reader, to understand the process we go through to choose the appropriate study design, methods 
and measures. In the following section, I will exemplify specific and state-of-the-art research approaches 
and tools that are being applied to mHealth intervention research, which use traditional approaches, this 
“toolbox”, as a foundation.   
1.1 Research approaches and study designs 
Research approaches and study designs are dependent on the field of study. These narrow the ways in 
which to address a research problem including: what questions to ask, whom or what to “ask”, how to ask 
them, in what setting to seek these answers and how to approach data collection and analysis. For 
example, while Logical Research approaches are more commonly used in mathematics, qualitative 
approaches focus more on exploring aspects of society, human behaviour, decision-making etc. (1). Jason 
and Reed, in their paper “The use of mixed methods in studying a chronic illness”, they perfectly 
summarized the benefits of the different approaches to research when they wrote: “quantitative 
procedures have the most power to appeal to collaborators in funding and policy, while qualitative studies 
are more likely to empower community members and gain insights about how to identify and work with 
participants” (2). 
Qualitative (constructivist approach): the aim of this approach is to understand or explore human 
experience or social occurrences, based on the notion that reality is subjective. This involves observing 
and describing what changes occur for individuals or groups, how these individuals experience the 
changes and explaining why they may be occurring. The geographical setting, culture, social norms, 
political structure or even fashion trends in which these individuals exist are often considered in parallel 
with the observations or feedback, i.e. data that are gathered (3).  
Pros: explanatory, e.g. can help explain participants’ motivations, and intentions, data can be continuous 
and/or universal for participants, e.g. beliefs. Cons: no way to conclusively and objectively measure the 
amount something has changed, analysis is largely biased based upon the formal and informal 
backgrounds of those conducting the study, not considered to be an approach of high enough rigor to 
influence healthcare policy or practice change. 
Quantitative (positivist approach):  the aim is to measure the difference between distinct, often numerical, 
outcomes and interpret them as “X cause”, or independent variables, resulted in “Y effect”, or dependent 
variables. Depending on the study, there can be several X’s and Y’s measured at once. This often involves 
organizing a study so that enough variables are controlled and accounted for statistical analyses to be able 
to conclusively determine to what degree the X variables were associated with the Y variables (4).  
Pros: measurable, objective, conclusive, e.g. can say decisively how much something has changed and to 
what extent it has changed in relation to other measured variables, reproducible based on specific, 
validated and dictated methods, low bias, considered to be an approach of high enough rigor to influence 
healthcare practice and/or policy. Cons: cannot explain how or why changes occurred, data can only be 
gathered at distinct points in time.  
Mixed-methods: the aim of this approach is to explain a situation more comprehensively than qualitative 
or quantitative on their own. This involves combining both qualitative and quantitative data based on 
theoretical frameworks for or assumptions about how these types of data affect one another (4).  
Pros: can help to explain not only what has changed but also how and why, combines the benefits of both 
qualitative and quantitative approaches. Cons: difficult to reproduce, analysis of different data types are, 
to an extent, subjective based upon the theoretical framework or assumptions made, not considered to be 
an approach of high enough rigor to influence healthcare policy or practice change. 
Participatory action research: as the most recent addition to the toolkit of research approaches, 
participatory research was originally based upon research about what users wanted, performed in public 
sectors such as commerce, marketing and business (5). This form of research is based on involving the 
“end-users”, i.e. those stakeholders who will be affected by or use the outcome, in the decision-making 
throughout the design, development and testing phases of whatever the end result aims to be, e.g. a 
product, service or improvement to existing system (6).  
Pros: has a greater chance of the outcome becoming a useful and used product or service because the 
needs and considerations, of those who will be using it, have been taken into account. Cons: difficult to 
reproduce, there is a great possibility that several influencing variables were/could not be accounted for, 
not considered to be an approach of high enough rigor to influence healthcare policy or practice change. 
1.2 Data and associated analysis 
Methods are established protocols for how data can be collected, measured and analysed. While in the 
medical realm, repeatable, measurable and objective quantitative data is king, as mentioned in the section 
above, each type of data fills in a different piece of the puzzle that we are trying to understand – each of 
which must be treated differently. We cannot statistically analyse two sentences, nor can we completely 
explain why someone’s physical activity habits changed by measuring the distance they ran that week. 
How the data is collected (from whom or what), measured and analysed change how we can and should 
interpret the outcome of research intervention studies. In other words, no amount of data can be useful 
without a way to structure and interpret it in context.  
Interviews and focus groups: Interviews are conducted between a research team member and a participant 
in the study. Interviews can be one-on-one or group interviews. Focus groups involve multiple 
participants in a study, usually grouped by like participants, e.g. patients vs. HCPs. Data are often 
collected as research team member observations, audio and/or visual recordings, which are then 
transferred to text for analysis. 
Qualitative analysis can focus on describing the feedback, experiences, ideas and physical/written 
material through one of five methods: i) content analysis, whereby data are grouped and tabulated, e.g. 
pros and cons, ii) narrative analysis, whereby participants’ stories are described in context with one 
another, e.g. a set of stories given by the same family describe a year in their life, iii) discourse analysis, 
whereby the details of a conversation or written text are account for, e.g. speech including every pause or 
natural language trait, iv) framework analysis, whereby iterative stages of processing the data occur to 
structure, codify, map and interpret the data, or v) grounded theory, whereby an idea or theory is based 
upon the set of data that was collected and then compare to similar situations to see if that established 
theory holds.  
Co-design: is a form of participatory research whereby, in the case of healthcare, patients, their family, 
friends and formal HCPs are gathered to not only say what needs to change in a self-management 
technology, medical process or treatment, but how to change it and, in some cases, factors that need to be 
taken into account to correctly measure if that change is successful (5). Data can be gathered as audio 
and/or visual recordings of meeting(s), participants’ drawings or paper-prototypes, pictures, and written 
notes. Analysis is performed in the same way as described above under Interviews and focus groups.   
Questionnaires and surveys: these can be both or either quantitative and/or qualitative data depending on 
the questionnaire type and the data collected. They can also be standardized, i.e. iteratively tested and 
validated through several studies, participant groups and settings (7), or designed by the author for use in 
a specific study. A questionnaire is meant to explore a participants’ perspective, and collects open-ended 
or free-written responses as its data, is an example of an author-designed qualitative questionnaire. If 
these responses are ordered and assigned numerical values, they can be analysed using statistical methods 
(8). For standardized questionnaires, it is most common to perform statistical analysis to measure the 
change in responses as a distinct value. Examples of these standardized ordinal questionnaires include 
customer satisfaction and diagnostic questionnaires, e.g. Diabetes related distress scale (9). In these cases, 
even if the response choices are worded as a scale from “agree” to “disagree”, these options correspond to 
ordinal values, i.e. “1-disagree” and “3-agree”, whereby a change in response indicates more or less 
agreement with a given statement. Analysis for standardized questionnaires can be performed by 
statistically comparing these responses between participants and/or between repeated measurements over 
time. Statistical models are applied based on the type of data, when the data was collected, what or whom 
is being compared in the analysis and assumptions about the population from which the data was 
collected. For qualitative data, analysis can follow the same approaches as those of transcripts from co-
design, interviews or focus groups, as described above.  
Quantitative measurements: these include anything that can be counted. Within health intervention 
research, this often involves pre-post or repeated measures of clinical data, e.g. blood pressure, or 
indications of quantifiable status, e.g. standardized questionnaires to measure behavioural decisions (10). 
These are often collected via standardized procedures, e.g. blood pressure measured via a medical grade 
blood pressure cuff at the clinic by a nurse practitioner in a specific manner, or validated diagnostic 
questionnaires, e.g. scales for self-efficacy, anxiety, depression etc. Statistical analysis is performed in the 
same way as that of standardized questionnaires or those that collect numerical data (11). If there are too 
few participants or responses or too many gaps in the data, alternative methods can be used such as 
descriptive statistics, whereby the data itself is summarized and/or the magnitude of change is simply 
described in conjunction with any other gathered data, instead of compared using a statistical model. 
Descriptive statistics are also generally used to report a summary of all collected data before formal or in-
depth analysis is performed. 
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Appendix B 
Ethical approval documents for PhD-related studies 
1. Exempt from REC approval (Co-design workshops): “2017/1759 Workshop for design
av datadelingssystem” 
2. PVO approval (Co-design workshops): “GODKJENNING AV BEHANDLING AV
PERSONOPPLYSNINGER” 
3. Exempt from REC approval (mixed-method study): “2018/719  Studie av
datadelingssystem mellom diabetespasienter og helsevesenet” 
4. PVO approval (mixed-method study): “ANBEFALING – BEHANDLING AV
PERSONOPPLYSNINGER” 
5. Finnmark PVO approval to include Finnmark Hospital (mixed-method study):
“ANBEFALING – BEHANDLING AV PERSONOPPLYSNINGER” 
119 
Region: Saksbehandler: Telefon: Vår dato: Vår referanse:
REK nord Veronica Sørensen 77620758 22.09.2017 2017/1759/REK nord
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2017/1759 Workshop for design av datadelingssystem
Vi viser til innsendt fremleggingsvurderingsskjema datert 15.09.2017. 
 Eirik ÅrsandProsjektleder:
Bakgrunn og formål (original):
Målet med workshoppene:
Målet med disse workshoppene er å samle pasienter/superbrukere med diabetes type 1 og type 2, og
helsepersonell – for å diskutere og designe funksjonalitet som et datadelings system, der pasienter kan dele
sine egeninnsamlede data under konsultasjonen med helsepersonell (typisk sykepleiere).
Spørsmål vi ønsker besvart: 
1. Hvordan en konsultasjon der pasienten har data å vise helsepersonell ideelt bør foregå.
2. Hvordan disse data bør vises slik at både pasient og helsepersonell forstår pasientens helsesituasjonen på
en best mulig måte.
3. Hvordan et slikt datadelingssystem kan designes slik at man oppnår en best mulig beslutningsstøtte for
diabetesbehandling.
4. Hvordan systemet kan støtte en best mulig oppfølging av pasientens egenbehandling og helsesitasjon.
Spørsmålene vil bli besvart under workshoppene ved å diskutere disse med 3-4 pasienter (første workshop
type 2 og andre workshop type 1) første del av dagen, deretter diskuter det med 3-4 helsepersonell separat,
og til slutt bringe alle sammen og diskutere disse i en "co-design" sesjon. Det vil bli tatt lydopptak av
diskusjonene og analysert i ettertid. I tillegg vil vi be deltakerne å skrive ned forslag til spørsmålene.
Forskerne vil også gjøre notater av reaksjonene og engasjement av alle deltakerne under de ulike
diskusjonene. 
Framleggingsplikt
De prosjektene som skal framlegges for REK er prosjekt som dreier seg om "medisinsk og helsefaglig
forskning på mennesker, humant biologisk materiale eller helseopplysninger", jf. helseforskningsloven (h) §
2. "Medisinsk og helsefaglig forskning" er i h § 4 a) definert som "virksomhet som utføres med
vitenskapelig metodikk for å skaffe til veie ny kunnskap om helse og sykdom". Det er altså formålet med
studien som avgjør om et prosjekt skal anses som framleggelsespliktig for REK eller ikke.
I dette prosjektet beskrives formålet som å samle pasienter/superbrukere med diabetes type 1 og type 2, og
helsepersonell i workshoper for å diskutere og designe funksjonalitet som et datadelings system, der
pasienter kan dele sine egeninnsamlede data under konsultasjonen med helsepersonell (typisk sykepleiere).
REK anser  at slik prosjektet fremstår nå , faller det ikke inn under definisjonen av de prosjekt som skal
vurderes etter helseforskningsloven. 
Godkjenning fra andre instanser
Det påhviler prosjektleder å undersøke hvilke eventuelle godkjenninger som er nødvendige fra eksempelvis
personvernombudet ved den aktuelle institusjon eller Norsk senter for forskningsdata (NSD).
Veiledning vedrørende framleggingsplikt
Etter søknaden fremstår prosjektet ikke som et medisinsk og helsefaglig forskningsprosjekt som faller
innenfor helseforskningsloven. Prosjektet er ikke framleggingspliktig, jf. hfl § 2.
Prosjektleder skriver at «Siden dette omsøkte workshop aktiviteten er del av et større prosjekt, der formålet
er å forbedre kommunikasjonen mellom pasient og helsepersonell, som igjen kan forbedre pasientenes helse,
vil vi undersøke om vi skal søke REK eller ikke.»
Dersom det er slik at data som  samles inn i dette prosjektet og som defineres som helseopplysninger ,skal
benyttes i et senere forskningsprosjekt, vil REK anbefale at dette kommer eksplisitt frem i samtykkeskrivet
til deltagerne.
Videre har prosjektleder skrevet at «Vi vil også forsikre oss om at det er grei praksis å kompensere
pasientene med tapt arbeidsfortjeneste på 2000». Det uttales i forarbeidene til helseforskingloven at et
honorar ikke må vær av en slik art og størrelse at det er eget til utilbørlig påvirkning av deltager. Selv om
2000 kroner isolert sett kan  høres mye ut, må prosjektleder vurdere beløpets størrelse opp mot hvor mye
innsats og tid som er påkrevet av  hver enkelt deltager.  
Vi ber om at alle henvendelser sendes inn via vår saksportal:  eller på e-posthttp://helseforskning.etikkom.no
til: .post@helseforskning.etikkom.no
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GODKJENNING AV BEHANDLING AV PERSONOPPLYSNINGER 
Det vises til Meldeskjema for forskningsprosjekt, kvalitetsprosjekt og annen aktivitet som 
medfører behandling av personopplysninger som er melde- eller konsesjonspliktig i henhold 
til helseregisterloven og personopplysningsloven med forskrifter, mottatt 15.9.2017 
Meldingen gjelder prosjektet/registeret: 
Nr. 0751 
Navn på prosjektet: Workshop for design av datadelingssystem, del av prosjektet: 
«Full Flow of Health Data Between Patients and Health Care System» 
Prosjektet er et forskningsprosjekt hvor Universitetssykehuset Nord-Norge HF er 
behandlingsansvarlig.  
Formål: «Målet med disse workshoppene er å samle pasienter/superbrukere med 
diabetes type 1 og type 2, og  helsepersonell – for å diskutere og designe 
funksjonalitet som et datadelings system, der pasienter kan dele sine egeninnsamlede 
data under konsultasjonen med helsepersonell (typisk sykepleiere, fastleger og 
spesialister).» 
REK nord sak 2017/1759 har vurdert prosjektet, og finner at behandlingen av 
personopplysningene ikke faller inn under medisinsk- og helsefaglig forskning etter 
Helseforskningsloven. Prosjektet trenger ikke REK godkjenning. Behandlingen vil være 
regulert av § 7-27 i Personopplysningsforskriften og hjemlet etter Helseregisterloven § 6, jf. 
Personopplysningsloven § 11. Forskningsprosjekt vil som hovedregel kreve samtykke. 
PVOs anbefaling forutsetter at prosjektet gjennomføres i tråd med de opplysningene som er 
gitt i henhold til Personopplysningsloven og Helseregisterloven med forskrifter. 
PVO gjør oppmerksom på at dersom registeret skal brukes til annet formål enn det som er 
nevnt i meldingen, må dette meldes særskilt. 
PVO skal ha melding når registeret er slettet. PVO skal også ha melding dersom registeret 
ikke er slettet eller ikke ferdig behandlet innen 3 år.  
Med hjemmel i Personopplysningsforskriften § 7-12 godkjenner PVO at behandlingen av 
personopplysningene settes i gang som beskrevet. 
Med vennlig hilsen 
UNIVERSITETSSYKEHUSET NORD-NORGE HF 
Kristin Andersen 
Personvernombud forskning 
Kopi: Stein Olav Skrøvseth 
Region: Saksbehandler: Telefon: Vår dato: Vår referanse:
REK nord 07.05.2018 2018/719/REK nord
Deres dato: Deres referanse:
20.03.2018
Vår referanse må oppgis ved alle henvendelser
Besøksadresse:
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2018/719  Studie av datadelingssystem mellom diabetespasienter og helsevesenet
Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av
Regional komité for medisinsk og helsefaglig forskningsetikk (REK nord) i møtet 19.04.2018. Vurderingen
er gjort med hjemmel i helseforskningsloven § 10.
 Universitetssykehuset Nord-Norge HFForskningsansvarlig institusjon:
 Eirik ÅrsandProsjektleder:
Prosjektleders prosjektomtale (original):
Formålet med studien er å gi et teste et system for deling av pasientgenerert data under kliniske
konsultasjoner mellom personer med Type 1 og Type 2 diabetes, og helsepersonell, og vurdering av dette.
Metoden brukt i studien vil være måling av både systemets funksjonalitet og brukbarhet, og en vurdering av
helseeffekt og effekt på pasient-kliniker forhold, gjennom spørreskjema, journalsystem (HbA1c og
blodtrykk), intervju og fokusgrupper. Systemet under utprøving er basert på en egenutviklet forskningsapp
for innsamling av pasientdata og et egenutviklet sikkert system for visning av informasjon basert på disse
data. Studien vil demonstrere mulighetene og effektene ved en ny måte å fasilitere en pasient-sentrert
diskusjon omkring egenbehandling basert på egeninnsamlede data. Vi vil også undersøke om dette vil øke
pasientenes engasjement i egen helse.
Vurdering
Framleggingsplikt
De prosjektene som skal framlegges for REK er prosjekt som dreier seg om "medisinsk og helsefaglig
forskning på mennesker, humant biologisk materiale eller helseopplysninger", jf. helseforskningsloven (h) §
2. "Medisinsk og helsefaglig forskning" er i h § 4 a) definert som "virksomhet som utføres med
vitenskapelig metodikk for å skaffe til veie ny kunnskap om helse og sykdom". Det er altså formålet med
studien som avgjør om et prosjekt skal anses som framleggelsespliktig for REK eller ikke.
Selv om det skal innhentes helseopplysninger og at et av delmålene angis som «reseraching the effects of
the designes solutions on health outcomes» vurderer REK at formålet med prosjektet ikke er å fremskaffe ny
kunnskap om helse og sykdom, men uttesting av et datadelingssystem med diabetes som «case». Prosjektet
skal således ikke vurderes etter helseforskningsloven.
Godkjenning fra andre instanser
Det påhviler prosjektleder å undersøke hvilke eventuelle godkjenninger som er nødvendige fra eksempelvis
personvernombudet ved den aktuelle institusjon eller Norsk senter for forskningsdata (NSD).
Vedtak
Etter søknaden fremstår prosjektet ikke som et medisinsk og helsefaglig forskningsprosjekt som faller
  § innenfor helseforskningsloven. Prosjektet er ikke framleggingspliktig, jf. hfl 2.
Klageadgang
Du kan klage på komiteens vedtak, jf. helseforskningsloven § 10 og forvaltningsloven § 28 flg. Klagen
sendes til REK nord. Klagefristen er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av






Postadresse: Avdeling: Kvalitets- og utviklingssenteret Telefon: 77 62 60 00 
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9038 TROMSØ Fakturaadr: UNN HF, c/o Fakturamottak, Postboks 3232, 7439 Trondheim E-post: personvernombudet@unn.no 
Eirik Årsand 
Nasjonalt senter for e-helseforskning 
Deres ref.: Vår ref.: 
2018/4027 
Saksbehandler/dir.tlf.: 
Kristin Andersen/776 26506 
Dato: 
9.8.2018 
ANBEFALING – BEHANDLING AV PERSONOPPLYSNINGER 
Det vises til Meldeskjema for forsknings- og kvalitetsprosjekt og annen aktivitet som 
medfører behandling av personopplysninger, mottatt 25.5.2018 samt avklaringer i e-post 
senere 
Meldingen gjelder prosjektet/registeret: 
Nr. 02080 
Navn på prosjektet: FullFlow - Full Flow of Health Data Between Patients and 
Health Care Systems 
Prosjektet er et forskningsprosjekt basert på samtykke, hvor Universitetssykehuset Nord-
Norge HF er behandlingsansvarlig.  
Formål: Formålet med studien er å gi et teste et system for deling av pasientgenerert 
data under kliniske konsultasjoner mellom personer med Type 1 og Type 2 diabetes, 
og helsepersonell, og vurdering av dette. Metoden brukt i studien vil være måling av 
både systemets funksjonalitet og brukbarhet, og en vurdering av helseeffekt og effekt 
på pasient-kliniker forhold, gjennom spørreskjema, journalsystem (HbA1c og 
blodtrykk), intervju og fokusgrupper. 
Systemet under utprøving er basert på en egenutviklet forskningsapp for innsamling 
av pasientdata og et egenutviklet sikkert system for visning av informasjon basert på 
disse data. Studien vil demonstrere mulighetene og effektene ved en ny måte å 
fasilitere en pasient-sentrert diskusjon omkring egenbehandling basert på 
egeninnsamlede data. Vi vil også undersøke om dette vil øke pasientenes 
engasjement i egen helse. 
REK har vurdert prosjektet, og finner at behandlingen av personopplysningene ikke faller 
inn under medisinsk- og helsefaglig forskning etter Helseforskningsloven. Behandlingen 
vil være hjemlet etter Helseregisterloven § 6, jf. Personopplysningsloven § 10.  
PVO har på bakgrunn av tilsendte meldeskjema med vedlegg registrert prosjektet og 
forutsetter at prosjektet gjennomføres i tråd med de opplysningene som er gitt og i henhold 
til Personopplysningsloven og Helseregisterloven med forskrifter.  
PVO forutsetter at infoskrivet oppdateres med å fjerne henvisning til REK-godkjenning. 
Når/hvis man tar i bruk PAM-løsning fra USA må dette meldes som endring til PVO og 
oppdateres i infoskrivet. Oppdatert infoskriv og avtale med Insignia (USA) må vedlegges 
endringsmeldingen. 
PVO gjør oppmerksom på at dersom registeret skal brukes til annet formål enn det som er 
nevnt i meldingen, må dette meldes særskilt. 
PVO skal ha melding når registeret er slettet. PVO skal også ha melding dersom registeret 
ikke er slettet eller ikke ferdig behandlet innen 3 år.  
Med hjemmel i Personopplysningsloven § 10, jf. Personvernforordningens artikkel 39, 
anbefaler PVO at behandlingen kan iverksettes. 
Med vennlig hilsen 
UNIVERSITETSSYKEHUSET NORD-NORGE HF 
for Personvernombudet 
Kristin Andersen 
Kopi: Senterleder Stein Olav Skrøvseth 
Postadresse: Avdeling: Fag, forskning og samhandling Telefon: 78 42 10 00 
Finnmarkssykehuset HF Internett: www.finnmarkssykehuset.no  
Sykehusveien 35 
9601 Hammerfest 
E-post: personvernombudet@unn.no  
Eirik Årsand 
Nasjonalt senter for e-helseforskning 
 Deres ref.: Vår ref.: 
2018/2558 
Saksbehandler/dir.tlf.: 
Eva Henriksen / 95731836 
Dato: 
7.11.2018 
ANBEFALING – BEHANDLING AV PERSONOPPLYSNINGER 
Det vises til Meldeskjema for forsknings- og kvalitetsprosjekt og annen aktivitet som 
medfører behandling av personopplysninger, mottatt 2.10.2018. 
Meldingen gjelder prosjektet/registeret: 
Nr. 036 
Navn på prosjektet: FullFlow - Full Flow of Health Data Between Patients and 
Health Care Systems 
Prosjektet er et forskningsprosjekt hvor Universitetssykehuset Nord-Norge HF er 
dataansvarlig og Finnmarkssykehuset HF deltar. 
Formål: «Formålet med studien er å et teste et system for deling av pasientgenerert 
data under kliniske konsultasjoner mellom personer med Type 1 og Type 2 diabetes, 
og helsepersonell, og vurdering av dette. Metoden brukt i studien vil være måling av 
både systemets funksjonalitet og brukbarhet, og en vurdering av helseeffekt og effekt 
på pasient-kliniker forhold, gjennom spørreskjema, journalsystem (HbA1c og 
blodtrykk), intervju og fokusgrupper. 
Systemet under utprøving er basert på en egenutviklet forskningsapp for innsamling 
av pasientdata og et egenutviklet sikkert system for visning av informasjon basert på 
disse data. Studien vil demonstrere mulighetene og effektene ved en ny måte å 
asilitere en pasient-sentrert diskusjon omkring egenbehandling basert på 
egeninnsamlede data. Vi vil også undersøke om dette vil øke pasientenes 
engasjement i egen helse.» 
REK har vurdert prosjektet og finner at behandlingen av personopplysningene ikke faller 
inn under medisinsk- og helsefaglig forskning etter Helseforskningsloven. Prosjektet 
trenger ikke REK godkjenning. Behandlingen vil være hjemlet etter Helseregisterloven § 6, 
jf. Personvernforordningen artikkel 6.1.a) og artikkel 9.2.j).  
Personvernombudet (PVO) ved UNN har tidligere tilrådd samme prosjekt hos UNN 
(prosjekt nr. 02080, ref. 2018/4027). Meldeskjemaet til PVO i Finnmarkssykehuset inneholdt 
ingen egne vedlegg, men vedleggene sendt til PVO UNN gjelder også i dette tilfelle.  
PVO har på bakgrunn av tilsendt meldeskjema, samt vedleggene til meldingen sendt til PVO 
UNN, registrert prosjektet og forutsetter at prosjektet gjennomføres i tråd med de 
opplysningene som er gitt i henhold til Personopplysningsloven og Helseregisterloven med 
forskrifter. 
PVO skal ha melding når prosjektet er slutt. PVO skal ha melding hvert 3. år inntil 
prosjektet er avsluttet. 
Med hjemmel i Personvernforordningens artikkel 39, anbefaler PVO at behandlingen kan 
iverksettes. 




Kopi: Kvalitets- og utviklingssjef Anne Grethe Olsen 
Appendix C 
Results of the 2016 online survey and HCP co-design 
workshop 
“Differentiating Presentation Of Patient-gathered Data Between Type 1 And 2
Diabetes During Consultations”
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3-mg NG 15 minutes later (opposite nostril); 4) 2 concurrent 3-
mg NG doses (both nostrils).
Results: 32 subjects were enrolled (T1D: 23, T2D: 9).
Number of subjects who received Trts 1, 2, 3, 4 were 27, 28, 25
and 29, respectively. Baseline (BL) blood glucose was 40-
181 mg/dL. For Trts 1-4, PK parameters of change from BL for
glucagon were mean area under the curve 0-3 hrs: 2471, 4097,
4639, and 3611 hr  pg/mL, median Tmax: 0.17, 0.33, 0.50, and
0.33 hrs; PD parameters of change from BL for glucose were
mean area under the effect concentration 0-3 hrs: 157, 168, 190,
and 194 hr mg/dL, median Tmax: 0.75, 1.00, 1.00, and 1.00 hrs.
Repeated NG doses resulted in higher glucagon concentrations,
but gave glucose responses comparable to single dose (Figure).
The only serious adverse event (AE; cellulitis) was not drug-
related. Most drug-related AEs were transient and resolved
within 2 hours.
Conclusions: Although repeat dosing resulted in greater
systemic glucagon exposure, it did not result in a meaningful
increase in observed glucose response. All NG treatments were
well-tolerated.
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DIFFERENTIATING PRESENTATION OF PATIENT-
GATHERED DATA BETWEEN TYPE 1 AND 2
DIABETES DURING CONSULTATIONS
M. Bradway1, A. Holubová2, R. Joakimsen3, E. Årsand1
1University Hospital of North Norway, Norwegian Centre
for E-Health Research, Tromsø, Norway
2Czech Technical University in Prague, Faculty of Biomedical
Engineering, Prague, Czech Republic
3University Hospital of North Norway, Institute of Clinical
Medicine, Tromsø, Norway
Background and Aims: The integration of mobile health
(mHealth) technology within medical practice is a discussion
riddled with debate and unresolved questions. In addition to
privacy and security is the question of how to present patients’
mHealth self-gathered data during consultations. For chronic and
resource-heavy illnesses, such as diabetes, it is necessary to
consider adaptive formatting for the presentation of patients’
sensor/app data to medical personnel, with the aim to determine
sound strategies and formats for presentation during consulta-
tions.
Methods: Both an anonymous online patient survey as well
as three workshops involving clinicians involved in diabetes
treatment, EHR-vendors, patients and researchers were con-
ducted. Diabetes patients in Norway answered questions re-
lated to experienced challenges and desired consultation
discussion topics, given more time for discussing self-
gathered data.
Results: Individuals with Type 1 (n = 15) and Type 2 (n = 9)
completed the survey (Figure 1). While ‘‘motivation’’ was a
common challenge, stress management (Type 1), BG variability,
exercise and mood (Type 2) were the most wanted consultation
topics. The workshops revealed large differences in preferred
ways of data presentation, e.g. GPs preferred quick ways of re-
viewing data during consultation, while specialist preferred to
receive and review more detailed data before consultations
(Table 1).
Conclusions: Due to numerous factors associated with dia-
betes, it is necessary to not only consider a patient’s diabetes type
and clinicians’ specialties but also patients’ personal challenges,
resources, and capacity when preparing patient-gathered data for
consultations. The Full Flow project (2016-19) will study use of
dynamic data-formats for presenting patient-gathered data dur-
ing consultations.
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THE IMPLEMENTATION OF MYSTAR CONNECT
CLINICAL INFORMATION SYSTEM IMPROVES
INTERMEDIATE OUTCOMES IN 42498 PEOPLE
WITH DIABETES
V. Provenzano1, D. Brancato1, G. Picone1, A. Scorsone1,
M. Fleres1, G. Saura1, V. Aiello1, F. Provenzano1, A. Di Noto1,
L. Spano1
1Hospital of Partinico, Regional Reference Center
for Diabetology and Insulin Pumps, Palermo, Italy
Background and Aims: The Diabetes Network of Palermo
District links all the public healthcare diabetes resources
of Palermo District. Since 2012, DNPD implemented a Chronic
Care Model (CCM) mainly based on the full sharing of
clinical data between primary care resources and special-
ized diabetes centers, through a single clinical information
system (MyStar Connect). Aim of the present study is to
assess if the implementation of MyStar Connect was fol-
lowed by an improvement of the management of people with
diabetes.
Methods: Assessment of the trend of the proportion
of people with diabetes who yearly (from 2012 until to
2015) achieved some target values of intermediate (primary)
outcomes: HbA1C <7.0%; LDL <100 mmHg; systolic blood


















































Results of the grey literature search 
“Frameworks for evaluating mHealth technologies lack patient focus” 
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Frameworks for evaluating mHealth 
technologies lack patient focus
Meghan Bradway1,2, Konstantinos Antypas1,3, Natalia Wroblewska4, Jennifer Lee5, Eirik Årsand1,2
1 Norwegian Centre for E-health Research, University Hospital of North Norway, Tromsø, Norway
2 UiT The Arctic University of Norway, Department of Clinical Medicine, Tromsø, Norway
3 The University of Oslo, Institute of Health and Society, Oslo, Norway 
4 University of Cambridge, Faculty of Biology, Cambridge, United Kingdom 
5 University of Cambridge, Department of Politics and International Studies, Cambridge, United Kingdom 
Figure 1. Descriptions of data extracted 
Table 1. Descriptions of the three main types of identified mHealth frameworks.
Introduction
There have been many attempts to create multi-
level frameworks for mHealth evaluation. However, 
due to the complex environment of mHealth 
technologies, there has been no consensus on 
a standard. With the aim of providing input for 
a consensus, we performed a review of 
different mHealth assessment frameworks.
Methods
Literature searches were performed in 
Google Scholar, Google and PUBMED 
for publically available descriptions of 
mHealth assessment efforts and strat-
egies. Exclusion criteria included descrip-
tions of single method “frameworks”, e.g. 
questionnaires. The data extraction strategy 
is described in Figure 1.
Figure 2. The extent to which domains were covered and which audiences 
were targeted by implementation frameworks.
Results
Three main types of frameworks were identified: imple-
mentation frameworks (n=20), assessment frame-
works (n=28), and service frameworks (n=13). These 
frameworks are defined/described in Table 1. The most 
commonly covered areas in the implementation frame-
works were security 
(n=18), privacy (n = 17), 
usability (n = 16), and 
user experience (n = 
16). Target audiences 
included devel-
opers, policy-makers, 
researchers, and health 
professionals (Figure 2).
Discussion
While user experience was considered a 
common priority for frameworks, with the most 
frequent users of mHealth being individual 
citizens, surprisingly few frameworks had this 
stakeholder group as its target audience.
Conclusion
Stakeholder-specific frameworks spanning a 
diversity of target audiences have both advan-
tages and disadvantages, but overall, create a 
fragmented mHealth assessment landscape. It 
is clear that any one existing framework cannot 
be expected to assess all the different aspects 
of mHealth. In order to develop one compre-
hensive framework, or interoperable frame-
works, coordination of stakeholder expertise is 
needed. As citizens are the most experienced 
and prevalent mHealth users, they must be 
involved in the development and have easy 
access to the framework(s).
Appendix E 
Results of Tailoring project goal setting 
“Goal-setting and duration of app use: selected results from the “Tailoring Type 2 Diabetes 
Self-Management” RCT” 
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Goal-setting and duration of app use: selected results from the
“Tailoring Type 2 Diabetes Self-Management” RCT
Meghan Bradway1,2, Alain Giordanengo1,3, Håvard K. Blixgård1, Silje C. Wangberg4, Eirik Årsand1,2
1 Norwegian Centre for E-health Research, University Hospital of North Norway, Tromsø, Norway
2 UiT The Arctic University of Norway, Department of Clinical Medicine, Tromsø, Norway
3 UiT The Arctic University of Norway, Department of Computer Science, Tromsø, Norway
4 UiT The Arctic University of Norway, Department of Health and Care Sciences, Tromsø, Norway 
Introduction
Setting goals and seeing one’s 
progress is a motivating factor in 
self-management. Here we present 
results from a study where partici-
pants were able to register and review 
self-management measures in either 
a tailored (Intervention group) and/
or simple version (Control group) of a 
diabetes diary app.
Methods
Participants were randomized to 
the Control group (used the regular 
Diabetes Diary app for the first 
3-months and the tailored version for
3-months) and Intervention group
(used the tailored app for the full
6-months) (Figure 1). We compared
the number and types of baseline-
goals, reported via a questionnaire, and
usage-patterns for those who regis-
tered in the app.
Figure 1.Illustration of the regular Diabetes Diary app (A) and Tailored Diabetes Diary 
app, including screen displaying progress on goals (B).app, including screen displaying 
progress on goals (B).
Table 1. Goals and registration patterns and duration of usage for those who registered in the app 
(n=20)
Results
While all participants set at least one goal (n=41), only half (n=20) 
made registrations in the app. No significant difference was found 
between groups in terms of number of goals or registrations. Those 
who made more “Registration types” than baseline “Number of goals” 
(n=12), used the app for, on average, 4.08-months. Those who made 
fewer “Registration types” than their baseline goals (n=8) used the 
app for 3.12-months (Table 1). 
Discussion
Setting goals seems to contribute 
to duration and focus of self-man-
agement app-usage. Also, not only 
patients but researchers and clinicians 
must make tailored and realistic goals 
for each patient - evidence for which 
includes those who were unable to or 
did not register as many measures as 
they intended.
Conclusion
This analysis not only suggests that 
goal setting may imply future app-use, 
it also demonstrates what more can be 
explored by focusing analysis on those 
who chose, themselves, to use apps in 
addition to comparing assigned inter-
vention groups.
Appendix F 
Results of Tailoring project usage-log analysis 
“What can be Learned by Analyzing Patient-gathered Data From a Self-Management 
Diabetes App”  
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to the following standardized questionnaires: WHO-5, Summary
Of Diabetes Self-Care Activities Assessment (SDSCA), and
Perceived Competence Scale (PCS). The app continuously col-
lected patient-gathered self-management data.
Results: Participants in both groups offered written feedback
regarding what was useful (Table 1) and what could be improved
in the apps (Table 2).
Discussion/conclusion: Written comments are rarely an-
swered by participants. We believe that because these partici-
pants were ‘‘self-recruited’’, they were more engaged. This is
evident in their willingness to provide both constructive criticism
and details for future development of mHealth technologies. This
also demonstrates what we can expect from - and the value of -
involving engaged users of technology aids in diabetes research
today.
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WHAT CAN BE LEARNED BY ANALYZING PATIENT-
GATHERED DATA FROM A SELF-MANAGEMENT
DIABETES APP
M. Bradway1, H. Blixgård1, M. Muzný2, A. Giordanengo1,
S.C. Wangberg3, E. Årsand1
1University Hospital of North Norway, Norwegian Centre for
E-health Research, Tromsø, Norway
2Charles University in Prague, Spin-Off Company and
Research Results Commercialization Center- 1st Faculty of
Medicine, Prague, Czech Republic
3UiT - The Arctic University of Norway, Department of Health
and Care Sciences- Faculty of Health Sciences, Narvik, Norway
Introduction: Self-management interventions for diabetes
are still limited in the analysis of patient-gathered data and
mHealth usage - focusing mainly on HbA1c. From the ‘‘Tai-
loring Type 2 Diabetes Self-Management’’ RCT, we analysed
detailed app-data as a supplement to the traditional measures.
Methods: Participants were randomized to two groups. The
Control group used the regular Diabetes Diary app for the first 3-
months and the tailored version for 3-months. The Intervention
group used the tailored app for the full 6-months (Figure 1).
Measures were taken at 0, 3, and 6-months including HbA1c. The
app continuously stored user-recorded each blood glucose, in-
sulin dose, diet, and exercise registration.
Results: N = 16 participants were randomized to the Control
group and n = 25 to the Intervention group. Total registrations
made and HbA1c did not differ significantly between those who
made registrations in the in the Control (n = 12) and Intervention
groups (n = 8). Therefore, all participants who registered in the
app were treated as one cohort in the following analysis (n = 20)
(Figure 2). While not significant, participants seemed to reduce
HbA1c between zero and three months.














































Discussion/conclusion: By looking past assigned groups to
additionally include app-usage patterns, we may be able to more
effectively address how and why participants do - or do not -
engage in mHealth-use over time, and which functionalities are
most relevant to them. By incorporating such understanding, we
may also be able to address when, and for which functionalities,
users need encouragement to self-manage via apps, during both
future interventions and daily clinical practice.
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HEART RATE VARIABILITY DURING
HYPOGLYCEMIA IN PATIENTS WITH TYPE 1
DIABETES AND IMPAIRED AWARENESS OF
HYPOGLYCEMIA
M. Koeneman1, M. Olde Bekkink1, S.J. Bredie1, B.E. de Galan1
1Radboud university medical center, Internal medicine,
Nijmegen, The Netherlands
Background: Patients with type 1 diabetes (T1D) and im-
paired awareness of hypoglycemia (IAH) are at very high risk
of severe, potentially hazardous, hypoglycemia and would
benefit from an early alert device for the detection of hypo-
glycemia. Heart rate variability (HRV) may change at the ini-
tiation of hypoglycemia due to sympathetic nervous system
activity. The aim of this study was to investigate whether these
HRV-changes are retained in patients with T1D and IAH, in
whom sympathetic nervous system activation during hypo-
glycemia is reduced.
Methods: Eligible participants underwent a modified hyper-
insulinemic hypoglycemic clampwhile HRV was measured si-
multaneously by a Vital Connect Health Patch on their chest.
Parameters of HRV included Square root of the mean standard
differences of successive R-R intervals (RMSSD) representing
parasympathetic nervous system activity and low and high fre-
quency ratio (LF:HF) representing sympathetic nervous system
activity.
Results: We included a total of 10 patients (4 men, age
38.5 – 4.4 years, diabetes duration 21.7 – 4.3 years, HbA1c
55.2 – 1.5 mmol/L, modified Clarke score 3.7 – 0.3). The glucose
nadir during the clamp averaged 2.8 – 0.1 mmol/L, which elicited
minimal symptoms. Preliminary data analysis shows typical HRV
patterns at the initiation of hypoglycemia, i.e. a decrease in RMSSD
and an increase in LF:HF ratio (figure 1). Group differences also
showed decreased RMMSD (36.1 – 24.5 to 25.7 – 9.5) and in-
creased LF:HF ratio (1.35 – 0.35 to 1.52 – 0.24). Final results are
pending.
Conclusion: Hypoglycemia affects HRV patterns in patients
with type 1 diabetes and IAH. Considering developments in
wearable devices and data analytics,real time HRV seems
promising for early detection of hypoglycemia in patients with
IAH.
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DIABETES APPS USAGE AMONG INDIAN
ENDOCRINOLOGISTS
K. Balachandran1
1Sri Ramachandra Institute of Higher Education and Research,
Endocrinology, Chennai, India
Aims: To assess the knowledge,attitudes and usage of dia-
betes smartphone apps among Indian Endocrinologists.
Materials and Methods: An online survey was done with
REDCap and was emailed to a list of Indian Endocrinologists.
The survey link was also disseminated through a WhatsApp
group of Endocrinologists with 256 members. The endocrinol-
ogists were encouraged to share the link with their friends and
colleagues. One hundred and ninety one(191) people completed
the survey. Of these, 179 were endocrinologists. The analysis
was limited to Indian Endocrinologists.
Results: 179 endocrinologists from India participated in
the sur- vey. Majority of them were from the urban area.
The mean experience of the respondents was 9.22 years
(SD = 5.25 years). Their patient profiles included questions on
litera- cy and specifically English literacy. In the survey, 74.7
% of the respondents felt their patients were literate(SD-
19.47%) and 53.8% of patients were felt to be English literate
(SD = 22.48%). 59.3% responded that their patients had
smartphones. Only 16.5 % had ever prescribed an app. Heal-
thifyMe, MyFitnessPal and GoogleFit were the most com-
monly prescribed apps.
Conclusion: The usage of diabetes apps is very low among
Indian Endocrinologists. The main barriers to usage is
awareness of the doctor. Availability of apps in local lan-
guages, diabetic education through the app and emergency
alert/notification to the physician are the top preferred fea-
tures in a prospective diabetes app. Incorporating mobile
technology in diabetes management should start with im-
proving physician awareness.



















































Dette spørreskjema tar ca 5 minutter å fylle ut. Tusen takk for at du deltar i studien og hjelper oss med
denne forskningen!




Kun tall er tillatt i dette feltet.
Svaret ditt må være mellom 1900 og 2017
Vennligst skriv her:
[]Kjønn
Velg kun en av følgende:
 Kvinne
 Mann
[]Hvilken er den høyste utdanning du har fullført?
Velg alternativene som passer
Vennligst velg alle som passer:
 Grunnskole
 Ett- eller toåring videregående skole
 Studieforberedende utdanningsprogram, allmennfaglig (studiekompetanse), gymnas, eller
Artium
 Høgskole eller universitet mindre enn fem år
 Høgskole eller universitet mer enn fem år
[]Hvilket årstall ble din diabetes oppdaget?
Kun tall er tillatt i dette feltet.
Vennligst skriv her:
[]Hvilken type medisin bruker du til din diabetes?
(dersom du bruker både insulin og Piller/tabeletter
velger du "insulin")
Velg ett av alternativene




[]Bruker du noen av de følgende verktøy:
Velg alternativene som passer
Vennligst velg alle som passer:
 Insulinpen
 Insulinpumpe
 CGM (kontinuerlig blodsukkermåler)
 Blodsukkermåler
 Diabetesdagboka appen
 Andre apper for diabetes (ikke Diabetesdagboka)
 Smartklokke eller andre bærbare sensorer
 Papirdagbok
Annet: 
[]Omentrent hvor mange ganger måler du blodsukkeret





Hvor ofte teller/vurderer du karbohydrater eller kalorier




[]Lager du regelmessige mål for egenbehandling av din
diabetes?
Velg kun en av følgende:
 Ja
 Nei
[]Har du noen ganger hatt for lavt/høyt blodsukker?
Velg kun en av følgende:
 Ja
 Nei
[]Hvis ja, hvor mange ganger har du hatt det den siste
uka?
Vennligst skriv her:
Antall ganger for lavt blodsukker:
Antall ganger for høyt blodsukker:
Spørsmål - Empowerment
[]Generelt sett tror jeg at jeg:









jeg ikke er fornøyd
med.
...kan få mine














...kan finne måter å












...vet nok om meg
selv som person
slik at jeg kan ta de
valgene som er






















Jeg føler meg forstått
av helsepersonellet
Helsepersonellet
uttrykker tillit til min














oppmuntrer meg til å
stille spørsmål
Helsepersonellet
lytter til hvordan jeg
kunne tenke meg å
gjøre ting
Helsepersonellet
prøver å forstå mitt
syn før de foreslår en
ny måte å gjøre ting
på
Spørsmål - Trivsel og velvære
[]I de siste to ukene har jeg ...
















Følt meg glad og i
godt humør
Følt meg rolig og
avslappet
Følt meg aktiv og
sterk
Følt meg opplagt og
uthvilt når jeg våkner
Følt at mitt daglige liv
har vært fylt av ting
som interesserer meg
Send undersøkelse.
Takk for at du fullførte denne undersøkelsen.
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Dette spørreskjema tar ca 5 minutter å fylle ut. Tusen takk for at du deltar i studien og hjelper oss med
denne forskningen!
Det er 11 spørsmål i denne undersøkelsen.
Spørsmål - Om systemet
[]Var informasjonen i systemet nyttig for deg? (Likert-
skala, 5 verdier)  
Velg ett av alternativene






[]Hvilke funksjoner brukte du i Datadelingssystemet
sammen med din lege/sykepleier som var nyttig for
deg:  
Velg alternativene som passer





 Detaljert visning (grafer og tabeller)
 Alle data i en graf
 Periodevisning (hver datatype i egne grafer over valgt periode)
 Døgnfordeling (hver datatype i egne grafer over 24 timer)
 Sum over tid (sum av hver datatype per dag over valgt periode)
 Liste av data
Annet: 
[]Bruk av systemet ga meg bedre forståelse for: 
Velg alternativene som passer








[]Planla du og din lege/sykepleier hva du skulle
gjøre/fokusere på fram til neste konsultasjon?  
Velg kun en av følgende:
 Ja
 Nei
[]Var anbefalningene fra din lege/sykepleier nyttig for
deg etter denne konsultasjon?
Velg kun en av følgende:
 Ja
 Nei
[]Tror du anbefalingene du fikk er oppnåelige? Dvs. er
du i stand til å gjennomføre det dere planla før neste
konsultasjon?
Velg kun en av følgende:
 Ja
 Nei
[]Hva mer ville du gjerne hatt av funksjoner og/eller




















Jeg føler meg forstått
av helsepersonellet
Helsepersonellet
uttrykker tillit til min
evne til å gjøre
endringer
Helsepersonellet
oppmuntrer meg til å
stille spørsmål
Helsepersonellet
lytter til hvordan jeg
kunne tenke meg å
gjøre ting
Helsepersonellet
prøver å forstå mitt
syn før de foreslår en




      1 = Helt
uenig
         5 = Helt enig
Vennligst velg passende besvarelse til hvert alternativ:
1    2    3    4    5
Jeg kunne tenke meg å bruke dette systemet ofte
Jeg synes systemet er unødvendig komplisert
Jeg synes systemet er enkelt å bruke
1    2    3    4    5
Jeg skulle gjerne hatt teknisk hjelp for å være i stand til å
bruke systemet
Jeg synes de ulike delene i systemet henger fint sammen
Jeg synes det var for mye uoverensstemmelse mellom de
ulike delene i systemet
Jeg vil tro at de fleste vil kunne lære seg dette systemet
veldig raskt
Jeg synes dette systemet er veldig tungvindt å bruke
Jeg føler at jeg mestrer dette systemet veldig bra
Jeg trenger å lære meg mange flere ting før jeg kan
komme i gang med å bruke systemet
Spørsmål- Empowerment
[]Generelt sett tror jeg at jeg:









jeg ikke er fornøyd
med.
...kan få mine









...kan finne måter å
















uenig Litt enig Svært enig
...vet nok om meg
selv som person
slik at jeg kan ta de
valgene som er




Spørsmål - Trivsel og velvære
[]I de siste to ukene har jeg ...
















Følt meg glad og i
godt humør
Følt meg rolig og
avslappet
Følt meg aktiv og
sterk
Følt meg opplagt og
uthvilt når jeg våkner
Følt at mitt daglige liv
har vært fylt av ting
som interesserer meg
Send undersøkelse.
Takk for at du fullførte denne undersøkelsen.
Appendix I 
Mixed-method: HCP pre-study survey of FullFlow data-
sharing system 
“Spørsmål angående bruk av Full Flow systemet, 2019” 
(Questions about using the FullFlow system, 2019) 
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Tusen takk for at du tok deg tid til å svare! 
Spørsmål angående bruk av Full Flow systemet, 2019 
Rolle: Diabetessykepleier □    Lege □   Annet: _______________ 
1. Tror du dette systemet vil være nyttig som del av
konsultasjonen?
□ Ja    □ Nei   □ Vet ikke       Evt. kommentarer: 
2. Ville du hatt mer eller annen informasjon fra pasientene enn
det systemet ser ut til å kunne gi deg? □ Ja    □ Nei
Hvis ja, skriv litt om hvilken type informasjon du ville hatt:
3. Ville du foretrukket å fjerne noe av den informasjonen
systemet kan vise deg? □ Ja    □ Nei   Hvis ja, spesifiser hvilken:
4. Har du noen kommentarer eller forslag til oss?
Appendix J 
Mixed-method study: HCP questionnaire after each 
consultation 
“FF7 - Spørreskjema etter hver konsultasjon for helsepersonell” 
(Questionnaire after each healthcare consultation) 
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FF7 - Spørreskjema etter hver konsultasjon for
helsepersonell
Til utfylling etter hver konsultasjon der helspersonell
har benyttet FullFlow-systemet.









[]Var informasjonen i Datadelingssystemet nyttig for
deg? (Likert-skala, 5 verdier) 
Velg ett av alternativene






[]Hvilke funksjoner i Datadelingssystemet ble benyttet
under konsultasjonen:
Velg alternativene som passer





 Detaljert visning (grafer og tabeller)
 Alle data i en graf
 Periodevisning (hver datatype i egne grafer over valgt periode)
 Døgnfordeling (hver datatype i egne grafer over 24 timer)
 Sum over tid (sum av hver datatype per dag over valgt periode)
 Liste av data
Annet: 
[]Hvis du krysset av for "Ingen" i forrige spørsmål,
Hvorfor brukte du ikke systemet?
Velg alternativene som passer




[]Hvilke ting ble diskutert under konsultasjonen:
Velg alternativene som passer









[]I hvilken grad bidro informasjonen presentert av
systemet til å kunne gi konkrete anbefalninger og
planer til pasienten, sammenlignet med uten bruk av
systemet?
Velg ett av alternativene
Velg kun en av følgende:
 Ingen grad
 Begrenset grad
 En viss grad
 Stor grad
 Veldig stor grad
[]Etter å ha brukt systemet, forstod du denne
pasientens situasjon bedre?
Velg kun en av følgende:
 Ja
 Nei
[]Har du noen betenkeligheter med å benytte et system
slik som dette?
Velg alternativene som passer






[]Hva mer ville du gjerne hatt av funksjoner og/eller
hvordan ville du endret systemet?
Vennligst skriv her:
Send undersøkelse.
Takk for at du fullførte denne undersøkelsen.
Appendix K 
Identifying qualitative analysis gaps 
“Qualitative evaluations of mHealth interventions: Current gaps and future directions” 
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Qualitative evaluations of mHealth 
interventions: Current gaps and future 
directions  
Meghan BRADWAYa,b, and Kari LEIBOWITZc, Kathleen A. GARRISONd, Lauren 
HOWEe, Eirik ÅRSANDa,f 
aNorwegian Centre for E-Health Research, University Hospital of North Norway 
bDepartment of Clinical Medicine, UiT- The Arctic University of Norway
cDepartment of Psychology, Stanford University 
dDepartment of Psychiatry, Yale School of Medicine 
eDepartment of Business Administration, University of Zurich 
fDepartment of Computer Science, UiT- The Arctic University of Norway 
Abstract. Psycho-social factors are often addressed in behavioral health studies. 
While the purpose of many mHealth interventions is to facilitate behavior change, 
the focus is more prominently on the functionality and usability of the technology 
and less on the psycho-social factors that contribute to behavior change. Here we 
aim to identify the extent to which mHealth interventions for patient self-
management address psychological factors. By understanding users' motivations, 
facilitators, and mindsets, we can better tailor mHealth interventions to promote 
behavior change.  
Keywords Self-management, apps, behavior change, psycho-social factors 
1. Introduction
Mobile health (mHealth) technologies (e.g., smartphone apps or wearables), affect 
patients’ self-management (SM), clinical care, and health research. Especially for those 
with chronic health conditions like diabetes, mHealth enables patients to gather relevant 
data such as information about blood glucose, diet, and physical activity to better 
understand their health and make decisions about diabetes SM. With this knowledge at 
their fingertips, patients are now encouraged to participate in their care by sharing 
mHealth data with their healthcare providers (HCPs). As patients do this, HCPs will need 
to adjust their approach to patient care and guidance, and health researchers need to 
understand how mHealth technologies impact the ways patients and providers work 
together. 
The purpose of most health and mHealth interventions for lifestyle-related health 
issues, e.g. diabetes, is to facilitate health management and, if necessary, behavior change. 
Research on mHealth interventions has focused on user experiences, with some pre-post 
measures of health behavior change, e.g. frequency of blood glucose measurements. 
However, less attention is placed on users’ environments, motivations, or interactions 
with others [1]. Both internal (e.g., self-efficacy, sense of control, mindsets about health) 
and external factors (e.g., social connection, communication, and the patient-provider 
relationship) influence the process of health behavior change. If we do not address these 
factors within mHealth intervention studies, we will not be able to understand the 
comprehensive impact of such technologies.  
We propose that it is critical to design research questions that capture psycho-social 
factors in behavior change. Therefore, we have assessed the prevalence of questions 
related to these concepts in mHealth intervention studies, thereby revealing current gaps 
and future directions. 
2. Methods
We aimed to identify articles that were published after the release of the 2015 Guidance 
for Industry and Food and Drug Administration Staff regarding how to address mHealth 
technologies [2]. These articles would thereby reflect the most updated efforts to assess 
new mHealth technologies, including those that address these new guidelines. We 
reviewed studies published in English between Jan. 1, 2015 and Jan. 18, 2019, describing 
mHealth interventions for patient self-management of WHO’s listed major chronic non-
communicable diseases (NCD) [3], as well as chronic mental illnesses. We searched 
Medline, PubMed, Google Scholar, and ProQuest Research Library for combinations of 
“mobile application” or wearable, and self-management or self-efficacy, and patient. We 
focused on qualitative questions asked in the following methods: study-specific 
questionnaires, interviews, and focus groups. Methods that described the purpose of the 
inquiry, e.g. satisfaction, without listing the questions themselves, were also included. 
Questions asked to both patients and HCPs were then grouped under emergent themes 
and then overarching categories: user experiences and four major psycho-social theories 
of behavior change: behavior change intentions, facilitators/barriers, measures of 
behavior change.   
3. Results
The search resulted in 31 articles. Twenty-four articles included qualitative questions 
(Figure 1).  
Figure 1. PRISMA diagram describing the selection of articles for data synthesis. 
Emergent categories (n=18) were identified, and then grouped under broader categories 
(n=4).  
Table 1. Behavior change categories, sub-categories and example questions identified within qualitative 
methods used in mHealth interventions 
Categories 
[Refs] 




 Experience (n=43) 
 Usability (n=24) 
 App description (n=19)
 Usefulness/efficacy (n=5) 
 Satisfaction (n=8) 
 Suggested improvements  (n=4) 
 Questions described, not listed 
(n=5 articles) 
 What were the main issues/difficulties you 
were facing when using the system? 
 The app had a remind/alert functionality
 Overall, I am satisfied with how easy it is to 
use the App 
 (Nurse) Viewing daily measurements allowed 





[5, 6, 10, 12, 
22-24] 
 SM behaviors or tasks (n=14) 
 General health (n=7)
 General life and habits (n=6) 
 Mood (n=2)
 The Fitbit helps me be more active
 How did you feel this morning when you 
woke up? 
 How healthy do you think your diet is? 
 I often forget pills or take them late 
Behavior 
change 
intentions [4, 5, 
8, 10, 11, 15, 
19, 22, 25, 26] 
 Intentions (n=27)
 Expectations (n=20) 
 Questions described, not listed 
(n=1 article) 
  (Provider) How confident are you that you 
will use the data from HeartMapp for 
decision making on patient care? 
 How likely do you think this app will help you 
lead a healthier lifestyle for better control of 
your diabetes 
 How comfortable would you feel sharing the 
information on this app with a family 




change [4, 6, 
15, 22, 25] 
 Self-efficacy/ autonomy (n=11) 
 Needs were/were not met 
(n=9) 
 App would facilitate control 
over SM (n=3) 
 Motivation (n=2)
 I know what helps me stay motivated to care 
for my diabetes 
 I am able to turn my diabetes goals into a 
workable plan 
 I can ask for support for having and caring for 
my diabetes when I need it 
We identified 204 questions and six articles that did not list their questions but, 
instead, described the topic of their inquiries. User experience was the most represented 
category (n=103 questions in n=13 articles, and n=5 articles addressing this category). 
Other inquiries focused on motivation, goals, and control [22], daily or SM habits [23, 
24], confidence in future use [25] and focus on intention of use [26]. It is important to 
note that articles cited under a category may contain few questions that address that 
category, e.g. Fortuna et al. only included one question that addressed the category 
Facilitators and barriers [4]. Two of the seven articles that used interviews included 
questions that expanded upon previous feedback, e.g. “Anything else?”, “What makes 
you say that?”. While it was most common that patients were the target of inquiries 
(n=192 questions addressed to patients), three studies queried HCPs on satisfaction, 
experiences, and expectations (n=13 questions, n=1 interview).  
4. Discussion
The number of questions related to Behavior change intentions and Facilitators or
barriers to behavior change (n=72), compared to those about User experience and 
Measures of change (n=132), demonstrates the weight of inquiry in research toward the 
latter. While psycho-social factors influence the use of mHealth, this review shows that 
there are relatively few assessments of these forces in mHealth studies. For example, by 
inquiring about motivation as well as intention and external support, studies could 
provide a greater understanding of not just how much something has changed after a 
study, but also why. We need to understand the context, i.e. motivations, facilitators and 
mindsets, to which we are introducing mHealth interventions to understand what makes 
mHealth-use relevant and sustainable. Inherent factors within patients and HCPs, such 
as perceived roles and responsibility within chronic health care, influence how these 
users choose to –or not to- use an mHealth intervention. By including questions that 
address psycho-social factors, in addition to those that measure objective or quantitative 
pre-post factors, we can begin to explain when, how and why users choose to engage 
with mHealth in such ways that do –or do not- lead to sustainable health behavior change. 
5. Conclusion
This review has demonstrated that while the qualitative questions asked in mHealth 
intervention studies do cover essential information, e.g. usability, there is a gap in our 
understanding of how and why users’ choose to use mHealth interventions. By 
leveraging underutilized psycho-social factors, we can better understand the reasons for 
mHealth-use and study outcomes. Future studies could then tailor interventions to 
address end-user needs and more effectively optimize these technologies to facilitate 
health behavior change.   
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Discussion Guide (Patients) 
Full Flow Study-end Focus group 
Spring 2020 
Time Activities or visual aids etc. 
12h Introduction (over lunch) 
15-
20 
 Meet participants in the reception
 Corona forhåndsregler: no hand-shake, hand wash, toilets
 Confidentiality and consent forms, parking slips
 12h-15h, Audio recorded
 Coffee and tea available outside + ice cream (if hypos)
 Introductions, ice-breaker!
 Honest responses :D
 45 min sessions
a. How you chose to (or not) use the app Diabetesdagboka
b. Experiences during the consultation with your
healthcare provider after sharing your data
c. Impressions of the data-sharing system
d. Improvements that should be made
 10 minute breaks
 Travel, reimbursement etc.
 Explain briefly how a Focus group meeting works
- FOOD + Audio recorder
- Put up all posters (tape)
- Agenda (main titles on
power-point)
- Coins or something else
for ice-breaker
I. We will start by getting to know how you used the app on your own – what were your priorities
and how you chose to use it. 
- Underline that reasons for NOT using the system is as important!
- RELATE TO POSTER (R2P)
- Introduce the big screen posters at the front of the room and ask them to show and tell!
Instruct: Initials - Yellow (used), green (liked), red (didn’t like) 
(If they are shy, we can mark/draw for them) 
15-
20 
1. Who of you used the app, and for how long? Why or why
not did you use the app for your self-management?
- For Q1 Why did you use
the app, Q2 and Q3. Per





- Meghan makes notes
about who says what
with initial first
2. How did you use the app?
a. If not, why?
3. Describe situations in which using the app was helpful or
frustrating? Please explain.
4. Did the possibility of sharing your data change how you
gathered data and what data you gathered? (how often,
how careful your measurements were, added notes with
your measurements etc.)
a. If you didn’t use the app very much- did being in
the study change your self-management or
anything else related to your diabetes health?
II. Now we will talk about what it was like to share your data (or not) and how the conversation
with your doctor went 
- R2P
- Introduce the big screen posters at the front of the room of the patient and doctor together
(blank screen)! 
10 
5. Think about a time BEFORE this study you had a really
successful conversation with your doctor (before sharing
your data). What happened in that interaction?
- Meghan/Per put key
words in the speech
bubbles on the posters
(if possible) or noted in
the powerpoint
10 min Break (12:50) 
45 
6. Who of you shared your data during the consultation? If
not, why not? What were your intentions or hopes for
sharing your data?
7. Before you went to the consultation, how did you expect
sharing your data would or would not help?
a. Follow-up: help yourself, help the doctor, help the
discussion





- Meghan makes notes
about who says what
with initial first
- R2P
- Introduce the big screen posters at the front of the room of the patient and doctor
together (FullFlow system)! 
8. Recall when you shared your data during the consultation- 
can you describe how the conversation progressed?
a. If needed: what did you want to focus on, what
questions did the doctor ask you, what
information did the doctor bring up, e.g. lab
results
b. Ask if they sat on same side of table- eirik wants
this for idea of “collaborating”
- Meghan/ Per put key
words in the speech
bubbles on the posters
(if possible) or noted in
the powerpoint
9. Please explain how you felt when you shared your data
during the consultation.
a. If needed: e.g. did using the system make you feel
anxious, comforted, etc. confident, engaged?)
- For Q11 and 13. Per





- Meghan makes notes
about who says what
with initial first
10. Was it easier for you to explain your situation (self-
management, priorities, etc.) to your doctor when using the
system?
11. Did you receive all of the feedback based on your shared
data, that you hoped for from your doctor?
a. Follow-up: How do you wish your doctor could
have used your shared data?
12. Did using the system with your HCP change how you self-
managed?
a. If yes, How?
b. If no, why not?
13. Ideally, how would you want your HCP to receive/use your
data? And how to use the system in future consultations?
10 min Break (13:45) 
III. We would also like to know your practical experience with the system and sharing your data
during the consultation 
- R2P
- Instruct to take some minutes to go up to the print outs of the system screens and mark with
yellow, red and green what was used, didn’t like and liked 
- (If they are shy, we can mark/draw for them)
30 
14. During the consultation, was the data or information
presenting on the screen relevant to you?
- For Q16. Per types key




- Meghan makes notes
about who says what
with initial first
15. Was it easy to understand what was presented on the
screen when you shared your data?
16. What was/were the most useful functions/features? What
was the least useful/helpful?
17. Did the system help you to understand your diabetes
health better?
18. How do you think this kind of system would affect medical
services?
a. Follow-up or if needed: would it change how you
use medical services?
- Only if time and if they
seem to have some
good ideas
IV. Can you think of anything that helped you use the app and/or system, or made it difficult?
19. Did anything encourage you to use the app and/or system?
a. If needed: e.g. Family/friends, automatic
reminders, routines that you made?





- Meghan makes notes




20. What aspects of your daily life made it difficult to use the
app and/or system?
a. If needed: e.g., too busy, forgot?
21. Do you need support to collect and share data? (in the
most effective way? To be successful?)
a. If needed: e.g. Training, family/friends, support
services, encouragement from your doctors?
5 min Break (14:25/30) 
V. Finally, we would like to know what you think about any improvements that could be made
- R2P (if they want)
- Instruct: if you wish (or if we need clarification) spend some minutes drawing in blue marker on
ANY poster, any improvements you may have 
22. (about the system they have been exposed to) Open-
ended questions about what improvements should be
made; pros and cons about the system
a. If needed: specific potential facilitators, such as
reminders, triggers to schedule an appointment,
video visits, text messages, emails, chat, etc.





- Meghan makes notes
about who says what
with initial first
23. (things that could facilitate effective use, surrounding or
within the app/system) If you could wave a magic wand and
create anything in or around the app/system to make it
easier to use the system with your doctor, what would you 
change? 
a. Clarify if no response: not only about the system
itself but support to use it, e.g. reminders from
your doctor to collect and share your data, maybe
connect to your appointment reminder (requires
more integration/interoperability)
VI. Wrapping up
- Any forms that need to be filled out
- Travel, reimbursement etc.
10 
Thank you – how their input is valuable 
Filling out reimbursement forms etc. 
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Discussion Guide (HCPs) 
FullFlow Feasibility Study-End Focus Group 
Spring 2020 
Time Activities or visual aids etc. 
Introduction (over lunch or after lunch?) 
15-20 
1. Welcome and summary of why we are here
(state our honest transparent intentions:
we know that this is not the perfect system,
but this is a way of starting to gather
information and knowledge about how
these should be made in the future so
please give us your honest feedback)
2. remind of their own app and FF system
3. Give everyone some time to grab lunch
4. Go through the agenda so that everyone
knows what to expect
a. Main headings (as seen in the headings
below)
b. 45min sessions then 10min break
5. Round of introductions
Ice breaker (if necessary and have time)
- FOOD
- Agenda (main titles on power-point or
printed)
- Coins or something else for ice-
breaker
- Give people numbers to write on their
paper poster and the order when
speaking so that we can keep track (or
Meghan keeps track)
I. We want to know how you usually meet your patients
10 
1. Think about a time you had a really
successful conversation with your patient
(before using this system).
a. What happened in that interaction?
- Researcher to write down aspects of a
good consultation (have a section of
the wall with this so that we can
reference and compare it to how the
system was used to SEE visually
where we could improve)
- Perhaps: Unbiased opinions first and
then say “patients said X” on high
level and then have them
comment/reflect
II. When you used the system, how was your experience?
10-15 
2. Who of you reviewed patient-gathered
data using the tested system, during the
consultation?
a. If not, why not?
b. What were your intentions or hopes for
receiving patient-shared data in this
way?
3. Did you believe that this would help the
consultation and discussion with your
patients?
10 min Break 
20 
4. (prompt them: we want to focus on your
experience here and then we will talk about
the functionalities and system itself in the
next section) Recall when you used the
system - can you describe how the
conversation progressed?
a. If needed: e.g. what did you want to
focus on, what questions did the
patient ask you, what more information
did you need in addition to that
presented by the system up, e.g. lab
results, to provide feedback to your
patient?
- Print outs of the screens or
characters, figures so that they could
interact with something while telling
their experience
5. Please explain how you felt using the
system:
a. were you confident in its functions and
your ability to use it, was it frustrating?
b. Did you feel motivated to review and
give feedback based on the shared
data?
III. We would also like to know what you thought about the system itself
25 
6. Did the system present data or information
that was relevant to you?
- Own-print outs so they can mark for
themselves (yellow highlighter to
illustrate what was used and a green
highlighter for what you did like and
red for not like)
- Large print outs of the screens so that
participants can interact with them
while they explain their experiences,
what they liked/didn’t like etc. (don’t
mark the big ones until the
“improvements section”)
- Perhaps: Unbiased opinions first and
then say “patients said X” on high
level and then have them comment
7. Was it easy to understand what was
presented by the system?
8. What was/were the most useful
functions/features? What was the least
useful/helpful?
9. How do you think this kind of system would
affect medical services?
a. E.g. would it change how you
practice/your workflow etc.? EHR or
the way you meet the patient?
- Perhaps: Unbiased opinions first and
then say “patients said X” on high
level and then have them comment
10min Break 
IV. What, if anything, did you learn?
V. How did you use that understanding to help your patient?
10. Did the system help you to understand your
patients' health/self-management progress
better?
- Print out representations of patient
self-management and post it on the
wall (we put it on the wall) next to a
a. If needed: Do you learn anything more
about your patient's priorities, health,
self-management by looking more
detailed into the patient's own
gathered data?
picture of the patient when they 
mention what they learned about 
their patient (give them the option of 
posting it too)  
11. Did you receive all of the data that you had
hoped for from your patient?
a. Did you receive enough data to provide
feedback to your patient?
12. Did using the system help you provide
feedback or make decisions about their
health?
a. If yes, how?
b. If not, why not?
- Write around the patient what kind of
feedback was given
- Perhaps: Unbiased opinions first and
then say “patients said X” on high
level and then have them comment
10 min break 
VI. Can you think of anything that helped or discouraged you to use the system?
20 
13. Did anyone or anything encourage you to
use the system?
a. If needed: was there anything in the
time that we are living now, affect why
they decided to use the system, e.g. all
of the different mHealth sensors and
apps out there or media, or your
patients have brought data before/or
asked for it before)
- Write on post-its or printed out
images of things and post it around
the large print-outs on the wall (green
for things that helped and red for
things that discouraged)
14. Were there any aspects of your daily life
and practice that discouraged your use of
the system?
a. If needed: What aspects of your clinical
practice, standards or job expectations
made it difficult to use the app and/or
system? (e.g., too busy, forgot, too
time consuming)?
15. Ideally, how do you want to use the data
that patients share through the system?
a. Idealy, how do you want you and your
patient to use the data-sharing system
together in future consultations?
16. Do you need support to use the system and
data that patients share?
a. For example, training or guidelines?
VII. Finally, we would like to know what you think about any improvements that could be made
30 
17. Open-ended questions about what
improvements should be made;
a. pros and cons about the system
b. specific potential facilitators, such as
reminders, triggers to schedule an
- Give them some minutes to write or
brainstorm and then either they or
one of us write their feedback on the
large print-outs what they think could
be improved
appointment, video visits, text 
messages, emails, chat, other 
information that should be presented 
to be useful  
- Sketching or paper prototypes what
they would change if they want
- Perhaps: Unbiased opinions first and
then say “patients said X” on high
level and then have them comment
18. If you could wave a magic wand and create
anything in or around the app/system to
make it easier to use the system with your
patient (as you describe above), what
would you change?
a. What would help you to use the system
more efficiently/effectively/ or support
to use the system at all?
b. Think of external things – outside the
system, that would help: e.g. Training,
support services, encouragement from
your superiors?
- Have post-its or paper to post on the
wall when they mention a support
service that could help (perhaps the
researchers do this as the patients
talk about it)
- Perhaps: Unbiased opinions first and
then say “patients said X” on high
level and then have them comment
VIII. Wrapping up
10 
Thank you – how their input is valuable - Any forms to be filled out
Filling out reimbursement forms etc. 
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The need for updated evaluation approaches 
for e-health and m-health interventions - 
a dynamic concept for more efficient trials
Eirik Årsand1,2, Håvard Blixgård1, Miroslav Muzny1,3, Alain Giordanengo1,4, Meghan Bradway1,2
1Norwegian Centre for E-health Research, University Hospital of North Norway (UNN), Tromsø, Norway
2UiT – The Arctic University of Norway, Department of Clinical Medicine, Tromsø, Norway
3Fakulty of Biomedical Engineering, Czech Technical University in Prague, Czech Republic
4UiT – The Arctic University of Norway, Department of Computer Science, Tromsø, Norway
Background
Clinical trials are notorious for falling behind 
schedule and over budget. In fact, nearly 90% 
of clinical trials fail to reach intended outcomes 
on time. Today, mobile health (m-health) tech-
nologies, e.g. apps for diabetes self- 
management, provide additional challenges by 
developing faster than clinical trials are able 
to evaluate them. Therefore, approaches to 
assess m-health self-management interven-
tions, especially randomized controlled trials, 
must adapt. 
Results
An electronic study-management concept was 
developed. Modules with functionalities  
specific to major trial stages (Figure 1), several 
of which have been separately tested with 
success, facilitate a new holistic system for 
evaluation of e-health and m-health trials. The 
concept is acknowledged by Datatilsynet and 
REK (ref. 2013/1906/REK sør-øst B), and is 
currently under test as part of the “Tailoring 
Type 2 Diabetes Self-Management” project.
Figure 1. Visual representation of the elements in the proposed e-health and m-health research evaluation concept.
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A review of traditional e-health and m-health 
assessment studies revealed that tested inter-
ventions were often outdated by the time trials 
ended, thus reducing their quality and potential 
impact. Major bottlenecks were identified and 
a holistic platform for electronically supporting 
study management was proposed. Specific 
technological functionalities were designed 
through collaboration between researchers, 
patients, medical experts, and improved 
through consultation with our hospital’s 
research unit, the regional ethical board (REK) 
and Norwegian Data Protection Authority 
(Datatilsynet).
Conclusion
We expect this concept to enable researchers 
to more efficiently handle the administra-
tional-, patient-, and data-related tasks of 
m-health and e-health interventions. By
utilizing this concept in an ongoing clinical
trial, we will demonstrate the potential of eval-
uating m-health technologies as disease and
self-management treatment interventions.
Appendix O 
Mixed-method study: HCP pre-study survey results and 
Experience with study-admin platform  
 “Healthcare Personnel’s’ Expectations of a System for Sharing and Using Patient-gathered Data” 
(pg. A-148) 
“Lessons Learned From Using a Remote Study-Management Platform: Use in an mHealth Diabetes 
Study” (pg. A-149) 
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HEALTHCARE PERSONNEL’S EXPECTATIONS
OF A SYSTEM FOR SHARING AND USING PATIENT-
GATHERED DATA
INFORMATICS IN THE SERVICE OF MEDICINE;
TELEMEDICINE, SOFTWARE AND OTHER
TECHNOLOGIES
E. Årsand1, M. Bradway1, A. Giordanengo1,
A.H. Hansen2, G. Hartvigsen3
1University Hospital of North Norway, Norwegian Center
For E-health Research, Tromsø, Norway, 2University Hospital
of North Norway, Centre For Quality Improvement
And Development, Tromsø, Norway, 3UiT - The Arctic University
of Norway, Department Of Informatics, Tromsø, Norway
Background and Aims: Personal health-sensors and devices
are quickly entering the marked, answering the needs of people
with diabetes’ self-management. This has led to an increasing
amount of patient-gathered health data, which we foresee will be
important in meetings between healthcare personnel and pa-
tients. Building on the previous FI-STAR project, we address this
issue in the current FullFlow project.
Methods: Prior to testing an in-house developed system that
allows people with diabetes to share their self-gathered data
during consultations, we queried healthcare personnel (n = 17; 12
GPs, 4 nurses, and 1 nutritionist) about their perceptions of, and
suggestions for, the proposed system.
Results: All the healthcare personnel informants reported that
they expected the designed system to be useful during consultations.
Ten of them gave specific suggestions about how they expected the
system to function, including: 1) possibilities for remote consulta-
tions; 2) support for keeping track of types of carbohydrates, not
only amount; 3) support for keeping track of lipid levels; 4) auto-
matic data transfer from apps, e.g. Strava, and devices, e.g. glucose
meters and insulin pens; 5) support for all kinds of mobile phones; 6)
integration of this system’s functions with electronic health record
systems; 7) highlighting changes since last consultation; 8) transfer
of consultation notes and hospital system information into the pa-
tients’ app to provide them with tailored recommendations for
follow-up at the next consultation.
Conclusions: Healthcare personnel are positive to a system
for using patient-gathered data, and they contribute with creative
and specific suggestions for how such systems should work.
431 / Abstract ID 955
THE TELECONSULTATION AS AN EXPERIMENTAL
EXCHANGE OF INFORMATION BETWEEN GENERAL
PRACTITIONERS AND HOSPITAL SPECIALISTS
INFORMATICS IN THE SERVICE OF MEDICINE;
TELEMEDICINE, SOFTWARE AND OTHER
TECHNOLOGIES
C. Baggiore1, F. Manetti1, A. De Bellis1, F. Falciani2,
P. Zoppi3, B. Lazzari4, E. Croppi5, S. Michelagnoli6, N. Troisi7,
R. Lombardi7, F. Turini7
1Azienda Sanitaria USL Toscana Centro, Soc Diabetologia,
Firenze, Italy, 2Azienda Sanitaria USL Toscana Centro,
Osservatorio Lesioni Cutanee, Firenze, Italy, 3Azienda
Sanitaria USL Toscana Centro, Dipartimento Assistenza
Infermieristica, Firenze, Italy, 4Azienda Sanitaria USL Toscana
Centro, Tecnologie Informatiche, Firenze, Italy, 5Azienda
Sanitaria USL Toscana Centro, Medicina Generale, Firenze,
Italy, 6Azienda Sanitaria USL Toscana Centro, Dipartimento
Chirurgico, Firenze, Italy, 7Azienda Sanitaria USL Toscana
Centro, Soc Chirurgia Vascolare, Firenze, Italy
Background and Aims: People with diabetes have a 15–25%
risk of developing a foot ulcer during their lifetime. In Tuscany,
out of an estimated population of over 100,000 diabetics there is
an expected incidence of 2,000 new diabetic ulcers per year. In
order to create a timely and better management of the patient
suffering from skin lesions on the lower limbs, it is essential to
promote synergy and communicative interaction between health
professionals in the area and those in the hospital.
Methods: Starting from June 2019, a teleconsultation project
between the Department of General Medicine and the Foot Clinic
of the San Giovanni di Dio Hospital in Florence will be tested
within the northwest area of the Vast Tuscany Center Area.
Results: Through the web telemedicine platform, GPs will be
able to transmit requests for advice, images of skin lesions, rel-
evant clinical information and the patient summary of subjects at
risk . The teleconsultation service will send to the Foot Clinic
specialist chosen by the GP, a notification on their mobile phone
with the aim of reducing response times to a minimum.
Conclusions: The immediacy of the exchange of clinical in-
formation between GPs and hospital specialists allows the cre-
ation of an integrated management model based on the centrality
of the person. Sending the report of the specialist visit directly to
the GP through web platform, allows to eliminate misunder-
standings and facilitates the continuity of assistance, producing
in the end a greater participation of the patient in the care process.
432 / Abstract ID 790
A COMBINED BIOFEEDBACK-VIRTUAL REALITY
SMARTPHONE APPLICATION TO COPE WITH FEAR
OF HYPOGLYCEMIA
INFORMATICS IN THE SERVICE OF MEDICINE;
TELEMEDICINE, SOFTWARE AND OTHER
TECHNOLOGIES
A. Bezalel1, S. Shiri2, U. Feintuch3, K. Bashan1,
M. Schechter1, O. Mosenzon1
1Hadassah Hebrew University Hospital, Clinical Research
Center, Diabetes Unit, Ein Kerem, Jerusalem, Israel,
2Hadassah University Hospital – Mount Scopus, Department
Of Physical & Medical Rehabilitation, Jerusalem, Israel,
3Lomdim Latzon Enterprises, Research Department, Jerusalem,
Israel
Background and Aims: Fear of hypoglycemia (FOH) refers
to phobic avoidance reactions associated with hypoglycemia.
FOH is associated with poor glycemic control and its conse-
quences, necessitating the development of effective methods to
address this condition. We present a pilot study, combining bio-
feedback (BF) with a virtual reality (VR) smartphone application.
Methods: Patients with type 1 diabetes suffering from FOH as
evaluated by the ‘‘Hypoglycemia Fear Survey-II’’ questionnaire
[composed of two subscales; Behaviors (HFS-B) and Worries
(HFS-W)] were randomly assigned to either treatment with BF or
BF+VR. All participants were instructed to use a smartphone ap-
plication daily for two weeks. They were exposed to virtual stimuli:
mild low glucometer readings (85–125) and practiced reducing
their physiological arousal using a galvanic skin response (GSR)
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biofeedback system. In the BF+VR arm successful relaxation was
reinforced by exposure to their own virtual smile; this stimulus has
the potential of activating brain reward mechanisms. Primary
outcome was defined as the change in the HFS-Worries scale.
Results: Five participants were recruited and randomly as-
signed to receive BF+VR (n = 3) or BF alone (n = 2). Participants
demonstrated a significant improvement in their HFS score
(an average reduction of 7.4 points from a baseline of 83.4), mostly
attributed to a reduction in the HFS-Worries subscale (5.8 points).
This improvement was durable for a 2 month period. There was no
clear trend towards superiority of the BF+VR over BF alone.
Conclusions: The results of this feasibility study, using a
smartphone-based virtual reality application to treat FOH, call
for a larger randomized controlled trial.
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INTERVENTION STUDIES NEED TO ADAPT
TO ADDRESS PATIENT NEEDS FOR DIABETES
SELF-MANAGEMENT
INFORMATICS IN THE SERVICE OF MEDICINE;
TELEMEDICINE, SOFTWARE AND OTHER
TECHNOLOGIES
M. Bradway1,2, D. Larbi1, P. Randine1,3, K. Antypas1,4,
E. Gabarron1,5, E. Årsand1,2
1University Hospital of North Norway, Norwegian Center
For E-health Research, Tromsø, Norway, 2University
of Tromsø - The Arctic University of Norway, Department
Of Clinical Medicine, Tromsø, Norway, 3University
of Tromsø – The Arctic University of Norway, Department
Of Computer Science, Tromsø, Norway, 4SINTEF, Health
Research, Oslo, Norway, 5UiT - The Arctic University
of Norway, Department Of Psychology, Tromsø, Norway
Background and Aims: Research on health technologies
traditionally report clinical measures. However, with mHealth
and online resources for diabetes self-management, individuals
are calling for more, diverse evidence. We compare two reviews
to determine to what extent mHealth and online intervention
studies address patient-reported needs.
Methods: A systematic review (Review 1) searched for reported
outcomes of mHealth and online intervention studies (PROSPERO
registration: CRD42018115246). A literature review (Review 2)
searched for patient-reported needs for diabetes self-management.
Both covered articles published between 2015 and 2019. For ease of
comparison, the co-authors categorized the results.
Results: Reviews 1 and 2 resulted in n = 31 and n = 21 arti-
cles, respectively. Main categories of reported outcomes were:
support from/access to resources, usability/suitability, patient
empowerment/engagement, clinical outcomes, and data protec-
tion. Main needs categories were: support/access to services, in-
formation, coping and patient engagement/empowerment, and
technology. Thus, the research outcomes and patient needs
were in general very different. For example, under the category
support/access to services, reported intervention outcomes in-
cluded peers, coordinated-care services and relevant informa-
tion. However, specific patient-reported needs included resources
and services to self-management activities, e.g. gyms, feedback
on self-management performance and reminders.
Conclusions: A reason for these differences is that research
interventions occur within closed and controllable systems,
whereas patient-reported needs result from experience in the
real-world, with a multitude of resources. Future interventions
can address this by include more contextual information, e.g.
about participants’ access to resources, as baseline measures. In
doing so, we can provide evidence of the relationship that these
resources have on the success of the intervention.
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LESSONS LEARNED FROM USING A REMOTE
STUDY-MANAGEMENT PLATFORM: USE IN AN
MHEALTH DIABETES STUDY
INFORMATICS IN THE SERVICE OF MEDICINE;
TELEMEDICINE, SOFTWARE AND OTHER
TECHNOLOGIES
M. Bradway1,2, P. Randine1,3, E. Årsand1,2
1University Hospital of North Norway, Norwegian Center
For E-health Research, Tromsø, Norway, 2University
of Tromsø - The Arctic University of Norway, Department
Of Clinical Medicine, Tromsø, Norway, 3University
of Tromsø – The Arctic University of Norway, Department
Of Computer Science, Tromsø, Norway
Background and Aims: The use of an online study-man-
agement system can help to ease the burden of both participation
in, and administration of, mHealth interventions. We describe the
benefits and challenges of using such a platform to manage an
intervention (FullFlow Project) involving both patients and their
providers in the testing of an mHealth data-sharing system.
Methods: Our remote study-management platform consists
of: a website used to monitor status and message the participants,
a local server for automatic data-collection and analysis (Piwik,
now Matomo) and an open source survey tool (LimeSurvey).
Patient recruitment was initiated through health providers and
continued through the platform. Two researchers and one de-
veloper administrated the study.
Results: The benefits of this platform included security and
efficiency in distributing study-information and messages, as well as
supporting participants from a single platform, based on open-source
systems. For example, if a participant was not actively engaged in
the intervention, we could then send messages specific to their sit-
uation. In the platforms’ current implementation, we have experi-
enced three main challenges: 1-Participant follow-up requires
manual tracking and initiation of messaging; 2-Data-collection re-
quires manual review of data and interaction logs, from separate
sources; and 3-Data-analysis requires specific programming to
combine the differently structured output from each data source.
Conclusions: Future improvements to the system can include
automation of tasks and additional software that can facilitate the
organization of these data for analysis. For example, automatic
merging of data-sources and generation of simple reports would
make the system more efficient, which is especially important for
mHealth interventions.
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ONTOLOGY-BASED MODELING OF MEDICAL
PROFILES OF DIABETIC PATIENTS
INFORMATICS IN THE SERVICE OF MEDICINE;
TELEMEDICINE, SOFTWARE AND OTHER
TECHNOLOGIES
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Abstract 
Clinicians now insist that health authorities and researchers 
provide practical evidence and strategies for reacting to and 
handling patient-gathered data (PGD) and mobile health 
(mHealth) devices. With diabetes as a use-case, we present a 
summary of our own studies and a narrative scientific literature 
review to exemplify the progress of clinicians’ perceptions of 
mHealth. We then compare these results to a narrative review 
of official clinical practice guidelines related to mHealth use 
(2013-2017) to demonstrate similarities and differences 
between what clinicians perceive as opportunities for mHealth 
and what health authorities are providing. Review of mHealth 
studies revealed that clinicians have become more willing to 
accept mHealth technologies and use patient-generated data 
over time. However, review of clinical practice guidelines 
revealed several barriers to using mHealth in clinical practice. 
Results of this comparison indicate 1) the need for a balance of 
clinician and patient participation and feedback during 
mHealth studies, and 2) health authorities’ lack of sufficient 
guidance to clinicians for practically using mHealth in their 
daily practice.  
Keywords: 
Clinicians, Diabetes, Mobile Health, mHealth, mDiabetes, 
Consultation. 
Introduction 
Traditionally, medical devices for diabetes self-management 
and treatment were validated by health authorities. As such, 
clinicians were provided with structured guidelines and 
protocols for how to instruct their patients to use such 
technologies and relate to the subsequent gathered data. More 
and more commonly patient-operated mobile health (mHealth) 
tools enable patients to become more knowledgeable of their 
own health challenges and more in control of treatment 
priorities by providing them the means to better understand 
their own disease. As such, the novelties of mHealth throw a 
completely different spin on the priorities of patient care; 
clinicians are now expected to adapt not only to patients’ new 
capacity to self-manage but also analyze larger patient-
generated data sets.  
Considering the lack of validation and testing within clinical 
settings, it is understandable that many medical personnel are 
concerned with various factors surrounding the clinical 
integration of e.g. mHealth apps [1]. Furthermore, because 
most often apps are designed for use by patients only, and not 
clinicians [2], initial evaluation studies within the medical 
realm focused upon answering questions relevant to individual 
patient users and not medical practice [3, 4]. Only until more 
recently was the concept of medical integration and evaluation 
considered [5]. Thus, medical personnel are now reacting to 
changes within two different environments: 1) the rapid 
increase of patient-centered mHealth, for example mobile 
diabetes (mDiabetes) tools, within the commercial sector as 
well as 2) pressures from patients to integrate such technologies 
within the medical sector. 
The purpose of this paper is to identify the change in clinicians’ 
perceptions related to mHealth between 2013 and 2017. By 
comparing this progress to the guidelines provided by regional 
and national health authorities, e.g. government agencies and 
those who create medical standards, we identify and emphasize 
the lack of necessary support for clinicians as well as the 
importance of including them in the planning and 
implementation of mHealth within clinical practices. This is 
especially important in primary health care, where research 
activities and partnerships with general practitioners’ (GPs’) 
offices are not as common as they are amongst health care 
personnel at hospitals. 
Methods 
Three narrative reviews were conducted. The first two were of 
health research literature, published between 2013 and 2017, 
that described mHealth interventions in which patient-gathered 
data were shared with clinicians. These were then compared to 
the third, which was a review of best practice recommendations 
produced by healthcare authorities, during the same period, 
regarding how clinicians should use patient-gathered mHealth 
data.  
The first review was of mHealth interventions completed at our 
own University Hospital of North Norway’s (UNN) Norwegian 
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Centre for E-health Research (NSE). These activities began 
with the REgioNs of Europe WorkING together for HEALTH 
(RENEWING HEALTH) Norwegian Pilot study (2013) [6, 7] 
in which individuals with Type 2 Diabetes were encouraged to 
discuss their use of an mHealth app for diabetes self-
management, called the Few Touch Application (FTA), during 
consultations. During the 2014 annual Diabetes Research 
Conference in Oslo, Norway, we surveyed clinicians about 
their perceptions of a “clinician interface” of the patient-
operated Diabetes Diary smartphone app. The next study that 
was conducted, concerning clinicians’ use and relation to 
mHealth, was the Norwegian diabetes pilot of the international 
FI-STAR study [8]. Two GP’s and a specialist participated in a 
clinician workshop in October 2016 to reflect upon what is 
needed to share patient-gathered mHealth data during 
consultations. In 2017 we invited patients and clinicians to 
participate in a co-design workshop, in both peer and joint 
sessions, to design their ideal mHealth data-sharing system, and 
indicate their preparedness for relating to mHealth. Workshops 
were audio-recorded, transcribed and translated into English.  
To contextualize our own reports, we conducted a second 
narrative review of literature describing clinicians’ perceptions 
of mHealth and patient-gathered data reported from similar 
studies within Europe and America. PubMed and Google 
Scholar were used to search scientific literature produced 
between 2013 and 2017. The following search strategy was 
used for PubMed: clinician, practitioner, provider, or nurse 
AND barriers, concern, motivations, perspective, opinion, 
viewpoint or outlooks AND apps, mHealth, mobile health, 
wearables, or sensors. The following search strategy was used 
for Google Scholar: combinations of clinician, practitioner, 
provider, or nurse AND apps, mHealth, mobile health, 
wearables, or sensors. Resulting articles were exported to the 
Systematic Reviews web app, Rayyan [9], for sorting and 
selection. Analysis included screening for reports of clinicians’ 
firsthand experience with mHealth data presented by patients 
during clinical interventions. Author MB collected and 
reviewed the full-text of the publications, where data extraction 
included clinicians’ perceptions of using mHealth in clinical 
practice, which were categorized as either perceived benefits or 
barriers. Benefits can be seen as clinicians’ willingness to use 
mHealth, while concerns and needs represent the uncertainty 
toward using mHealth that needs to be resolved. Inclusion 
criteria were that literature must i) be published between 2013-
2017 in English, ii) describe patient-operated mobile apps as 
part of the intervention, iii) describe studies included inquiry 
and reported responses of health care providers within America 
or Europe. Publications were excluded if i) they did not survey 
health care providers as part of the study, if ii) no abstract was 
found to support initial review processes, if iii) it only included 
“medical devices” [10], if iv) the intervention primarily 
provided basic mobile phone functions, e.g. SMS, from health 
providers for patient self-management.  
• The third review was of official recommendations produced
by health authorities related to how healthcare practitioners
should react to, or use patients’ own-gathered mHealth data
or tools during consultations. Guidelines were searched for in
European, Norwegian and American health authorities’
websites including The World Health Organization (WHO),
the European Commission (EU), Health Care Information
and Management Systems Society (HIMSS), and the
Norwegian Health Directorate, using versions of the
following terms: “clinical practice guidelines”,
recommendations AND Europe, Norway, America AND 
mHealth, mobile health, apps. Analysis included screening 
for any recommendations related to how clinicians 
themselves should react to and\or use patient-gathered data 
and mobile health technologies in daily clinical practice. This 
did not include recommendations for health facility managers 
or security systems. Data extraction included 
recommendations for how clinicians could relate to mHealth 
during consultations. These recommendations were then 
compared to the clinicians’ needs to relate to, as presented in 
the previous two narrative reviews. Inclusion criteria were as 
follows: must mention daily medical activities performed by 
health professionals related to patient-operated mHealth 
technologies or their self-gathered data. Guidelines must also 
be published open-access between 2013-2017 within 
governmental, health authorities’ and/or organizational 
reports. In focusing on publically available documents, we 
stress the importance of ease of access and use of these 
clinical practice guidelines for health care personnel 
themselves. Documents were disregarded if they i) provided 
no recommendations directly to health care practitioners for 
mHealth-use, ii) Only described design and/or evaluation 
guidelines for mHealth interventions studies, iii) Merely 
commented on issues related to mHealth-use during clinical 
practice, without direct input from clinicians themselves, iv) 
Only described appropriate use of clinicians’ own mobile 
device during working hours.  
Results 
First, we summarized the clinician-related responses to 
mHealth interventions for our research activities, annually 
between 2013 and 2017. Table 1 summarizes the results related 
to clinicians’ perceptions of the mHealth tools that were 
presented to them, both from previously published and 
unpublished (UP) reports from our studies.  
Table 1- Own research: clinicians’ perceptions related to use 
of mHealth tools and patient-gathered data (PGD) 
Ref. Benefits Concerns and needs 
2013 
UP 






• Unclear financing (n=12/23)






• Better preparations of
consultations 
(n=15/15)









• Clinicians would need more
“direct experience”








of the patient situation




• Not all patients present data,






• Easier to present PGD
• Eager to discuss app
data as graphs and
trends
• Patients reflect on data
• Patients can and should
take initiative during
consults
• Must operate with existing
medical technology
• Data can be “noisy”
• Patients need intensive
training about how to
collect data for medical
purposes
• Not all patients present data
2017 
[13] 
• Can base discussion
and advice on
personalized data
• Result in more concrete
discussions
• Patients can become




• Patients don’t always
present their data
• Must be easy to collect data
• Chance of data overload
• Could be too time
consuming
• Clinicians still need to learn
more about mHealth tools
Second, we summarize results of both narrative literature 
reviews of mHealth intervention studies and official clinical 
practice guidelines in order to contextualize our own findings 
and gain a greater understanding of the overall needs expressed 
by clinicians within the evolving field of mHealth.  
The keyword searches in PubMed and Google Scholar results 
in 71 and 64 results, respectively. Initial review of titles and 
abstracts was based upon the inclusion criteria as described in 
the Methods section. 129 publications were excluded because 
medical practitioners were not directly surveyed and/or because 
the intervention did not involve patient-operated mHealth tools, 
leaving only 6 publications for full-text review (see Figure 1). 
Responses were then separated into benefits and barriers for 
relating to mHealth tools during clinical practice (see Table 2). 
Figure 1- PRISMA flow diagram describing selection of 
scientific literature for review 
Three of the reviewed publications reported clinicians’ 
perspectives on the potential use of mHealth in general, while 
the remaining three papers reported clinicians’ perspectives of 
a presented or tested mHealth system. The paper by Bonilla et 
al. [14] reported percentages of respondents’ perceptions for 
each question, which allowed the authors of this paper to 
highlight how clinicians’ perceptions differed between certain 
benefits and barriers. Table 2 summarizes the overall results of 
these six publications, ordered by publication year. 
Table 2- Scientific literature search results: clinicians’ 
perceptions related to use of mHealth tools and patient-
gathered data (PGD). 
Ref. Benefits Concerns and needs 
2013 
[15] 
• Simple to use




• React to problems in
real time
• Rapid technology progress
• Unclear impacts of technology
• Content/data overload
• Too time consuming










• Increased amount of
valuable data
• Cost
• Time consuming to operate
• Validity of applications
• Reliability of patient-provided
data
• Risk of misinterpretation
• Safety/privacy
 [16] 












• Lack of direct view of patient
data
• Limited data flow and
interoperability
• Limited functionalities for
follow-up 
• Technology limited to specific
device
• Competition with traditional
care
Results from review of clinical practice recommendations 
2016 
[17] 
• More possibilities for
teaching patients







• Limited data flow interop.
• Time consuming
• Tech. integration would
compete with other
priorities
• No guidelines for handling
sensitive information
 [18] 






• Must be endorsed by
experts
• Discomfort using electronic
communication with patient











N=16 documents were identified from the search of clinical 
practice guidelines for mHealth. We excluded one document 
because it was not in English, and two documents because 
they were behind a pay-wall, leaving 13 for full-text review. 
We excluded 8 recommendations that do not offer practical 
solutions for clinicians in their every-day practice (see Figure 
2).  
Figure 2 – PRISMA flow diagram describing selection of 
clinical practice guidelines for review. 
Table 3 summarizes the recommendations provided by health 
authorities for how clinicians should relate to mHealth and 
patient-gathered data (PGD). This enabled us to compare if 
such recommendations meet clinicians’ needs, as presented by 
the concerns and needs reported in Tables 1 and 2. 
 Table 3 – Health authorities’ clinical practice 
recommendations for clinicians’ use of mHealth and PGD. 
Discussion 
Clinicians have traditionally relied upon health authorities and 
management to provide guidance regarding clinical practice. 
As demonstrated, with the introduction of mobile health 
technologies to the options of patient self-management aids, 
clinicians have been and continue to be at a loss for answers. 
Despite these initial limitations, clinicians are acknowledging 
the benefits of these technologies more and more over recent 
years, especially since patients require more frequent support 
than the medical system is able to provide. Given the diversity 
of mHealth-generated data, health authorities and facility 
managers must provide support and suggestions for how care 
providers should relate to such technologies within differing 
clinical specialties in order for integration of mHealth to be 
successful.  
The results of this paper also suggest an answer to the looming 
question; are the recommendations provided by regulatory 
bodies evolving quickly enough to meet the needs to clinicians 
in the rapidly changing environment of mHealth? Comparison 
of clinicians’ perceptions of mHealth over time and guidance 
produced by regulatory bodies demonstrate that health and care 
authorities are beginning to propose the type of specific 
suggestions for relating to mHealth that clinicians need. 
However, the majority of the official activities under-way 
involve preparation for secure technological integration on the 
back-end. There have been few guidelines or recommendations 
for how clinicians can use data gathered by mHealth tools such 
as apps and sensors in daily practice. Questions remain 
regarding how patient-gathered lifestyle and health data should 
be weighted and considered along-side clinically generated 
information, e.g. lab results, to inform and generate actionable 
health recommendations. In addition, it is unclear which data is 
appropriate for providers to register and store within their own 
EHR systems. Health providers are responsible for judging 
which information is medically necessary and relevant for 
clinical decisions versus which information is sensitive to the 
individual and, therefore, should not be shared with the rest of 
the coordinated care team. This task is made exponentially 
more difficult with the added volume and detail of patient-
gathered data, and our current research project Full Flow of 
Health Data Between Patients and Health Care Systems will 
address this in the coming clinical study of a mHealth system 
during clinical practice in Norway.  
Conclusion 
We have seen a development in mHealth where mobile 
technology, such as apps for mobile phones, smartwatches, and 
patient-operated sensors, have led to a situation in which 
patients are bringing new and more data into the clinical 
settings. mHealth is a rapidly developing field and clinicians 
need sufficient guidance to respond to the frequent changes and 
challenges that this new environment calls for. As this paper 
demonstrates, while official guidelines published by health 
authorities reference standards for back-end requirements for 
technological communication between EHRs and mHealth 
devices, they do not provide sufficient support for clinicians’ in 
Ref. Recommendations 
2015 
[20] Proposes Continua as the standard for welfare technology 
[21] 
Guidelines for recommending apps to patients: 
• Tailor app recommendations to patients and discuss consent
regarding use of data and limits to consent
• Discuss effective apps with colleagues
• “Adhere to legislation and regulation (if existing) and/or
professional obligations”
• If the app is used for monitoring, the physician should
instruct the patient how to respond to the information
provided
• Clinicians should look for the following characteristics
before choosing an app:
• Endorsement by professional or reputable health
organization
• Usability and evidence of impact - clinicians may also test
the app themselves before recommending it
• Reliability of information: inquire about how the patient
intends to use the app to determine if the information
provided is appropriate
• Privacy/security: inform patients of added security risk of
using apps, and even recommend apps with additional
levels of authentication vs. apps without
• Avoids conflicts of interest and fragmentation of health
information
[22] 
• Do not use medical apps that do not have a CE Mark, or if
they do not “meet the requirements of the medical device
directives and regulations”
• “Exercise professional judgment before relying on
information from an app”
[23] • Clinicians should differentiate medical and non-medicalmobile apps – differentiating characteristics are provided
2016 
[24] 
• Clinicians should tailor recommendations to the disease and





their daily struggle to relate to mHealth. Therefore, the authors 
advocate for a greater voice and active involvement of health 
professionals in the development of any new processes, 
protocols or official standards, regardless of their specialty, to 
relate to mHealth successfully on a daily basis. It is time to 
integrate mHealth learning into medical and continued-
education for practicing clinicians. 
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Abstract 
Research often presents patient needs from perceptions of healthcare professionals and researchers. Today, 
patients can formulate tailored questions and seek solutions for what they need to self-manage in many ways. 
We aimed to compare reported outcomes of mHealth and online intervention studies for diabetes self-
management to patient-reported needs, from a systematic review and a literature review respectively. Although 
we found similarities between the reported outcomes and the patient-reported needs, research has yet to meet 
all patient needs. Comprehensive methods for development and testing of interventions should be explored to 
meet the specific needs of patients. 
Keywords 
mHealth, diabetes, online, evaluation, patients, needs. 
1 INTRODUCTION 
Evidence for models of diabetes self-management focus on 
medical devices and clinically relevant measures, and not 
those that are reportedly relevant for the patients who are 
the intended users [1,2]. Technology such as mHealth and 
online tools and services intend to aid patients’ diabetes 
self-management (SM) and provide additional support and 
information to that from traditional diabetes care and 
medical technology. In fact, patients with diabetes, have 
expressed impatience and dissatisfaction with the medically 
approved technology-based solutions, leading to the rise of 
the Do-It-Yourself (DIY) movement of hacking 
technologies to provide the functions and support that 
patients need [3]. However, the tradition within health 
intervention research has been to mostly focus on 
addressing and reporting clinical evidence and outcomes 
such as change in hemoglobin A1c and cholesterol levels, 
and not so much on other patient-relevant factors [2]. This 
raises the question: to what extent is mHealth and online 
intervention research targeting what is important for the 
patient and their needs in diabetes care? 
“Patient needs” are often described in scientific literature as 
activities or actions that patients have to take to achieve 
good diabetes health. In other words, it is often focused on 
what healthcare professionals (HCPs) and researchers, not 
patients, perceive as patient needs [4]. When reported, 
patient needs are usually inferred from patients’ feedback 
about their experience with mHealth or online interventions 
as part of an intervention study [5,6]. However, these do not 
comprehensively cover the overall needs for aiding their 
self-management. 
2 METHODS 
We compare results from two reviews: Review 1 identified 
reported outcomes of mHealth and online intervention 
studies for diabetes SM, and Review 2 identified patient-
reported needs and facilitating factors for diabetes SM. 
While performed separately, categorization of the results 
for each review were discussed and agreed upon by all co-
authors.  
2.1 Search strategy for Review 1 - reported 
outcomes of mHealth and online interventions 
The first review was a systematic literature review, with the 
overall aim of identifying methods and evaluation criteria 
used during mHealth and online interventions for diabetes 
SM. Several categories of information were extracted from 
the resulting literature. However, for the purpose of this 
paper, we will focus on reporting only a selection of the 
extracted data, i.e. reported outcomes. The following are 
examples of terms within titles and abstracts of literature 
found in CINAHL, EMBASE, MEDLINE and Web of 
Science, and published between Jan 1, 2015 and June 21, 
2018 for the search strategy: [mHealth or web-based] AND 
[self-assessment OR self-care] AND [assessment OR
guidelines]. The detailed search strategy is published along 
with the protocol of the systematic review in PROSPERO 
(Registration number: CRD42018115246). Articles were 
included if: they reported a relevant framework, guideline, 
questionnaire or other relevant criteria for evaluating 
mHealth or online interventions for patients – with all types 
of diabetes. Articles were excluded if: the evaluation only 
included medical measurements or did not include patients. 
Articles with only abstracts available, reviews, and 
dissertations were also excluded. Data extraction was 
performed by two co-authors (PR, MB). The main author 
(DL) performed inductive qualitative analysis and grouping
of the outcomes. All stages from search strategy to data
extraction and synthesis were contributed to and approved
by all co-authors.
2.2 Search strategy for Review 2 - patient-
reported needs 
The second review was a literature review aimed at 
identifying patient-reported needs related to the facilitation 
and performance of SM activities, including but not limited 
to those based on the use of mHealth technologies and 
online SM aids. Our search strategy included combinations 
of the following terms in titles and abstracts searched within 
Google (grey literature search) and PubMed that were 
published between Jan. 1, 2015 and August 17, 2019: 
[patient-reported needs OR want OR information needs OR 
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needs OR unmet needs] AND [patients] AND [diabetes OR
mHealth OR online]. Literature, news articles and other 
resulting publications were included if they reported needs 
and wishes for SM and SM aids by patients with diabetes. 
Literature was excluded if the feedback was from non-
patients, or from patients during development or testing of 
a specific app or online intervention only. This is because 
we aimed to identify unbiased feedback about needs for SM 
and factors that facilitated SM, without the context of 
development or testing of an app for a purpose that was 
chosen by the researchers, not the patients. Data extraction 
included patient-reported needs and facilitating factors 
related to diabetes self-management. Co-author (MB) 
performed inductive qualitative analysis and grouping of 
the needs.  
2.3 Comparison of reported outcomes vs. patient-
reported needs 
We performed a comparison based on the individual topics, 
i.e. reported outcomes and patient-reported needs,
independent of the previously established categories.
Comparison of the individual topics was discussed and
agreed upon by all co-authors. By comparing individual
reported outcomes and patient-reported needs, we were able
to identify which patient needs are addressed by
intervention studies and which still need to be addressed in
the future.
3 RESULTS 
3.1  Results from Review 1 – reported outcomes of 
mHealth and online interventions 
The search strategy resulted in the identification of n=1681 
mHealth and online intervention studies. After removing 
duplicates, most were excluded because no evaluation was 
reported, the focus of the study was not on diabetes or apps 
and online interventions, was not in English, not peer-
reviewed or published before 2015. The selection process is 
described in Figure 1. 
Figure 1 is a PRISMA flow chart diagram of Review 1. 
The analysis of mHealth and online interventions studies 
resulted in six categories, each with outcomes reported from 
evaluations. The Usability and Suitability of apps and
interventions category (see Table 1) had the most reported 
outcomes. Of these, the most commonly reported outcome 
was the Features and functions of an mHealth or online 
intervention. The Features and functions included the 
different types of tools for self-management such as 
diabetes diaries and glucose monitors, their characteristics 
and the users’ experiences with these tools. mHealth and 
online interventions tend to focus on their effect on self-
management, self-efficacy and autonomy, and clinical 
health measures such as hemoglobin A1c and blood 
pressure. See Table 1 for the full list of reported outcomes. 
Reported Outcomes Refs 
Usability and Suitability of apps 
and/or online interventions 
[5, 7-32] 
• Tailorability
• Features and functions
• Ease-of-use
• Challenges of use (from HCPs and patients)
• Suggestions for development and improvement
• Feasibility of integration into care practice
• User interface design
Effect on patient empowerment 
and engagement 
[5-7, 10-12, 14, 17-
20, 22, 25-29, 31, 
33-35]
• Self-management




Effect on clinical health 
measures 
[6, 7, 9, 12, 14, 16, 
18, 20, 22, 26, 29, 
34] 
• Quality of life
• Psychological symptoms
• Physical symptoms
• Clinically measured data
• Changes in patient-recorded health measures
Data protection [11, 13, 15, 17, 22, 
32] 
• Security and privacy
• Security regulations (or national standards)
Support from and access to [6, 9-11, 13, 14, 17, 
18, 20, 24, 25, 27-
29, 31, 33, 35] 
• Peers
• Family
• Coordinated healthcare services
• Relevant diabetes information
Other         [9, 28] 
• Cost of development
• Recommendation of technical solutions to patients by
HCPs 
Table 1 Results of Review 1, reported outcomes from 
mHealth and online interventions. 
3.2  Results from Review 2 - patient-reported needs 
The search strategy in PubMed and Google resulted in 160 
manuscripts with references to “patients’ needs” for 
diabetes self-management. Review of the titles, abstracts 
and brief descriptions, followed by review of full texts, 
resulted in the exclusion of 139 manuscripts, largely 
because the needs were not directly reported by patients, or 
were not related to diabetes. Figure 2 details the 
identification and selection of included literature. 
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Figure 2 is a PRISMA flow chart diagram of Review 2. 
Four categories of needs were identified from the 
qualitative assessment of reported patient needs. The most 
commonly reported needs were related to Support and
access to services, including both Emotional and practical 
tailored support from family, peers and HCPs to encourage 
and guide SM. The second group of most common needs 
were related to Coping, patient engagement and
empowerment. Patients saw the importance of being 
motivated and having confidence in their ability to perform 
SM tasks. This included being able to determine the best 
action in different situations, e.g. vacation, or if they needed 
to adjust how they managed their disease, e.g. because their 
metabolism and other factors changed as they grew older. 
While patients reported that they needed routines and more 
structure in their SM, they also wanted more relaxed and 
less strict SM goals, e.g. they did not like to feel ashamed 
or defeated by not reaching a diabetes-related goal. Because 
this review focused on general SM needs and facilitators of 
SM, fewer articles (n=6) described needs specifically 
related to mHealth or online interventions.  
Further, many of the reported needs were inter-related. For 
example, patients wanted information about how their 
lifestyle choices affected their diabetes health, and vice 
versa. This information could be provided by HCPs’ 
feedback about their SM performance, or from visualization 
of previously registered lifestyle and health data in an app 
(seen under Support and access to services and Technology
needs, respectively, in Table 2). Table 2 provides more 
detail of the categorized needs that patients reported. 
3.3 Comparing review results: Research foci vs. 
patient needs 
When comparing the topics of the reported outcomes of 
mHealth and online interventions and the patient-reported 
needs (see Venn diagram, Figure 3), we found many 
commonalities. The green section of the Venn diagram (B) 
illustrates these commonalities, with some individual topics 
such as Relevant diabetes information, and Feasibility of 
integration into care practice, reported as outcomes of 
interventions covering a variety of individual topics from 
the patient-reported needs.    
The yellow section of the Venn diagram (A) illustrates only 
reported outcomes from the mHealth and online 
interventions such as Cost of development, and Challenges 
to use from both HCPs and patients. The blue section of the 
Venn diagram (C) which illustrates only patient-reported 
needs, include individual topics such as Access to updated 
research results and policy changes related to diabetes SM, 
and How to cope with negative feelings and stress related 
to SM. 
Patient-reported needs Refs 
Information needs [36-46] 
• Clinical tests and disease function
• Options, risks, symptoms of treatments and
medications
• How lifestyle impacts disease
• How disease impacts life
• Population level disease info
• Information for family and friends
• Quality, reliable, tailored education and information
• Awareness of updated research and healthcare policies
Support and access to services
(HCPs, peers, family) needs 
[36-45,47-56] 
• Sharing data, e.g. from app to HCP, and from
electronic health records to patient
• Emotional and practical tailored support
• Feedback on SM performance and reminders
• Variety of always-available health services/SM aid
options
• Resources and services that facilitate SM activities,
e.g. gyms




• Participation in own healthcare decisions
• Motivation
• Self-efficacy
• Self-control/discipline, e.g. daily routines
• SM plan/goals that are not too strict
• How to adjust SM to e.g. different situations, as disease
progresses
• How to cope with negative feelings, stress, insecurity
about disease
• Avoid burden of disease for self and family
• Balancing life and SM responsibilities
Technology needs [36, 41, 47, 48, 
50, 56] 
• Simple and relevant visualization
• Automatic entry of different types of data
• Access to previous activity records
• Ease-of-use, e.g. always available
Table 2 Results of Review 2, patient-reported needs. 




Figure 3 Venn diagram comparing results of both reviews, based on individual topics: A. topics that only appeared in reported 




The reported needs of patients and the reported outcomes of 
research did overlap a lot. There are still however, patient-
reported needs that research has yet to address in order to 
optimize the self-management of diabetes patients.  
4.1  Patients want to share data  
The patients’ need to share their own gathered health data 
from apps with HCP has little representation in research 
outcomes. Only recently have technology developers, 
health authorities and researchers accepted the need to 
address both patients’ and healthcare practitioners’ use of 
these technologies, for example in consultations [57]. As a 
new and emerging field, patient-generated health data 
integration faces challenges in the every-day clinical 
setting, as well as from continuous development and use 
[58]. In addition to its significant effect on patients’ health, 
patient-generated data integration improves communication 
between HCPs and patients [58]. With input from HCPs 
about this shared data, patients could receive more 
supportive and tailored services, e.g. medication advice, 
and tools for coping with emotional and psychological 
distress. With the continuous advancement in technology, 
more of the already existing and future diabetes 
interventions could incorporate this function to help 
improve SM activities. This is especially true for diabetes, 
which is the fastest growing target audience for both 
individual and integrated mHealth systems [59]. 
4.2  Patients want more information  
The patient-reported need for Awareness of updated 
research and healthcare policies is among those needs not 
well-represented in the reported outcomes from mHealth 
and online intervention studies. Considering the importance 
that some categories of patients place in the digital sources 
of information [60], patients must be given the opportunity 
to access and understand research that pertains to their 
disease condition. We must also acknowledge that because 
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this information is published in a language and platform, 
e.g. scientific journals, that target researchers, not patients, 
it is understandable that patients do not feel that they have 
access to this information. If researchers would be more 
active in their production of popular science articles, 
participation in social media or blogs, this information 
could be more accessible and understandable for patients.  
Patients also reported a strong need for evidence, 
information and support. Some important questions to ask 
regarding these topics are: for which patient group is the 
evidence, i.e. reported outcomes, relevant? And, are there 
factors or needs that precede patients’ needs for SM? For 
example, Majeed-Ariss et al. report the needs of a group of 
British-Pakistani women who struggle with receiving 
health information and recommendations in English [51]. 
In this case, there was a fundamental barrier, i.e. 
communication, which needed to be overcome before these 
women could be expected to perform recommended SM 
activities, let alone to achieve diabetes health goals. 
4.3  Involving Patients in SM interventions 
Platforms or devices addressing the majority of the patient 
needs in mHealth and online interventions should be a 
priority for researchers. Similarly to Majeed-Ariss et al. 
[51], Berkowitz et al. [54] report that, in addition to 
healthcare services, patient needs include community 
resources and access to gyms that serve to lower the barriers 
to performing SM activities. Because patient needs relate to 
both medical and non-medical factors, research should 
involve patients from the beginning of SM aid-development 
to the identification and organization of a preventative or 
related service and support network, e.g. family and peers. 
Designing mHealth or online interventions that allow for 
personalization or tailoring based on each individual’s 
needs at their stage of SM or disease progress, can be 
another way for research to significantly address patient-
reported needs for SM. 
4.4  Limitations 
Based on experience in the field of mHealth development 
and evaluation, which iteratively involves patients, we 
know that data and personal security and privacy, as well as 
clinical efficacy of SM aids are both important to patients 
[61]. However, because Review 2 focused on general SM 
needs reported by patients, with less emphasis on needs 
from mHealth or health technologies, these were not 
included in the extraction of patient-reported needs.  
Due to the differences in aims and the kind of data we hoped 
to extract from the two reviews used in this paper, the time 
span of the searches, the databases accessed, and the type 
of review (systematic versus non-systematic review) were 
different. In addition, the reviews were limited to articles 
published in English language. 
 
5 CONCLUSION 
There are many patient-reported needs not addressed in 
today’s diabetes mHealth and online intervention studies. 
In order to meet the needs of patients, facilitate the 
expectations and treatment goals of care teams and improve 
overall health and wellbeing for those living with diabetes, 
comprehensive interventions and methods for developing 
and testing mHealth and online interventions should be 
further explored. With today’s technologies, it is more 
feasible and possible to realize the potential of patient 
empowerment and improved self-efficacy via mHealth and 
online interventions. Patients’ desire to share information 
with their HCPs can reinforce the potential of collaborating 
with their healthcare teams as opposed to only following 
directions. Therefore, the more we know about the 
challenges that patients face, the specific needs for patients’ 
self-management, and the ability of health services to 
support these needs, the more effectively we can develop 
tools and services, and provide relevant interventions for 
both patients and HCPs. 
 
6 REFERENCES 
[1]  Bongaerts, B.W.C., et al. “Effectiveness of chronic care 
models for the management of type 2 diabetes mellitus 
in Europe: a systematic review and meta-analysis” in 
BMJ Open Vol. 7, Issue 3, p. e013076. 2017. 
[2]  Egginton, J.S., et al. “Care management for Type 2 
diabetes in the United States: a systematic review and 
meta-analysis” in BMC Health Serv Res Vol. 12, Issue 
1, p. 72. 2012. 
[3]    Omer, T. “Empowered citizen 'health hackers' who are 
not waiting” in BMC Med Vol. 14, Issue 1, p. 118. 
2016. 
[4] Powers, M.A., et al. “Diabetes Self-management 
Education and Support in Type 2 Diabetes: A Joint 
Position Statement of the American Diabetes 
Association, the American Association of Diabetes 
Educators, and the Academy of Nutrition and 
Dietetics” in Diabetes Care Vol. 38, Issue 7, pp. 1372-
1382. 2015. 
[5]  Knight, B.A., et al. “Qualitative assessment of user 
experiences of a novel smart phone application 
designed to support flexible intensive insulin therapy 
in type 1 diabetes” in BMC Med Inform Decis Mak 
Vol. 16, p. 119. 2016. 
[6]  Husted, G.R., et al. “Exploring the Influence of a 
Smartphone App (Young with Diabetes) on Young 
People's Self-Management: Qualitative Study” in 
JMIR Mhealth Uhealth Vol 6, Issue 2, p. e43. 2018. 
[7] Kim, Y.J., et al. “A smartphone application 
significantlyimproved diabetes self-care activities 
with high user satisfaction” in Diabetes Metab J Vol. 
39, Issue 3, pp. 207-217. 2015. 
[8]   Dewi, D.S., et al. “Kansei Engineering Approach for 
Designing a Self-monitoring Blood Glucose 
Application” in Int J Technol Vol. 8, Issue 2, pp. 272-
282. 2017. 
[9]   Wake, D.J., et al. “MyDiabetesMyWay: An Evolving 
National Data Driven Diabetes Self-Management 
Platform” in J Diabetes Sci Technol Vol 10, Issue 5, 
pp. 1050-8. 2016. 
[10] Castensoe-Seidenfaden, P., et al. “Designing a Self-
management App for Young People With Type 1 
Diabetes: Methodological Challenges, Experiences, 
and Recommendations” in JMIR Mhealth Uhealth 
Vol. 5, Issue 10, p. e124. 2017. 
[11] Jeon, E., et al. “Development of the IMB Model and 
an Evidence-Based Diabetes Self-management 
Mobile Application” in Healthc Inform Res Vol. 24, 
Issue 2, pp. 125-138. 2018. 
[12] Ramadas, A., et al. “A web-based dietary intervention 
for people with type 2 diabetes: development, 
Proceedings of the 17th Scandinavian Conference on Health Informatics, 12 -13 Nov 2019, Oslo Norway
34
implementation, and evaluation” in Int J Behav Med 
Vol. 22, Issue 3, pp. 365-73. 2015. 
[13] Conway, N., et al. “mHealth applications for diabetes:
User preference and implications for app
development” in Health Informatics J Vol. 22, Issue
4, pp. 1111-1120. 2016.
[14] Nicholson, W.K., et al. “The Gestational Diabetes
Management System (GooDMomS): development,
feasibility and lessons learned from a patient-
informed, web-based pregnancy and postpartum
lifestyle intervention” in BMC Pregnancy Childbirth
Vol. 16, p. 277. 2016.
[15] Bernhard, G., et al. “Developing a Shared Patient-
Centered, Web-Based Medication Platform for Type
2 Diabetes Patients and Their Health Care Providers:
Qualitative Study on User Requirements” in J Med
Internet Res Vol. 20, Issue 3, p. e105. 2018.
[16] Klaassen, R., et al. “Design and Evaluation of a
Pervasive Coaching and Gamification Platform for
Young Diabetes Patients” in Sensors Vol. 18, Issue 2,
p. e402. 2018.
[17] Tieu, L., et al. “Barriers and Facilitators to Online
Portal Use Among Patients and Caregivers in a Safety
Net Health Care System: A Qualitative Study”  in J
Med Internet Res Vol. 17, Issue 12, p. e275. 2015.
[18] Desveaux, L., et al. “A Mobile App to Improve Self-
Management of Individuals With Type 2 Diabetes:
Qualitative Realist Evaluation” in J Med Internet Res
Vol. 20, Issue 3, p. e81. 2018.
[19] Gianfrancesco, C., et al. “Exploring the feasibility of
use of an online dietary assessment tool (myfood24)
in women with gestational diabetes” in Nutrients Vol.
10, Issue 9, p. e1147. 2018.
[20] Pludwinski, S., et al. “Participant experiences in a
smartphone-based health coaching intervention for
type 2 diabetes: A qualitative inquiry” in J Telemed
Telecare Vol. 22, Issue 3, pp. 172-178. 2016.
[21] Jo, S., et al. “Development and Evaluation of a
Smartphone Application for Managing Gestational
Diabetes Mellitus” in Healthc Inform Res Vol. 22,
Issue 1, pp. 11-21. 2016.
[22] Lamprinos, I., et al. “Modular ICT-based patient
empowerment framework for self-management of
diabetes: Design perspectives and validation results”
in Int J Med Inform Vol. 91, pp. 31-43. 2016.
[23] Ashurst, E.J., et al. “Is the Health App Challenge
approach of patient-led application conception,
development, and review worthwhile?” in Health
Policy Technol Vol. 6, Issue 1, pp. 83-92. 2017.
[24] Zhang, Y.Y., et al. “Exploration of Users' Perspectives
and Needs and Design of a Type 1 Diabetes
Management Mobile App: Mixed-Methods Study” in
JMIR Mhealth Uhealth Vol. 6, Issue 9, p. e11400.
2018.
[25] Skar, J.B., et al. “Women's experiences with using a
smartphone app (the Pregnant+ app) to manage
gestational diabetes mellitus in a randomised
controlled trial” in Midwifery Vol. 58, pp. 102-108.
2018.
[26] Drion, I., et al. “The Effects of a Mobile Phone
Application on Quality of Life in Patients With Type
1 Diabetes Mellitus: A Randomized Controlled Trial”
in J Diabetes Sci Technol Vol. 9, Issue 5, pp. 1086-91.
2015.
[27] Peng, W., et al. “Exploring the Challenges and
Opportunities of Health Mobile Apps for Individuals
with Type 2 Diabetes Living in Rural Communities”
in Telemed J E Health Vol. 22, Issue 9, pp. 733-738.
2016.
[28] Petersen, M., et al. “Development and testing of a
mobile application to support diabetes self-
management for people with newly diagnosed type 2
diabetes: a design thinking case study” in BMC Med
Inform Decis Mak Vol. 17, Issue 1, p. 91. 2017.
[29] Torbjørnsen, A., et al. “Acceptability of an mHealth
App Intervention for Persons With Type 2 Diabetes
and its Associations With Initial Self-Management:
Randomized Controlled Trial” in JMIR Mhealth
Uhealth Vol. 6, Issue 5, p. e125. 2018.
[30] Georgsson, M., et al. “Quantifying usability: an
evaluation of a diabetes mHealth system on
effectiveness, efficiency, and satisfaction metrics with
associated user characteristics” in J Am Med Inform
Assoc Vol. 23, Issue 1, pp. 5-11. 2016.
[31] Muller, I., et al. “Effects on Engagement and Health
Literacy Outcomes of Web-Based Materials
Promoting Physical Activity in People With Diabetes:
An International Randomized Trial” in J Med Internet
Res Vol. 19, Issue 1, p. e21. 2017.
[32] Neinstein, A., et al. “A case study in open source
innovation: developing the Tidepool Platform for
interoperability in type 1 diabetes management” in J
Am Med Inform Assoc Vol. 23, Issue 2, pp. 324-332.
2016.
[33] Brady, E., et al. “Accessing support and empowerment
online: The experiences of individuals with diabetes”
in Health Expectations Vol. 20, Issue 5, pp. 1088-
1095. 2017.
[34] Quinn, C.C., et al. “Older Adult Self-Efficacy Study of
Mobile Phone Diabetes Management” in Diabetes
Technol Ther Vol.7, Issue 7, pp. 455-61. 2015.
[35] Park, S., et al. “The Role of Digital Engagement in the
Self-Management of Type 2 Diabetes” in Health
Commun Vol. 31, Issue 12, pp. 1557-1565. 2016.
[36] Jung, M., et al. “Understanding Patients' Needs in
Diabetes for Mobile Health - A Case Study” in 2016
IEEE 29th International Symposium on Computer-
Based Medical Systems (CBMS). 2016.
[37] Papaspurou, M., et al. “Fears and Health Needs of
Patients with Diabetes: A Qualitative Research in
Rural Population” in Med Arch Vol. 69, Issue 3, pp.
190-195. 2015.
[38] Weymann, N., et al. “Information and decision support
needs in patients with type 2 diabetes” in Health
Informatics J Vol. 22, Issue 1, pp. 46-59. 2016.
[39] Crangle, C.E., et al. “Exploring patient information
needs in type 2 diabetes: A cross sectional study of
questions” in PLOS One Vol 13, Issue 11, p.
e0203429. 2018.
[40] Crangle, C.E., et al. “Soliciting and Responding to
Patients' Questions about Diabetes Through Online
Sources” in Diabetes Technol Ther Vol. 19, Issue 3,
pp. 194-199. 2017.
[41] Kabeza, C.B., et al. “Assessment of Rwandan diabetic
patients' needs and expectations to develop their first
diabetes self-management smartphone application
(Kir'App)” in Ther Adv Endocrinol Metab Vol. 10, p.
2042018819845318. 2019.
Proceedings of the 17th Scandinavian Conference on Health Informatics, 12 -13 Nov 2019, Oslo Norway
35
[42] Svedbo Engström, M., et al. “What is important for
you? A qualitative interview study of living with
diabetes and experiences of diabetes care to establish
a basis for a tailored Patient-Reported Outcome
Measure for the Swedish National Diabetes Register”
in BMJ Open Vol. 6, Issue 3, p. e010249. 2016.
[43] Elliott, J.A., et al. “A cross-sectional assessment of
diabetes self-management, education and support
needs of Syrian refugee patients living with diabetes
in Bekaa Valley Lebanon” in Conflict and Health Vol.
12, Issue 1, p. 40. 2018.
[44] Carolan, M., et al. “Experiences of diabetes self-
management: a focus group study among Australians
with type 2 diabetes” in J Clin Nurs Vol. 24, Issue 7-
8, pp. 1011-23. 2015.
[45] Timpel, P., et al. “Individualising Chronic Care
Management by Analysing Patients' Needs - A Mixed
Method Approach” in Int J Integr Care Vol. 17, Issue
6, p. 2. 2017.
[46] Mikhael, E.M., et al. “Self-management knowledge
and practice of type 2 diabetes mellitus patients in
Baghdad, Iraq: a qualitative study” in Diabetes Metab
Syndr Obes Vol. 12, pp. 1-17. 2019.
[47] Zhang, Y., et al. “Exploration of Users’ Perspectives
and Needs and Design of a Type 1 Diabetes
Management Mobile App: Mixed-Methods Study” in
JMIR Mhealth Uhealth Vol. 6, Issue 9, p. e11400.
2018.
[48] Zhang, Y., et al. “Use, Perspectives, and Attitudes
Regarding Diabetes Management Mobile Apps
Among Diabetes Patients and Diabetologists in China:
National Web-Based Survey” in JMIR Mhealth
Uhealth Vol. 7, Issue 2, p. e12658. 2019.
[49] Fu, H.N., et al. “Influence of Patient Characteristics
and Psychological Needs on Diabetes Mobile App
Usability in Adults With Type 1 or Type 2 Diabetes:
Crossover Randomized Trial” in JMIR Diabetes Vol.
4, Issue 2, p. e11462. 2019.
[50] Baptista, S., et al. “What Do Adults with Type 2
Diabetes Want from the "Perfect" App? Results from
the Second Diabetes MILES: Australia (MILES-2)
Study” in Diabetes Technol Ther Vol. 21, Issue 7, pp.
393-399. 2019.
[51] Majeed-Ariss, R., et al. “British-Pakistani women's
perspectives of diabetes self-management: the role of
identity” in J Clin Nurs Vol. 24, Issue 17-18, pp. 2571-
80. 2015.
[52] Pettus, J.H., et al. “Adjunct Therapy in Type 1
Diabetes: A Survey to Uncover Unmet Needs and
Patient Preferences Beyond HbA1c Measures” in
Diabetes Technol Ther Vol. 21, Issue 6, pp. 336-343.
2019.
[53] Dobson, R., et al. “The Use of Mobile Health to
Deliver Self-Management Support to Young People
With Type 1 Diabetes: A Cross-Sectional Survey” in
JMIR Diabetes Vol. 2, Issue 1, p. e4. 2017.
[54] Berkowitz, S.A., et al. “Addressing Unmet Basic
Resource Needs as Part of Chronic Cardiometabolic
Disease Management” in JAMA Intern Med Vol. 177,
Issue 2, pp. 244-252. 2017.
[55] “Major health systems’ mHealth initiatives are failing
to meet patient needs” Universe mHealth, Dallas,
United States of America, 2019. Available from:
https://universemhealth.com/major-health-systems-
mhealth-initiatives-are-failing-to-meet-patient-needs/ 
(Accessed: 28th August, 2019). 
[56] Safavi, K., et al. “Accenture 2018 Consumer Survey
on Digital Health” Accenture: accenture.com. 2018.
[57] DG CONNECT. “mHealth in Europe: Preparing the
ground – consultation results published” Digital





[58] Ryu, B., et al. “Impact of an Electronic Health Record-
Integrated Personal Health Record on Patient
Participation in Health Care: Development and
Randomized Controlled Trial of MyHealthKeeper” in
J Med Internet Res Vol. 19, Issue 12, p. e401. 2017.
[59] “mHealth App Economics 2017: Current Status and
Future Trends in Mobile Health” Research2guidance,
7th Ed. Berlin, Germany. 2017. Available from:
https://research2guidance.com/product/mhealth-
economics-2017-current-status-and-future-trends-in-
mobile-health/ (Accessed: 28th August, 2019).
[60] Kuske, S., et al. “Diabetes-related information-seeking
behaviour: a systematic review” in Syst Rev, Vol. 6,
Issue 1, p. 212. 2017.
[61] HIPAA Journal. “Patient Privacy and Security Are
Greatest Healthcare Concerns for Consumers” HIPAA
Journal, 2018. Available from:
https://www.hipaajournal.com/patient-privacy-and-
security-are-greatest-healthcare-concerns-for-
consumers/ (Accessed: 28th August, 2019).
7 ACKNOWLEDGEMENT 
This paper is a product of the “Design and validation of 
instruments to assess efficacy, effectiveness and safety of 
apps and online resources aimed at Norwegians with 
diabetes” project, funded by Helse Nord (HNF1425-18).
Proceedings of the 17th Scandinavian Conference on Health Informatics, 12 -13 Nov 2019, Oslo Norway
36
